activity_comment	activity_id	assay_chembl_id	assay_description	assay_type	canonical_smiles	data_validity_comment	molecule_chembl_id	relation	standard_type	standard_units	standard_value	target_chembl_id	target_organism	type	units	value
	72612	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	COc1ccc2[nH]c3c(c2c1)CC(=O)Nc1ccccc1-3		CHEMBL95827	=	IC50	nM	900.0	CHEMBL308	Homo sapiens	IC50	uM	0.9
	72612	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	COc1ccc2[nH]c3c(c2c1)CC(=O)Nc1ccccc1-3		CHEMBL95827	=	IC50	nM	900.0	CHEMBL308	Homo sapiens	IC50	uM	0.9
	72615	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	CC(C)(C)OC(=O)C1C(=O)N(C(=O)OC(C)(C)C)c2ccccc2-c2c1c1cc(Br)ccc1n2C(=O)OC(C)(C)C	Outside typical range	CHEMBL420455	=	IC50	nM	150000.0	CHEMBL308	Homo sapiens	IC50	uM	150.0
	72620	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	CC(C)(C)OC(=O)n1c2c(c3cc(Br)ccc31)CC(=O)Nc1ccccc1-2		CHEMBL100312	=	IC50	nM	70000.0	CHEMBL308	Homo sapiens	IC50	uM	70.0
	73687	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	IC50	nM	400.0	CHEMBL308	Homo sapiens	IC50	uM	0.4
	74688	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2cc(Br)ccc2N1		CHEMBL98360	=	IC50	nM	300.0	CHEMBL308	Homo sapiens	IC50	uM	0.3
	74691	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2cc(O)c(O)cc2N1		CHEMBL329063	=	IC50	nM	3000.0	CHEMBL308	Homo sapiens	IC50	uM	3.0
	74694	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	COC(=O)CN1C(=O)Cc2c([nH]c3ccc(Br)cc23)-c2ccccc21		CHEMBL317539	=	IC50	nM	6400.0	CHEMBL308	Homo sapiens	IC50	uM	6.4
	75874	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	COc1cc2c(cc1OC)-c1[nH]c3ccc(C(F)(F)F)cc3c1CC(=O)N2		CHEMBL328194	=	IC50	nM	280.0	CHEMBL308	Homo sapiens	IC50	uM	0.28
	75878	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	CSC1=Nc2ccccc2-c2[nH]c3ccc(Br)cc3c2C1		CHEMBL328164	=	IC50	nM	43000.0	CHEMBL308	Homo sapiens	IC50	uM	43.0
	76961	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	CCC(CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL52387	=	IC50	nM	650.0	CHEMBL308	Homo sapiens	IC50	uM	0.65
	76966	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	COc1cc2c(cc1OC)-c1[nH]c3ccc(Br)cc3c1CC(=O)N2		CHEMBL319373	=	IC50	nM	200.0	CHEMBL308	Homo sapiens	IC50	uM	0.2
	78064	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	O=C1Cc2c([nH]c3c(Cl)cccc23)-c2ccccc2N1		CHEMBL318471	=	IC50	nM	1400.0	CHEMBL308	Homo sapiens	IC50	uM	1.4
	78067	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	SC1=Nc2ccccc2-c2[nH]c3ccc(Br)cc3c2C1		CHEMBL52551	=	IC50	nM	2300.0	CHEMBL308	Homo sapiens	IC50	uM	2.3
	80392	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	IC50	nM	35.0	CHEMBL308	Homo sapiens	IC50	uM	0.035
	81560	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	O=C1Cc2c(n(CCO)c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL99803	=	IC50	nM	3000.0	CHEMBL308	Homo sapiens	IC50	uM	3.0
	82616	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	Cc1cccc2c3c([nH]c12)-c1ccccc1NC(=O)C3		CHEMBL98501	=	IC50	nM	3000.0	CHEMBL308	Homo sapiens	IC50	uM	3.0
	82619	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	O=C1Cc2c([nH]c3ccccc23)-c2cc(Br)ccc2N1		CHEMBL316940	=	IC50	nM	3300.0	CHEMBL308	Homo sapiens	IC50	uM	3.3
	83585	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	ONC1=Nc2ccccc2-c2[nH]c3ccc(Br)cc3c2C1		CHEMBL98275	=	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	uM	1.0
	84585	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	N#Cc1ccc2[nH]c3c(c2c1)CC(=O)Nc1ccccc1-3		CHEMBL299756	=	IC50	nM	24.0	CHEMBL308	Homo sapiens	IC50	uM	0.024
	84588	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	O=C1Cc2c([nH]c3c(Br)cccc23)-c2ccccc2N1		CHEMBL318911	=	IC50	nM	1300.0	CHEMBL308	Homo sapiens	IC50	uM	1.3
	85671	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	O=C1Cc2c([nH]c3ccccc23)-c2ccccc2N1		CHEMBL430574	=	IC50	nM	7000.0	CHEMBL308	Homo sapiens	IC50	uM	7.0
	86581	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	CC(C)(C)OC(=O)N1C(=O)Cc2c(n(C(=O)OC(C)(C)C)c3ccc(Br)cc23)-c2ccccc21	Outside typical range	CHEMBL317562	=	IC50	nM	1000000.0	CHEMBL308	Homo sapiens	IC50	uM	1000.0
	86584	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	CN1C(=O)Cc2c([nH]c3ccc(Br)cc23)-c2ccccc21		CHEMBL316485	=	IC50	nM	20000.0	CHEMBL308	Homo sapiens	IC50	uM	20.0
	88690	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	O=C1Cc2c([nH]c3ccc(F)cc23)-c2ccccc2N1		CHEMBL99037	=	IC50	nM	1600.0	CHEMBL308	Homo sapiens	IC50	uM	1.6
	89608	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	O=C1Cc2c([nH]c3ccc(C(F)(F)F)cc23)-c2ccccc2N1		CHEMBL329505	=	IC50	nM	400.0	CHEMBL308	Homo sapiens	IC50	uM	0.4
	89611	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	O=C1Cc2c([nH]c3ccc(C(F)(F)F)cc23)-c2cc(Br)ccc2N1		CHEMBL100309	=	IC50	nM	240.0	CHEMBL308	Homo sapiens	IC50	uM	0.24
	89614	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	COC(=O)Cn1c2c(c3cc(Br)ccc31)CC(=O)Nc1ccccc1-2		CHEMBL100220	=	IC50	nM	1400.0	CHEMBL308	Homo sapiens	IC50	uM	1.4
	92649	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	CCn1c2c(c3cc(Br)ccc31)CC(=O)Nc1ccccc1-2		CHEMBL328627	=	IC50	nM	23000.0	CHEMBL308	Homo sapiens	IC50	uM	23.0
	94578	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	CCc1cccc2c3c([nH]c12)-c1ccccc1NC(=O)C3		CHEMBL317150	=	IC50	nM	3800.0	CHEMBL308	Homo sapiens	IC50	uM	3.8
	94581	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	CC(C)(C)OC(=O)C1C(=O)N(C(=O)OC(C)(C)C)c2ccccc2-c2[nH]c3ccc(Br)cc3c21		CHEMBL100485	=	IC50	nM	80000.0	CHEMBL308	Homo sapiens	IC50	uM	80.0
	95565	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	Cn1c2c(c3cc(Br)ccc31)CC(=O)Nc1ccccc1-2		CHEMBL318208	=	IC50	nM	6200.0	CHEMBL308	Homo sapiens	IC50	uM	6.2
	96649	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	COc1cccc2c1NC(=O)Cc1c-2[nH]c2ccccc12	Outside typical range	CHEMBL99423	=	IC50	nM	430000.0	CHEMBL308	Homo sapiens	IC50	uM	430.0
	97667	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2cccc(O)c2N1		CHEMBL95477	=	IC50	nM	40000.0	CHEMBL308	Homo sapiens	IC50	uM	40.0
	97670	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	CCN1C(=O)Cc2c([nH]c3ccc(Br)cc23)-c2ccccc21	Outside typical range	CHEMBL97844	=	IC50	nM	470000.0	CHEMBL308	Homo sapiens	IC50	uM	470.0
	98692	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	O=C1Cc2c([nH]c3cc(Cl)cc(Cl)c23)-c2ccccc2N1		CHEMBL316512	=	IC50	nM	2500.0	CHEMBL308	Homo sapiens	IC50	uM	2.5
	98695	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	COc1cc2c(cc1OC)-c1[nH]c3ccccc3c1CC(=O)N2		CHEMBL431634	=	IC50	nM	4300.0	CHEMBL308	Homo sapiens	IC50	uM	4.3
	100544	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1Cc1ccccc1		CHEMBL99779	=	IC50	nM	35000.0	CHEMBL308	Homo sapiens	IC50	uM	35.0
	100548	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	C=CCn1c2c(c3cc(Br)ccc31)CC(=O)Nc1ccccc1-2		CHEMBL99280	=	IC50	nM	60000.0	CHEMBL308	Homo sapiens	IC50	uM	60.0
	101634	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	O=C1Cc2c([nH]c3cc(Br)ccc23)-c2ccccc2N1		CHEMBL98554	=	IC50	nM	1300.0	CHEMBL308	Homo sapiens	IC50	uM	1.3
	102690	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	COc1cccc2c1NC(=O)Cc1c-2[nH]c2ccc(Br)cc12	Outside typical range	CHEMBL330398	=	IC50	nM	250000.0	CHEMBL308	Homo sapiens	IC50	uM	250.0
	103601	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@@H](O)C1		CHEMBL418203	=	IC50	nM	300.0	CHEMBL308	Homo sapiens	IC50	uM	0.3
	103604	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	O=C1Cc2c([nH]c3ccc(Cl)cc23)-c2ccccc2N1		CHEMBL98153	=	IC50	nM	600.0	CHEMBL308	Homo sapiens	IC50	uM	0.6
	103607	CHEMBL662511	In vitro inhibitory activity against cyclin-dependent kinase 1-cyclin B (Cyclin-Dependent Kinase) harvested from starfish oocytes.	B	Cc1ccc2[nH]c3c(c2c1)CC(=O)Nc1ccccc1-3		CHEMBL317964	=	IC50	nM	2000.0	CHEMBL308	Homo sapiens	IC50	uM	2.0
	108038	CHEMBL660796	Inhibition of Cyclin-dependent kinase 1	B	CC(C)C(CO)Nc1nc(NCc2cccc(O)c2)c2ncn(C(C)C)c2n1		CHEMBL84944	=	IC50	nM	100.0	CHEMBL308	Homo sapiens	IC50	uM	0.1
	110542	CHEMBL660796	Inhibition of Cyclin-dependent kinase 1	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCO)nc21		CHEMBL86066	=	IC50	nM	9400.0	CHEMBL308	Homo sapiens	IC50	uM	9.4
	115964	CHEMBL660796	Inhibition of Cyclin-dependent kinase 1	B	CC(C)C(CO)Nc1nc(NCc2ccccc2O)c2ncn(C(C)C)c2n1		CHEMBL83320	=	IC50	nM	10.0	CHEMBL308	Homo sapiens	IC50	uM	0.01
	118470	CHEMBL660802	Inhibition of Cyclin-dependent kinase 1	B	CC(C)n1cnc2c(NC3CCCC3)nc(NCCCO)nc21		CHEMBL315837	=	IC50	nM	2400.0	CHEMBL308	Homo sapiens	IC50	uM	2.4
	119600	CHEMBL660796	Inhibition of Cyclin-dependent kinase 1	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21		CHEMBL83980	=	IC50	nM	2500.0	CHEMBL308	Homo sapiens	IC50	uM	2.5
	124664	CHEMBL660796	Inhibition of Cyclin-dependent kinase 1	B	CC(C)n1cnc2c(N)nc(NCCCO)nc21		CHEMBL84140	=	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	131160	CHEMBL660796	Inhibition of Cyclin-dependent kinase 1	B	Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc21		CHEMBL280074	=	IC50	nM	4600.0	CHEMBL308	Homo sapiens	IC50	uM	4.6
	133599	CHEMBL660796	Inhibition of Cyclin-dependent kinase 1	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NC[C@@H](C)O)nc21		CHEMBL84436	=	IC50	nM	1100.0	CHEMBL308	Homo sapiens	IC50	uM	1.1
	141889	CHEMBL660802	Inhibition of Cyclin-dependent kinase 1	B	CC(C)n1cnc2c(NCc3ccccc3)ncnc21		CHEMBL85015	=	IC50	nM	3500.0	CHEMBL308	Homo sapiens	IC50	uM	3.5
	141941	CHEMBL660796	Inhibition of Cyclin-dependent kinase 1	B	CC(C)n1cnc2c(NC34CC5CC(CC(C5)C3)C4)nc(NCCCO)nc21		CHEMBL83719	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	304733	CHEMBL666135	Inhibitory concentration against Cyclin dependent kinase 1.	B	CCC(CO)Nc1nc(NCc2cccc(O)c2)c2nc(Cl)n(C(C)C)c2n1		CHEMBL101166	=	IC50	nM	6000.0	CHEMBL308	Homo sapiens	IC50	uM	6.0
	305589	CHEMBL657992	Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.	B	CN1CNc2ncnc(NCc3ccccc3)c21	Outside typical range	CHEMBL133377	>	IC50	nM	1000000.0	CHEMBL308	Homo sapiens	IC50	uM	1000.0
	306902	CHEMBL657992	Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.	B	CN1CNc2ncnc(N)c21	Outside typical range	CHEMBL334619	>	IC50	nM	500000.0	CHEMBL308	Homo sapiens	IC50	uM	500.0
	307354	CHEMBL666135	Inhibitory concentration against Cyclin dependent kinase 1.	B	CCC(CO)Nc1nc(NCc2ccccc2)c2nc(C)n(C(C)C)c2n1		CHEMBL100645	=	IC50	nM	8000.0	CHEMBL308	Homo sapiens	IC50	uM	8.0
	308743	CHEMBL666135	Inhibitory concentration against Cyclin dependent kinase 1.	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	=	IC50	nM	450.0	CHEMBL308	Homo sapiens	IC50	uM	0.45
	309641	CHEMBL657992	Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.	B	Nc1nc(NCc2ccccc2)c2[nH]cnc2n1		CHEMBL133214	=	IC50	nM	90000.0	CHEMBL308	Homo sapiens	IC50	uM	90.0
	310846	CHEMBL657993	Inhibition of purified Cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis (precipitation at the higher concentration tested)	B	Nc1[nH]c(Cl)nc2ncnc1-2	Outside typical range	CHEMBL134192	>	IC50	nM	1000000.0	CHEMBL308	Homo sapiens	IC50	uM	1000.0
	311371	CHEMBL666135	Inhibitory concentration against Cyclin dependent kinase 1.	B	CC(C)n1cnc2c(Nc3cccc(Cl)c3)nc(NC3CCC(N)CC3)nc21		CHEMBL102871	=	IC50	nM	30.0	CHEMBL308	Homo sapiens	IC50	uM	0.03
	312284	CHEMBL657992	Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.	B	Cn1cnc2c(NCc3ccccc3)nc(Cl)nc21		CHEMBL133042	=	IC50	nM	12000.0	CHEMBL308	Homo sapiens	IC50	uM	12.0
	312285	CHEMBL657992	Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	=	IC50	nM	200.0	CHEMBL308	Homo sapiens	IC50	uM	0.2
	313563	CHEMBL657992	Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.	B	Cn1cnc2c(N)nc(Cl)nc21		CHEMBL317398	=	IC50	nM	70000.0	CHEMBL308	Homo sapiens	IC50	uM	70.0
	314881	CHEMBL657992	Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.	B	c1ccc(CNc2ncnc3[nH]cnc23)cc1	Outside typical range	CHEMBL228862	=	IC50	nM	200000.0	CHEMBL308	Homo sapiens	IC50	uM	200.0
	316016	CHEMBL657992	Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.	B	Cn1cnc2c(NCc3ccccc3)ncnc21		CHEMBL131098	=	IC50	nM	40000.0	CHEMBL308	Homo sapiens	IC50	uM	40.0
	316017	CHEMBL657992	Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.	B	CC(C)=CCNc1nc(NCCO)nc2c1ncn2C		CHEMBL131382	=	IC50	nM	65000.0	CHEMBL308	Homo sapiens	IC50	uM	65.0
	316018	CHEMBL657992	Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.	B	CN1CN=C(NCc2ccccc2)c2[nH]cnc21	Outside typical range	CHEMBL336556	=	IC50	nM	300000.0	CHEMBL308	Homo sapiens	IC50	uM	300.0
	316423	CHEMBL666135	Inhibitory concentration against Cyclin dependent kinase 1.	B	CCC(CO)Nc1nc(NCc2ccccc2)c2nc(Cl)n(C(C)C)c2n1		CHEMBL100079	=	IC50	nM	20000.0	CHEMBL308	Homo sapiens	IC50	uM	20.0
	317723	CHEMBL666135	Inhibitory concentration against Cyclin dependent kinase 1.	B	CCCOc1nc2c(NCc3ccccc3)nc(NC(CC)CO)nc2n1C(C)C		CHEMBL317865	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	317726	CHEMBL666135	Inhibitory concentration against Cyclin dependent kinase 1.	B	CCC(CO)Nc1nc(NCc2ccccc2)c2nc(NCCCO)n(C(C)C)c2n1		CHEMBL318289	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	319692	CHEMBL657992	Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.	B	Cc1nc(N)c2[nH]cnc2n1	Outside typical range	CHEMBL330897	=	IC50	nM	320000.0	CHEMBL308	Homo sapiens	IC50	uM	320.0
	320897	CHEMBL657992	Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.	B	CN(c1nc(Cl)nc2c1ncn2C)C1CCCCC1	Outside typical range	CHEMBL337161	=	IC50	nM	130000.0	CHEMBL308	Homo sapiens	IC50	uM	130.0
	322144	CHEMBL657992	Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.	B	OCCNc1nc(NCc2ccccc2)c2ncn(CCO)c2n1		CHEMBL130681	=	IC50	nM	8000.0	CHEMBL308	Homo sapiens	IC50	uM	8.0
	322145	CHEMBL657992	Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.	B	CCC(CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL52387	=	IC50	nM	650.0	CHEMBL308	Homo sapiens	IC50	uM	0.65
	323613	CHEMBL657992	Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.	B	CN1CN=C(N)c2[nH]cnc21	Outside typical range	CHEMBL131896	=	IC50	nM	400000.0	CHEMBL308	Homo sapiens	IC50	uM	400.0
	324688	CHEMBL657992	Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.	B	CC(O)CNc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL130280	=	IC50	nM	900.0	CHEMBL308	Homo sapiens	IC50	uM	0.9
	325906	CHEMBL657993	Inhibition of purified Cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis (precipitation at the higher concentration tested)	B	Nc1nc(N)c2nc[nH]c2n1		CHEMBL388596	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	325907	CHEMBL657992	Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.	B	CN1C=Nc2[nH]cnc2C1NCc1ccccc1	Outside typical range	CHEMBL133290	>	IC50	nM	1000000.0	CHEMBL308	Homo sapiens	IC50	uM	1000.0
	327669	CHEMBL666135	Inhibitory concentration against Cyclin dependent kinase 1.	B	CCC(CO)Nc1nc(NCc2ccccc2)c2nc(N)n(C(C)C)c2n1		CHEMBL100500	=	IC50	nM	70000.0	CHEMBL308	Homo sapiens	IC50	uM	70.0
	327672	CHEMBL666135	Inhibitory concentration against Cyclin dependent kinase 1.	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	IC50	nM	50.0	CHEMBL308	Homo sapiens	IC50	uM	0.05
	328659	CHEMBL657992	Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.	B	Cn1cnc2c(NCc3ccccc3)nc(N)nc21		CHEMBL337454	=	IC50	nM	40000.0	CHEMBL308	Homo sapiens	IC50	uM	40.0
	328660	CHEMBL657992	Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCO)nc21		CHEMBL86066	=	IC50	nM	2000.0	CHEMBL308	Homo sapiens	IC50	uM	2.0
	329163	CHEMBL666135	Inhibitory concentration against Cyclin dependent kinase 1.	B	CCC(CO)Nc1nc(NCc2ccccc2)c2nc(O)n(C(C)C)c2n1		CHEMBL100670	=	IC50	nM	65000.0	CHEMBL308	Homo sapiens	IC50	uM	65.0
	329166	CHEMBL666135	Inhibitory concentration against Cyclin dependent kinase 1.	B	Cc1nc2c(Nc3cccc(Cl)c3)nc(NC3CCC(N)CC3)nc2n1C(C)C		CHEMBL103567	=	IC50	nM	14000.0	CHEMBL308	Homo sapiens	IC50	uM	14.0
	330316	CHEMBL666135	Inhibitory concentration against Cyclin dependent kinase 1.	B	CCC(CO)Nc1nc(NCc2ccccc2)c2nc(Br)n(C(C)C)c2n1		CHEMBL320873	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	331172	CHEMBL657992	Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.	B	CN(c1nc(NCCO)nc2c1ncn2C)C1CCCCC1		CHEMBL129977	=	IC50	nM	6000.0	CHEMBL308	Homo sapiens	IC50	uM	6.0
	331173	CHEMBL657992	Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.	B	CC[C@@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL133342	=	IC50	nM	800.0	CHEMBL308	Homo sapiens	IC50	uM	0.8
	333014	CHEMBL666135	Inhibitory concentration against Cyclin dependent kinase 1.	B	CC(C)C(CO)Nc1nc(Nc2cccc(Cl)c2)c2nc(Cl)n(C(C)C)c2n1		CHEMBL103272	=	IC50	nM	13000.0	CHEMBL308	Homo sapiens	IC50	uM	13.0
	335198	CHEMBL657992	Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.	B	Nc1[nH]c(NCCO)nc2ncnc1-2	Outside typical range	CHEMBL130306	=	IC50	nM	200000.0	CHEMBL308	Homo sapiens	IC50	uM	200.0
	335600	CHEMBL666135	Inhibitory concentration against Cyclin dependent kinase 1.	B	CCC(CO)Nc1nc(NCc2ccccc2)c2nc(S)n(C(C)C)c2n1		CHEMBL99782	=	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	336402	CHEMBL657992	Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.	B	Nc1ncnc2[nH]cnc12	Outside typical range	CHEMBL226345	=	IC50	nM	200000.0	CHEMBL308	Homo sapiens	IC50	uM	200.0
	336403	CHEMBL657992	Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.	B	Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc21		CHEMBL280074	=	IC50	nM	6000.0	CHEMBL308	Homo sapiens	IC50	uM	6.0
	338997	CHEMBL657993	Inhibition of purified Cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis (precipitation at the higher concentration tested)	B	Cn1cnc2c(N)ncnc21	Outside typical range	CHEMBL65976	>	IC50	nM	350000.0	CHEMBL308	Homo sapiens	IC50	uM	350.0
	340438	CHEMBL657992	Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.	B	CC(C)=CCNc1nc(Cl)nc2c1ncn2C		CHEMBL131695	=	IC50	nM	40000.0	CHEMBL308	Homo sapiens	IC50	uM	40.0
	341658	CHEMBL657992	Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.	B	Cn1cnc2c(N)nc(NCCO)nc21		CHEMBL132369	=	IC50	nM	50000.0	CHEMBL308	Homo sapiens	IC50	uM	50.0
	343173	CHEMBL666135	Inhibitory concentration against Cyclin dependent kinase 1.	B	CCC(CO)Nc1nc(NCc2ccccc2)c2nc([N+](=O)[O-])n(C(C)C)c2n1		CHEMBL447237	=	IC50	nM	16000.0	CHEMBL308	Homo sapiens	IC50	uM	16.0
	344000	CHEMBL657992	Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.	B	OCCNc1nc(NCc2ccccc2)c2[nH]cnc2n1		CHEMBL133213	=	IC50	nM	25000.0	CHEMBL308	Homo sapiens	IC50	uM	25.0
	345347	CHEMBL657992	Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.	B	CC(C)n1cnc2c(NCc3ccccc3)nc(Cl)nc21		CHEMBL131378	=	IC50	nM	17000.0	CHEMBL308	Homo sapiens	IC50	uM	17.0
	345348	CHEMBL657992	Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.	B	CN1C=Nc2[nH]cnc2C1N	Outside typical range	CHEMBL422980	>	IC50	nM	1000000.0	CHEMBL308	Homo sapiens	IC50	uM	1000.0
	346267	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CCC(C)(O)C#Cc1nc(NCc2ccc(OC)c(OC)c2)c2ncn(C(C)C)c2n1		CHEMBL281525	=	IC50	nM	300.0	CHEMBL308	Homo sapiens	IC50	uM	0.3
	346269	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccccc3)nc(C#CC3(O)CCCC3)nc21		CHEMBL336776	=	IC50	nM	500.0	CHEMBL308	Homo sapiens	IC50	uM	0.5
	346381	CHEMBL660789	Inhibition of cyclin-dependent kinase 1	B	COc1cccc(CNc2nc(N3CCC[C@@H]3CO)nc3c2ncn3C(C)C)c1		CHEMBL3085240	=	IC50	nM	300.0	CHEMBL308	Homo sapiens	IC50	uM	0.3
	346383	CHEMBL660789	Inhibition of cyclin-dependent kinase 1	B	COc1cc(CNc2nc(N3CCC[C@@H]3CO)nc3c2ncn3C(C)C)cc(OC)c1		CHEMBL3085235	=	IC50	nM	300.0	CHEMBL308	Homo sapiens	IC50	uM	0.3
	347578	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	COc1cc(CNc2nc(I)nc3c2ncn3C(C)C)cc(OC)c1		CHEMBL130161	=	IC50	nM	4200.0	CHEMBL308	Homo sapiens	IC50	uM	4.2
	347580	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccccc3C(F)(F)F)nc(N3CCC[C@@H]3CO)nc21		CHEMBL3085244	=	IC50	nM	4000.0	CHEMBL308	Homo sapiens	IC50	uM	4.0
	348972	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CCC(C)(O)C#Cc1nc(Nc2ccc(Cl)c(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL26513	=	IC50	nM	200.0	CHEMBL308	Homo sapiens	IC50	uM	0.2
	348974	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccccc3)nc(N[C@H](CO)Cc3ccccc3)nc21		CHEMBL2111870	=	IC50	nM	7300.0	CHEMBL308	Homo sapiens	IC50	uM	7.3
	348976	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	Ic1nc(NCc2ccccc2)c2ncn(C3CCCC3)c2n1		CHEMBL132948	=	IC50	nM	75000.0	CHEMBL308	Homo sapiens	IC50	uM	75.0
	348978	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3cc(C(F)(F)F)cc(C(F)(F)F)c3)nc(I)nc21		CHEMBL130315	=	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	349816	CHEMBL820001	Inhibition of cyclin-dependent kinase 1 cdc2	B	Oc1cc2cccc[n+]2c2c(Cl)cccc12.[Cl-]	Outside typical range	CHEMBL175225	>	IC50	nM	1000000.0	CHEMBL308	Homo sapiens	IC50	mM	1.0
	351674	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccc(Cl)cc3)nc(N3CCC[C@@H]3CO)nc21		CHEMBL3085241	=	IC50	nM	330.0	CHEMBL308	Homo sapiens	IC50	uM	0.33
	353111	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccccc3)nc(C#CC3(O)CCCCC3)nc21		CHEMBL134239	=	IC50	nM	180.0	CHEMBL308	Homo sapiens	IC50	uM	0.18
	353113	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(N(Cc3ccccc3)Cc3ccccc3)nc(N3CCC[C@@H]3CO)nc21		CHEMBL3085249	=	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	353115	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3ccc(Cl)c(Cl)c3)nc(N3CCC[C@@H]3CO)nc21		CHEMBL3085248	=	IC50	nM	430.0	CHEMBL308	Homo sapiens	IC50	uM	0.43
	354671	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	Nc1nc(Cl)c2ncn(C3CCCC3)c2n1	Outside typical range	CHEMBL335743	=	IC50	nM	260000.0	CHEMBL308	Homo sapiens	IC50	uM	260.0
	354673	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	OC[C@H]1CCCN1c1nc(NCc2ccccc2)c2ncn(C3CCCC3)c2n1		CHEMBL3085251	=	IC50	nM	700.0	CHEMBL308	Homo sapiens	IC50	uM	0.7
	354675	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3cccc(I)c3)nc(N3CCC[C@@H]3CO)nc21		CHEMBL3085252	=	IC50	nM	450.0	CHEMBL308	Homo sapiens	IC50	uM	0.45
	356125	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccccc3)nc(CCCCO)nc21		CHEMBL134003	=	IC50	nM	3000.0	CHEMBL308	Homo sapiens	IC50	uM	3.0
	356127	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccccc3)nc(/C=C/CCCO)nc21		CHEMBL133242	=	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	uM	1.0
	356129	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3cccc(Br)c3)nc(I)nc21		CHEMBL130903	=	IC50	nM	1300.0	CHEMBL308	Homo sapiens	IC50	uM	1.3
	356131	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3cccc(Cl)c3)nc(N3CCC[C@@H]3CO)nc21		CHEMBL77369	=	IC50	nM	430.0	CHEMBL308	Homo sapiens	IC50	uM	0.43
	357621	CHEMBL660789	Inhibition of cyclin-dependent kinase 1	B	COc1ccc(CNc2nc(N3CCC[C@@H]3CO)nc3c2ncn3C(C)C)cc1		CHEMBL3085238	=	IC50	nM	210.0	CHEMBL308	Homo sapiens	IC50	uM	0.21
	358903	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CCC(C)(O)C#Cc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL26564	=	IC50	nM	200.0	CHEMBL308	Homo sapiens	IC50	uM	0.2
	358905	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccccc3)nc(N[C@@H](CO)Cc3ccccc3)nc21		CHEMBL2112682	=	IC50	nM	2700.0	CHEMBL308	Homo sapiens	IC50	uM	2.7
	358907	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccccc3)nc(N3CCC(O)C3)nc21		CHEMBL335966	=	IC50	nM	42000.0	CHEMBL308	Homo sapiens	IC50	uM	42.0
	360289	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	=	IC50	nM	450.0	CHEMBL308	Homo sapiens	IC50	uM	0.45
	360291	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3cccc(C(F)(F)F)c3)nc(I)nc21		CHEMBL337715	=	IC50	nM	5300.0	CHEMBL308	Homo sapiens	IC50	uM	5.3
	360293	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccccc3)nc(N3CCC[C@H]3CO)nc21		CHEMBL2112683	=	IC50	nM	2100.0	CHEMBL308	Homo sapiens	IC50	uM	2.1
	361488	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CCC(C)(O)C#Cc1nc(NCc2ccc3c(c2)OCO3)c2ncn(C(C)C)c2n1		CHEMBL286491	=	IC50	nM	200.0	CHEMBL308	Homo sapiens	IC50	uM	0.2
	362872	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CCC(C)(O)C#Cc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL282193	=	IC50	nM	60.0	CHEMBL308	Homo sapiens	IC50	uM	0.06
	362874	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccccc3)nc(C#CCCO)nc21		CHEMBL337411	=	IC50	nM	350.0	CHEMBL308	Homo sapiens	IC50	uM	0.35
	362876	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3ccccc3)nc(I)nc21		CHEMBL130904	=	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	uM	1.0
	362878	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccccc3C(F)(F)F)nc(I)nc21		CHEMBL336995	=	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	362971	CHEMBL660789	Inhibition of cyclin-dependent kinase 1	B	CC(C)n1cnc2c(NCc3cccc(C(F)(F)F)c3)nc(N3CCC[C@H]3CO)nc21		CHEMBL3085231	=	IC50	nM	700.0	CHEMBL308	Homo sapiens	IC50	uM	0.7
	362973	CHEMBL660789	Inhibition of cyclin-dependent kinase 1	B	CC(C)n1cnc2c(NCc3cc(C(F)(F)F)cc(C(F)(F)F)c3)nc(N3CCC[C@@H]3CO)nc21		CHEMBL3085232	=	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	uM	1.0
	364541	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccccc3)nc(N(CCO)Cc3ccccc3)nc21		CHEMBL130597	=	IC50	nM	2500.0	CHEMBL308	Homo sapiens	IC50	uM	2.5
	364543	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccccc3)nc(CCCO)nc21		CHEMBL132687	=	IC50	nM	2500.0	CHEMBL308	Homo sapiens	IC50	uM	2.5
	364682	CHEMBL660789	Inhibition of cyclin-dependent kinase 1	B	COc1ccccc1CNc1nc(N2CCC[C@@H]2CO)nc2c1ncn2C(C)C		CHEMBL3085234	=	IC50	nM	1800.0	CHEMBL308	Homo sapiens	IC50	uM	1.8
	366003	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(N3CC=CCC3)nc(NCCO)nc21	Outside typical range	CHEMBL133740	=	IC50	nM	110000.0	CHEMBL308	Homo sapiens	IC50	uM	110.0
	366005	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccccc3)nc(N[C@H](C)CO)nc21		CHEMBL2112678	=	IC50	nM	850.0	CHEMBL308	Homo sapiens	IC50	uM	0.85
	366007	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	C=CCN(C)c1nc(I)nc2c1ncn2C(C)C		CHEMBL131031	=	IC50	nM	11000.0	CHEMBL308	Homo sapiens	IC50	uM	11.0
	366009	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	OC[C@H]1CCCN1c1nc(NCc2ccccc2)c2ncn(C3CCCCC3)c2n1		CHEMBL3085242	=	IC50	nM	40000.0	CHEMBL308	Homo sapiens	IC50	uM	40.0
	367439	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccc(C(F)(F)F)cc3)nc(I)nc21		CHEMBL131083	=	IC50	nM	4300.0	CHEMBL308	Homo sapiens	IC50	uM	4.3
	367441	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3ccccc3)nc(N3CCC[C@@H]3CO)nc21		CHEMBL3085243	=	IC50	nM	300.0	CHEMBL308	Homo sapiens	IC50	uM	0.3
	368828	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	C=CCN(C)c1nc(NCCO)nc2c1ncn2C	Outside typical range	CHEMBL129973	=	IC50	nM	470000.0	CHEMBL308	Homo sapiens	IC50	uM	470.0
	368830	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CCC(O)CCc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL134233	=	IC50	nM	3000.0	CHEMBL308	Homo sapiens	IC50	uM	3.0
	368832	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CCC(C)(O)CCc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL338924	=	IC50	nM	1300.0	CHEMBL308	Homo sapiens	IC50	uM	1.3
	370247	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCC(O)c3ccccc3)nc21		CHEMBL440717	=	IC50	nM	6500.0	CHEMBL308	Homo sapiens	IC50	uM	6.5
	370249	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)[C@H](CO)Nc1nc(NCc2ccc3c(c2)OCO3)c2ncn(C(C)C)c2n1		CHEMBL3085239	=	IC50	nM	20.0	CHEMBL308	Homo sapiens	IC50	uM	0.02
	371599	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccccc3)nc(C#CC(C)(O)c3ccccc3)nc21		CHEMBL336351	=	IC50	nM	600.0	CHEMBL308	Homo sapiens	IC50	uM	0.6
	371601	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	C=CCN(C)c1nc(NCCO)nc2c1ncn2C(C)C	Outside typical range	CHEMBL336176	=	IC50	nM	150000.0	CHEMBL308	Homo sapiens	IC50	uM	150.0
	371715	CHEMBL660789	Inhibition of cyclin-dependent kinase 1	B	CCC(C)(O)C#Cc1nc(NCc2ccc(Cl)c(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL25840	=	IC50	nM	430.0	CHEMBL308	Homo sapiens	IC50	uM	0.43
	373199	CHEMBL660789	Inhibition of cyclin-dependent kinase 1	B	CC(C)n1cnc2c(NCc3ccc(C(F)(F)F)cc3)nc(N3CCC[C@@H]3CO)nc21		CHEMBL3085233	=	IC50	nM	800.0	CHEMBL308	Homo sapiens	IC50	uM	0.8
	374494	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CCCCNc1nc(C#CC(C)(O)Cc2ccccc2)nc2c1ncn2C(C)C		CHEMBL133461	=	IC50	nM	300.0	CHEMBL308	Homo sapiens	IC50	uM	0.3
	374496	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CCCCC(CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL336537	=	IC50	nM	2500.0	CHEMBL308	Homo sapiens	IC50	uM	2.5
	374498	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccccc3)nc(CCC(C)(O)c3ccccc3)nc21		CHEMBL335069	=	IC50	nM	4500.0	CHEMBL308	Homo sapiens	IC50	uM	4.5
	374601	CHEMBL660789	Inhibition of cyclin-dependent kinase 1	B	CC(C)n1cnc2c(NC(CO)c3ccccc3)nc(N3CCC[C@H]3CO)nc21		CHEMBL2112679	=	IC50	nM	800.0	CHEMBL308	Homo sapiens	IC50	uM	0.8
	375898	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	OC[C@H]1CCCN1c1nc(NCc2ccccc2)c2ncn(Cc3ccccc3)c2n1	Outside typical range	CHEMBL3085250	=	IC50	nM	200000.0	CHEMBL308	Homo sapiens	IC50	uM	200.0
	377244	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CCOc1ccc(Nc2nc(C#CC(C)(O)CC)nc3c2ncn3C(C)C)cc1		CHEMBL280623	=	IC50	nM	200.0	CHEMBL308	Homo sapiens	IC50	uM	0.2
	377246	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)(C)n1cnc2c(NCc3ccccc3)nc(N3CCC[C@@H]3CO)nc21		CHEMBL3085246	=	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	378644	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccccc3)nc(N[C@H](CO)c3ccccc3)nc21		CHEMBL2111871	=	IC50	nM	4300.0	CHEMBL308	Homo sapiens	IC50	uM	4.3
	378646	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccccc3)nc(N3CCC[C@@H]3CO)nc21		CHEMBL2111872	=	IC50	nM	650.0	CHEMBL308	Homo sapiens	IC50	uM	0.65
	378743	CHEMBL660789	Inhibition of cyclin-dependent kinase 1	B	CC(C)n1cnc2c(NCc3ccc4c(c3)OCO4)nc(N3CCC[C@@H]3CO)nc21		CHEMBL3085237	=	IC50	nM	350.0	CHEMBL308	Homo sapiens	IC50	uM	0.35
	380071	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	COc1ccc(CNc2nc(I)nc3c2ncn3C(C)C)cc1		CHEMBL130175	=	IC50	nM	850.0	CHEMBL308	Homo sapiens	IC50	uM	0.85
	380162	CHEMBL660789	Inhibition of cyclin-dependent kinase 1	B	CCC(O)C#Cc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL445125	=	IC50	nM	500.0	CHEMBL308	Homo sapiens	IC50	uM	0.5
	381405	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccccc3)nc(C#CCO)nc21		CHEMBL132243	=	IC50	nM	1200.0	CHEMBL308	Homo sapiens	IC50	uM	1.2
	381407	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Cl)nc(I)nc21	Outside typical range	CHEMBL337291	=	IC50	nM	150000.0	CHEMBL308	Homo sapiens	IC50	uM	150.0
	382993	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccccc3)nc(C#CCCCO)nc21		CHEMBL134080	=	IC50	nM	200.0	CHEMBL308	Homo sapiens	IC50	uM	0.2
	382995	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccccc3)nc(C#CCCCCO)nc21		CHEMBL132469	=	IC50	nM	330.0	CHEMBL308	Homo sapiens	IC50	uM	0.33
	382997	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CCCC(CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL131697	=	IC50	nM	900.0	CHEMBL308	Homo sapiens	IC50	uM	0.9
	382999	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccccc3)nc(CCCCCO)nc21		CHEMBL335852	=	IC50	nM	2800.0	CHEMBL308	Homo sapiens	IC50	uM	2.8
	384300	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccccc3)nc(N[C@@H](CO)c3ccccc3)nc21		CHEMBL2112681	=	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	uM	1.0
	384302	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	Ic1nc(NCc2ccccc2)c2ncn(Cc3ccccc3)c2n1		CHEMBL133477	=	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	384304	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	C=CCN(C)c1nc(I)nc2c1ncn2C		CHEMBL336117	=	IC50	nM	18000.0	CHEMBL308	Homo sapiens	IC50	uM	18.0
	384306	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3ccc(Br)cc3)nc(N3CCCC3CO)nc21		CHEMBL334507	=	IC50	nM	300.0	CHEMBL308	Homo sapiens	IC50	uM	0.3
	385717	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CCC(C)(O)C#Cc1nc(NCc2ccc(Cl)cc2)c2ncn(C(C)C)c2n1		CHEMBL24484	=	IC50	nM	60.0	CHEMBL308	Homo sapiens	IC50	uM	0.06
	385719	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc21		CHEMBL280074	=	IC50	nM	7000.0	CHEMBL308	Homo sapiens	IC50	uM	7.0
	385721	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccccc3)nc(N[C@@H](C)CO)nc21		CHEMBL2111873	=	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	uM	1.0
	385723	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccc(Cl)c(Cl)c3)nc(N3CCC[C@@H]3CO)nc21		CHEMBL3085245	=	IC50	nM	430.0	CHEMBL308	Homo sapiens	IC50	uM	0.43
	387373	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CCC(C)(O)C#Cc1nc(Nc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL284899	=	IC50	nM	400.0	CHEMBL308	Homo sapiens	IC50	uM	0.4
	387375	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CCC(C)(O)C#Cc1nc(Nc2ccc(OC)cc2)c2ncn(C(C)C)c2n1		CHEMBL23317	=	IC50	nM	200.0	CHEMBL308	Homo sapiens	IC50	uM	0.2
	387377	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	COc1ccc(CNc2nc(C#CC3(O)CCCCCC3)nc3c2ncn3C(C)C)cc1		CHEMBL436368	=	IC50	nM	500.0	CHEMBL308	Homo sapiens	IC50	uM	0.5
	387379	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3ccc(Br)cc3)nc(I)nc21		CHEMBL440163	=	IC50	nM	1300.0	CHEMBL308	Homo sapiens	IC50	uM	1.3
	387381	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccccc3)nc(I)nc21		CHEMBL133533	=	IC50	nM	8000.0	CHEMBL308	Homo sapiens	IC50	uM	8.0
	387383	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	COc1cccc(CNc2nc(I)nc3c2ncn3C(C)C)c1		CHEMBL133055	=	IC50	nM	2300.0	CHEMBL308	Homo sapiens	IC50	uM	2.3
	387484	CHEMBL660789	Inhibition of cyclin-dependent kinase 1	B	CC(C)n1cnc2c(NC(CO)c3ccccc3)nc(N3CCC[C@@H]3CO)nc21		CHEMBL2111869	=	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	387486	CHEMBL660789	Inhibition of cyclin-dependent kinase 1	B	CCC(C)(O)C#Cc1nc(NCc2ccc(OC)cc2)c2ncn(C(C)C)c2n1		CHEMBL422759	=	IC50	nM	230.0	CHEMBL308	Homo sapiens	IC50	uM	0.23
	388932	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CCC(C)(O)C#Cc1nc(NCc2ccc(N(C)C)cc2)c2ncn(C(C)C)c2n1		CHEMBL23525	=	IC50	nM	150.0	CHEMBL308	Homo sapiens	IC50	uM	0.15
	388934	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CCC(C)(O)C#Cc1nc(NCCc2ccc(OC)cc2)c2ncn(C(C)C)c2n1		CHEMBL336283	=	IC50	nM	400.0	CHEMBL308	Homo sapiens	IC50	uM	0.4
	388936	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	Ic1nc(NCc2ccccc2)c2ncn(C3CCCCC3)c2n1		CHEMBL335938	=	IC50	nM	90000.0	CHEMBL308	Homo sapiens	IC50	uM	90.0
	388938	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3cccc(Br)c3)nc(N3CCC[C@@H]3CO)nc21		CHEMBL3085236	=	IC50	nM	330.0	CHEMBL308	Homo sapiens	IC50	uM	0.33
	390258	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CCOc1ccc(CNc2nc(C#CC(C)(O)CC)nc3c2ncn3C(C)C)cc1		CHEMBL282330	=	IC50	nM	180.0	CHEMBL308	Homo sapiens	IC50	uM	0.18
	390260	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	CCC(CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL52387	=	IC50	nM	650.0	CHEMBL308	Homo sapiens	IC50	uM	0.65
	390262	CHEMBL661624	Inhibition of Cyclin-dependent kinase 1 (CDK1)	B	COc1ccccc1CNc1nc(I)nc2c1ncn2C(C)C		CHEMBL338617	=	IC50	nM	7200.0	CHEMBL308	Homo sapiens	IC50	uM	7.2
	394907	CHEMBL820000	Inhibition of cdc2 kinase	B	COc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL95692	>	IC50	nM	100.0	CHEMBL308	Homo sapiens	IC50	nM	100.0
	418888	CHEMBL820000	Inhibition of cdc2 kinase	B	COc1nccc(-c2c(-c3ccc(F)cc3)ncn2[C@H]2CC[C@H](O)CC2)n1		CHEMBL97162	>	IC50	nM	50.0	CHEMBL308	Homo sapiens	IC50	nM	50.0
	430438	CHEMBL657991	Inhibition of Cdc2	B	COc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)cc1OC		CHEMBL327300	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	515459	CHEMBL661623	Inhibition of cyclin B activated Cyclin-dependent kinase 1 (CDK1)	B	CN1CCC(c2c(O)cc(O)c3c2O/C(=C\c2ccccc2Cl)C3=O)CC1		CHEMBL48614	=	IC50	nM	600.0	CHEMBL308	Homo sapiens	IC50	uM	0.6
	516667	CHEMBL661623	Inhibition of cyclin B activated Cyclin-dependent kinase 1 (CDK1)	B	CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@@H](O)C1		CHEMBL418203	=	IC50	nM	100.0	CHEMBL308	Homo sapiens	IC50	uM	0.1
	541705	CHEMBL661623	Inhibition of cyclin B activated Cyclin-dependent kinase 1 (CDK1)	B	CN1CCC(c2c(O)cc(O)c3c2O/C(=C\c2ccc(S(N)(=O)=O)cc2)C3=O)CC1		CHEMBL48362	=	IC50	nM	9.0	CHEMBL308	Homo sapiens	IC50	uM	0.009
	549302	CHEMBL661623	Inhibition of cyclin B activated Cyclin-dependent kinase 1 (CDK1)	B	CN1CCC(c2c(O)cc(O)c3c2O/C(=C\c2ccc(N4CCN(C)CC4)cc2)C3=O)CC1		CHEMBL46181	=	IC50	nM	800.0	CHEMBL308	Homo sapiens	IC50	uM	0.8
	551662	CHEMBL661623	Inhibition of cyclin B activated Cyclin-dependent kinase 1 (CDK1)	B	CN1CCC(c2c(O)cc(O)c3c2O/C(=C\c2ccccc2)C3=O)CC1		CHEMBL51709	=	IC50	nM	110.0	CHEMBL308	Homo sapiens	IC50	uM	0.11
	553004	CHEMBL661623	Inhibition of cyclin B activated Cyclin-dependent kinase 1 (CDK1)	B	CN1CCC(c2c(O)cc(O)c3c2O/C(=C\c2ccc([N+](=O)[O-])cc2)C3=O)CC1		CHEMBL45477	=	IC50	nM	60.0	CHEMBL308	Homo sapiens	IC50	uM	0.06
	558054	CHEMBL660795	Inhibition of Cyclin-dependent kinase 1	B	CN(C)CCNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc4ccccn34)n2)cc1		CHEMBL72548	=	IC50	nM	15.0	CHEMBL308	Homo sapiens	IC50	uM	0.015
	572158	CHEMBL666136	Inhibition of Cyclin dependent kinase 1 at 10 uM	B	O=C(O)Cc1c2ccccc2n2c1[nH]c(=O)c1ccccc12		CHEMBL92361	=	Inhibition	%	51.0	CHEMBL308	Homo sapiens	Inhibition	%	51.0
	578270	CHEMBL660801	Inhibition of Cyclin-dependent kinase 1	B	C[C@H](O)CNc1cc(-c2[nH]c3cccnc3c2-c2ccc(F)cc2)ccn1		CHEMBL142425	>	IC50	nM	25000.0	CHEMBL308	Homo sapiens	IC50	uM	25.0
	578717	CHEMBL660795	Inhibition of Cyclin-dependent kinase 1	B	COCCCNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc4ccccn34)n2)cc1		CHEMBL73243	=	IC50	nM	6.0	CHEMBL308	Homo sapiens	IC50	uM	0.006
	593262	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3ccc(Cl)cc3Cl)nc(NCCO)nc21	Outside typical range	CHEMBL75633	=	IC50	nM	2700000.0	CHEMBL308	Homo sapiens	IC50	uM	2700.0
	594481	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(=O)O)c(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23254	=	IC50	nM	20000.0	CHEMBL308	Homo sapiens	IC50	uM	20.0
	594490	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)[C@H](CO)Nc1nc(Nc2ccc(F)c(Cl)c2)c2ncn(C(C)C)c2n1	Outside typical range	CHEMBL80213	=	IC50	nM	360000.0	CHEMBL308	Homo sapiens	IC50	uM	360.0
	595721	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)C[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1	Outside typical range	CHEMBL80586	=	IC50	nM	530000.0	CHEMBL308	Homo sapiens	IC50	uM	530.0
	595730	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	COc1ccc(CNc2nc(N[C@H](CO)C(C)C)nc3c2ncn3C(C)C)cc1	Outside typical range	CHEMBL415271	=	IC50	nM	600000.0	CHEMBL308	Homo sapiens	IC50	uM	600.0
	597108	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccccc3)nc(N3CCCCC3CCO)nc21	Outside typical range	CHEMBL76592	=	IC50	nM	160000.0	CHEMBL308	Homo sapiens	IC50	uM	160.0
	597109	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CCCCNc1nc(N2CCCCC2CCO)nc2c1ncn2C(C)C	Outside typical range	CHEMBL80859	=	IC50	nM	1300000.0	CHEMBL308	Homo sapiens	IC50	uM	1300.0
	598269	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1	Outside typical range	CHEMBL306783	=	IC50	nM	300000.0	CHEMBL308	Homo sapiens	IC50	uM	300.0
	598270	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccc4ccccc4c3)nc(N3CCCCC3CCO)nc21	Outside typical range	CHEMBL76917	=	IC50	nM	1200000.0	CHEMBL308	Homo sapiens	IC50	uM	1200.0
	599647	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	IC50	nM	35000.0	CHEMBL308	Homo sapiens	IC50	uM	35.0
	599648	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)[C@H](CO)N(Cc1cccc(F)c1)c1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1	Outside typical range	CHEMBL445311	=	IC50	nM	5000000.0	CHEMBL308	Homo sapiens	IC50	uM	5000.0
	600820	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H](CO)c3ccccc3)nc21	Outside typical range	CHEMBL311571	=	IC50	nM	400000.0	CHEMBL308	Homo sapiens	IC50	uM	400.0
	600821	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	COc1ccc(CNc2nc(NCCCO)nc3c2ncn3C(C)C)cc1	Outside typical range	CHEMBL77413	=	IC50	nM	1200000.0	CHEMBL308	Homo sapiens	IC50	uM	1200.0
	600822	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3ccccc3Cl)nc(NCCO)nc21	Outside typical range	CHEMBL307367	=	IC50	nM	4300000.0	CHEMBL308	Homo sapiens	IC50	uM	4300.0
	600823	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)[C@H](CO)N(CC1CCCCC1)c1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1	Outside typical range	CHEMBL77119	=	IC50	nM	5300000.0	CHEMBL308	Homo sapiens	IC50	uM	5300.0
	600824	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3cccc(Cl)c3)nc(N[C@H](CO)c3ccccc3)nc21	Outside typical range	CHEMBL432356	=	IC50	nM	800000.0	CHEMBL308	Homo sapiens	IC50	uM	800.0
	600825	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	Cc1ccc(CN(c2nc(Nc3cccc(Cl)c3)c3ncn(C(C)C)c3n2)[C@@H](CO)C(C)C)cc1	Outside typical range	CHEMBL80203	=	IC50	nM	10000000.0	CHEMBL308	Homo sapiens	IC50	uM	10000.0
	602030	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H](CO)Cc3ccccc3)nc21	Outside typical range	CHEMBL77365	=	IC50	nM	500000.0	CHEMBL308	Homo sapiens	IC50	uM	500.0
	602031	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3cccc(Cl)c3)nc(NCc3ccccc3C(F)(F)F)nc21	Outside typical range	CHEMBL306288	=	IC50	nM	4000000.0	CHEMBL308	Homo sapiens	IC50	uM	4000.0
	602032	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	COc1ccc(CNc2nc(N3CCC(O)CC3)nc3c2ncn3C(C)C)cc1	Outside typical range	CHEMBL75924	=	IC50	nM	6500000.0	CHEMBL308	Homo sapiens	IC50	uM	6500.0
	602033	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCCC(c3ccccc3)c3ccccc3)nc(N3CCCCC3CCO)nc21	Outside typical range	CHEMBL80758	=	IC50	nM	9000000.0	CHEMBL308	Homo sapiens	IC50	uM	9000.0
	602037	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)[C@H](CO)Nc1nc(Nc2ccccc2)c2ncn(C(C)C)c2n1	Outside typical range	CHEMBL76670	=	IC50	nM	240000.0	CHEMBL308	Homo sapiens	IC50	uM	240.0
	603292	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3cccc(Cl)c3)nc(NC3(CO)CCCC3)nc21	Outside typical range	CHEMBL305823	=	IC50	nM	500000.0	CHEMBL308	Homo sapiens	IC50	uM	500.0
	603293	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	COc1ccc(CNc2nc(N(CCO)Cc3ccccc3)nc3c2ncn3C(C)C)cc1	Outside typical range	CHEMBL420571	=	IC50	nM	2800000.0	CHEMBL308	Homo sapiens	IC50	uM	2800.0
	603294	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)[C@@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1	Outside typical range	CHEMBL80611	=	IC50	nM	500000.0	CHEMBL308	Homo sapiens	IC50	uM	500.0
	604800	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3cccc(Cl)c3)nc(NCCN(C)C)nc21	Outside typical range	CHEMBL309495	=	IC50	nM	4400000.0	CHEMBL308	Homo sapiens	IC50	uM	4400.0
	605845	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)[C@H](CO)Nc1nc(Nc2ccc(Cl)cc2)c2ncn(C(C)C)c2n1		CHEMBL77262	=	IC50	nM	80000.0	CHEMBL308	Homo sapiens	IC50	uM	80.0
	605846	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3cccc(F)c3)nc(NCCO)nc21	Outside typical range	CHEMBL309978	=	IC50	nM	400000.0	CHEMBL308	Homo sapiens	IC50	uM	400.0
	605847	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3cccc(Cl)c3)nc(N3CCC[C@@H]3CO)nc21	Outside typical range	CHEMBL77369	=	IC50	nM	620000.0	CHEMBL308	Homo sapiens	IC50	uM	620.0
	605848	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	COc1ccc(CNc2nc(NCCO)nc3c2ncn3C(C)C)cc1	Outside typical range	CHEMBL80754	=	IC50	nM	700000.0	CHEMBL308	Homo sapiens	IC50	uM	700.0
	605849	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccccc3C(F)(F)F)nc(N3CCCCC3CCO)nc21	Outside typical range	CHEMBL77291	=	IC50	nM	3000000.0	CHEMBL308	Homo sapiens	IC50	uM	3000.0
	606999	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3cccc(Cl)c3)nc(N3CCCCC3CCO)nc21	Outside typical range	CHEMBL80693	=	IC50	nM	1400000.0	CHEMBL308	Homo sapiens	IC50	uM	1400.0
	607000	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3cccc(Cl)c3)nc(N(CCO)Cc3ccccc3)nc21	Outside typical range	CHEMBL312406	=	IC50	nM	5000000.0	CHEMBL308	Homo sapiens	IC50	uM	5000.0
	607001	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	COc1ccc(CNc2nc(N3CCN(CCO)CC3)nc3c2ncn3C(C)C)cc1	Outside typical range	CHEMBL78227	=	IC50	nM	7000000.0	CHEMBL308	Homo sapiens	IC50	uM	7000.0
	608272	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3cccc(Cl)c3)nc(N(CCO)CCO)nc21	Outside typical range	CHEMBL77610	=	IC50	nM	220000.0	CHEMBL308	Homo sapiens	IC50	uM	220.0
	608273	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3cccc(Cl)c3)nc(N[C@H](CO)CC3CCCCC3)nc21	Outside typical range	CHEMBL311488	=	IC50	nM	5000000.0	CHEMBL308	Homo sapiens	IC50	uM	5000.0
	608288	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)[C@H](CO)Nc1nc(Nc2ccc(N)c(Cl)c2)c2ncn(C(C)C)c2n1	Outside typical range	CHEMBL78214	=	IC50	nM	33000000.0	CHEMBL308	Homo sapiens	IC50	mM	33.0
	609437	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	COc1ccc(CNc2nc(N[C@@H](CO)CC(C)C)nc3c2ncn3C(C)C)cc1		CHEMBL77732	=	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	610646	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1	Outside typical range	CHEMBL80713	=	IC50	nM	330000.0	CHEMBL308	Homo sapiens	IC50	uM	330.0
	610666	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3ccc4ccccc4c3)nc(NCCO)nc21	Outside typical range	CHEMBL80168	=	IC50	nM	430000000.0	CHEMBL308	Homo sapiens	IC50	mM	430.0
	611809	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	COc1ccc(CNc2nc(N[C@@H](CO)C(C)C)nc3c2ncn3C(C)C)cc1	Outside typical range	CHEMBL80898	=	IC50	nM	230000.0	CHEMBL308	Homo sapiens	IC50	uM	230.0
	611810	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	COc1ccc(CNc2nc(NCC(O)CO)nc3c2ncn3C(C)C)cc1	Outside typical range	CHEMBL312530	=	IC50	nM	1300000.0	CHEMBL308	Homo sapiens	IC50	uM	1300.0
	613066	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)[C@H](CO)Nc1nc(Nc2ccc(Br)cc2)c2ncn(C(C)C)c2n1		CHEMBL312078	=	IC50	nM	40000.0	CHEMBL308	Homo sapiens	IC50	uM	40.0
	613067	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3ccc(Cl)cc3)nc(N3CCCCC3CCO)nc21	Outside typical range	CHEMBL419094	=	IC50	nM	790000.0	CHEMBL308	Homo sapiens	IC50	uM	790.0
	613068	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	COc1ccc(CNc2nc(N3CCCCCC3)nc3c2ncn3C(C)C)cc1	Outside typical range	CHEMBL76784	=	IC50	nM	4000000.0	CHEMBL308	Homo sapiens	IC50	uM	4000.0
	613069	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)[C@H](CO)N(Cc1ccc(F)cc1)c1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1	Outside typical range	CHEMBL276120	=	IC50	nM	10000000.0	CHEMBL308	Homo sapiens	IC50	uM	10000.0
	614405	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1	Outside typical range	CHEMBL14762	=	IC50	nM	700000.0	CHEMBL308	Homo sapiens	IC50	uM	700.0
	614414	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCCNc3ccccc3)nc(N3CCCCC3CCO)nc21	Outside typical range	CHEMBL79491	=	IC50	nM	1500000.0	CHEMBL308	Homo sapiens	IC50	uM	1500.0
	614415	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)[C@H](CO)N(Cc1ccccc1)c1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1	Outside typical range	CHEMBL80755	=	IC50	nM	5000000.0	CHEMBL308	Homo sapiens	IC50	uM	5000.0
	614416	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	COc1ccc(CNc2nc(N3CCN(C)CC3)nc3c2ncn3C(C)C)cc1	Outside typical range	CHEMBL76921	=	IC50	nM	10800000.0	CHEMBL308	Homo sapiens	IC50	uM	10800.0
	618460	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	COc1ccc(CNc2nc(N(CCN(C)C)Cc3ccccc3)nc3c2ncn3C(C)C)cc1	Outside typical range	CHEMBL75809	=	IC50	nM	5000000.0	CHEMBL308	Homo sapiens	IC50	uM	5000.0
	618461	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3cccc(Cl)c3)nc(NC3c4ccccc4C[C@H]3O)nc21	Outside typical range	CHEMBL77145	=	IC50	nM	5000000.0	CHEMBL308	Homo sapiens	IC50	uM	5000.0
	619786	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)[C@H](CO)Nc1nc(Nc2ccc(Cl)c(C(=O)O)c2)c2ncn(C(C)C)c2n1		CHEMBL78223	=	IC50	nM	30000.0	CHEMBL308	Homo sapiens	IC50	uM	30.0
	619787	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	COc1ccc(CNc2nc(NC3(CO)CCCC3)nc3c2ncn3C(C)C)cc1	Outside typical range	CHEMBL306183	=	IC50	nM	450000.0	CHEMBL308	Homo sapiens	IC50	uM	450.0
	619788	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3ccccc3C(F)(F)F)nc(NCCO)nc21	Outside typical range	CHEMBL307891	=	IC50	nM	10000000.0	CHEMBL308	Homo sapiens	IC50	uM	10000.0
	620777	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CCN(CCO)c1nc(NCc2ccc(OC)cc2)c2ncn(C(C)C)c2n1	Outside typical range	CHEMBL80920	=	IC50	nM	1200000.0	CHEMBL308	Homo sapiens	IC50	uM	1200.0
	620778	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCCCc3ccccc3)nc(N3CCCCC3CCO)nc21	Outside typical range	CHEMBL80701	=	IC50	nM	1300000.0	CHEMBL308	Homo sapiens	IC50	uM	1300.0
	620779	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	IC50	nM	35000.0	CHEMBL308	Homo sapiens	IC50	uM	35.0
	620795	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)[C@H](CO)Nc1nc(Nc2ccc(Cl)c(N)c2)c2ncn(C(C)C)c2n1	Outside typical range	CHEMBL311354	=	IC50	nM	52000000.0	CHEMBL308	Homo sapiens	IC50	mM	52.0
	622072	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3ccc(F)c(Cl)c3)nc(NCCO)nc21	Outside typical range	CHEMBL415270	=	IC50	nM	290000.0	CHEMBL308	Homo sapiens	IC50	uM	290.0
	622073	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3cccc(Cl)c3)nc(NC3c4ccccc4C[C@@H]3O)nc21	Outside typical range	CHEMBL79764	=	IC50	nM	300000.0	CHEMBL308	Homo sapiens	IC50	uM	300.0
	622074	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CCC(C)[C@@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1	Outside typical range	CHEMBL309227	=	IC50	nM	500000.0	CHEMBL308	Homo sapiens	IC50	uM	500.0
	624558	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	COc1ccc(CNc2nc(NCC(O)CN)nc3c2ncn3C(C)C)cc1	Outside typical range	CHEMBL419830	=	IC50	nM	1600000.0	CHEMBL308	Homo sapiens	IC50	uM	1600.0
	624563	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	COc1ccccc1Nc1nc(NCCO)nc2c1ncn2C(C)C	Outside typical range	CHEMBL75973	=	IC50	nM	9000000.0	CHEMBL308	Homo sapiens	IC50	uM	9000.0
	626041	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)[C@H](CO)Nc1nc(Nc2ccc(O)c(C(=O)O)c2)c2ncn(C(C)C)c2n1		CHEMBL74799	=	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	626042	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC[C@H](CO)Nc1nc(NCc2ccc(OC)cc2)c2ncn(C(C)C)c2n1	Outside typical range	CHEMBL310590	=	IC50	nM	130000.0	CHEMBL308	Homo sapiens	IC50	uM	130.0
	626043	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)[C@H](CO)Nc1nc(NCc2cccc(I)c2)c2ncn(C(C)C)c2n1	Outside typical range	CHEMBL76761	=	IC50	nM	170000.0	CHEMBL308	Homo sapiens	IC50	uM	170.0
	626044	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3cccc(Cl)c3)nc(NCCCO)nc21	Outside typical range	CHEMBL80895	=	IC50	nM	900000.0	CHEMBL308	Homo sapiens	IC50	uM	900.0
	626045	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	COc1ccc(CNc2nc(N(C)CC(O)c3ccccc3)nc3c2ncn3C(C)C)cc1	Outside typical range	CHEMBL80562	=	IC50	nM	1000000.0	CHEMBL308	Homo sapiens	IC50	uM	1000.0
	627062	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21	Outside typical range	CHEMBL311228	=	IC50	nM	220000.0	CHEMBL308	Homo sapiens	IC50	uM	220.0
	627063	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	COc1ccc(CNc2nc(NCC(O)c3ccccc3)nc3c2ncn3C(C)C)cc1	Outside typical range	CHEMBL75319	=	IC50	nM	2800000.0	CHEMBL308	Homo sapiens	IC50	uM	2800.0
	628379	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	COc1cccc(Nc2nc(NCCO)nc3c2ncn3C(C)C)c1	Outside typical range	CHEMBL311741	=	IC50	nM	400000.0	CHEMBL308	Homo sapiens	IC50	uM	400.0
	628380	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CCN(c1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1)[C@@H](CO)C(C)C	Outside typical range	CHEMBL77122	=	IC50	nM	5000000.0	CHEMBL308	Homo sapiens	IC50	uM	5000.0
	628381	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3ccc(N)cc3)nc(N3CCCCC3CCO)nc21	Outside typical range	CHEMBL310271	=	IC50	nM	230000.0	CHEMBL308	Homo sapiens	IC50	uM	230.0
	628400	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3cccc(Br)c3)nc(NCCO)nc21	Outside typical range	CHEMBL80916	=	IC50	nM	270000.0	CHEMBL308	Homo sapiens	IC50	uM	270.0
	629741	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3cccc(C(F)(F)F)c3)nc(NCCO)nc21	Outside typical range	CHEMBL79329	=	IC50	nM	420000.0	CHEMBL308	Homo sapiens	IC50	uM	420.0
	629742	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(NCc3cccc(I)c3)nc(N3CCCCC3CCO)nc21	Outside typical range	CHEMBL77126	=	IC50	nM	6000000.0	CHEMBL308	Homo sapiens	IC50	uM	6000.0
	629743	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)=CCNc1nc(N)nc2c1ncn2C(C)C		CHEMBL77155	=	IC50	nM	45000.0	CHEMBL308	Homo sapiens	IC50	uM	45.0
	630984	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3ccccc3)nc(N3CCCCC3CCO)nc21	Outside typical range	CHEMBL308714	=	IC50	nM	130000.0	CHEMBL308	Homo sapiens	IC50	uM	130.0
	630985	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	COc1ccc(CNc2nc(NC(CO)CO)nc3c2ncn3C(C)C)cc1	Outside typical range	CHEMBL75795	=	IC50	nM	560000.0	CHEMBL308	Homo sapiens	IC50	uM	560.0
	630986	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3cccc(Cl)c3)nc(N[C@H](CO)C(C)(C)C)nc21	Outside typical range	CHEMBL540188	=	IC50	nM	2300000.0	CHEMBL308	Homo sapiens	IC50	uM	2300.0
	631763	CHEMBL660798	Selectivity for cyclin-dependent kinase-1, CDK1	B	N[C@H]1CC[C@H](Nc2nc(Nc3ccc(P(=O)(O)CP(=O)(O)O)cc3)c3ncn(C4CCCC4)c3n2)CC1		CHEMBL3084838	=	Selectivity		10.0	CHEMBL308	Homo sapiens	Selectivity		10.0
	632266	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	COc1ccc(CNc2nc(N3CCCCC3CCO)nc3c2ncn3C(C)C)cc1	Outside typical range	CHEMBL80674	=	IC50	nM	210000.0	CHEMBL308	Homo sapiens	IC50	uM	210.0
	632267	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3cccc(Cl)c3)nc(N(CCO)CCCO)nc21	Outside typical range	CHEMBL77064	=	IC50	nM	230000.0	CHEMBL308	Homo sapiens	IC50	uM	230.0
	632268	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	CC(C)n1cnc2c(Nc3cccc(Cl)c3)nc(N(CCN(C)C)Cc3ccccc3)nc21	Outside typical range	CHEMBL80402	=	IC50	nM	7000000.0	CHEMBL308	Homo sapiens	IC50	uM	7000.0
	632285	CHEMBL661621	Binding affinity to cyclin-dependent kinase 1 (CDK1)	B	COc1ccc(CNc2nc(N(CCO)CCCO)nc3c2ncn3C(C)C)cc1	Outside typical range	CHEMBL80225	=	IC50	nM	250000.0	CHEMBL308	Homo sapiens	IC50	uM	250.0
	641522	CHEMBL660799	Inhibition of Cyclin-dependent kinase 1	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	>	IC50	nM	8000.0	CHEMBL308	Homo sapiens	IC50	uM	8.0
	715865	CHEMBL847140	Tested in vitro for inhibition of serine/threonine kinase Cdc2	B	Cc1ccccc1-c1cn(-c2ccccc2)c2ncnc(N)c12		CHEMBL174634	=	IC50	nM	90000.0	CHEMBL308	Homo sapiens	IC50	uM	90.0
	715870	CHEMBL847140	Tested in vitro for inhibition of serine/threonine kinase Cdc2	B	Nc1ncnc2c1c(-c1ccccc1)cn2-c1ccccc1CO		CHEMBL429057	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	717183	CHEMBL847140	Tested in vitro for inhibition of serine/threonine kinase Cdc2	B	Nc1ncnc2c1c(-c1ccccc1)cn2-c1cccc(CNCCO)c1		CHEMBL176702	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	718315	CHEMBL847140	Tested in vitro for inhibition of serine/threonine kinase Cdc2	B	Nc1ncnc2c1c(-c1ccccc1)cn2-c1ccc(CO)cc1		CHEMBL367442	=	IC50	nM	30000.0	CHEMBL308	Homo sapiens	IC50	uM	30.0
Not Determined	720610	CHEMBL847141	Inhibition of serine/threonine kinase Cdc2 (Not determined)	B	O=c1[nH]cnc2c1c(-c1ccccc1)cn2-c1ccccc1		CHEMBL173474		IC50	nM		CHEMBL308	Homo sapiens	IC50	uM	
	720615	CHEMBL847140	Tested in vitro for inhibition of serine/threonine kinase Cdc2	B	COc1ccc(-c2cn(-c3ccccc3)c3ncnc(N)c23)cc1		CHEMBL176705	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	720620	CHEMBL847140	Tested in vitro for inhibition of serine/threonine kinase Cdc2	B	Nc1ncnc2c1c(-c1ccccc1)cn2-c1ccccc1CNCCO		CHEMBL176470	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	722686	CHEMBL847140	Tested in vitro for inhibition of serine/threonine kinase Cdc2	B	Nc1ncnc2c1c(-c1cccc(Cl)c1)cn2-c1ccccc1		CHEMBL176309	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	725112	CHEMBL847140	Tested in vitro for inhibition of serine/threonine kinase Cdc2	B	CCOC(=O)c1ccc(-c2cn(-c3ccccc3)c3ncnc(N)c23)cc1		CHEMBL369014	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	727657	CHEMBL847140	Tested in vitro for inhibition of serine/threonine kinase Cdc2	B	COc1cccc(-c2cn(-c3ccccc3)c3ncnc(N)c23)c1		CHEMBL172973	=	IC50	nM	43000.0	CHEMBL308	Homo sapiens	IC50	uM	43.0
	727666	CHEMBL847140	Tested in vitro for inhibition of serine/threonine kinase Cdc2	B	Nc1ncnc2c1c(-c1ccccc1)cn2-c1ccc(CNCCO)cc1		CHEMBL173453	=	IC50	nM	82500.0	CHEMBL308	Homo sapiens	IC50	uM	82.5
	729941	CHEMBL847140	Tested in vitro for inhibition of serine/threonine kinase Cdc2	B	COc1cccc(-c2cn(-c3ccc(CCN(C)CCO)cc3)c3ncnc(N)c23)c1		CHEMBL105436	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
Not Determined	732294	CHEMBL847141	Inhibition of serine/threonine kinase Cdc2 (Not determined)	B	Clc1ncnc2c1c(-c1ccccc1)cn2-c1ccccc1		CHEMBL426229		IC50	nM		CHEMBL308	Homo sapiens	IC50	uM	
	736001	CHEMBL847140	Tested in vitro for inhibition of serine/threonine kinase Cdc2	B	COc1cccc(-c2cn(-c3ccc(CC(=O)NCCO)cc3)c3ncnc(N)c23)c1		CHEMBL175409	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	741238	CHEMBL847140	Tested in vitro for inhibition of serine/threonine kinase Cdc2	B	COc1cccc(-c2cn(-c3cccc(CO)c3)c3ncnc(N)c23)c1		CHEMBL176815	=	IC50	nM	33000.0	CHEMBL308	Homo sapiens	IC50	uM	33.0
	741243	CHEMBL847140	Tested in vitro for inhibition of serine/threonine kinase Cdc2	B	COc1cccc(-c2cn(-c3ccc(CNCCO)cc3)c3ncnc(N)c23)c1		CHEMBL424375	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	742606	CHEMBL847140	Tested in vitro for inhibition of serine/threonine kinase Cdc2	B	CNc1ncnc2c1c(-c1ccccc1)cn2-c1ccccc1		CHEMBL366831	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	742611	CHEMBL847140	Tested in vitro for inhibition of serine/threonine kinase Cdc2	B	Nc1ncnc2c1c(-c1ccccc1)cn2-c1cccc(CO)c1		CHEMBL173478	=	IC50	nM	47000.0	CHEMBL308	Homo sapiens	IC50	uM	47.0
	746480	CHEMBL847140	Tested in vitro for inhibition of serine/threonine kinase Cdc2	B	Nc1ncnc2c1c(-c1ccccc1)cn2-c1ccccc1		CHEMBL169757	=	IC50	nM	54000.0	CHEMBL308	Homo sapiens	IC50	uM	54.0
	765668	CHEMBL660793	Inhibition of Cyclin-dependent kinase 1	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	8.0	CHEMBL308	Homo sapiens	IC50	uM	0.008
	776798	CHEMBL660793	Inhibition of Cyclin-dependent kinase 1	B	CCN1CCOCCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCOCC1		CHEMBL103055	=	IC50	nM	240.0	CHEMBL308	Homo sapiens	IC50	uM	0.24
Not Determined	830296	CHEMBL661617	Inhibition of Cyclin-dependent kinase 1 (not determined)	B	Nc1cccc(-c2cc(Nc3ccc(S(N)(=O)=O)cc3)[nH]n2)c1		CHEMBL319831		IC50	nM		CHEMBL308	Homo sapiens	IC50	nM	
	832576	CHEMBL666144	Inhibition of Cyclin-dependent kinase 1	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	IC50	nM	398.0	CHEMBL308	Homo sapiens	IC50	nM	398.0
Not Determined	834945	CHEMBL661617	Inhibition of Cyclin-dependent kinase 1 (not determined)	B	CN(C)c1ccc(-c2cc(Nc3ccc(S(N)(=O)=O)cc3)[nH]n2)cc1		CHEMBL323326		IC50	nM		CHEMBL308	Homo sapiens	IC50	nM	
	837391	CHEMBL666144	Inhibition of Cyclin-dependent kinase 1	B	Nc1ccc(-c2cc(Nc3ccc(S(N)(=O)=O)cc3)[nH]n2)cc1		CHEMBL321517	=	IC50	nM	501.0	CHEMBL308	Homo sapiens	IC50	nM	501.0
	838648	CHEMBL666144	Inhibition of Cyclin-dependent kinase 1	B	COc1cccc(-c2cc(Nc3ccc(S(N)(=O)=O)cc3)[nH]n2)c1		CHEMBL319685	=	IC50	nM	398.0	CHEMBL308	Homo sapiens	IC50	nM	398.0
	841105	CHEMBL666144	Inhibition of Cyclin-dependent kinase 1	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(Br)cc3)[nH]n2)cc1		CHEMBL319903	=	IC50	nM	126.0	CHEMBL308	Homo sapiens	IC50	nM	126.0
Not Determined	841107	CHEMBL661617	Inhibition of Cyclin-dependent kinase 1 (not determined)	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(N4CCOCC4)c3)[nH]n2)cc1		CHEMBL103039		IC50	nM		CHEMBL308	Homo sapiens	IC50	nM	
	841109	CHEMBL666144	Inhibition of Cyclin-dependent kinase 1	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(NS(=O)(=O)c4ccccc4)c3)[nH]n2)cc1		CHEMBL319103	=	IC50	nM	501.0	CHEMBL308	Homo sapiens	IC50	nM	501.0
Not Determined	850655	CHEMBL661617	Inhibition of Cyclin-dependent kinase 1 (not determined)	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(Br)c3)[nH]n2)cc1		CHEMBL103285		IC50	nM		CHEMBL308	Homo sapiens	IC50	nM	
Not Determined	851715	CHEMBL661617	Inhibition of Cyclin-dependent kinase 1 (not determined)	B	COc1ccc(-c2cc(Nc3ccc(S(N)(=O)=O)cc3)[nH]n2)cc1F		CHEMBL102241		IC50	nM		CHEMBL308	Homo sapiens	IC50	nM	
Not Determined	852814	CHEMBL661617	Inhibition of Cyclin-dependent kinase 1 (not determined)	B	CS(=O)(=O)Nc1ccc(Nc2cc(-c3cccc(Br)c3)[nH]n2)cc1		CHEMBL418985		IC50	nM		CHEMBL308	Homo sapiens	IC50	nM	
Not Determined	853948	CHEMBL661617	Inhibition of Cyclin-dependent kinase 1 (not determined)	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(F)cc3)[nH]n2)cc1		CHEMBL103382		IC50	nM		CHEMBL308	Homo sapiens	IC50	nM	
	853950	CHEMBL666144	Inhibition of Cyclin-dependent kinase 1	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	IC50	nM	200.0	CHEMBL308	Homo sapiens	IC50	nM	200.0
	855040	CHEMBL666144	Inhibition of Cyclin-dependent kinase 1	B	CS(=O)(=O)Nc1cccc(-c2cc(Nc3ccc(S(N)(=O)=O)cc3)[nH]n2)c1		CHEMBL421578	=	IC50	nM	501.0	CHEMBL308	Homo sapiens	IC50	nM	501.0
Not Determined	863107	CHEMBL661617	Inhibition of Cyclin-dependent kinase 1 (not determined)	B	NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL329040		IC50	nM		CHEMBL308	Homo sapiens	IC50	nM	
Not Determined	863109	CHEMBL661617	Inhibition of Cyclin-dependent kinase 1 (not determined)	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc([N+](=O)[O-])cc3)[nH]n2)cc1		CHEMBL317703		IC50	nM		CHEMBL308	Homo sapiens	IC50	nM	
	863111	CHEMBL666144	Inhibition of Cyclin-dependent kinase 1	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)[nH]n2)cc1		CHEMBL321939	=	IC50	nM	794.0	CHEMBL308	Homo sapiens	IC50	nM	794.0
	910411	CHEMBL660800	Inhibition of Cyclin-dependent kinase 1	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCOCCOCCOCCn1cc2c2cccnc21		CHEMBL340935	=	IC50	nM	4428.0	CHEMBL308	Homo sapiens	IC50	uM	4.428
	915718	CHEMBL660800	Inhibition of Cyclin-dependent kinase 1	B	O=C1NC(=O)C2=C1c1cn(c3ncccc13)CCOCCOCCOCCn1cc2c2cccnc21		CHEMBL340776	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	918238	CHEMBL660800	Inhibition of Cyclin-dependent kinase 1	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCOCCOCCOCCn1cc2c2ccccc21		CHEMBL340259	=	IC50	nM	1251.0	CHEMBL308	Homo sapiens	IC50	uM	1.251
	931179	CHEMBL660800	Inhibition of Cyclin-dependent kinase 1	B	O=C1NC(=O)C2=C1c1cn(c3ncccc13)CCOCCOCCOCCOCCn1cc2c2cccnc21		CHEMBL337642	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	952079	CHEMBL666141	Inhibition of Cyclin-dependent kinase 1 (CDK1) at 12.5 uM ATP	B	Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1		CHEMBL303958	=	IC50	nM	2900.0	CHEMBL308	Homo sapiens	IC50	uM	2.9
	958720	CHEMBL666141	Inhibition of Cyclin-dependent kinase 1 (CDK1) at 12.5 uM ATP	B	NC(=O)c1ccc(Nc2nc(N)c(N=O)c(OCC3CCCCC3)n2)cc1		CHEMBL101801	=	IC50	nM	70.0	CHEMBL308	Homo sapiens	IC50	uM	0.07
	961036	CHEMBL666141	Inhibition of Cyclin-dependent kinase 1 (CDK1) at 12.5 uM ATP	B	NC(=O)c1ccc(Nc2nc(N)cc(OCC3CCCCC3)n2)cc1		CHEMBL319709	=	IC50	nM	63000.0	CHEMBL308	Homo sapiens	IC50	uM	63.0
	963546	CHEMBL666141	Inhibition of Cyclin-dependent kinase 1 (CDK1) at 12.5 uM ATP	B	CSc1ccc(Nc2nc(N)c(N=O)c(OCC3CCCCC3)n2)cc1		CHEMBL322568	=	IC50	nM	220.0	CHEMBL308	Homo sapiens	IC50	uM	0.22
	971311	CHEMBL666141	Inhibition of Cyclin-dependent kinase 1 (CDK1) at 12.5 uM ATP	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nc(OCC2CCCCC2)c1N=O		CHEMBL318999	=	IC50	nM	5.0	CHEMBL308	Homo sapiens	IC50	uM	0.005
	973804	CHEMBL666141	Inhibition of Cyclin-dependent kinase 1 (CDK1) at 12.5 uM ATP	B	NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL319467	=	IC50	nM	9.5	CHEMBL308	Homo sapiens	IC50	uM	0.0095
	978647	CHEMBL666141	Inhibition of Cyclin-dependent kinase 1 (CDK1) at 12.5 uM ATP	B	Nc1nc(OCC2CCCCC2)c2nc[nH]c2n1		CHEMBL269881	=	IC50	nM	7000.0	CHEMBL308	Homo sapiens	IC50	uM	7.0
	984953	CHEMBL666141	Inhibition of Cyclin-dependent kinase 1 (CDK1) at 12.5 uM ATP	B	Nc1cc(OCC2CCCCC2)nc(Nc2ccc(S(N)(=O)=O)cc2)n1		CHEMBL104467	=	IC50	nM	5300.0	CHEMBL308	Homo sapiens	IC50	uM	5.3
	984955	CHEMBL666141	Inhibition of Cyclin-dependent kinase 1 (CDK1) at 12.5 uM ATP	B	Nc1nc(Nc2cccc(Br)c2)nc(OCC2CCCCC2)c1N=O		CHEMBL107530	=	IC50	nM	800.0	CHEMBL308	Homo sapiens	IC50	uM	0.8
	986272	CHEMBL666141	Inhibition of Cyclin-dependent kinase 1 (CDK1) at 12.5 uM ATP	B	COc1ccc(Nc2nc(N)c(N=O)c(OCC3CCCCC3)n2)cc1		CHEMBL102636	=	IC50	nM	230.0	CHEMBL308	Homo sapiens	IC50	uM	0.23
	988824	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@H]3CC[C@H](N)CC3)nc21		CHEMBL367691	=	IC50	nM	39.0	CHEMBL308	Homo sapiens	IC50	uM	0.039
	988825	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(C#N)c3)nc(N[C@H]3CC[C@H](O)CC3)nc21		CHEMBL172140	=	IC50	nM	28.0	CHEMBL308	Homo sapiens	IC50	uM	0.028
	988826	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(F)c3)nc(NCCN)nc21		CHEMBL439841	=	IC50	nM	600.0	CHEMBL308	Homo sapiens	IC50	uM	0.6
	989869	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(C(F)(F)F)c3)nc(N[C@H]3CC[C@H](N)CC3)nc21		CHEMBL173608	=	IC50	nM	140.0	CHEMBL308	Homo sapiens	IC50	uM	0.14
Not Active	992198	CHEMBL660792	Inhibition of cyclin-dependent kinase 1 (CDK1) (Not active)	B	CCn1cnc2c(Nc3cccc(C(F)(F)F)c3)nc(NCCO)nc21		CHEMBL366632		IC50	nM		CHEMBL308	Homo sapiens	IC50	uM	
	993242	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	IC50	nM	31.0	CHEMBL308	Homo sapiens	IC50	uM	0.031
	993243	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(C#N)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL366620	=	IC50	nM	350.0	CHEMBL308	Homo sapiens	IC50	uM	0.35
	994559	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3ccc(F)cc3)nc(NCCN)nc21.Cl		CHEMBL540874	=	IC50	nM	450.0	CHEMBL308	Homo sapiens	IC50	uM	0.45
	994579	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3ccc(F)cc3)nc(NCCN)nc21		CHEMBL176488	=	IC50	nM	450.0	CHEMBL308	Homo sapiens	IC50	uM	0.45
	995843	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@H]3CC[C@@H](N)CC3)nc21		CHEMBL173459	=	IC50	nM	39.0	CHEMBL308	Homo sapiens	IC50	uM	0.039
	998315	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(OC)c3)nc(NCCO)nc21		CHEMBL414651	=	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	uM	1.0
Not Active	998316	CHEMBL660792	Inhibition of cyclin-dependent kinase 1 (CDK1) (Not active)	B	CCn1cnc2c(Nc3cccc(C#N)c3)nc(NCCO)nc21		CHEMBL171860		IC50	nM		CHEMBL308	Homo sapiens	IC50	uM	
	998317	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N3CCCCC3CO)nc21		CHEMBL176559	=	IC50	nM	39.0	CHEMBL308	Homo sapiens	IC50	uM	0.039
	1000676	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N3CCC[C@@H]3CN)nc21		CHEMBL368351	=	IC50	nM	41.0	CHEMBL308	Homo sapiens	IC50	uM	0.041
	1000678	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3ccc(F)cc3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL172848	=	IC50	nM	150.0	CHEMBL308	Homo sapiens	IC50	uM	0.15
	1003150	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(F)c3)nc(N[C@H]3CC[C@@H](N)CC3)nc21		CHEMBL173353	=	IC50	nM	350.0	CHEMBL308	Homo sapiens	IC50	uM	0.35
	1003151	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3ccc(F)cc3)nc(N[C@H]3CC[C@H](O)CC3)nc21		CHEMBL174977	=	IC50	nM	40.0	CHEMBL308	Homo sapiens	IC50	uM	0.04
	1003152	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(C(F)(F)F)c3)nc(NCCN)nc21.Cl		CHEMBL534909	=	IC50	nM	700.0	CHEMBL308	Homo sapiens	IC50	uM	0.7
	1003157	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	IC50	nM	25.0	CHEMBL308	Homo sapiens	IC50	uM	0.025
	1003162	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@H]3CCC[C@@H](N)C3)nc21		CHEMBL368278	=	IC50	nM	120.0	CHEMBL308	Homo sapiens	IC50	uM	0.12
	1004505	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N3CCC[C@@H]3CO)nc21		CHEMBL366734	=	IC50	nM	80.0	CHEMBL308	Homo sapiens	IC50	uM	0.08
	1005896	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(NCCN)nc21		CHEMBL173647	=	IC50	nM	80.0	CHEMBL308	Homo sapiens	IC50	uM	0.08
	1007030	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(C(F)(F)F)c3)nc(N[C@H]3CC[C@@H](N)CC3)nc21		CHEMBL174162	=	IC50	nM	290.0	CHEMBL308	Homo sapiens	IC50	uM	0.29
	1007031	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(C(F)(F)F)c3)nc(N[C@H]3CC[C@H](O)CC3)nc21		CHEMBL368215	=	IC50	nM	28.0	CHEMBL308	Homo sapiens	IC50	uM	0.028
	1008290	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(F)c3)nc(N[C@H]3CC[C@H](N)CC3)nc21		CHEMBL366642	=	IC50	nM	150.0	CHEMBL308	Homo sapiens	IC50	uM	0.15
	1010788	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3ccc(F)cc3)nc(N[C@H]3CC[C@H](N)CC3)nc21		CHEMBL171891	=	IC50	nM	31.0	CHEMBL308	Homo sapiens	IC50	uM	0.031
	1010789	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@H]3CC[C@H](O)CC3)nc21		CHEMBL177138	=	IC50	nM	30.0	CHEMBL308	Homo sapiens	IC50	uM	0.03
	1010790	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	IC50	nM	110.0	CHEMBL308	Homo sapiens	IC50	uM	0.11
	1010795	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(C(F)(F)F)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL176576	=	IC50	nM	310.0	CHEMBL308	Homo sapiens	IC50	uM	0.31
	1012055	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(OC)c3)nc(N[C@H]3CC[C@H](O)CC3)nc21		CHEMBL368202	=	IC50	nM	90.0	CHEMBL308	Homo sapiens	IC50	uM	0.09
	1012056	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(C(F)(F)F)c3)nc(NCCN)nc21		CHEMBL173237	=	IC50	nM	700.0	CHEMBL308	Homo sapiens	IC50	uM	0.7
	1012057	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(C#N)c3)nc(NCCN)nc21		CHEMBL175158	=	IC50	nM	560.0	CHEMBL308	Homo sapiens	IC50	uM	0.56
	1012058	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(F)c3)nc(NCCO)nc21		CHEMBL171975	=	IC50	nM	440.0	CHEMBL308	Homo sapiens	IC50	uM	0.44
	1013210	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3ccc(F)cc3)nc(N[C@H]3CC[C@@H](N)CC3)nc21		CHEMBL173619	=	IC50	nM	100.0	CHEMBL308	Homo sapiens	IC50	uM	0.1
	1014492	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(OC)c3)nc(N[C@H]3CC[C@H](N)CC3)nc21		CHEMBL176834	=	IC50	nM	160.0	CHEMBL308	Homo sapiens	IC50	uM	0.16
	1015888	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(NCCO)nc21		CHEMBL367245	=	IC50	nM	330.0	CHEMBL308	Homo sapiens	IC50	uM	0.33
	1015899	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3ccc(F)cc3)nc(NCCO)nc21		CHEMBL367614	=	IC50	nM	380.0	CHEMBL308	Homo sapiens	IC50	uM	0.38
	1017320	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(C#N)c3)nc(N[C@H]3CC[C@H](N)CC3)nc21		CHEMBL435330	=	IC50	nM	85.0	CHEMBL308	Homo sapiens	IC50	uM	0.085
	1017321	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(OC)c3)nc(NCCN)nc21		CHEMBL366698	=	IC50	nM	550.0	CHEMBL308	Homo sapiens	IC50	uM	0.55
	1019836	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@H]3CC[C@@H](N)CC3)nc21		CHEMBL173459	=	IC50	nM	140.0	CHEMBL308	Homo sapiens	IC50	uM	0.14
	1019837	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3ccc(OC)cc3)nc(NCCN)nc21		CHEMBL368743	=	IC50	nM	550.0	CHEMBL308	Homo sapiens	IC50	uM	0.55
	1019838	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(F)c3)nc(NCCN)nc21.Cl		CHEMBL537838	=	IC50	nM	600.0	CHEMBL308	Homo sapiens	IC50	uM	0.6
	1019840	CHEMBL661622	Inhibition of Cyclin-dependent kinase 1, CDK1-related human bladder carcinoma (T24) cell proliferation	F	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@H]3CC[C@@H](O)CC3)nc21		CHEMBL177057	=	IC50	nM	30.0	CHEMBL308	Homo sapiens	IC50	uM	0.03
	1019842	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(OC)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL175143	=	IC50	nM	230.0	CHEMBL308	Homo sapiens	IC50	uM	0.23
	1021124	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(OC)c3)nc(N[C@H]3CC[C@@H](N)CC3)nc21		CHEMBL172811	=	IC50	nM	340.0	CHEMBL308	Homo sapiens	IC50	uM	0.34
	1024835	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(C#N)c3)nc(NCCN)nc21.Cl		CHEMBL557975	=	IC50	nM	560.0	CHEMBL308	Homo sapiens	IC50	uM	0.56
	1024855	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(C#N)c3)nc(N[C@H]3CC[C@@H](N)CC3)nc21		CHEMBL176908	=	IC50	nM	350.0	CHEMBL308	Homo sapiens	IC50	uM	0.35
	1024856	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(F)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL173737	=	IC50	nM	250.0	CHEMBL308	Homo sapiens	IC50	uM	0.25
	1026003	CHEMBL660791	Inhibitory activity against cyclin-dependent kinase 1 (CDK1) was determined	B	CCn1cnc2c(Nc3cccc(F)c3)nc(N[C@H]3CC[C@H](O)CC3)nc21		CHEMBL174773	=	IC50	nM	32.0	CHEMBL308	Homo sapiens	IC50	uM	0.032
	1067010	CHEMBL661321	Inhibition of Cell division cycle 2 (cdc2) kinase	B	CCCCCCCCCCCCOP(=O)([O-])OCC[N+]1(C)CCCCC1	Outside typical range	CHEMBL89135	>	IC50	nM	1000000.0	CHEMBL308	Homo sapiens	IC50	uM	1000.0
	1068013	CHEMBL660794	Inhibition of Cyclin-dependent kinase 1	B	O=C(Nc1ccc(Cl)cc1)c1ccccc1NCc1ccncc1		CHEMBL101683	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	1069528	CHEMBL661321	Inhibition of Cell division cycle 2 (cdc2) kinase	B	CCCCCCCCCCCCCCOP(=O)([O-])OCC[N+]1(C)CCOCC1	Outside typical range	CHEMBL89141	>	IC50	nM	1000000.0	CHEMBL308	Homo sapiens	IC50	uM	1000.0
	1069532	CHEMBL661321	Inhibition of Cell division cycle 2 (cdc2) kinase	B	CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+]1(C)CCOCC1	Outside typical range	CHEMBL88487	>	IC50	nM	1000000.0	CHEMBL308	Homo sapiens	IC50	uM	1000.0
	1070528	CHEMBL660794	Inhibition of Cyclin-dependent kinase 1	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	1070665	CHEMBL661321	Inhibition of Cell division cycle 2 (cdc2) kinase	B	C=COCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+]1(C)CCCCC1	Outside typical range	CHEMBL86560	>	IC50	nM	1000000.0	CHEMBL308	Homo sapiens	IC50	uM	1000.0
	1089098	CHEMBL661620	Inhibition of Cyclin-dependent kinase 1 enzyme from starfish oocytes	B	Nc1nc(OCC2CCCCC2)c2nc[nH]c2n1		CHEMBL269881	=	Ki	nM	5000.0	CHEMBL308	Homo sapiens	Ki	uM	5.0
	1090011	CHEMBL661321	Inhibition of Cell division cycle 2 (cdc2) kinase	B	C=COCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+]1(C)CCOCC1	Outside typical range	CHEMBL89650	>	IC50	nM	1000000.0	CHEMBL308	Homo sapiens	IC50	uM	1000.0
	1090021	CHEMBL661321	Inhibition of Cell division cycle 2 (cdc2) kinase	B	CCCCCCCCCCCCCCOP(=O)([O-])OCC[N+]1(C)CCCCC1	Outside typical range	CHEMBL314931	>	IC50	nM	1000000.0	CHEMBL308	Homo sapiens	IC50	uM	1000.0
	1091095	CHEMBL661321	Inhibition of Cell division cycle 2 (cdc2) kinase	B	C=COCCCCCCCCCCCCOP(=O)([O-])OCC[N+]1(C)CCOCC1	Outside typical range	CHEMBL86791	>	IC50	nM	1000000.0	CHEMBL308	Homo sapiens	IC50	uM	1000.0
	1091099	CHEMBL661321	Inhibition of Cell division cycle 2 (cdc2) kinase	B	CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+]1(C)CCCCC1	Outside typical range	CHEMBL89618	>	IC50	nM	1000000.0	CHEMBL308	Homo sapiens	IC50	uM	1000.0
	1092275	CHEMBL661321	Inhibition of Cell division cycle 2 (cdc2) kinase	B	CCCCCCCCCCCCOP(=O)([O-])OCC[N+]1(C)CCOCC1	Outside typical range	CHEMBL418940	>	IC50	nM	1000000.0	CHEMBL308	Homo sapiens	IC50	uM	1000.0
	1097829	CHEMBL661321	Inhibition of Cell division cycle 2 (cdc2) kinase	B	C=COCCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+]1(C)CCOCC1	Outside typical range	CHEMBL89292	>	IC50	nM	1000000.0	CHEMBL308	Homo sapiens	IC50	uM	1000.0
	1097839	CHEMBL661321	Inhibition of Cell division cycle 2 (cdc2) kinase	B	CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C	Outside typical range	CHEMBL125	>	IC50	nM	1000000.0	CHEMBL308	Homo sapiens	IC50	uM	1000.0
	1099034	CHEMBL661321	Inhibition of Cell division cycle 2 (cdc2) kinase	B	C=COCCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+]1(C)CCCCC1	Outside typical range	CHEMBL89013	>	IC50	nM	1000000.0	CHEMBL308	Homo sapiens	IC50	uM	1000.0
	1099191	CHEMBL661619	Inhibition of Cyclin-dependent kinase 1 enzyme from starfish oocytes	B	c1nc(OCC2CCCCC2)c2nc[nH]c2n1		CHEMBL405551	=	IC50	nM	18000.0	CHEMBL308	Homo sapiens	IC50	uM	18.0
	1100330	CHEMBL661619	Inhibition of Cyclin-dependent kinase 1 enzyme from starfish oocytes	B	Cn1cnc2c(OCC3CCCCC3)nc(N)nc21		CHEMBL94794	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	1142479	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)NCc2ccccc2)cc1		CHEMBL1964242	=	IC50	nM	52.0	CHEMBL308	Homo sapiens	IC50	nM	52.0
	1142487	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	CNS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1234085	=	IC50	nM	2900.0	CHEMBL308	Homo sapiens	IC50	nM	2900.0
	1143808	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(/N=N/c2c(O)[nH]c3cccc(I)c23)cc1		CHEMBL314397	=	IC50	nM	110.0	CHEMBL308	Homo sapiens	IC50	nM	110.0
	1143810	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	IC50	nM	74.0	CHEMBL308	Homo sapiens	IC50	nM	74.0
	1144372	CHEMBL656370	Inhibitory activity against CDK1 Ser/Thr kinase	B	Nc1ccc(Nc2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)cc1		CHEMBL332612	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	uM	1.0
	1144380	CHEMBL656370	Inhibitory activity against CDK1 Ser/Thr kinase	B	O=[N+]([O-])c1cccc(-c2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)c1		CHEMBL118904	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	1145031	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccccc32)cc1		CHEMBL438721	=	IC50	nM	1300.0	CHEMBL308	Homo sapiens	IC50	nM	1300.0
	1145033	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL270132	=	IC50	nM	17.0	CHEMBL308	Homo sapiens	IC50	nM	17.0
	1145035	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)Nc2ccccn2)cc1		CHEMBL1276446	=	IC50	nM	100.0	CHEMBL308	Homo sapiens	IC50	nM	100.0
	1145043	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	CNS(=O)(=O)Cc1ccc(N/N=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1234086	=	IC50	nM	56.0	CHEMBL308	Homo sapiens	IC50	nM	56.0
	1145615	CHEMBL656370	Inhibitory activity against CDK1 Ser/Thr kinase	B	Nc1cccc(-c2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)c1		CHEMBL332882	=	IC50	nM	680.0	CHEMBL308	Homo sapiens	IC50	uM	0.68
	1146498	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	CCc1ccc2c(c1)NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271182	=	IC50	nM	660.0	CHEMBL308	Homo sapiens	IC50	nM	660.0
	1146500	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	COCCOCCOCCOCCN(C)S(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1964249	=	IC50	nM	45.0	CHEMBL308	Homo sapiens	IC50	nM	45.0
	1148293	CHEMBL656370	Inhibitory activity against CDK1 Ser/Thr kinase	B	COc1cccc(Nc2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)c1		CHEMBL120979	=	IC50	nM	4300.0	CHEMBL308	Homo sapiens	IC50	uM	4.3
	1149044	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	Cc1c([N+](=O)[O-])ccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272667	=	IC50	nM	87.0	CHEMBL308	Homo sapiens	IC50	nM	87.0
	1149527	CHEMBL656370	Inhibitory activity against CDK1 Ser/Thr kinase	B	COc1ccc(CNc2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)cc1		CHEMBL122245	=	IC50	nM	5000.0	CHEMBL308	Homo sapiens	IC50	uM	5.0
	1150271	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL269850	=	IC50	nM	3000.0	CHEMBL308	Homo sapiens	IC50	nM	3000.0
	1150273	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	IC50	nM	300.0	CHEMBL308	Homo sapiens	IC50	nM	300.0
	1150275	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(Oc4ccccc4)c32)cc1		CHEMBL409104	=	IC50	nM	290.0	CHEMBL308	Homo sapiens	IC50	nM	290.0
	1150277	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	IC50	nM	230.0	CHEMBL308	Homo sapiens	IC50	nM	230.0
	1151480	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccc(O)cc4)c32)cc1		CHEMBL411865	=	IC50	nM	150.0	CHEMBL308	Homo sapiens	IC50	nM	150.0
	1152635	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	CC(C)CC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL429142	=	IC50	nM	16.0	CHEMBL308	Homo sapiens	IC50	nM	16.0
	1152637	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4cccnc4)cc32)cc1		CHEMBL271953	=	IC50	nM	51.0	CHEMBL308	Homo sapiens	IC50	nM	51.0
	1152639	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cc(Br)ccc32)cc1		CHEMBL271183	=	IC50	nM	520.0	CHEMBL308	Homo sapiens	IC50	nM	520.0
	1152641	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4[nH]ncc4c32)cc1		CHEMBL272833	=	IC50	nM	120.0	CHEMBL308	Homo sapiens	IC50	nM	120.0
	1152643	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)N[n+]2ccc3ccccc3c2)cc1		CHEMBL2112297	=	IC50	nM	42.0	CHEMBL308	Homo sapiens	IC50	nM	42.0
	1152645	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	CN(C)CCNS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1964248	=	IC50	nM	5500.0	CHEMBL308	Homo sapiens	IC50	nM	5500.0
	1152817	CHEMBL660790	In vitro inhibition of Cyclin-dependent kinase 1 (CDK-1) expressed in baculovirus	B	O=C(Nc1cccc(C(F)(F)F)c1)c1ccccc1NCc1ccncc1		CHEMBL153843	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	nM	10000.0
	1153158	CHEMBL656370	Inhibitory activity against CDK1 Ser/Thr kinase	B	CN(C)c1ccc(Nc2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)cc1		CHEMBL332765	=	IC50	nM	350.0	CHEMBL308	Homo sapiens	IC50	uM	0.35
	1153931	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3cccc(CO)c32)cc1		CHEMBL271137	=	IC50	nM	1700.0	CHEMBL308	Homo sapiens	IC50	nM	1700.0
	1153933	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	IC50	nM	330.0	CHEMBL308	Homo sapiens	IC50	nM	330.0
	1153935	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	COc1cccc(OC)c1CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271136	=	IC50	nM	9.3	CHEMBL308	Homo sapiens	IC50	nM	9.3
	1155248	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(/C=C/c4ccc(O)cc4)c32)cc1		CHEMBL272380	=	IC50	nM	170.0	CHEMBL308	Homo sapiens	IC50	nM	170.0
	1155250	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	CN(C)C(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL409868	=	IC50	nM	130.0	CHEMBL308	Homo sapiens	IC50	nM	130.0
	1155252	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	CN(C)S(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1964247	=	IC50	nM	50.0	CHEMBL308	Homo sapiens	IC50	nM	50.0
	1155254	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)NCCc2c[nH]cn2)cc1		CHEMBL1964251	=	IC50	nM	38.0	CHEMBL308	Homo sapiens	IC50	nM	38.0
	1155870	CHEMBL656370	Inhibitory activity against CDK1 Ser/Thr kinase	B	Clc1cccc(Nc2[nH]cnc3nnc(NCc4ccccc4)c2-3)c1		CHEMBL121796	=	IC50	nM	7400.0	CHEMBL308	Homo sapiens	IC50	uM	7.4
	1156653	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc([N+](=O)[O-])c32)cc1		CHEMBL409619	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	nM	1000.0
	1156655	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL445945	=	IC50	nM	15.0	CHEMBL308	Homo sapiens	IC50	nM	15.0
	1157791	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)Nc2ccccc2)cc1		CHEMBL1964244	=	IC50	nM	41.0	CHEMBL308	Homo sapiens	IC50	nM	41.0
	1158338	CHEMBL656370	Inhibitory activity against CDK1 Ser/Thr kinase	B	Oc1cccc(-c2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)c1		CHEMBL331906	=	IC50	nM	200.0	CHEMBL308	Homo sapiens	IC50	uM	0.2
	1158346	CHEMBL656370	Inhibitory activity against CDK1 Ser/Thr kinase	B	Nc1ccc(-c2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)cc1		CHEMBL332906	=	IC50	nM	4500.0	CHEMBL308	Homo sapiens	IC50	uM	4.5
	1159239	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(O)cc32)cc1		CHEMBL409690	=	IC50	nM	77.0	CHEMBL308	Homo sapiens	IC50	nM	77.0
	1159241	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(S(=O)(=O)O)cc32)cc1		CHEMBL412091	=	IC50	nM	130.0	CHEMBL308	Homo sapiens	IC50	nM	130.0
	1159243	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3cc(CO)ccc32)cc1		CHEMBL410293	=	IC50	nM	740.0	CHEMBL308	Homo sapiens	IC50	nM	740.0
	1159245	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	CNS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1964245	=	IC50	nM	64.0	CHEMBL308	Homo sapiens	IC50	nM	64.0
	1159253	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	CS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1964260	=	IC50	nM	39.0	CHEMBL308	Homo sapiens	IC50	nM	39.0
	1159261	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(CS(=O)(=O)NCCO)cc1		CHEMBL1964258	=	IC50	nM	200.0	CHEMBL308	Homo sapiens	IC50	nM	200.0
	1160476	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	CCOC(=O)c1cccc2c1/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL408210	=	IC50	nM	130.0	CHEMBL308	Homo sapiens	IC50	nM	130.0
	1160478	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	IC50	nM	12.0	CHEMBL308	Homo sapiens	IC50	nM	12.0
	1160486	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)NCCOCCO)cc1		CHEMBL1964259	=	IC50	nM	12.0	CHEMBL308	Homo sapiens	IC50	nM	12.0
	1161891	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	CS(=O)(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272389	=	IC50	nM	350.0	CHEMBL308	Homo sapiens	IC50	nM	350.0
	1161893	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	IC50	nM	790.0	CHEMBL308	Homo sapiens	IC50	nM	790.0
	1162574	CHEMBL656370	Inhibitory activity against CDK1 Ser/Thr kinase	B	Clc1cccc(CNc2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)c1		CHEMBL333231	=	IC50	nM	16000.0	CHEMBL308	Homo sapiens	IC50	uM	16.0
	1162582	CHEMBL656370	Inhibitory activity against CDK1 Ser/Thr kinase	B	COc1ccc(-c2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)cc1		CHEMBL332971	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	1163393	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	O=C1Nc2ccc(-c3cnco3)cc2/C1=C/Nc1ccc2c(c1)CS(=O)(=O)C2		CHEMBL1234087	=	IC50	nM	19.0	CHEMBL308	Homo sapiens	IC50	nM	19.0
	1164790	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1794054	=	IC50	nM	290.0	CHEMBL308	Homo sapiens	IC50	nM	290.0
	1164792	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(S(=O)(=O)Nc2nccs2)cc1		CHEMBL1234088	=	IC50	nM	3800.0	CHEMBL308	Homo sapiens	IC50	nM	3800.0
	1166068	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccc(Cl)cc21		CHEMBL412097	=	IC50	nM	220.0	CHEMBL308	Homo sapiens	IC50	nM	220.0
	1166070	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	Nc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271842	=	IC50	nM	1400.0	CHEMBL308	Homo sapiens	IC50	nM	1400.0
	1166653	CHEMBL656370	Inhibitory activity against CDK1 Ser/Thr kinase	B	CC(C)(C)OC(=O)Nc1ccc(Nc2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)cc1		CHEMBL120703	=	IC50	nM	57000.0	CHEMBL308	Homo sapiens	IC50	uM	57.0
	1167444	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	CCc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL411425	=	IC50	nM	46.0	CHEMBL308	Homo sapiens	IC50	nM	46.0
	1167446	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	Cc1cc(C)c2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269846	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	nM	10000.0
	1167448	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	CNS(=O)(=O)Cc1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1964256	=	IC50	nM	170.0	CHEMBL308	Homo sapiens	IC50	nM	170.0
	1167952	CHEMBL656370	Inhibitory activity against CDK1 Ser/Thr kinase	B	COc1cccc(CNc2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)c1		CHEMBL123189	=	IC50	nM	3100.0	CHEMBL308	Homo sapiens	IC50	uM	3.1
	1168727	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	IC50	nM	10.0	CHEMBL308	Homo sapiens	IC50	nM	10.0
	1168729	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NC(=O)c1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271778	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	nM	1000.0
	1168731	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	COc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL260103	=	IC50	nM	210.0	CHEMBL308	Homo sapiens	IC50	nM	210.0
	1168733	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4[nH]nnc4c32)cc1		CHEMBL271952	=	IC50	nM	150.0	CHEMBL308	Homo sapiens	IC50	nM	150.0
	1169282	CHEMBL656370	Inhibitory activity against CDK1 Ser/Thr kinase	B	CC(C)(C)OC(=O)Nc1ccc(-c2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)cc1		CHEMBL420885	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	1170041	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	CC(C)c1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL411426	=	IC50	nM	37.0	CHEMBL308	Homo sapiens	IC50	nM	37.0
	1170049	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(-c4cc[nH]n4)c32)cc1		CHEMBL272684	=	IC50	nM	250.0	CHEMBL308	Homo sapiens	IC50	nM	250.0
	1170051	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	Cc1cccc2c1NC(=O)/C2=C\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL408131	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	nM	10000.0
	1170053	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4[nH]nc(Cl)c4c32)cc1		CHEMBL269882	=	IC50	nM	83.0	CHEMBL308	Homo sapiens	IC50	nM	83.0
	1171205	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	IC50	nM	2800.0	CHEMBL308	Homo sapiens	IC50	nM	2800.0
	1171207	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	N=C(N)NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1234089	=	IC50	nM	2500.0	CHEMBL308	Homo sapiens	IC50	nM	2500.0
	1171630	CHEMBL656370	Inhibitory activity against CDK1 Ser/Thr kinase	B	Clc1cccc(Nc2[nH]nc3ncnc(NCc4ccccc4)c23)c1		CHEMBL119982	=	IC50	nM	9000.0	CHEMBL308	Homo sapiens	IC50	uM	9.0
	1172509	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(I)cc32)cc1		CHEMBL273060	=	IC50	nM	95.0	CHEMBL308	Homo sapiens	IC50	nM	95.0
	1172511	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	IC50	nM	69.0	CHEMBL308	Homo sapiens	IC50	nM	69.0
	1172513	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	IC50	nM	29.0	CHEMBL308	Homo sapiens	IC50	nM	29.0
	1172515	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	CS(=O)(=O)Cc1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL235849	=	IC50	nM	1200.0	CHEMBL308	Homo sapiens	IC50	nM	1200.0
	1173812	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	CC(C)(C)c1ccc2c(c1)NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271777	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	nM	10000.0
	1173814	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)NCCO)cc1		CHEMBL1964246	=	IC50	nM	41.0	CHEMBL308	Homo sapiens	IC50	nM	41.0
	1173816	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	Cc1cccc(C)c1NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1964252	=	IC50	nM	14000.0	CHEMBL308	Homo sapiens	IC50	nM	14000.0
	1173818	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)Cc1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1964257	=	IC50	nM	100.0	CHEMBL308	Homo sapiens	IC50	nM	100.0
	1174295	CHEMBL656370	Inhibitory activity against CDK1 Ser/Thr kinase	B	Oc1cccc(Nc2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)c1		CHEMBL121954	=	IC50	nM	3000.0	CHEMBL308	Homo sapiens	IC50	uM	3.0
	1175157	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Br)cc32)cc1		CHEMBL411491	=	IC50	nM	780.0	CHEMBL308	Homo sapiens	IC50	nM	780.0
	1175159	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	CC(C)Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL411224	=	IC50	nM	19.0	CHEMBL308	Homo sapiens	IC50	nM	19.0
	1175161	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(F)cc32)cc1		CHEMBL273061	=	IC50	nM	290.0	CHEMBL308	Homo sapiens	IC50	nM	290.0
	1175163	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)cc1		CHEMBL272387	=	IC50	nM	170.0	CHEMBL308	Homo sapiens	IC50	nM	170.0
	1175165	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL409731	=	IC50	nM	12.0	CHEMBL308	Homo sapiens	IC50	nM	12.0
	1175167	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	CN(c1ccccn1)S(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1964253	=	IC50	nM	64.0	CHEMBL308	Homo sapiens	IC50	nM	64.0
	1175169	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	CC(=O)NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1964243	=	IC50	nM	910.0	CHEMBL308	Homo sapiens	IC50	nM	910.0
	1175324	CHEMBL660790	In vitro inhibition of Cyclin-dependent kinase 1 (CDK-1) expressed in baculovirus	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	nM	10000.0
	1175349	CHEMBL660790	In vitro inhibition of Cyclin-dependent kinase 1 (CDK-1) expressed in baculovirus	B	Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL276711	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	nM	10000.0
	1176437	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	IC50	nM	15.0	CHEMBL308	Homo sapiens	IC50	nM	15.0
	1176439	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	IC50	nM	19.0	CHEMBL308	Homo sapiens	IC50	nM	19.0
	1176447	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	Cc1cc(Cl)cc2c1NC(=O)/C2=C\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL410517	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	nM	10000.0
	1176449	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc2c(c1)CS(=O)(=O)C2		CHEMBL391229	=	IC50	nM	31.0	CHEMBL308	Homo sapiens	IC50	nM	31.0
	1177753	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	IC50	nM	2300.0	CHEMBL308	Homo sapiens	IC50	nM	2300.0
	1177755	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc([N+](=O)[O-])cc32)cc1		CHEMBL411886	=	IC50	nM	710.0	CHEMBL308	Homo sapiens	IC50	nM	710.0
	1177757	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	COc1ccc2c(c1Cl)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271822	=	IC50	nM	1700.0	CHEMBL308	Homo sapiens	IC50	nM	1700.0
	1178971	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc(C(=O)O)cc32)cc1		CHEMBL272668	=	IC50	nM	150.0	CHEMBL308	Homo sapiens	IC50	nM	150.0
	1179478	CHEMBL656370	Inhibitory activity against CDK1 Ser/Thr kinase	B	COc1ccc(Nc2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)cc1		CHEMBL122411	=	IC50	nM	5800.0	CHEMBL308	Homo sapiens	IC50	uM	5.8
	1179486	CHEMBL656370	Inhibitory activity against CDK1 Ser/Thr kinase	B	COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC		CHEMBL29197	=	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	1180347	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccc(-c3cnco3)cc21		CHEMBL411887	=	IC50	nM	7.1	CHEMBL308	Homo sapiens	IC50	nM	7.1
	1180349	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410883	=	IC50	nM	2.8	CHEMBL308	Homo sapiens	IC50	nM	2.8
	1180351	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL407709	=	IC50	nM	43.0	CHEMBL308	Homo sapiens	IC50	nM	43.0
	1180538	CHEMBL660790	In vitro inhibition of Cyclin-dependent kinase 1 (CDK-1) expressed in baculovirus	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1.O=C(O)CCC(=O)O		CHEMBL75232	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	nM	10000.0
	1181714	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cc(Oc4ccccc4)ccc32)cc1		CHEMBL272885	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	nM	10000.0
	1181716	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	Cc1ccc2c(c1Cl)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL411490	=	IC50	nM	250.0	CHEMBL308	Homo sapiens	IC50	nM	250.0
	1181718	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	N=C(N)NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1964255	=	IC50	nM	45.0	CHEMBL308	Homo sapiens	IC50	nM	45.0
	1182246	CHEMBL656370	Inhibitory activity against CDK1 Ser/Thr kinase	B	Oc1ccc(Nc2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)cc1		CHEMBL122182	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	uM	1.0
	1183031	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	CCOc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL411696	=	IC50	nM	550.0	CHEMBL308	Homo sapiens	IC50	nM	550.0
	1183033	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	CC(C)Oc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271160	=	IC50	nM	41.0	CHEMBL308	Homo sapiens	IC50	nM	41.0
	1183035	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	IC50	nM	60.0	CHEMBL308	Homo sapiens	IC50	nM	60.0
	1183037	CHEMBL666140	Inhibitory activity against human cyclin-dependent kinase 1 (CDK1)	B	COCCOCCOCCOCCNS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1964250	=	IC50	nM	72.0	CHEMBL308	Homo sapiens	IC50	nM	72.0
	1183190	CHEMBL660790	In vitro inhibition of Cyclin-dependent kinase 1 (CDK-1) expressed in baculovirus	B	O=C(Nc1cccc(-c2cncc3ccccc23)c1)c1ccccc1NCc1ccncc1		CHEMBL347537	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	nM	10000.0
	1183570	CHEMBL656370	Inhibitory activity against CDK1 Ser/Thr kinase	B	Clc1cccc(Nc2[nH]cnc3nnc(-c4ccccc4)c2-3)c1		CHEMBL119977	=	IC50	nM	2800.0	CHEMBL308	Homo sapiens	IC50	uM	2.8
	1183578	CHEMBL656370	Inhibitory activity against CDK1 Ser/Thr kinase	B	Oc1ccc(-c2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)cc1		CHEMBL118130	=	IC50	nM	260.0	CHEMBL308	Homo sapiens	IC50	uM	0.26
	1191689	CHEMBL666142	Inhibition of human cyclin-dependent kinase 1	B	C[C@H](Nc1cc(-c2sc(C3CCN(C)CC3)nc2-c2ccc(F)cc2)ccn1)c1ccccc1		CHEMBL2111784	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	1197964	CHEMBL661618	Inhibition of human cyclin-dependent kinase 1 at 10 uM	B	COc1ccc(C#CC(C)(C)N)cc1C(=O)c1ccc(Nc2ccc(F)cc2F)cc1	Outside typical range	CHEMBL419409	=	Inhibition	%	-32.0	CHEMBL308	Homo sapiens	Inhibition	%	-32.0
	1199245	CHEMBL666142	Inhibition of human cyclin-dependent kinase 1	B	CN1CCN(c2ccc3c(n2)nc(-c2ccc(F)cc2)n3-c2ccnc(NC3CCCC3)n2)CC1		CHEMBL120185	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	1200647	CHEMBL666142	Inhibition of human cyclin-dependent kinase 1	B	OC1(c2nc(-c3ccc(F)cc3)c(-c3ccnc(NC4CCCCC4)c3)o2)CCNCC1		CHEMBL121405	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	1200668	CHEMBL661618	Inhibition of human cyclin-dependent kinase 1 at 10 uM	B	COc1cc2[nH]c(C)nc2cc1C(=O)c1ccc(Nc2ccc(F)cc2F)cc1		CHEMBL120067	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	Inhibition	%	0.0
	1213080	CHEMBL661322	Inhibition of Cell division control protein 2, Cdk-1 (Inactive at 1 mM ATP)	B	CN1CCN([C@H]2CC[C@@H](n3cc(-c4ccc(Oc5ccccc5)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL47203	>	IC50	nM	20000.0	CHEMBL308	Homo sapiens	IC50	uM	20.0
	1215193	CHEMBL666142	Inhibition of human cyclin-dependent kinase 1	B	CN1CCC(O)(c2cn(-c3ccnc(NC4CCCC4)n3)c(-c3cccc(C(F)(F)F)c3)n2)CC1		CHEMBL118258	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	1400107	CHEMBL833497	Inhibition of human cyclin-dependent kinase 1	B	OCCCNc1cc(-c2ccnc(Nc3cccc(Cl)c3)n2)ccn1		CHEMBL300389	=	IC50	nM	17.0	CHEMBL308	Homo sapiens	IC50	uM	0.017
	1400109	CHEMBL833497	Inhibition of human cyclin-dependent kinase 1	B	OCCCNc1cncc(-c2cc(Nc3cccc(Cl)c3)ncn2)c1		CHEMBL355578	=	IC50	nM	2400.0	CHEMBL308	Homo sapiens	IC50	uM	2.4
	1400121	CHEMBL833497	Inhibition of human cyclin-dependent kinase 1	B	OCCCNc1cncc(-c2cncc(Nc3cccc(Cl)c3)n2)c1		CHEMBL177688	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	1400285	CHEMBL833497	Inhibition of human cyclin-dependent kinase 1	B	OCCCNc1cncc(-c2cnc(Nc3cccc(Cl)c3)cn2)c1		CHEMBL368997	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	1400287	CHEMBL833497	Inhibition of human cyclin-dependent kinase 1	B	OCCCNc1cncc(-c2ncc(Nc3cccc(Cl)c3)cn2)c1		CHEMBL177548	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	1400289	CHEMBL833497	Inhibition of human cyclin-dependent kinase 1	B	OCCCNc1ccc(-c2ncncc2Nc2cccc(Cl)c2)cn1		CHEMBL369217	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	1400291	CHEMBL833497	Inhibition of human cyclin-dependent kinase 1	B	OCCCNc1cncc(-c2cncc(Nc3cccc(Cl)c3)n2)n1		CHEMBL178743	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	1400293	CHEMBL833497	Inhibition of human cyclin-dependent kinase 1	B	OCCCNc1cccc(-c2cncc(Nc3cccc(Cl)c3)n2)n1		CHEMBL177384	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	1400295	CHEMBL833497	Inhibition of human cyclin-dependent kinase 1	B	OCCCNc1cc(-c2cncc(Nc3cccc(Cl)c3)n2)ccn1		CHEMBL177434	=	IC50	nM	500.0	CHEMBL308	Homo sapiens	IC50	uM	0.5
	1400297	CHEMBL833497	Inhibition of human cyclin-dependent kinase 1	B	OCCCNc1cnccc1-c1cncc(Nc2cccc(Cl)c2)n1		CHEMBL178484	=	IC50	nM	2220.0	CHEMBL308	Homo sapiens	IC50	uM	2.22
	1400300	CHEMBL833497	Inhibition of human cyclin-dependent kinase 1	B	OCCCNc1ccc(-c2cncc(Nc3cccc(Cl)c3)n2)nc1		CHEMBL177806	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	1400302	CHEMBL833497	Inhibition of human cyclin-dependent kinase 1	B	OCCCNc1ncc(-c2cncc(Nc3cccc(Cl)c3)n2)s1		CHEMBL368786	=	IC50	nM	8080.0	CHEMBL308	Homo sapiens	IC50	uM	8.08
	1400304	CHEMBL833497	Inhibition of human cyclin-dependent kinase 1	B	OCCCNc1ncc(-c2cncc(Nc3cccc(Cl)c3)n2)o1		CHEMBL368936	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	1490901	CHEMBL832701	Inhibition of cyclin dependent kinase (CDK1)	B	OCCCNc1cncc(-c2ncnc(Nc3cccc(Cl)c3)n2)c1		CHEMBL365937	=	IC50	nM	60.0	CHEMBL308	Homo sapiens	IC50	uM	0.06
	1490903	CHEMBL832701	Inhibition of cyclin dependent kinase (CDK1)	B	OCCCNc1cncc(-c2ncnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL363590	=	IC50	nM	344.0	CHEMBL308	Homo sapiens	IC50	uM	0.344
	1490905	CHEMBL832701	Inhibition of cyclin dependent kinase (CDK1)	B	OCCCNc1cncc(-c2ncnc(Nc3ccc(N4CCOCC4)cc3)n2)c1		CHEMBL191377	=	IC50	nM	1240.0	CHEMBL308	Homo sapiens	IC50	uM	1.24
	1490907	CHEMBL827932	Inhibition of cyclin dependent kinase CDK1	B	OCCCNc1cc(-c2ncnc(Nc3cccc(Cl)c3)n2)ccn1		CHEMBL191336	=	IC50	nM	21.0	CHEMBL308	Homo sapiens	IC50	uM	0.021
	1491030	CHEMBL832701	Inhibition of cyclin dependent kinase (CDK1)	B	OCCCNc1cncc(-c2ncnc(Nc3cccc(Cl)c3)n2)n1		CHEMBL193029	=	IC50	nM	971.0	CHEMBL308	Homo sapiens	IC50	uM	0.971
	1491032	CHEMBL832701	Inhibition of cyclin dependent kinase (CDK1)	B	Nc1nc(Nc2cccc(Cl)c2)nc(-c2ccnc(NCCCO)c2)n1		CHEMBL190805	=	IC50	nM	1108.0	CHEMBL308	Homo sapiens	IC50	uM	1.108
	1492282	CHEMBL829323	Inhibition of cyclin-dependent kinase 1 (CDK 1)	B	COc1ccc(-c2oc3ncnc(NCCO)c3c2-c2ccc(OC)cc2)cc1		CHEMBL190201	=	IC50	nM	29400.0	CHEMBL308	Homo sapiens	IC50	uM	29.4
	1492368	CHEMBL829323	Inhibition of cyclin-dependent kinase 1 (CDK 1)	B	OCCNc1ncnc2oc(-c3ccccc3)c(-c3ccccc3)c12	Outside typical range	CHEMBL189434	>	IC50	nM	200000.0	CHEMBL308	Homo sapiens	IC50	uM	200.0
	1492372	CHEMBL829323	Inhibition of cyclin-dependent kinase 1 (CDK 1)	B	CN(CCO)c1ncnc2oc(-c3ccccc3)c(-c3ccccc3)c12	Outside typical range	CHEMBL364811	=	IC50	nM	111400.0	CHEMBL308	Homo sapiens	IC50	uM	111.4
	1492375	CHEMBL829323	Inhibition of cyclin-dependent kinase 1 (CDK 1)	B	O=C(O)CNc1ncnc2oc(-c3ccccc3)c(-c3ccccc3)c12	Outside typical range	CHEMBL363302	>	IC50	nM	200000.0	CHEMBL308	Homo sapiens	IC50	uM	200.0
	1492378	CHEMBL829323	Inhibition of cyclin-dependent kinase 1 (CDK 1)	B	OCCNc1ncnc2[nH]c(-c3ccccc3)c(-c3ccccc3)c12		CHEMBL366312	=	IC50	nM	5000.0	CHEMBL308	Homo sapiens	IC50	uM	5.0
	1492382	CHEMBL829323	Inhibition of cyclin-dependent kinase 1 (CDK 1)	B	CC(O)CNc1[nH]cnc2nc(-c3ccccc3)c(-c3ccccc3)c1-2		CHEMBL371415	=	IC50	nM	3700.0	CHEMBL308	Homo sapiens	IC50	uM	3.7
	1492385	CHEMBL829323	Inhibition of cyclin-dependent kinase 1 (CDK 1)	B	OCC(O)CNc1[nH]cnc2nc(-c3ccccc3)c(-c3ccccc3)c1-2		CHEMBL372247	=	IC50	nM	1500.0	CHEMBL308	Homo sapiens	IC50	uM	1.5
	1507334	CHEMBL876148	Inhibition of Serine/threonine kinase Cdc2 (Cdc2)	B	CC(CN(C)C)Oc1ccc(Cl)cc1NC(=O)Nc1cnc(C#N)cn1		CHEMBL425904	>	IC50	nM	50000.0	CHEMBL308	Homo sapiens	IC50	nM	50000.0
	1507351	CHEMBL876148	Inhibition of Serine/threonine kinase Cdc2 (Cdc2)	B	CC1(COc2ccc(Cl)cc2NC(=O)Nc2cnc(C#N)cn2)COC1		CHEMBL192161	>	IC50	nM	50000.0	CHEMBL308	Homo sapiens	IC50	nM	50000.0
	1513789	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	FC(F)(F)c1cnc(Nc2ccc3[nH]cnc3c2)nc1Nc1ccc2[nH]cnc2c1		CHEMBL193519	=	IC50	nM	10.0	CHEMBL308	Homo sapiens	IC50	nM	10.0
	1513790	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	Brc1cnc(Nc2ccc3[nH]cnc3c2)nc1Nc1ccc2[nH]cnc2c1		CHEMBL372503	=	IC50	nM	14.0	CHEMBL308	Homo sapiens	IC50	nM	14.0
	1517692	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	FC(F)(F)c1cnc(Nc2cccc(Cl)c2)nc1Nc1ccc2[nH]cnc2c1		CHEMBL372672	=	IC50	nM	22.0	CHEMBL308	Homo sapiens	IC50	nM	22.0
	1517813	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	CN(c1cccc(Cl)c1)c1ncc(C(F)(F)F)c(Nc2ccc3[nH]cnc3c2)n1		CHEMBL195717	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	nM	1000.0
	1517950	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	Clc1cccc(Nc2ncc(Br)c(Nc3ccc4[nH]cnc4c3)n2)c1		CHEMBL370728	=	IC50	nM	9.0	CHEMBL308	Homo sapiens	IC50	nM	9.0
	1517951	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	FC(F)(F)c1cnc(Nc2ccccc2Cl)nc1Nc1ccc2[nH]cnc2c1		CHEMBL193935	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	nM	1000.0
	1517952	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	Cc1cccc(Nc2ncc(C(F)(F)F)c(Nc3ccc4[nH]cnc4c3)n2)c1		CHEMBL444874	=	IC50	nM	15.0	CHEMBL308	Homo sapiens	IC50	nM	15.0
	1517953	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	FC(F)(F)c1ccc(Nc2ncc(C(F)(F)F)c(Nc3ccc4[nH]cnc4c3)n2)cc1		CHEMBL363138	=	IC50	nM	15.0	CHEMBL308	Homo sapiens	IC50	nM	15.0
	1517954	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	Brc1cnc(Nc2ccc(Oc3cccnc3)cc2)nc1Nc1ccc2[nH]cnc2c1		CHEMBL195831	=	IC50	nM	248.0	CHEMBL308	Homo sapiens	IC50	nM	248.0
	1517975	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	FC(F)(F)c1cnc(Nc2ccc3[nH]cnc3c2)nc1Nc1ccccc1Cl		CHEMBL194721	=	IC50	nM	0.9	CHEMBL308	Homo sapiens	IC50	nM	0.9
	1518332	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	Fc1cnc(Nc2ccc3[nH]cnc3c2)nc1Nc1ccc2[nH]cnc2c1		CHEMBL194028	=	IC50	nM	430.0	CHEMBL308	Homo sapiens	IC50	nM	430.0
	1518333	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	c1cc(Nc2ccc3[nH]cnc3c2)nc(Nc2ccc3[nH]cnc3c2)n1		CHEMBL193350	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	nM	1000.0
	1518334	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	Brc1cnc(Nc2ccc3[nH]ccc3c2)nc1Nc1ccc2[nH]ccc2c1		CHEMBL365554	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	nM	1000.0
	1518335	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	FC(F)(F)c1cnc(Nc2ccc3[nH]ccc3c2)nc1Nc1ccc2[nH]ccc2c1		CHEMBL370536	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	nM	1000.0
	1518487	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	FC(F)(F)c1cnc(Nc2ccc3[nH]cnc3c2)nc1Nc1cccc(Cl)c1		CHEMBL193922	=	IC50	nM	3.0	CHEMBL308	Homo sapiens	IC50	nM	3.0
	1518488	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	FC(F)(F)c1cnc(Nc2ccc3[nH]cnc3c2)nc1Nc1ccc(Cl)cc1		CHEMBL193367	=	IC50	nM	4.0	CHEMBL308	Homo sapiens	IC50	nM	4.0
	1518489	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	Fc1ccc(Nc2nc(Nc3ccc4[nH]cnc4c3)ncc2Br)cc1		CHEMBL195423	=	IC50	nM	4.0	CHEMBL308	Homo sapiens	IC50	nM	4.0
	1518750	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	COc1ccc(Nc2nc(Nc3ccc4[nH]cnc4c3)ncc2C(F)(F)F)cc1		CHEMBL372464	=	IC50	nM	8.0	CHEMBL308	Homo sapiens	IC50	nM	8.0
	1518758	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	Brc1cnc(Nc2ccc3[nH]cnc3c2)nc1Nc1ccc2c(c1)OCO2		CHEMBL372465	=	IC50	nM	9.0	CHEMBL308	Homo sapiens	IC50	nM	9.0
	1518759	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	Brc1cnc(Nc2ccc3[nH]cnc3c2)nc1Nc1ccc(Oc2cccnc2)cc1		CHEMBL194032	=	IC50	nM	34.0	CHEMBL308	Homo sapiens	IC50	nM	34.0
	1518760	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	Clc1cccc(CNc2nc(Nc3ccc4[nH]cnc4c3)ncc2Br)c1Cl		CHEMBL192374	=	IC50	nM	126.0	CHEMBL308	Homo sapiens	IC50	nM	126.0
	1518761	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	Cc1ccccc1Oc1nc(Nc2ccc3[nH]cnc3c2)ncc1C(F)(F)F		CHEMBL370522	=	IC50	nM	4.0	CHEMBL308	Homo sapiens	IC50	nM	4.0
	1518762	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	Cc1ccccc1Sc1nc(Nc2ccc3[nH]cnc3c2)ncc1C(F)(F)F		CHEMBL194124	=	IC50	nM	135.0	CHEMBL308	Homo sapiens	IC50	nM	135.0
	1518763	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	Fc1ccc(Oc2nc(Nc3ccc4[nH]cnc4c3)ncc2C(F)(F)F)cc1		CHEMBL370316	=	IC50	nM	32.0	CHEMBL308	Homo sapiens	IC50	nM	32.0
	1518764	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	FC(F)(F)c1cnc(Nc2ccc3[nH]cnc3c2)nc1Oc1ccc(Cl)cc1		CHEMBL195595	=	IC50	nM	252.0	CHEMBL308	Homo sapiens	IC50	nM	252.0
	1518765	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	FC(F)(F)c1cnc(Nc2ccc3[nH]cnc3c2)nc1Oc1ccc(Br)cc1		CHEMBL193936	=	IC50	nM	562.0	CHEMBL308	Homo sapiens	IC50	nM	562.0
	1518766	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	FC(F)(F)c1ccc(Oc2nc(Nc3ccc4[nH]cnc4c3)ncc2C(F)(F)F)cc1		CHEMBL192076	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	nM	1000.0
	1518770	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	COc1cccc(Oc2nc(Nc3ccc4[nH]cnc4c3)ncc2C(F)(F)F)c1		CHEMBL371792	=	IC50	nM	160.0	CHEMBL308	Homo sapiens	IC50	nM	160.0
	1518771	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	COc1cccc(Sc2nc(Nc3ccc4[nH]cnc4c3)ncc2C(F)(F)F)c1		CHEMBL195262	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	nM	1000.0
	1518772	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	Brc1cnc(Nc2ccc3[nH]cnc3c2)nc1NC1CCc2ccccc21		CHEMBL370485	=	IC50	nM	34.0	CHEMBL308	Homo sapiens	IC50	nM	34.0
	1518773	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	Brc1cnc(Nc2ccc3[nH]cnc3c2)nc1NC1CCCc2ccccc21		CHEMBL362967	=	IC50	nM	392.0	CHEMBL308	Homo sapiens	IC50	nM	392.0
	1518774	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	CCOc1nc(Nc2ccc3[nH]cnc3c2)ncc1C(F)(F)F		CHEMBL194495	=	IC50	nM	77.0	CHEMBL308	Homo sapiens	IC50	nM	77.0
	1518775	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	CC(C)Oc1nc(Nc2ccc3[nH]cnc3c2)ncc1C(F)(F)F		CHEMBL191893	=	IC50	nM	25.0	CHEMBL308	Homo sapiens	IC50	nM	25.0
	1518776	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	CC(C)COc1nc(Nc2ccc3[nH]cnc3c2)ncc1C(F)(F)F		CHEMBL192216	=	IC50	nM	2.0	CHEMBL308	Homo sapiens	IC50	nM	2.0
	1518777	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	FC(F)(F)c1cnc(Nc2ccc3[nH]cnc3c2)nc1OC1CCCCC1		CHEMBL193860	=	IC50	nM	43.0	CHEMBL308	Homo sapiens	IC50	nM	43.0
	1518876	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	Fc1cnc(Nc2ccc3[nH]ccc3c2)nc1Nc1ccc2[nH]ccc2c1		CHEMBL365599	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	nM	1000.0
	1518877	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	c1cc(Nc2ccc3[nH]ccc3c2)nc(Nc2ccc3[nH]ccc3c2)n1		CHEMBL194882	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	nM	1000.0
	1518878	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	N#CNc1ccc(Nc2ncc(C(F)(F)F)c(Nc3ccc4[nH]cnc4c3)n2)cc1NC#N		CHEMBL195641	=	IC50	nM	10.0	CHEMBL308	Homo sapiens	IC50	nM	10.0
	1519139	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	NS(=O)(=O)c1ccc(Nc2ncc(C(F)(F)F)c(Nc3ccc4[nH]cnc4c3)n2)cc1		CHEMBL194540	=	IC50	nM	0.1	CHEMBL308	Homo sapiens	IC50	nM	0.1
	1519426	CHEMBL827874	Inhibitory concentration against Cyclin dependent kinase 1	B	FC(F)(F)c1cnc(Nc2ccc(Br)cc2)nc1Nc1ccc2[nH]cnc2c1		CHEMBL364935	=	IC50	nM	11.0	CHEMBL308	Homo sapiens	IC50	nM	11.0
	1653639	CHEMBL861481	Inhibitory activity against CDK1	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	1664660	CHEMBL863536	Inhibition of CDK1 at 10 uM	B	COc1ccc(C#CC(C)(C)N)cc1-c1[nH]nc2nc(Nc3ccc(F)cc3F)ccc12		CHEMBL200820	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	Inhibition	%	0.0
	1664708	CHEMBL863536	Inhibition of CDK1 at 10 uM	B	COc1ccc(C#CC(C)(C)N)cc1-c1[nH]nc2nc(Nc3ccc(F)cc3F)ncc12	Outside typical range	CHEMBL370808	=	Inhibition	%	-16.0	CHEMBL308	Homo sapiens	Inhibition	%	-16.0
	1664750	CHEMBL863536	Inhibition of CDK1 at 10 uM	B	COc1ccc(C#CC(C)(C)O)cc1-c1[nH]nc2nc(Nc3ccc(F)cc3F)cnc12	Outside typical range	CHEMBL370156	=	Inhibition	%	-13.0	CHEMBL308	Homo sapiens	Inhibition	%	-13.0
	1666754	CHEMBL865810	Inhibitory activity against CDC2	B	COc1cc(-c2ccc3c(c2)NC(=O)/C3=C\c2ccc[nH]2)ccc1O		CHEMBL202930	>	IC50	nM	50000.0	CHEMBL308	Homo sapiens	IC50	nM	50000.0
	1666765	CHEMBL865810	Inhibitory activity against CDC2	B	COc1cc(-c2ccc3c(c2)NC(=O)/C3=C\c2c[nH]c3ncccc23)ccc1O		CHEMBL383316	=	IC50	nM	454.0	CHEMBL308	Homo sapiens	IC50	nM	454.0
	1666777	CHEMBL865810	Inhibitory activity against CDC2	B	COc1cc(-c2ccc3c(c2)NC(=O)/C3=C\c2ncc[nH]2)ccc1O		CHEMBL199299	=	IC50	nM	251.0	CHEMBL308	Homo sapiens	IC50	nM	251.0
	1693253	CHEMBL867702	Inhibition of CDK1 using 100 uM ATP	B	Brc1cccc(-c2cc(NCc3ccncc3)n3ncnc3n2)c1		CHEMBL203006	=	IC50	nM	8800.0	CHEMBL308	Homo sapiens	IC50	uM	8.8
	1693254	CHEMBL867702	Inhibition of CDK1 using 100 uM ATP	B	N[C@H]1CC[C@H](Nc2cc(Nc3ccc(S(=O)(=O)c4ccccc4)cc3)n3ncnc3n2)CC1		CHEMBL382607	=	IC50	nM	4300.0	CHEMBL308	Homo sapiens	IC50	uM	4.3
	1693255	CHEMBL867702	Inhibition of CDK1 using 100 uM ATP	B	CS(=O)(=O)c1ccc(Nc2cc(N[C@H]3CC[C@H](N)CC3)nc3ncnn23)cc1		CHEMBL206659	=	IC50	nM	16000.0	CHEMBL308	Homo sapiens	IC50	uM	16.0
	1693256	CHEMBL867702	Inhibition of CDK1 using 100 uM ATP	B	CN(C)S(=O)(=O)c1ccc(Nc2cc(N[C@H]3CC[C@H](N)CC3)nc3ncnn23)cc1		CHEMBL202695	=	IC50	nM	5600.0	CHEMBL308	Homo sapiens	IC50	uM	5.6
	1693257	CHEMBL867702	Inhibition of CDK1 using 100 uM ATP	B	CCN(CC)c1cc(Nc2ccc(S(N)(=O)=O)cc2)n2ncnc2n1		CHEMBL203571	=	IC50	nM	3400.0	CHEMBL308	Homo sapiens	IC50	uM	3.4
	1693258	CHEMBL867702	Inhibition of CDK1 using 100 uM ATP	B	NS(=O)(=O)c1ccc(Nc2cc(OC3CCCCC3)nc3ncnn23)cc1		CHEMBL203407	=	IC50	nM	140.0	CHEMBL308	Homo sapiens	IC50	uM	0.14
	1704939	CHEMBL864417	Inhibition of CDK1 at 10 uM ATP	B	N[C@H](COc1cncc(/C=C/c2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL383541	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	nM	10000.0
	1704961	CHEMBL864417	Inhibition of CDK1 at 10 uM ATP	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	0.4	CHEMBL308	Homo sapiens	IC50	nM	0.4
	1704962	CHEMBL864417	Inhibition of CDK1 at 10 uM ATP	B	N[C@H](COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL383264	=	IC50	nM	100.0	CHEMBL308	Homo sapiens	IC50	nM	100.0
	1722979	CHEMBL860194	Inhibition of CDC2	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	>	Ki	nM	8900.0	CHEMBL308	Homo sapiens	Ki	nM	8900.0
	1723032	CHEMBL860194	Inhibition of CDC2	B	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1C#N		CHEMBL210963	>	Ki	nM	8900.0	CHEMBL308	Homo sapiens	Ki	nM	8900.0
	1723072	CHEMBL860194	Inhibition of CDC2	B	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1Cl		CHEMBL210928	>	Ki	nM	8900.0	CHEMBL308	Homo sapiens	Ki	nM	8900.0
	1723073	CHEMBL860194	Inhibition of CDC2	B	CC(=O)Nc1cc(N)c(C#N)c(-c2ccccc2)n1		CHEMBL210032	>	Ki	nM	8900.0	CHEMBL308	Homo sapiens	Ki	nM	8900.0
	1723074	CHEMBL860194	Inhibition of CDC2	B	COc1cc(S(C)(=O)=O)c(OC)cc1CC(=O)Nc1cc(N)c(C#N)c(OC(C)C)n1		CHEMBL378627	>	Ki	nM	8900.0	CHEMBL308	Homo sapiens	Ki	nM	8900.0
	1723075	CHEMBL860194	Inhibition of CDC2	B	CCOc1nc(NC(C)=O)cc(N)c1C#N		CHEMBL208637	>	Ki	nM	8900.0	CHEMBL308	Homo sapiens	Ki	nM	8900.0
	1726463	CHEMBL861326	Inhibition of CDK1 at 5 uM ATP	B	N[C@H](COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL383264	=	IC50	nM	100.0	CHEMBL308	Homo sapiens	IC50	nM	100.0
	1726464	CHEMBL861326	Inhibition of CDK1 at 5 uM ATP	B	Nc1cc2cc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)ccc2cn1		CHEMBL210390	=	IC50	nM	22.0	CHEMBL308	Homo sapiens	IC50	nM	22.0
	1726465	CHEMBL861326	Inhibition of CDK1 at 5 uM ATP	B	N[C@H](COc1cncc(-c2ccc3cnc(F)cc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL210246	=	IC50	nM	3400.0	CHEMBL308	Homo sapiens	IC50	nM	3400.0
	1726466	CHEMBL861326	Inhibition of CDK1 at 5 uM ATP	B	C#Cc1ncc(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1ccc2cnccc2c1		CHEMBL207544	=	IC50	nM	4900.0	CHEMBL308	Homo sapiens	IC50	nM	4900.0
	1726467	CHEMBL861326	Inhibition of CDK1 at 5 uM ATP	B	N[C@H](COc1cnc(Cl)c(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL378963	=	IC50	nM	870.0	CHEMBL308	Homo sapiens	IC50	nM	870.0
	1736618	CHEMBL870940	Inhibition of CDK1	B	Cc1cc(-c2cnc(Nc3cnc(CN4CCN(C)CC4)cn3)s2)nc(OC2CCCCC2)n1		CHEMBL210540	=	IC50	nM	600.0	CHEMBL308	Homo sapiens	IC50	nM	600.0
	1736680	CHEMBL870940	Inhibition of CDK1	B	Cc1cc(-c2cnc(Nc3ccccn3)s2)nc(OC2CCCCC2)n1		CHEMBL427045	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	nM	10000.0
	1736703	CHEMBL870940	Inhibition of CDK1	B	Cc1cnc(OC2CCCCC2)nc1-c1cnc(Nc2ccccn2)s1		CHEMBL212049	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	nM	1000.0
	1736723	CHEMBL870940	Inhibition of CDK1	B	c1ccc(Nc2ncc(-c3ccnc(OC4CCCCC4)n3)s2)nc1		CHEMBL424696	=	IC50	nM	24.0	CHEMBL308	Homo sapiens	IC50	nM	24.0
	1737602	CHEMBL869289	Inhibition of CDK1	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	IC50	nM	6.0	CHEMBL308	Homo sapiens	IC50	nM	6.0
	1737630	CHEMBL869289	Inhibition of CDK1	B	Nc1nc(Nc2ccc(S(=O)(=O)NC(=O)[C@H](N)CO)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL212264	=	IC50	nM	1410.0	CHEMBL308	Homo sapiens	IC50	uM	1.41
	1737655	CHEMBL869289	Inhibition of CDK1	B	CCOC(=O)CCC(=O)NS(=O)(=O)c1ccc(Nc2nc(N)n(C(=O)c3c(F)cccc3F)n2)cc1		CHEMBL379193	=	IC50	nM	466.0	CHEMBL308	Homo sapiens	IC50	uM	0.466
	1737678	CHEMBL869289	Inhibition of CDK1	B	COCCOCC(=O)NS(=O)(=O)c1ccc(Nc2nc(N)n(C(=O)c3c(F)cccc3F)n2)cc1		CHEMBL210581	=	IC50	nM	1660.0	CHEMBL308	Homo sapiens	IC50	uM	1.66
	1737714	CHEMBL869289	Inhibition of CDK1	B	NCC(=O)NS(=O)(=O)c1ccc(Nc2nc(N)n(C(=O)c3c(F)cccc3F)n2)cc1		CHEMBL378248	=	IC50	nM	1070.0	CHEMBL308	Homo sapiens	IC50	uM	1.07
	1737763	CHEMBL869289	Inhibition of CDK1	B	CN1CCN(CCC(=O)NS(=O)(=O)c2ccc(Nc3nc(N)n(C(=O)c4c(F)cccc4F)n3)cc2)CC1		CHEMBL210765	=	IC50	nM	1340.0	CHEMBL308	Homo sapiens	IC50	uM	1.34
	1737819	CHEMBL869289	Inhibition of CDK1	B	Nc1nc(Nc2ccc(S(=O)(=O)NC(=O)CCC(=O)O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL209280	=	IC50	nM	494.0	CHEMBL308	Homo sapiens	IC50	uM	0.494
	1737865	CHEMBL869289	Inhibition of CDK1	B	Nc1nc(Nc2ccc(S(=O)(=O)NC(=O)CCN3CCOCC3)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL378420	=	IC50	nM	1550.0	CHEMBL308	Homo sapiens	IC50	uM	1.55
	1744510	CHEMBL867292	Inhibition of CDC2	B	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1Cl		CHEMBL377383	>	Ki	nM	8900.0	CHEMBL308	Homo sapiens	Ki	uM	8.9
	1769366	CHEMBL910892	Inhibition of CDK1	B	O=C(Nc1cc(CN[C@H]2Cc3ccc(Cl)cc3C2)n[nH]1)Nc1cccc2c1[C@@H]1CCCN1C2=O		CHEMBL336242	=	IC50	nM	1800.0	CHEMBL308	Homo sapiens	IC50	nM	1800.0
	1769369	CHEMBL910892	Inhibition of CDK1	B	O=C(Nc1ccccn1)Nc1cccc2c1[C@H]1CCCN1C2=O		CHEMBL141247	=	IC50	nM	122.0	CHEMBL308	Homo sapiens	IC50	nM	122.0
	1769372	CHEMBL910892	Inhibition of CDK1	B	C[C@@H]1C[C@H]2CN1CCn1nc3c(cccc3c1O)-c1nc3c(cccc3nc1O)O2		CHEMBL215803	=	IC50	nM	1.0	CHEMBL308	Homo sapiens	IC50	nM	1.0
	1777417	CHEMBL908826	Inhibition of CDK1/Cyclin B	B	COc1cccc(C(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2N)c1		CHEMBL408439	>	Ki	nM	10000.0	CHEMBL308	Homo sapiens	Ki	uM	10.0
	1777425	CHEMBL908826	Inhibition of CDK1/Cyclin B	B	COc1ccccc1C(=O)c1cnc(Nc2ccc(N3CCN(C)CC3)cc2)nc1N		CHEMBL383875	=	Ki	nM	1259.0	CHEMBL308	Homo sapiens	Ki	uM	1.259
	1777426	CHEMBL908826	Inhibition of CDK1/Cyclin B	B	Cc1ccccc1C(=O)c1cnc(Nc2ccc(N3CCN(C)CC3)cc2)nc1N		CHEMBL437330	>	Ki	nM	10000.0	CHEMBL308	Homo sapiens	Ki	uM	10.0
	1777427	CHEMBL908826	Inhibition of CDK1/Cyclin B	B	CN1CCN(c2ccc(Nc3ncc(C(=O)c4ccccc4C(F)(F)F)c(N)n3)cc2)CC1		CHEMBL385039	>	Ki	nM	10000.0	CHEMBL308	Homo sapiens	Ki	uM	10.0
	1777428	CHEMBL908826	Inhibition of CDK1/Cyclin B	B	CN1CCN(c2ccc(Nc3ncc(C(=O)c4cccc(C(F)(F)F)c4)c(N)n3)cc2)CC1		CHEMBL214838	>	Ki	nM	10000.0	CHEMBL308	Homo sapiens	Ki	uM	10.0
	1777429	CHEMBL908826	Inhibition of CDK1/Cyclin B	B	CN1CCN(c2ccc(Nc3ncc(C(=O)c4cccc(F)c4)c(N)n3)cc2)CC1		CHEMBL214458	>	Ki	nM	10000.0	CHEMBL308	Homo sapiens	Ki	uM	10.0
	1777460	CHEMBL908826	Inhibition of CDK1/Cyclin B	B	COc1c(C(=O)c2cnc(NC3CCN(S(C)(=O)=O)CC3)nc2N)cc(F)c(F)c1F		CHEMBL214183	=	Ki	nM	1667.0	CHEMBL308	Homo sapiens	Ki	uM	1.667
	1777461	CHEMBL908826	Inhibition of CDK1/Cyclin B	B	COc1cc(F)c(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL213713	=	Ki	nM	5.0	CHEMBL308	Homo sapiens	Ki	uM	0.005
	1777462	CHEMBL908826	Inhibition of CDK1/Cyclin B	B	COc1cc(F)c(F)cc1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL215086	=	Ki	nM	14.0	CHEMBL308	Homo sapiens	Ki	uM	0.014
	1777463	CHEMBL908826	Inhibition of CDK1/Cyclin B	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	=	Ki	nM	2.0	CHEMBL308	Homo sapiens	Ki	uM	0.002
	1777464	CHEMBL908826	Inhibition of CDK1/Cyclin B	B	CS(=O)(=O)N1CCC(Nc2ncc(C(=O)c3c(F)cccc3F)c(N)n2)CC1		CHEMBL265903	=	Ki	nM	38.0	CHEMBL308	Homo sapiens	Ki	uM	0.038
	1777465	CHEMBL908826	Inhibition of CDK1/Cyclin B	B	COc1cccc(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL385733	=	Ki	nM	17.0	CHEMBL308	Homo sapiens	Ki	uM	0.017
	1777466	CHEMBL908826	Inhibition of CDK1/Cyclin B	B	COc1ccc(Cl)cc1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL385373	=	Ki	nM	133.0	CHEMBL308	Homo sapiens	Ki	uM	0.133
	1777467	CHEMBL908826	Inhibition of CDK1/Cyclin B	B	COc1ccc(F)cc1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL268507	=	Ki	nM	14.0	CHEMBL308	Homo sapiens	Ki	uM	0.014
	1777468	CHEMBL908826	Inhibition of CDK1/Cyclin B	B	COc1cc(F)ccc1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL277351	=	Ki	nM	193.0	CHEMBL308	Homo sapiens	Ki	uM	0.193
	1777469	CHEMBL908826	Inhibition of CDK1/Cyclin B	B	CCOc1ccccc1C(=O)c1cnc(NC2CCN(C(C)=O)CC2)nc1N		CHEMBL216148	=	Ki	nM	2500.0	CHEMBL308	Homo sapiens	Ki	uM	2.5
	1777470	CHEMBL908826	Inhibition of CDK1/Cyclin B	B	CCOC(=O)N1CCC(Nc2ncc(C(=O)c3ccccc3C)c(N)n2)CC1		CHEMBL214433	=	Ki	nM	1108.0	CHEMBL308	Homo sapiens	Ki	uM	1.108
	1777471	CHEMBL908826	Inhibition of CDK1/Cyclin B	B	CCOC(=O)N1CCC(Nc2ncc(C(=O)c3ccccc3F)c(N)n2)CC1		CHEMBL214025	=	Ki	nM	1638.0	CHEMBL308	Homo sapiens	Ki	uM	1.638
	1777472	CHEMBL908826	Inhibition of CDK1/Cyclin B	B	CCS(=O)(=O)N1CCC(Nc2ncc(C(=O)c3ccccc3OC)c(N)n2)CC1		CHEMBL385190	=	Ki	nM	43.0	CHEMBL308	Homo sapiens	Ki	uM	0.043
	1777473	CHEMBL908826	Inhibition of CDK1/Cyclin B	B	COc1ccccc1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL216126	=	Ki	nM	28.0	CHEMBL308	Homo sapiens	Ki	uM	0.028
	1777474	CHEMBL908826	Inhibition of CDK1/Cyclin B	B	CCCC(=O)N1CCC(Nc2ncc(C(=O)c3ccccc3OC)c(N)n2)CC1		CHEMBL384356	=	Ki	nM	278.0	CHEMBL308	Homo sapiens	Ki	uM	0.278
	1777475	CHEMBL908826	Inhibition of CDK1/Cyclin B	B	COc1ccccc1C(=O)c1cnc(NC2CCN(C(C)=O)CC2)nc1N		CHEMBL217537	=	Ki	nM	181.0	CHEMBL308	Homo sapiens	Ki	uM	0.181
	1777476	CHEMBL908826	Inhibition of CDK1/Cyclin B	B	CCOC(=O)N1CCC(Nc2ncc(C(=O)c3ccccc3OC)c(N)n2)CC1		CHEMBL217443	=	Ki	nM	246.0	CHEMBL308	Homo sapiens	Ki	uM	0.246
	1777477	CHEMBL908826	Inhibition of CDK1/Cyclin B	B	CCNC(=O)N1CCC(Nc2ncc(C(=O)c3ccccc3OC)c(N)n2)CC1		CHEMBL385907	=	Ki	nM	1530.0	CHEMBL308	Homo sapiens	Ki	uM	1.53
	1777478	CHEMBL908826	Inhibition of CDK1/Cyclin B	B	COc1ccccc1C(=O)c1cnc(NC2CCN(C)CC2)nc1N		CHEMBL214831	=	Ki	nM	6615.0	CHEMBL308	Homo sapiens	Ki	uM	6.615
	1777479	CHEMBL908826	Inhibition of CDK1/Cyclin B	B	COc1ccccc1C(=O)c1cnc(NC2CCNCC2)nc1N		CHEMBL387448	=	Ki	nM	5841.0	CHEMBL308	Homo sapiens	Ki	uM	5.841
	1790094	CHEMBL873737	Inhibition of in vitro CDK1 kinase activity	B	COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1		CHEMBL202721	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	umol	10.0
	1790306	CHEMBL873752	Inhibition of CDK1	B	CN1CCN(c2ccc(Nc3ncc4ccn(C5CCCCC5)c4n3)cc2)CC1		CHEMBL214329	=	IC50	nM	1600.0	CHEMBL308	Homo sapiens	IC50	uM	1.6
Not Active	1810800	CHEMBL907884	Inhibition of CDK1	B	CCO/N=C/c1c(N)ncnc1Oc1ccc2[nH]c(C)cc2c1F		CHEMBL223892		Activity			CHEMBL308	Homo sapiens	Activity		
Not Active	1810804	CHEMBL907884	Inhibition of CDK1	B	COCCO/N=C/c1c(N)ncnc1Oc1ccc2[nH]c(C)cc2c1F		CHEMBL219983		Activity			CHEMBL308	Homo sapiens	Activity		
	1816520	CHEMBL911990	Inhibition of CDK1 at 1 uM	B	O=C1NCc2c3c(c4[nH]c5ccccc5c4c21)Cc1ccccc1-3		CHEMBL148471	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	Inhibition	%	30.0
	1816538	CHEMBL911990	Inhibition of CDK1 at 1 uM	B	O=C1NCc2c1c1c3ccccc3sc1c1[nH]c3ccccc3c21		CHEMBL221536	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	Inhibition	%	30.0
	1816539	CHEMBL911990	Inhibition of CDK1 at 1 uM	B	O=C1NCc2c1c1c(c3[nH]c4ccccc4c23)Cc2ccccc2-1		CHEMBL357490	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	Inhibition	%	30.0
	1816540	CHEMBL911990	Inhibition of CDK1 at 1 uM	B	O=C1NCc2c3c(c4[nH]c5ccccc5c4c21)CCc1ccccc1-3		CHEMBL374581	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	Inhibition	%	30.0
	1816541	CHEMBL911990	Inhibition of CDK1 at 1 uM	B	O=C1NC(=O)c2c1c1c(c3[nH]c4ccccc4c23)CCc2ccccc2-1		CHEMBL386636	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	Inhibition	%	30.0
	1824463	CHEMBL913841	Inhibition of Cdc2	B	CS(=O)(=O)Nc1cc2c(cc1Cl)NC(=O)Nc1cnc(C#N)c(n1)OCCCCCO2		CHEMBL223460	>	Ki	nM	10000.0	CHEMBL308	Homo sapiens	Ki	uM	10.0
	1824697	CHEMBL913841	Inhibition of Cdc2	B	N#Cc1ncc2nc1OCCCCCOc1cc(OCCCO)c(Cl)cc1NC(=O)N2		CHEMBL373598	>	Ki	nM	10000.0	CHEMBL308	Homo sapiens	Ki	uM	10.0
	1824773	CHEMBL913841	Inhibition of Cdc2	B	N#Cc1ncc2nc1OCCCCCOc1cc(CCCO)c(Cl)cc1NC(=O)N2		CHEMBL223367	>	Ki	nM	10000.0	CHEMBL308	Homo sapiens	Ki	uM	10.0
	1826444	CHEMBL919920	Inhibition of CDC2 using 5 to 10 ATP umol/L	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	=	IC50	nM	9800.0	CHEMBL308	Homo sapiens	IC50	nM	9800.0
	1856945	CHEMBL920652	Inhibition of CDK1	B	C/C(O)=C(\C#N)C(=O)Nc1cc(Br)ccc1Br	Outside typical range	CHEMBL228043	>	IC50	nM	500000.0	CHEMBL308	Homo sapiens	IC50	uM	500.0
	1881816	CHEMBL904794	Inhibition of CDK2	B	O=C1NCCc2[nH]c(-c3ccncc3)cc21		CHEMBL225519	=	IC50	nM	170.0	CHEMBL308	Homo sapiens	IC50	uM	0.17
	1881823	CHEMBL904794	Inhibition of CDK2	B	O=C1NCCc2[nH]c(-c3ccnc(-c4ccccc4)c3)cc21		CHEMBL388566	=	IC50	nM	18000.0	CHEMBL308	Homo sapiens	IC50	uM	18.0
	1881830	CHEMBL904794	Inhibition of CDK2	B	O=C1NCCc2[nH]c(-c3ccnc(-c4cnc5ccccc5c4)c3)cc21	Outside typical range	CHEMBL226403	>	IC50	nM	200000.0	CHEMBL308	Homo sapiens	IC50	uM	200.0
	1881840	CHEMBL904794	Inhibition of CDK2	B	O=C1NCCc2[nH]c(-c3ccnc(-c4ccccc4F)c3)cc21		CHEMBL226471	=	IC50	nM	30000.0	CHEMBL308	Homo sapiens	IC50	uM	30.0
	1916298	CHEMBL894159	Inhibition of recombinant CDC2 by radiometric assay	B	COc1cc(-c2ccc3c(c2)Nc2ccc(CC(=O)Nc4ccc(N5CCOCC5)cc4)cc2NC3=O)ccc1N		CHEMBL395080	>	IC50	nM	50000.0	CHEMBL308	Homo sapiens	IC50	uM	50.0
	1916356	CHEMBL894159	Inhibition of recombinant CDC2 by radiometric assay	B	COc1cc(-c2ccc3c(c2)Nc2ccc(C(C)(C)C(=O)Nc4ccc(N5CCOCC5)cc4)cc2NC3=O)ccc1N		CHEMBL389745	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	1922421	CHEMBL895922	Inhibition of CDK1	B	CNC(=O)c1cc(Oc2ccc3oc(Nc4ccc(Cl)c(OC[C@@H]5CCCN5C)c4)nc3c2)ccn1		CHEMBL231568	>	IC50	nM	40000.0	CHEMBL308	Homo sapiens	IC50	uM	40.0
	1944479	CHEMBL891253	Inhibition of CDC2 by radiometric assay	B	O=C(N[C@H]1CC[C@H](O)CC1)c1ccc2c(c1)Cc1c(-c3ccc(-c4ccc(O)cc4)cc3)n[nH]c1-2		CHEMBL438485	>	IC50	nM	50000.0	CHEMBL308	Homo sapiens	IC50	nM	50000.0
	1944480	CHEMBL891253	Inhibition of CDC2 by radiometric assay	B	O=C(NCc1ccncc1)c1ccc2c(c1)Cc1c(-c3ccc(-c4ccc(O)cc4)cc3)n[nH]c1-2		CHEMBL242753	>	IC50	nM	50000.0	CHEMBL308	Homo sapiens	IC50	nM	50000.0
	1956300	CHEMBL894747	Inhibition of CDK1 activity	B	N#Cc1cnc(Nc2ccccc2)nc1-c1ccccc1		CHEMBL411829	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	1956331	CHEMBL894747	Inhibition of CDK1 activity	B	CC(C)(N)c1ccc(-c2nc(Nc3ccc(OCCN4CCOCC4)cc3)ncc2C#N)cc1		CHEMBL234944	=	IC50	nM	21000.0	CHEMBL308	Homo sapiens	IC50	uM	21.0
	1956332	CHEMBL894747	Inhibition of CDK1 activity	B	CN1CCN(CCc2ccc(Nc3ncc(C#N)c(-c4ccc(C(C)(C)N)cc4)n3)cc2)CC1		CHEMBL394577	=	IC50	nM	5600.0	CHEMBL308	Homo sapiens	IC50	uM	5.6
	1956333	CHEMBL894747	Inhibition of CDK1 activity	B	CCc1nccn1CCc1ccc(Nc2ncc(C#N)c(-c3ccc(C(C)(C)N)cc3)n2)cc1		CHEMBL231824	=	IC50	nM	4800.0	CHEMBL308	Homo sapiens	IC50	uM	4.8
	1956334	CHEMBL894747	Inhibition of CDK1 activity	B	CC(C)(N)c1ccc(-c2nc(Nc3cccc(CCN4CCOCC4)c3)ncc2C#N)cc1		CHEMBL231801	=	IC50	nM	5700.0	CHEMBL308	Homo sapiens	IC50	uM	5.7
	1956335	CHEMBL894747	Inhibition of CDK1 activity	B	CC(C)(N)c1ccc(-c2nc(Nc3ccc(CCN4CCOCC4)cc3)ncc2C#N)cc1		CHEMBL231800	=	IC50	nM	4100.0	CHEMBL308	Homo sapiens	IC50	uM	4.1
	1956336	CHEMBL894747	Inhibition of CDK1 activity	B	CC(C)(C)c1nc(Nc2ccc(CCO)cc2)ncc1C#N		CHEMBL234699	=	IC50	nM	1100.0	CHEMBL308	Homo sapiens	IC50	uM	1.1
	1956337	CHEMBL894747	Inhibition of CDK1 activity	B	N#Cc1cnc(Nc2ccc(CCO)cc2)nc1-c1cc2ccccc2[nH]1		CHEMBL390186	=	IC50	nM	1700.0	CHEMBL308	Homo sapiens	IC50	uM	1.7
	1956338	CHEMBL894747	Inhibition of CDK1 activity	B	CC(C)(O)c1ccc(-c2nc(Nc3ccc(CCO)cc3)ncc2C#N)cc1		CHEMBL234697	=	IC50	nM	2700.0	CHEMBL308	Homo sapiens	IC50	uM	2.7
	1956339	CHEMBL894747	Inhibition of CDK1 activity	B	N#Cc1cnc(Nc2ccc(CCO)cc2)nc1-c1nc2ccccc2s1		CHEMBL234489	=	IC50	nM	560.0	CHEMBL308	Homo sapiens	IC50	uM	0.56
	1956340	CHEMBL894747	Inhibition of CDK1 activity	B	N#Cc1cnc(Nc2ccc(CCO)cc2)nc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL234275	=	IC50	nM	1900.0	CHEMBL308	Homo sapiens	IC50	uM	1.9
	1956341	CHEMBL894747	Inhibition of CDK1 activity	B	N#Cc1cnc(Nc2ccc(CCO)cc2)nc1-c1ccc(Br)cc1		CHEMBL234067	=	IC50	nM	2000.0	CHEMBL308	Homo sapiens	IC50	uM	2.0
	1956342	CHEMBL894747	Inhibition of CDK1 activity	B	COc1ccc(-c2nc(Nc3ccc(CCO)cc3)ncc2C#N)cc1		CHEMBL234065	=	IC50	nM	1500.0	CHEMBL308	Homo sapiens	IC50	uM	1.5
	1956343	CHEMBL894747	Inhibition of CDK1 activity	B	N#Cc1cnc(Nc2ccc(CCO)cc2)nc1-c1ccc2[nH]ccc2c1		CHEMBL389102	=	IC50	nM	410.0	CHEMBL308	Homo sapiens	IC50	uM	0.41
	1956344	CHEMBL894747	Inhibition of CDK1 activity	B	N#Cc1cnc(Nc2ccc(CCO)cc2)nc1-c1cccs1		CHEMBL245174	=	IC50	nM	470.0	CHEMBL308	Homo sapiens	IC50	uM	0.47
	1956345	CHEMBL894747	Inhibition of CDK1 activity	B	CC(C)(N)c1ccc(-c2nc(Nc3ccc(CCO)cc3)ncc2C#N)cc1		CHEMBL243017	=	IC50	nM	1600.0	CHEMBL308	Homo sapiens	IC50	uM	1.6
	1956346	CHEMBL894747	Inhibition of CDK1 activity	B	COc1ccccc1Nc1ncc(C#N)c(-c2ccccc2)n1		CHEMBL234084	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	1956347	CHEMBL894747	Inhibition of CDK1 activity	B	N#Cc1cnc(Nc2ccc(Cl)cc2)nc1-c1ccccc1		CHEMBL233877	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	1956348	CHEMBL894747	Inhibition of CDK1 activity	B	N#Cc1cnc(Nc2ccccc2Cl)nc1-c1ccccc1		CHEMBL390468	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	1956349	CHEMBL894747	Inhibition of CDK1 activity	B	N#Cc1cnc(Nc2ncccn2)nc1-c1ccccc1		CHEMBL233876	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	1956350	CHEMBL894747	Inhibition of CDK1 activity	B	N#Cc1cnc(Nc2nc3ccccc3[nH]2)nc1-c1ccccc1		CHEMBL233875	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	1956351	CHEMBL894747	Inhibition of CDK1 activity	B	N#Cc1cnc(Nc2ccc3ccccc3c2)nc1-c1ccccc1		CHEMBL390467	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	1956352	CHEMBL894747	Inhibition of CDK1 activity	B	Cc1ccc(Nc2ncc(C#N)c(-c3ccccc3)n2)cc1		CHEMBL233874	=	IC50	nM	3500.0	CHEMBL308	Homo sapiens	IC50	uM	3.5
	1956353	CHEMBL894747	Inhibition of CDK1 activity	B	COc1ccc(Nc2ncc(C#N)c(-c3ccccc3)n2)cc1		CHEMBL279574	=	IC50	nM	3300.0	CHEMBL308	Homo sapiens	IC50	uM	3.3
	1956354	CHEMBL894747	Inhibition of CDK1 activity	B	Cc1cc2cc(Nc3ncc(C#N)c(-c4ccccc4)n3)ccc2[nH]1		CHEMBL233669	=	IC50	nM	3300.0	CHEMBL308	Homo sapiens	IC50	uM	3.3
	1956355	CHEMBL894747	Inhibition of CDK1 activity	B	COc1cccc(Nc2ncc(C#N)c(-c3ccccc3)n2)c1		CHEMBL233668	=	IC50	nM	4200.0	CHEMBL308	Homo sapiens	IC50	uM	4.2
	1956356	CHEMBL894747	Inhibition of CDK1 activity	B	N#Cc1cnc(Nc2ccc(CCO)cc2)nc1-c1ccccc1		CHEMBL389343	=	IC50	nM	2000.0	CHEMBL308	Homo sapiens	IC50	uM	2.0
	1956357	CHEMBL894747	Inhibition of CDK1 activity	B	N#Cc1cnc(Nc2cccc(CN3CCOCC3)c2)nc1-c1ccccc1		CHEMBL233667	=	IC50	nM	2000.0	CHEMBL308	Homo sapiens	IC50	uM	2.0
	1956358	CHEMBL894747	Inhibition of CDK1 activity	B	N#Cc1cnc(Nc2ccc(CCC(=O)N3CCOCC3)cc2)nc1-c1ccccc1		CHEMBL233456	=	IC50	nM	2100.0	CHEMBL308	Homo sapiens	IC50	uM	2.1
	1956359	CHEMBL894747	Inhibition of CDK1 activity	B	N#Cc1cnc(Nc2ccc(CCN3CCCC3)cc2)nc1-c1ccccc1		CHEMBL233455	=	IC50	nM	6500.0	CHEMBL308	Homo sapiens	IC50	uM	6.5
	1956360	CHEMBL894747	Inhibition of CDK1 activity	B	COc1cc(Nc2ncc(C#N)c(-c3ccccc3)n2)ccc1CN1CCCC1		CHEMBL387829	=	IC50	nM	9000.0	CHEMBL308	Homo sapiens	IC50	uM	9.0
	1956361	CHEMBL894747	Inhibition of CDK1 activity	B	N#Cc1cnc(Nc2ccc(CN3CCCC3)cc2)nc1-c1ccccc1		CHEMBL233454	=	IC50	nM	6200.0	CHEMBL308	Homo sapiens	IC50	uM	6.2
	1956362	CHEMBL894748	Inhibition of CDK1 activity at 10 uM	B	N#Cc1cnc(Nc2ccccc2)nc1-c1ccccc1		CHEMBL411829	=	Inhibition	%	50.0	CHEMBL308	Homo sapiens	Inhibition	%	50.0
	1956363	CHEMBL894748	Inhibition of CDK1 activity at 10 uM	B	COc1ccccc1Nc1ncc(C#N)c(-c2ccccc2)n1		CHEMBL234084	=	Inhibition	%	50.0	CHEMBL308	Homo sapiens	Inhibition	%	50.0
	1956364	CHEMBL894748	Inhibition of CDK1 activity at 10 uM	B	N#Cc1cnc(Nc2ccc(Cl)cc2)nc1-c1ccccc1		CHEMBL233877	=	Inhibition	%	50.0	CHEMBL308	Homo sapiens	Inhibition	%	50.0
	1956365	CHEMBL894748	Inhibition of CDK1 activity at 10 uM	B	N#Cc1cnc(Nc2ccccc2Cl)nc1-c1ccccc1		CHEMBL390468	=	Inhibition	%	50.0	CHEMBL308	Homo sapiens	Inhibition	%	50.0
	1956366	CHEMBL894748	Inhibition of CDK1 activity at 10 uM	B	N#Cc1cnc(Nc2ncccn2)nc1-c1ccccc1		CHEMBL233876	=	Inhibition	%	50.0	CHEMBL308	Homo sapiens	Inhibition	%	50.0
	1956367	CHEMBL894748	Inhibition of CDK1 activity at 10 uM	B	N#Cc1cnc(Nc2nc3ccccc3[nH]2)nc1-c1ccccc1		CHEMBL233875	=	Inhibition	%	50.0	CHEMBL308	Homo sapiens	Inhibition	%	50.0
	1956368	CHEMBL894748	Inhibition of CDK1 activity at 10 uM	B	N#Cc1cnc(Nc2ccc3ccccc3c2)nc1-c1ccccc1		CHEMBL390467	=	Inhibition	%	50.0	CHEMBL308	Homo sapiens	Inhibition	%	50.0
	1960586	CHEMBL892529	Inhibition of CDK1	B	NC1=NC(=O)/C(=C/c2ccc3ncccc3c2)S1		CHEMBL396377	=	Ki	nM	150.0	CHEMBL308	Homo sapiens	Ki	uM	0.15
	1960587	CHEMBL892529	Inhibition of CDK1	B	O=C1N=C(N[C@@H]2C[C@H]2c2ccccc2)S/C1=C\c1ccc2ncccc2c1		CHEMBL235345	=	Ki	nM	20.0	CHEMBL308	Homo sapiens	Ki	uM	0.02
	1960588	CHEMBL892529	Inhibition of CDK1	B	O=C1N=C(NCc2cccs2)S/C1=C\c1ccc2ncccc2c1		CHEMBL393929	=	Ki	nM	35.0	CHEMBL308	Homo sapiens	Ki	uM	0.035
	1960656	CHEMBL892540	Antiproliferative activity against human HCT116 cells	F	NC1=NC(=O)/C(=C/c2ccc3ncccc3c2)S1		CHEMBL396377	=	IC50	nM	2530.0	CHEMBL308	Homo sapiens	IC50	uM	2.53
	1960657	CHEMBL892540	Antiproliferative activity against human HCT116 cells	F	O=C1N=C(N[C@@H]2C[C@H]2c2ccccc2)S/C1=C\c1ccc2ncccc2c1		CHEMBL235345	=	IC50	nM	2410.0	CHEMBL308	Homo sapiens	IC50	uM	2.41
	1960658	CHEMBL892540	Antiproliferative activity against human HCT116 cells	F	O=C1N=C(N[C@@H](CO)Cc2ccccc2)S/C1=C\c1ccc2ncccc2c1		CHEMBL393157	=	IC50	nM	1580.0	CHEMBL308	Homo sapiens	IC50	uM	1.58
	1960659	CHEMBL892540	Antiproliferative activity against human HCT116 cells	F	O=C1N=C(NCc2cccs2)S/C1=C\c1ccc2ncccc2c1		CHEMBL393929	=	IC50	nM	1140.0	CHEMBL308	Homo sapiens	IC50	uM	1.14
	1960660	CHEMBL892541	Antiproliferative activity against human H460a cells	F	NC1=NC(=O)/C(=C/c2ccc3ncccc3c2)S1		CHEMBL396377	=	IC50	nM	1820.0	CHEMBL308	Homo sapiens	IC50	uM	1.82
	1960661	CHEMBL892541	Antiproliferative activity against human H460a cells	F	O=C1N=C(N[C@@H]2C[C@H]2c2ccccc2)S/C1=C\c1ccc2ncccc2c1		CHEMBL235345	=	IC50	nM	2490.0	CHEMBL308	Homo sapiens	IC50	uM	2.49
Not Determined	1960662	CHEMBL892541	Antiproliferative activity against human H460a cells	F	O=C1N=C(N[C@@H](CO)Cc2ccccc2)S/C1=C\c1ccc2ncccc2c1		CHEMBL393157		IC50			CHEMBL308	Homo sapiens	IC50		
	1960663	CHEMBL892541	Antiproliferative activity against human H460a cells	F	O=C1N=C(NCc2cccs2)S/C1=C\c1ccc2ncccc2c1		CHEMBL393929	=	IC50	nM	1040.0	CHEMBL308	Homo sapiens	IC50	uM	1.04
	1960664	CHEMBL892542	Antiproliferative activity against human SW480 cells	F	NC1=NC(=O)/C(=C/c2ccc3ncccc3c2)S1		CHEMBL396377	=	IC50	nM	3100.0	CHEMBL308	Homo sapiens	IC50	uM	3.1
	1960665	CHEMBL892542	Antiproliferative activity against human SW480 cells	F	O=C1N=C(N[C@@H]2C[C@H]2c2ccccc2)S/C1=C\c1ccc2ncccc2c1		CHEMBL235345	=	IC50	nM	6580.0	CHEMBL308	Homo sapiens	IC50	uM	6.58
	1960666	CHEMBL892542	Antiproliferative activity against human SW480 cells	F	O=C1N=C(N[C@@H](CO)Cc2ccccc2)S/C1=C\c1ccc2ncccc2c1		CHEMBL393157	=	IC50	nM	3070.0	CHEMBL308	Homo sapiens	IC50	uM	3.07
	1960667	CHEMBL892542	Antiproliferative activity against human SW480 cells	F	O=C1N=C(NCc2cccs2)S/C1=C\c1ccc2ncccc2c1		CHEMBL393929	=	IC50	nM	2200.0	CHEMBL308	Homo sapiens	IC50	uM	2.2
	1960675	CHEMBL892543	Antiproliferative activity against human MDA435 cells	F	NC1=NC(=O)/C(=C/c2ccc3ncccc3c2)S1		CHEMBL396377	=	IC50	nM	1280.0	CHEMBL308	Homo sapiens	IC50	uM	1.28
	1960677	CHEMBL892543	Antiproliferative activity against human MDA435 cells	F	O=C1N=C(N[C@@H]2C[C@H]2c2ccccc2)S/C1=C\c1ccc2ncccc2c1		CHEMBL235345	=	IC50	nM	3340.0	CHEMBL308	Homo sapiens	IC50	uM	3.34
	1960678	CHEMBL892543	Antiproliferative activity against human MDA435 cells	F	O=C1N=C(N[C@@H](CO)Cc2ccccc2)S/C1=C\c1ccc2ncccc2c1		CHEMBL393157	=	IC50	nM	2030.0	CHEMBL308	Homo sapiens	IC50	uM	2.03
	1960679	CHEMBL892543	Antiproliferative activity against human MDA435 cells	F	O=C1N=C(NCc2cccs2)S/C1=C\c1ccc2ncccc2c1		CHEMBL393929	=	IC50	nM	1140.0	CHEMBL308	Homo sapiens	IC50	uM	1.14
	1960734	CHEMBL892545	Antiproliferative activity against human RKO cells	F	O=C1N=C(N[C@@H]2C[C@H]2c2ccccc2)S/C1=C\c1ccc2ncccc2c1		CHEMBL235345	=	IC50	nM	2340.0	CHEMBL308	Homo sapiens	IC50	uM	2.34
	1960736	CHEMBL892545	Antiproliferative activity against human RKO cells	F	O=C1N=C(N[C@@H](CO)Cc2ccccc2)S/C1=C\c1ccc2ncccc2c1		CHEMBL393157	=	IC50	nM	1390.0	CHEMBL308	Homo sapiens	IC50	uM	1.39
	1960737	CHEMBL892545	Antiproliferative activity against human RKO cells	F	O=C1N=C(NCc2cccs2)S/C1=C\c1ccc2ncccc2c1		CHEMBL393929	=	IC50	nM	2000.0	CHEMBL308	Homo sapiens	IC50	uM	2.0
	1960738	CHEMBL892545	Antiproliferative activity against human RKO cells	F	NC1=NC(=O)/C(=C/c2ccc3ncccc3c2)S1		CHEMBL396377	=	IC50	nM	1860.0	CHEMBL308	Homo sapiens	IC50	uM	1.86
	1960991	CHEMBL892705	Inhibition of CDK1	B	CC(C)(N)c1ccc(-c2nc(Nc3cccc(Br)c3)ncc2Cl)cc1		CHEMBL234443	=	IC50	nM	1040.0	CHEMBL308	Homo sapiens	IC50	uM	1.04
	1961010	CHEMBL892705	Inhibition of CDK1	B	CN(C)CCc1ccc(Nc2ncc(Cl)c(-c3n[nH]c4ccccc34)n2)cc1		CHEMBL233213	=	IC50	nM	781.0	CHEMBL308	Homo sapiens	IC50	uM	0.781
	1961011	CHEMBL892705	Inhibition of CDK1	B	CN(C)CCc1ccc(Nc2ncc(Cl)c(-c3cccc4cc[nH]c34)n2)cc1		CHEMBL234626	=	IC50	nM	334.0	CHEMBL308	Homo sapiens	IC50	uM	0.334
	1961012	CHEMBL892705	Inhibition of CDK1	B	CN(C)CCc1ccc(Nc2ncc(Cl)c(-c3ccc4cc[nH]c4c3)n2)cc1		CHEMBL234625	=	IC50	nM	1770.0	CHEMBL308	Homo sapiens	IC50	uM	1.77
	1961013	CHEMBL892705	Inhibition of CDK1	B	CN(C)CCc1ccc(Nc2ncc(Cl)c(-c3ccc4[nH]ccc4c3)n2)cc1		CHEMBL234624	=	IC50	nM	847.0	CHEMBL308	Homo sapiens	IC50	uM	0.847
	1961014	CHEMBL892705	Inhibition of CDK1	B	CN(C)CCc1ccc(Nc2ncc(Cl)c(-c3cccc4[nH]ccc34)n2)cc1		CHEMBL392743	=	IC50	nM	540.0	CHEMBL308	Homo sapiens	IC50	uM	0.54
	1961015	CHEMBL892705	Inhibition of CDK1	B	CN(C)CCc1ccc(Nc2ncc(Cl)c(-c3c[nH]c4ccccc34)n2)cc1		CHEMBL234452	=	IC50	nM	48.0	CHEMBL308	Homo sapiens	IC50	uM	0.048
	1961016	CHEMBL892705	Inhibition of CDK1	B	Cc1nc(C)c(-c2nc(Nc3ccc(CCN(C)C)cc3)ncc2Cl)s1		CHEMBL234451	=	IC50	nM	439.0	CHEMBL308	Homo sapiens	IC50	uM	0.439
	1961017	CHEMBL892705	Inhibition of CDK1	B	CN(C)CCc1ccc(Nc2ncc(Cl)c(-c3cccs3)n2)cc1		CHEMBL233380	=	IC50	nM	461.0	CHEMBL308	Homo sapiens	IC50	uM	0.461
	1961018	CHEMBL892705	Inhibition of CDK1	B	CN1CCN(CCc2ccc(Nc3ncc(Cl)c(-c4ccc(C(C)(C)N)cc4)n3)cc2)CC1		CHEMBL392306	=	IC50	nM	1610.0	CHEMBL308	Homo sapiens	IC50	uM	1.61
	1961019	CHEMBL892705	Inhibition of CDK1	B	CC(C)(N)c1ccc(-c2nc(Nc3ccc(CCN4CCOCC4)cc3)ncc2Cl)cc1		CHEMBL233209	=	IC50	nM	2770.0	CHEMBL308	Homo sapiens	IC50	uM	2.77
	1961020	CHEMBL892705	Inhibition of CDK1	B	CC(C)(N)c1ccc(-c2nc(Nc3ccc(CCN4CCCC4)cc3)ncc2Cl)cc1		CHEMBL233208	=	IC50	nM	808.0	CHEMBL308	Homo sapiens	IC50	uM	0.808
	1961021	CHEMBL892705	Inhibition of CDK1	B	CN(C)CCc1ccc(Nc2ncc(Cl)c(-c3ccc(C(C)(C)N)cc3)n2)cc1		CHEMBL393462	=	IC50	nM	1140.0	CHEMBL308	Homo sapiens	IC50	uM	1.14
	1961022	CHEMBL892705	Inhibition of CDK1	B	CNCCc1ccc(Nc2ncc(Cl)c(-c3ccc(C(C)(C)N)cc3)n2)cc1		CHEMBL393460	=	IC50	nM	1060.0	CHEMBL308	Homo sapiens	IC50	uM	1.06
	1961023	CHEMBL892705	Inhibition of CDK1	B	CC(C)(N)c1ccc(-c2nc(Nc3ccc(CCO)cc3)ncc2Cl)cc1		CHEMBL233205	=	IC50	nM	687.0	CHEMBL308	Homo sapiens	IC50	uM	0.687
	1961086	CHEMBL892705	Inhibition of CDK1	B	CCN1CCN(CCc2ccc(Nc3ncc(Cl)c(-c4ccc5cc[nH]c5c4)n3)cc2)CC1		CHEMBL398989	=	IC50	nM	1240.0	CHEMBL308	Homo sapiens	IC50	uM	1.24
	1961087	CHEMBL892705	Inhibition of CDK1	B	Clc1cnc(Nc2ccc(CCN3CCCC3)cc2)nc1-c1ccc2cc[nH]c2c1		CHEMBL233225	=	IC50	nM	1540.0	CHEMBL308	Homo sapiens	IC50	uM	1.54
	1961088	CHEMBL892705	Inhibition of CDK1	B	CN1CCN(CCc2ccc(Nc3ncc(Cl)c(-c4c[nH]c5ccccc45)n3)cc2)CC1		CHEMBL233224	=	IC50	nM	180.0	CHEMBL308	Homo sapiens	IC50	uM	0.18
	1963792	CHEMBL897017	Inhibition of CDK1	B	Cc1cc(N2CCCS2(=O)=O)c2oc(-c3ccc(O)c(O)c3)c(O)c(=O)c2c1		CHEMBL232557	=	IC50	nM	130.0	CHEMBL308	Homo sapiens	IC50	uM	0.13
	1963808	CHEMBL897017	Inhibition of CDK1	B	Cc1cc(N2CCCS2(=O)=O)c2oc(-c3ccc(O)c(C(F)(F)F)c3)c(O)c(=O)c2c1		CHEMBL233153	=	IC50	nM	63.0	CHEMBL308	Homo sapiens	IC50	uM	0.063
	1963809	CHEMBL897017	Inhibition of CDK1	B	Cc1cc(N2CCCS2(=O)=O)c2oc(-c3ccc(O)c(C#N)c3)c(O)c(=O)c2c1		CHEMBL233152	=	IC50	nM	160.0	CHEMBL308	Homo sapiens	IC50	uM	0.16
	1963810	CHEMBL897017	Inhibition of CDK1	B	Cc1cc(N2CCCS2(=O)=O)c2oc(-c3ccc(O)c(Br)c3)c(O)c(=O)c2c1		CHEMBL392776	=	IC50	nM	19.0	CHEMBL308	Homo sapiens	IC50	uM	0.019
	1963811	CHEMBL897017	Inhibition of CDK1	B	Cc1cc(N2CCCS2(=O)=O)c2oc(-c3ccc(O)c(Cl)c3)c(O)c(=O)c2c1		CHEMBL392775	=	IC50	nM	33.0	CHEMBL308	Homo sapiens	IC50	uM	0.033
	1963812	CHEMBL897017	Inhibition of CDK1	B	Cc1cc(N2CCCS2(=O)=O)c2oc(-c3ccc(O)cc3)c(O)c(=O)c2c1		CHEMBL232749	=	IC50	nM	450.0	CHEMBL308	Homo sapiens	IC50	uM	0.45
	1989401	CHEMBL899112	Inhibition of CDK1 expressed in Sf21 cells	B	CC(C)NCc1ccc(Nc2cc(-c3ccc(-c4ccc(O)cc4O)cc3)[nH]n2)cc1		CHEMBL398606	=	IC50	nM	3300.0	CHEMBL308	Homo sapiens	IC50	uM	3.3
	2021470	CHEMBL903502	Inhibition of CDK2	B	Fc1cccc(Cn2ncc3cc(Nc4ncnn5ccc(COC[C@@H]6CNCCO6)c45)ccc32)c1		CHEMBL246284	>	IC50	nM	50000.0	CHEMBL308	Homo sapiens	IC50	uM	50.0
	2034014	CHEMBL888275	Inhibition of CDK1	B	c1ccc2c(-c3cnc4[nH]nc(-c5nc6ccccc6[nH]5)c4c3)cncc2c1		CHEMBL391437	=	IC50	nM	23.0	CHEMBL308	Homo sapiens	IC50	uM	0.023
	2034015	CHEMBL888275	Inhibition of CDK1	B	CCNCc1cncc(-c2cnc3[nH]nc(-c4nc5c(COC)cccc5[nH]4)c3c2)c1C		CHEMBL249519	=	IC50	nM	110.0	CHEMBL308	Homo sapiens	IC50	uM	0.11
	2034016	CHEMBL888275	Inhibition of CDK1	B	COCc1cccc2[nH]c(-c3n[nH]c4ncc(-c5cncc(CN(C)C)c5)cc34)nc12		CHEMBL249518	=	IC50	nM	120.0	CHEMBL308	Homo sapiens	IC50	uM	0.12
	2034017	CHEMBL888275	Inhibition of CDK1	B	CCNCc1cncc(-c2cnc3[nH]nc(-c4nc5cc(OC)ccc5[nH]4)c3c2)c1		CHEMBL429478	=	IC50	nM	0.8	CHEMBL308	Homo sapiens	IC50	uM	0.0008
	2034018	CHEMBL888275	Inhibition of CDK1	B	CNCc1cncc(-c2cnc3[nH]nc(-c4nc5cc(OC(F)(F)F)ccc5[nH]4)c3c2)c1		CHEMBL400906	=	IC50	nM	9.0	CHEMBL308	Homo sapiens	IC50	uM	0.009
	2034019	CHEMBL888275	Inhibition of CDK1	B	CCNCc1cncc(-c2cnc3[nH]nc(-c4nc5cc(F)ccc5[nH]4)c3c2)c1		CHEMBL248713	=	IC50	nM	0.7	CHEMBL308	Homo sapiens	IC50	uM	0.0007
	2034020	CHEMBL888275	Inhibition of CDK1	B	CCNCc1cncc(-c2cnc3[nH]nc(-c4nc5cc(F)c(F)cc5[nH]4)c3c2)c1		CHEMBL248712	=	IC50	nM	1.1	CHEMBL308	Homo sapiens	IC50	uM	0.0011
	2034021	CHEMBL888275	Inhibition of CDK1	B	CCNCc1cncc(-c2cnc3[nH]nc(-c4nc5cc(N6CCN(C)CC6)ccc5[nH]4)c3c2)c1		CHEMBL400569	=	IC50	nM	3.0	CHEMBL308	Homo sapiens	IC50	uM	0.003
	2034022	CHEMBL888275	Inhibition of CDK1	B	CCCNCc1cncc(-c2cnc3[nH]nc(-c4nc5c(COC)cccc5[nH]4)c3c2)c1		CHEMBL400568	=	IC50	nM	7.4	CHEMBL308	Homo sapiens	IC50	uM	0.0074
	2034023	CHEMBL888275	Inhibition of CDK1	B	CNCc1cncc(-c2cnc3[nH]nc(-c4nc5c(COC)cccc5[nH]4)c3c2)c1		CHEMBL400749	=	IC50	nM	2.5	CHEMBL308	Homo sapiens	IC50	uM	0.0025
	2034024	CHEMBL888275	Inhibition of CDK1	B	COCc1cccc2[nH]c(-c3nn(C)c4ncc(-c5cncc6ccccc56)cc34)nc12		CHEMBL251740	=	IC50	nM	120.0	CHEMBL308	Homo sapiens	IC50	uM	0.12
	2034025	CHEMBL888275	Inhibition of CDK1	B	CCN(CC)C(=O)c1cccc2[nH]c(-c3n[nH]c4ncc(-c5cncc6ccccc56)cc34)nc12		CHEMBL251739	=	IC50	nM	53.0	CHEMBL308	Homo sapiens	IC50	uM	0.053
	2034026	CHEMBL888275	Inhibition of CDK1	B	CC(C)NC(=O)c1cccc2[nH]c(-c3n[nH]c4ncc(-c5cncc6ccccc56)cc34)nc12		CHEMBL249502	=	IC50	nM	39.0	CHEMBL308	Homo sapiens	IC50	uM	0.039
	2034027	CHEMBL888275	Inhibition of CDK1	B	O=C(O)c1cccc2[nH]c(-c3n[nH]c4ncc(-c5cncc6ccccc56)cc34)nc12		CHEMBL249501	=	IC50	nM	540.0	CHEMBL308	Homo sapiens	IC50	uM	0.54
	2034028	CHEMBL888275	Inhibition of CDK1	B	COC(=O)c1cccc2[nH]c(-c3n[nH]c4ncc(-c5cncc6ccccc56)cc34)nc12		CHEMBL399042	=	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	2034029	CHEMBL888275	Inhibition of CDK1	B	c1ccc2c(-c3cnc4[nH]nc(-c5nc6cc(N7CCOCC7)ccc6[nH]5)c4c3)cncc2c1		CHEMBL249500	=	IC50	nM	8.5	CHEMBL308	Homo sapiens	IC50	uM	0.0085
	2034030	CHEMBL888275	Inhibition of CDK1	B	CN1CCN(c2ccc3[nH]c(-c4n[nH]c5ncc(-c6cncc7ccccc67)cc45)nc3c2)CC1		CHEMBL249304	=	IC50	nM	14.0	CHEMBL308	Homo sapiens	IC50	uM	0.014
	2034031	CHEMBL888275	Inhibition of CDK1	B	CCN(CC)Cc1cccc2[nH]c(-c3n[nH]c4ncc(-c5cncc6ccccc56)cc34)nc12		CHEMBL249303	=	IC50	nM	1.8	CHEMBL308	Homo sapiens	IC50	uM	0.0018
	2034032	CHEMBL888275	Inhibition of CDK1	B	CC(C)NCc1cccc2[nH]c(-c3n[nH]c4ncc(-c5cncc6ccccc56)cc34)nc12		CHEMBL401064	=	IC50	nM	13.0	CHEMBL308	Homo sapiens	IC50	uM	0.013
	2034033	CHEMBL888275	Inhibition of CDK1	B	COCc1cccc2[nH]c(-c3n[nH]c4ncc(-c5cncnc5)cc34)nc12		CHEMBL249302	=	IC50	nM	1280.0	CHEMBL308	Homo sapiens	IC50	uM	1.28
	2034034	CHEMBL888275	Inhibition of CDK1	B	COCc1cccc2[nH]c(-c3n[nH]c4ncc(-c5ccncc5)cc34)nc12		CHEMBL249096	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	uM	1.0
	2034035	CHEMBL888275	Inhibition of CDK1	B	COCc1cccc2[nH]c(-c3n[nH]c4ncc(-c5cccnc5)cc34)nc12		CHEMBL400859	=	IC50	nM	29.0	CHEMBL308	Homo sapiens	IC50	uM	0.029
	2034036	CHEMBL888275	Inhibition of CDK1	B	COCc1cccc2[nH]c(-c3n[nH]c4ncc(-c5cnc6ccccc6c5)cc34)nc12		CHEMBL249095	=	IC50	nM	1360.0	CHEMBL308	Homo sapiens	IC50	uM	1.36
	2034037	CHEMBL888275	Inhibition of CDK1	B	CC(C)OCc1cccc2[nH]c(-c3n[nH]c4ncc(-c5cncc6ccccc56)cc34)nc12		CHEMBL249094	=	IC50	nM	99.0	CHEMBL308	Homo sapiens	IC50	uM	0.099
	2034038	CHEMBL888275	Inhibition of CDK1	B	COCc1cccc2[nH]c(-c3n[nH]c4ncc(-c5cncc6ccccc56)cc34)nc12		CHEMBL248891	=	IC50	nM	5.6	CHEMBL308	Homo sapiens	IC50	uM	0.0056
	2034039	CHEMBL888275	Inhibition of CDK1	B	OCc1cccc2[nH]c(-c3n[nH]c4ncc(-c5cncc6ccccc56)cc34)nc12		CHEMBL248890	=	IC50	nM	41.0	CHEMBL308	Homo sapiens	IC50	uM	0.041
	2034040	CHEMBL888275	Inhibition of CDK1	B	Cc1cccc2[nH]c(-c3n[nH]c4ncc(-c5cncc6ccccc56)cc34)nc12		CHEMBL400858	=	IC50	nM	97.0	CHEMBL308	Homo sapiens	IC50	uM	0.097
	2039033	CHEMBL923218	Inhibition of CDK2	B	Fc1cccc(Cn2ncc3cc(Nc4ncnn5ccc(COC[C@@H]6CNCCO6)c45)ccc32)c1		CHEMBL246284	>	IC50	nM	50000.0	CHEMBL308	Homo sapiens	IC50	uM	50.0
	2039057	CHEMBL923218	Inhibition of CDK2	B	NC1CCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)CC1		CHEMBL248108	=	IC50	nM	1900.0	CHEMBL308	Homo sapiens	IC50	uM	1.9
	2051689	CHEMBL941825	Inhibition of CDC2	B	N#Cc1ncc2nc1OCCCCOc1cc(NCc3cncs3)c(Cl)cc1NC(=O)N2		CHEMBL248757	>	Ki	nM	8913.0	CHEMBL308	Homo sapiens	Ki	uM	8.913
Not Active	2058392	CHEMBL926494	Inhibition of recombinant CDK1	B	O[C@]12C=C(c3nccc4c3[nH]c3ccccc34)[C@@H]3CCN(CCCC/C=C\CC1)C[C@@]31C[C@@H]3/C=C\CCCCN3[C@@H]21		CHEMBL403233		Activity			CHEMBL308	Homo sapiens	Activity		
	2082493	CHEMBL929005	Inhibition of CDK1	B	O=C(Cc1ccccc1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12		CHEMBL255255	=	IC50	nM	80.0	CHEMBL308	Homo sapiens	IC50	uM	0.08
	2082494	CHEMBL929005	Inhibition of CDK1	B	O=C(Cc1ccc(-c2ccncc2)cc1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12		CHEMBL254171	=	IC50	nM	60.0	CHEMBL308	Homo sapiens	IC50	uM	0.06
	2082495	CHEMBL929005	Inhibition of CDK1	B	O=C(Cc1ccc(-c2ccccc2)cc1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12		CHEMBL402759	=	IC50	nM	42.0	CHEMBL308	Homo sapiens	IC50	uM	0.042
	2082496	CHEMBL929005	Inhibition of CDK1	B	O=C(Cc1ccc2ccccc2c1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12		CHEMBL254979	=	IC50	nM	40.0	CHEMBL308	Homo sapiens	IC50	uM	0.04
	2082497	CHEMBL929005	Inhibition of CDK1	B	O=C(Cc1cccc2ccccc12)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12		CHEMBL254367	=	IC50	nM	67.0	CHEMBL308	Homo sapiens	IC50	uM	0.067
	2082498	CHEMBL929005	Inhibition of CDK1	B	CS(=O)(=O)c1ccc(CC(=O)Nc2n[nH]c3ccc(N4CCCS4(=O)=O)cc23)cc1		CHEMBL254170	=	IC50	nM	200.0	CHEMBL308	Homo sapiens	IC50	uM	0.2
	2082499	CHEMBL929005	Inhibition of CDK1	B	CSc1ccc(CC(=O)Nc2n[nH]c3ccc(N4CCCS4(=O)=O)cc23)cc1		CHEMBL415789	=	IC50	nM	40.0	CHEMBL308	Homo sapiens	IC50	uM	0.04
	2082500	CHEMBL929005	Inhibition of CDK1	B	O=C(Cc1ccc(N2CCCCC2)cc1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12		CHEMBL258040	=	IC50	nM	150.0	CHEMBL308	Homo sapiens	IC50	uM	0.15
	2082501	CHEMBL929005	Inhibition of CDK1	B	CCN(CC)c1ccc(CC(=O)Nc2n[nH]c3ccc(N4CCCS4(=O)=O)cc23)cc1		CHEMBL258039	=	IC50	nM	60.0	CHEMBL308	Homo sapiens	IC50	uM	0.06
	2082502	CHEMBL929005	Inhibition of CDK1	B	CN(C)c1ccc(CC(=O)Nc2n[nH]c3ccc(N4CCCS4(=O)=O)cc23)cc1		CHEMBL257831	=	IC50	nM	28.0	CHEMBL308	Homo sapiens	IC50	uM	0.028
	2082503	CHEMBL929005	Inhibition of CDK1	B	Nc1ccc(CC(=O)Nc2n[nH]c3ccc(N4CCCS4(=O)=O)cc23)cc1		CHEMBL255932	=	IC50	nM	60.0	CHEMBL308	Homo sapiens	IC50	uM	0.06
	2082504	CHEMBL929005	Inhibition of CDK1	B	O=C(Cc1ccc(O)cc1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12		CHEMBL255718	=	IC50	nM	28.0	CHEMBL308	Homo sapiens	IC50	uM	0.028
	2082505	CHEMBL929005	Inhibition of CDK1	B	Cc1ccc(CC(=O)Nc2n[nH]c3ccc(N4CCCS4(=O)=O)cc23)cc1		CHEMBL256558	=	IC50	nM	40.0	CHEMBL308	Homo sapiens	IC50	uM	0.04
	2082506	CHEMBL929005	Inhibition of CDK1	B	Cc1cccc(CC(=O)Nc2n[nH]c3ccc(N4CCCS4(=O)=O)cc23)c1		CHEMBL403605	=	IC50	nM	50.0	CHEMBL308	Homo sapiens	IC50	uM	0.05
	2082507	CHEMBL929005	Inhibition of CDK1	B	O=C(Cc1ccc(Br)cc1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12		CHEMBL402370	=	IC50	nM	22.0	CHEMBL308	Homo sapiens	IC50	uM	0.022
	2082508	CHEMBL929005	Inhibition of CDK1	B	O=C(Cc1cccc(Br)c1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12		CHEMBL402158	=	IC50	nM	47.0	CHEMBL308	Homo sapiens	IC50	uM	0.047
	2082509	CHEMBL929005	Inhibition of CDK1	B	O=C(Cc1ccc(Cl)cc1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12		CHEMBL402157	=	IC50	nM	12.0	CHEMBL308	Homo sapiens	IC50	uM	0.012
	2082510	CHEMBL929005	Inhibition of CDK1	B	O=C(Cc1cccc(Cl)c1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12		CHEMBL404504	=	IC50	nM	34.0	CHEMBL308	Homo sapiens	IC50	uM	0.034
	2082511	CHEMBL929005	Inhibition of CDK1	B	O=C(Cc1ccccc1Cl)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12		CHEMBL255463	=	IC50	nM	80.0	CHEMBL308	Homo sapiens	IC50	uM	0.08
	2082512	CHEMBL929005	Inhibition of CDK1	B	O=C(Cc1ccc(F)cc1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12		CHEMBL255263	=	IC50	nM	50.0	CHEMBL308	Homo sapiens	IC50	uM	0.05
	2082513	CHEMBL929005	Inhibition of CDK1	B	O=C(Cc1cccc(F)c1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12		CHEMBL255262	=	IC50	nM	30.0	CHEMBL308	Homo sapiens	IC50	uM	0.03
	2099488	CHEMBL949046	Inhibition of human Cdc2 kinase PY15 phosphorylation in HT29 cells by Western blot	B	O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1c2c2cc(O)ccc2n1CCCO		CHEMBL411662	=	IC50	nM	250.0	CHEMBL308	Homo sapiens	IC50	uM	0.25
	2099489	CHEMBL949046	Inhibition of human Cdc2 kinase PY15 phosphorylation in HT29 cells by Western blot	B	O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1c2c2cc(O)c(OCCCN3CCOCC3)cc2n1CCO		CHEMBL271715	=	IC50	nM	250.0	CHEMBL308	Homo sapiens	IC50	uM	0.25
	2099490	CHEMBL949046	Inhibition of human Cdc2 kinase PY15 phosphorylation in HT29 cells by Western blot	B	O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1c2c2cc(O)c(OCCCN3CCCC3)cc2n1CCO		CHEMBL270021	=	IC50	nM	30.0	CHEMBL308	Homo sapiens	IC50	uM	0.03
	2099491	CHEMBL949046	Inhibition of human Cdc2 kinase PY15 phosphorylation in HT29 cells by Western blot	B	CN(C)CCCOc1cc2c(cc1O)c1c3c(c(-c4ccccc4Cl)cc1n2CCO)C(=O)NC3=O		CHEMBL401776	=	IC50	nM	250.0	CHEMBL308	Homo sapiens	IC50	uM	0.25
	2099492	CHEMBL949046	Inhibition of human Cdc2 kinase PY15 phosphorylation in HT29 cells by Western blot	B	Cn1c2cc(OCCCN3CCCC3)c(O)cc2c2c3c(c(-c4ccccc4Cl)cc21)C(=O)NC3=O		CHEMBL255427	=	IC50	nM	30.0	CHEMBL308	Homo sapiens	IC50	uM	0.03
	2099493	CHEMBL949046	Inhibition of human Cdc2 kinase PY15 phosphorylation in HT29 cells by Western blot	B	CN(C)CCCOc1cc2c(cc1O)c1c3c(c(-c4ccccc4Cl)cc1n2C)C(=O)NC3=O		CHEMBL410261	=	IC50	nM	10.0	CHEMBL308	Homo sapiens	IC50	uM	0.01
	2099494	CHEMBL949046	Inhibition of human Cdc2 kinase PY15 phosphorylation in HT29 cells by Western blot	B	O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1[nH]c3cc(CCCCN4CCOCC4)c(O)cc3c21		CHEMBL403679	=	IC50	nM	250.0	CHEMBL308	Homo sapiens	IC50	uM	0.25
	2099495	CHEMBL949046	Inhibition of human Cdc2 kinase PY15 phosphorylation in HT29 cells by Western blot	B	O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1[nH]c3cc(CCCCN4CCCC4)c(O)cc3c21		CHEMBL272946	=	IC50	nM	200.0	CHEMBL308	Homo sapiens	IC50	uM	0.2
	2099496	CHEMBL949046	Inhibition of human Cdc2 kinase PY15 phosphorylation in HT29 cells by Western blot	B	CN(C)CCCCc1cc2[nH]c3cc(-c4ccccc4Cl)c4c(c3c2cc1O)C(=O)NC4=O		CHEMBL401746	=	IC50	nM	250.0	CHEMBL308	Homo sapiens	IC50	uM	0.25
	2110756	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Br)cc32)cc1		CHEMBL411491	=	IC50	nM	780.0	CHEMBL308	Homo sapiens	IC50	nM	780.0
	2110818	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL445945	=	IC50	nM	15.0	CHEMBL308	Homo sapiens	IC50	nM	15.0
	2110819	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	IC50	nM	12.0	CHEMBL308	Homo sapiens	IC50	nM	12.0
	2110820	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	IC50	nM	29.0	CHEMBL308	Homo sapiens	IC50	nM	29.0
	2110821	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL407709	=	IC50	nM	43.0	CHEMBL308	Homo sapiens	IC50	nM	43.0
	2110822	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4[nH]nnc4c32)cc1		CHEMBL271952	=	IC50	nM	150.0	CHEMBL308	Homo sapiens	IC50	nM	150.0
	2110823	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4[nH]nc(Cl)c4c32)cc1		CHEMBL269882	=	IC50	nM	83.0	CHEMBL308	Homo sapiens	IC50	nM	83.0
	2110824	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4[nH]ncc4c32)cc1		CHEMBL272833	=	IC50	nM	120.0	CHEMBL308	Homo sapiens	IC50	nM	120.0
	2110825	CHEMBL952119	Inhibition of CDK1	B	Cc1c([N+](=O)[O-])ccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272667	=	IC50	nM	87.0	CHEMBL308	Homo sapiens	IC50	nM	87.0
	2110826	CHEMBL952119	Inhibition of CDK1	B	COc1ccc2c(c1Cl)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271822	=	IC50	nM	1700.0	CHEMBL308	Homo sapiens	IC50	nM	1700.0
	2110827	CHEMBL952119	Inhibition of CDK1	B	Cc1ccc2c(c1Cl)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL411490	=	IC50	nM	250.0	CHEMBL308	Homo sapiens	IC50	nM	250.0
	2110828	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3cc(CO)ccc32)cc1		CHEMBL410293	=	IC50	nM	740.0	CHEMBL308	Homo sapiens	IC50	nM	740.0
	2110829	CHEMBL952119	Inhibition of CDK1	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	IC50	nM	790.0	CHEMBL308	Homo sapiens	IC50	nM	790.0
	2110830	CHEMBL952119	Inhibition of CDK1	B	CCc1ccc2c(c1)NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271182	=	IC50	nM	660.0	CHEMBL308	Homo sapiens	IC50	nM	660.0
	2110831	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cc(Br)ccc32)cc1		CHEMBL271183	=	IC50	nM	520.0	CHEMBL308	Homo sapiens	IC50	nM	520.0
	2110832	CHEMBL952119	Inhibition of CDK1	B	COc1cccc(OC)c1CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271136	=	IC50	nM	9.3	CHEMBL308	Homo sapiens	IC50	nM	9.3
	2110833	CHEMBL952119	Inhibition of CDK1	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	IC50	nM	60.0	CHEMBL308	Homo sapiens	IC50	nM	60.0
	2110834	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4cccnc4)cc32)cc1		CHEMBL271953	=	IC50	nM	51.0	CHEMBL308	Homo sapiens	IC50	nM	51.0
	2110835	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	IC50	nM	74.0	CHEMBL308	Homo sapiens	IC50	nM	74.0
	2110836	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	IC50	nM	230.0	CHEMBL308	Homo sapiens	IC50	nM	230.0
	2110837	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	IC50	nM	60.0	CHEMBL308	Homo sapiens	IC50	nM	60.0
	2110838	CHEMBL952119	Inhibition of CDK1	B	CN(C)C(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL409868	=	IC50	nM	130.0	CHEMBL308	Homo sapiens	IC50	nM	130.0
	2110839	CHEMBL952119	Inhibition of CDK1	B	NC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410883	=	IC50	nM	2.8	CHEMBL308	Homo sapiens	IC50	nM	2.8
	2110840	CHEMBL952119	Inhibition of CDK1	B	CC(C)CC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL429142	=	IC50	nM	16.0	CHEMBL308	Homo sapiens	IC50	nM	16.0
	2110841	CHEMBL952119	Inhibition of CDK1	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	IC50	nM	19.0	CHEMBL308	Homo sapiens	IC50	nM	19.0
	2110842	CHEMBL952119	Inhibition of CDK1	B	COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL409731	=	IC50	nM	12.0	CHEMBL308	Homo sapiens	IC50	nM	12.0
	2110843	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc(C(=O)O)cc32)cc1		CHEMBL272668	=	IC50	nM	150.0	CHEMBL308	Homo sapiens	IC50	nM	150.0
	2110844	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(S(=O)(=O)O)cc32)cc1		CHEMBL412091	=	IC50	nM	130.0	CHEMBL308	Homo sapiens	IC50	nM	130.0
	2110845	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)cc1		CHEMBL272387	=	IC50	nM	170.0	CHEMBL308	Homo sapiens	IC50	nM	170.0
	2110846	CHEMBL952119	Inhibition of CDK1	B	CS(=O)(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272389	=	IC50	nM	350.0	CHEMBL308	Homo sapiens	IC50	nM	350.0
	2110847	CHEMBL952119	Inhibition of CDK1	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	IC50	nM	2800.0	CHEMBL308	Homo sapiens	IC50	nM	2800.0
	2110848	CHEMBL952119	Inhibition of CDK1	B	Nc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271842	=	IC50	nM	1400.0	CHEMBL308	Homo sapiens	IC50	nM	1400.0
	2110849	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc([N+](=O)[O-])cc32)cc1		CHEMBL411886	=	IC50	nM	710.0	CHEMBL308	Homo sapiens	IC50	nM	710.0
	2110850	CHEMBL952119	Inhibition of CDK1	B	COc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL260103	=	IC50	nM	210.0	CHEMBL308	Homo sapiens	IC50	nM	210.0
	2110851	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(O)cc32)cc1		CHEMBL409690	=	IC50	nM	77.0	CHEMBL308	Homo sapiens	IC50	nM	77.0
	2110852	CHEMBL952119	Inhibition of CDK1	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	IC50	nM	330.0	CHEMBL308	Homo sapiens	IC50	nM	330.0
	2110853	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(I)cc32)cc1		CHEMBL273060	=	IC50	nM	95.0	CHEMBL308	Homo sapiens	IC50	nM	95.0
	2110854	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(F)cc32)cc1		CHEMBL273061	=	IC50	nM	290.0	CHEMBL308	Homo sapiens	IC50	nM	290.0
	2110855	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3cccc(CO)c32)cc1		CHEMBL271137	=	IC50	nM	1700.0	CHEMBL308	Homo sapiens	IC50	nM	1700.0
	2110856	CHEMBL952119	Inhibition of CDK1	B	CCOC(=O)c1cccc2c1/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL408210	=	IC50	nM	130.0	CHEMBL308	Homo sapiens	IC50	nM	130.0
	2110857	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(-c4cc[nH]n4)c32)cc1		CHEMBL272684	=	IC50	nM	250.0	CHEMBL308	Homo sapiens	IC50	nM	250.0
	2110858	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccc(O)cc4)c32)cc1		CHEMBL411865	=	IC50	nM	150.0	CHEMBL308	Homo sapiens	IC50	nM	150.0
	2110859	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(/C=C/c4ccc(O)cc4)c32)cc1		CHEMBL272380	=	IC50	nM	170.0	CHEMBL308	Homo sapiens	IC50	nM	170.0
	2110860	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(OCCc4ccncc4)c32)cc1		CHEMBL272217	=	IC50	nM	290.0	CHEMBL308	Homo sapiens	IC50	nM	290.0
	2110861	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(Oc4ccccc4)c32)cc1		CHEMBL409104	=	IC50	nM	290.0	CHEMBL308	Homo sapiens	IC50	nM	290.0
	2110862	CHEMBL952119	Inhibition of CDK1	B	CC(C)Oc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271160	=	IC50	nM	41.0	CHEMBL308	Homo sapiens	IC50	nM	41.0
	2110863	CHEMBL952119	Inhibition of CDK1	B	CCOc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL411696	=	IC50	nM	550.0	CHEMBL308	Homo sapiens	IC50	nM	550.0
	2110864	CHEMBL952119	Inhibition of CDK1	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	IC50	nM	15.0	CHEMBL308	Homo sapiens	IC50	nM	15.0
	2110865	CHEMBL952119	Inhibition of CDK1	B	CC(C)Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL411224	=	IC50	nM	19.0	CHEMBL308	Homo sapiens	IC50	nM	19.0
	2110866	CHEMBL952119	Inhibition of CDK1	B	CC(C)c1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL411426	=	IC50	nM	37.0	CHEMBL308	Homo sapiens	IC50	nM	37.0
	2110867	CHEMBL952119	Inhibition of CDK1	B	CCc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL411425	=	IC50	nM	46.0	CHEMBL308	Homo sapiens	IC50	nM	46.0
	2110868	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(/N=N/c2c(O)[nH]c3cccc(I)c23)cc1		CHEMBL314397	=	IC50	nM	110.0	CHEMBL308	Homo sapiens	IC50	nM	110.0
	2110869	CHEMBL952119	Inhibition of CDK1	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccc(-c3cnco3)cc21		CHEMBL411887	=	IC50	nM	7.1	CHEMBL308	Homo sapiens	IC50	nM	7.1
	2110870	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL270132	=	IC50	nM	17.0	CHEMBL308	Homo sapiens	IC50	nM	17.0
	2110871	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	IC50	nM	10.0	CHEMBL308	Homo sapiens	IC50	nM	10.0
	2110872	CHEMBL952119	Inhibition of CDK1	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccc(Cl)cc21		CHEMBL412097	=	IC50	nM	220.0	CHEMBL308	Homo sapiens	IC50	nM	220.0
	2110873	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	IC50	nM	300.0	CHEMBL308	Homo sapiens	IC50	nM	300.0
	2110874	CHEMBL952119	Inhibition of CDK1	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	IC50	nM	2300.0	CHEMBL308	Homo sapiens	IC50	nM	2300.0
	2110875	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL269850	=	IC50	nM	3000.0	CHEMBL308	Homo sapiens	IC50	nM	3000.0
	2110876	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccccc32)cc1		CHEMBL438721	=	IC50	nM	1300.0	CHEMBL308	Homo sapiens	IC50	nM	1300.0
	2110877	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc([N+](=O)[O-])c32)cc1		CHEMBL409619	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	nM	1000.0
	2110878	CHEMBL952119	Inhibition of CDK1	B	Cc1cc(Cl)cc2c1NC(=O)/C2=C\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL410517	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	nM	1000.0
	2110879	CHEMBL952119	Inhibition of CDK1	B	Cc1cc(C)c2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269846	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	nM	1000.0
	2110880	CHEMBL952119	Inhibition of CDK1	B	Cc1cccc2c1NC(=O)/C2=C\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL408131	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	nM	1000.0
	2110881	CHEMBL952119	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cc(Oc4ccccc4)ccc32)cc1		CHEMBL272885	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	nM	1000.0
	2110882	CHEMBL952119	Inhibition of CDK1	B	CC(C)(C)c1ccc2c(c1)NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271777	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	nM	1000.0
	2110883	CHEMBL952119	Inhibition of CDK1	B	NC(=O)c1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271778	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	nM	1000.0
	2136777	CHEMBL937646	Inhibition of Cdk1	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	nM	10000.0
	2136785	CHEMBL937646	Inhibition of Cdk1	B	O=C1Nc2ccc(S(=O)(=O)O)cc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL440411	=	IC50	nM	5.0	CHEMBL308	Homo sapiens	IC50	nM	5.0
	2136787	CHEMBL937646	Inhibition of Cdk1	B	O=Nc1c(-c2c(O)[nH]c3ccc(I)cc23)[nH]c2ccccc12		CHEMBL337300	=	IC50	nM	5.0	CHEMBL308	Homo sapiens	IC50	nM	5.0
	2137011	CHEMBL937639	Inhibition of p34cdc2	B	COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1		CHEMBL404941	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	nM	100000.0
	2137043	CHEMBL937646	Inhibition of Cdk1	B	O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12		CHEMBL126077	=	IC50	nM	180.0	CHEMBL308	Homo sapiens	IC50	nM	180.0
	2137089	CHEMBL937646	Inhibition of Cdk1	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21		CHEMBL413188	=	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	nM	10000.0
	2137178	CHEMBL937646	Inhibition of Cdk1	B	CC(C)n1cnc2c(NCc3ccccc3O)nc(NCCCO)nc21		CHEMBL419931	=	IC50	nM	100.0	CHEMBL308	Homo sapiens	IC50	nM	100.0
	2137330	CHEMBL937639	Inhibition of p34cdc2	B	O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1		CHEMBL304428	=	IC50	nM	250.0	CHEMBL308	Homo sapiens	IC50	nM	250.0
	2147101	CHEMBL934733	Inhibition of CDK1 by radioactive flashplate assay	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	2153712	CHEMBL928279	Inhibition of CDK1 at 20 uM	B	CN(C)CCOc1ccc2c(-c3c(-c4ccccn4)nn4c3CCC4)ccnc2c1		CHEMBL409525	<	Inhibition	%	50.0	CHEMBL308	Homo sapiens	Inhibition	%	50.0
	2153747	CHEMBL928279	Inhibition of CDK1 at 20 uM	B	c1ccc(-c2nn3c(c2-c2ccnc4cc(OCCN5CCOCC5)ccc24)CCC3)nc1		CHEMBL260015	<	Inhibition	%	50.0	CHEMBL308	Homo sapiens	Inhibition	%	50.0
	2188331	CHEMBL940604	Inhibition of Cdc2	B	Cn1c(=O)[nH]c2ncnc(NCCS(=O)(=O)O)c21		CHEMBL478797	=	IC50	nM	13000.0	CHEMBL308	Homo sapiens	IC50	uM	13.0
	2188335	CHEMBL940604	Inhibition of Cdc2	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	=	IC50	nM	200.0	CHEMBL308	Homo sapiens	IC50	uM	0.2
	2239662	CHEMBL1000365	Inhibition of Cdc2 Tyr15 phosphorylation in human HT29 cells by Western blot	B	O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1c2c2cc(O)ccc2n1CCCO		CHEMBL411662	=	IC50	nM	250.0	CHEMBL308	Homo sapiens	IC50	uM	0.25
	2239664	CHEMBL1000365	Inhibition of Cdc2 Tyr15 phosphorylation in human HT29 cells by Western blot	B	NC(=O)CCn1c2ccc(O)cc2c2c3c(c(-c4ccccc4Cl)cc21)C(=O)NC3=O		CHEMBL472542	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	2239668	CHEMBL1000365	Inhibition of Cdc2 Tyr15 phosphorylation in human HT29 cells by Western blot	B	N#CCCn1c2ccc(O)cc2c2c3c(c(-c4ccccc4Cl)cc21)C(=O)NC3=O		CHEMBL511280	<	IC50	nM	250.0	CHEMBL308	Homo sapiens	IC50	uM	0.25
	2239671	CHEMBL1000365	Inhibition of Cdc2 Tyr15 phosphorylation in human HT29 cells by Western blot	B	O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1c2c2cc(O)ccc2n1CCN1CCOCC1		CHEMBL529669	=	IC50	nM	250.0	CHEMBL308	Homo sapiens	IC50	uM	0.25
	2239674	CHEMBL1000365	Inhibition of Cdc2 Tyr15 phosphorylation in human HT29 cells by Western blot	B	CNCCCn1c2ccc(O)cc2c2c3c(c(-c4ccccc4Cl)cc21)C(=O)NC3=O		CHEMBL508541	<	IC50	nM	250.0	CHEMBL308	Homo sapiens	IC50	uM	0.25
	2239677	CHEMBL1000365	Inhibition of Cdc2 Tyr15 phosphorylation in human HT29 cells by Western blot	B	CN(C)CCNC(=O)CCn1c2ccc(O)cc2c2c3c(c(-c4ccccc4Cl)cc21)C(=O)NC3=O		CHEMBL462011	<	IC50	nM	250.0	CHEMBL308	Homo sapiens	IC50	uM	0.25
	2239680	CHEMBL1000365	Inhibition of Cdc2 Tyr15 phosphorylation in human HT29 cells by Western blot	B	CN(C)CC(O)Cn1c2ccc(O)cc2c2c3c(c(-c4ccccc4Cl)cc21)C(=O)NC3=O		CHEMBL517744	=	IC50	nM	250.0	CHEMBL308	Homo sapiens	IC50	uM	0.25
	2239683	CHEMBL1000365	Inhibition of Cdc2 Tyr15 phosphorylation in human HT29 cells by Western blot	B	CS(=O)(=O)NC(=O)CCn1c2ccc(O)cc2c2c3c(c(-c4ccccc4Cl)cc21)C(=O)NC3=O		CHEMBL460940	=	IC50	nM	250.0	CHEMBL308	Homo sapiens	IC50	uM	0.25
	2239686	CHEMBL1000365	Inhibition of Cdc2 Tyr15 phosphorylation in human HT29 cells by Western blot	B	O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1c2c2cc(O)ccc2n1CCc1nnn[nH]1		CHEMBL512342	=	IC50	nM	2500.0	CHEMBL308	Homo sapiens	IC50	uM	2.5
	2239689	CHEMBL1000365	Inhibition of Cdc2 Tyr15 phosphorylation in human HT29 cells by Western blot	B	O=C(O)CCCn1c2ccc(O)cc2c2c3c(c(-c4ccccc4Cl)cc21)C(=O)NC3=O		CHEMBL511992	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	2239692	CHEMBL1000365	Inhibition of Cdc2 Tyr15 phosphorylation in human HT29 cells by Western blot	B	O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1c2c2cc(O)ccc2n1CCCc1nnn[nH]1		CHEMBL471329	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	2239992	CHEMBL972549	Inhibition of CDK1	B	Nc1ncnc(Nc2ccc(OCc3ccccc3)c(Cl)c2)c1C(=O)Nc1ccccc1		CHEMBL461114	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	2240004	CHEMBL972549	Inhibition of CDK1	B	Nc1ncnc(Nc2ccc(OCc3ccccc3)c(Cl)c2)c1-c1nnc(CCN2CCOCC2)o1		CHEMBL472545	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	2240005	CHEMBL972549	Inhibition of CDK1	B	Nc1ncnc(Nc2ccc(OCc3ccccc3)c(Cl)c2)c1C(=O)NNC(=O)CCN1CCOCC1		CHEMBL472544	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	2240006	CHEMBL972549	Inhibition of CDK1	B	NNC(=O)c1c(N)ncnc1Nc1ccc(OCc2ccccc2)c(Cl)c1		CHEMBL511478	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	2240007	CHEMBL972549	Inhibition of CDK1	B	COc1ccc(NC(=O)c2c(N)ncnc2Nc2ccc(OCc3ccccc3)c(Cl)c2)cc1		CHEMBL472383	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	2240008	CHEMBL972549	Inhibition of CDK1	B	Nc1ncnc(Nc2ccc(OCc3ccccc3)c(Cl)c2)c1C(=O)OCc1cccc(F)c1		CHEMBL472382	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	2240009	CHEMBL972549	Inhibition of CDK1	B	CCN(CC)C(=O)c1c(N)ncnc1Nc1ccc(OCc2ccccc2)c(Cl)c1		CHEMBL452727	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	2240010	CHEMBL972549	Inhibition of CDK1	B	COCCNC(=O)c1c(N)ncnc1Nc1ccc(OCc2ccccc2)c(Cl)c1		CHEMBL517745	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	2240011	CHEMBL972549	Inhibition of CDK1	B	COc1ccc(CCNC(=O)c2c(N)ncnc2Nc2ccc(OCc3ccccc3)c(Cl)c2)cc1		CHEMBL461115	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	2240012	CHEMBL972549	Inhibition of CDK1	B	Nc1ncnc(Nc2ccc(OCc3ccccc3)c(Cl)c2)c1C(=O)NCCN1CCOCC1		CHEMBL518646	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	2240013	CHEMBL972549	Inhibition of CDK1	B	Nc1ncnc(Nc2ccc(OCc3ccccc3)c(Cl)c2)c1C(=O)NCCN1CCCCC1		CHEMBL462343	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	2240024	CHEMBL972548	Inhibition of CDK1 at 100 uM	B	Nc1ncnc(Nc2ccc(OCc3ccccc3)c(Cl)c2)c1C=O		CHEMBL461311	<	Inhibition	%	10.0	CHEMBL308	Homo sapiens	INH	%	10.0
	2240029	CHEMBL972548	Inhibition of CDK1 at 100 uM	B	Nc1ncnc(Nc2ccc(OCc3ccccc3)c(Cl)c2)c1C(=O)OCCN1CCOCC1		CHEMBL461113	<	Inhibition	%	10.0	CHEMBL308	Homo sapiens	INH	%	10.0
	2240030	CHEMBL972548	Inhibition of CDK1 at 100 uM	B	Nc1ncnc(Nc2ccc(OCc3ccccc3)c(Cl)c2)c1C(=O)O		CHEMBL512391	<	Inhibition	%	10.0	CHEMBL308	Homo sapiens	INH	%	10.0
	2240034	CHEMBL972548	Inhibition of CDK1 at 100 uM	B	N#Cc1c(N)ncnc1Nc1ccc(OCc2ccccc2)c(Cl)c1		CHEMBL500591	<	Inhibition	%	10.0	CHEMBL308	Homo sapiens	INH	%	10.0
Not Determined	2240035	CHEMBL972549	Inhibition of CDK1	B	COC(=O)c1c(N)ncnc1Nc1ccc(OCc2ccccc2)c(Cl)c1		CHEMBL516487		IC50			CHEMBL308	Homo sapiens	IC50		
	2268424	CHEMBL960828	Inhibition of Cdk1 at 10 uM	B	Clc1cccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)c1		CHEMBL522629	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2268744	CHEMBL960828	Inhibition of Cdk1 at 10 uM	B	Clc1cccc(-n2cc(-c3ccccc3NCc3c[nH]cn3)nn2)c1		CHEMBL464619	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2268745	CHEMBL960828	Inhibition of Cdk1 at 10 uM	B	FC(F)(F)c1cccc(-n2cc(-c3ccccc3NCc3ccnc4ccccc34)nn2)c1		CHEMBL517021	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2268746	CHEMBL960828	Inhibition of Cdk1 at 10 uM	B	Clc1cccc(-n2cc(-c3ccccc3NCc3ccnc4ccccc34)nn2)c1		CHEMBL516635	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2268747	CHEMBL960828	Inhibition of Cdk1 at 10 uM	B	FC(F)(F)c1cccc(-n2cc(-c3ccccc3NCc3ccc4c(c3)OCO4)nn2)c1		CHEMBL460959	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2268748	CHEMBL960828	Inhibition of Cdk1 at 10 uM	B	Clc1cccc(-n2cc(-c3ccccc3NCc3ccc4c(c3)OCO4)nn2)c1		CHEMBL460958	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2268749	CHEMBL960828	Inhibition of Cdk1 at 10 uM	B	Fc1ccc(CNc2ccccc2-c2cn(-c3cccc(Cl)c3)nn2)cc1F		CHEMBL460751	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2268750	CHEMBL960828	Inhibition of Cdk1 at 10 uM	B	Cc1cc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)ccc1C(F)(F)F		CHEMBL454403	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2268751	CHEMBL960828	Inhibition of Cdk1 at 10 uM	B	Cc1ccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)cc1C(F)(F)F		CHEMBL523320	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2268752	CHEMBL960828	Inhibition of Cdk1 at 10 uM	B	Clc1ccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)cc1Cl		CHEMBL491872	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2268753	CHEMBL960828	Inhibition of Cdk1 at 10 uM	B	FC(F)(F)c1ccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)cc1Cl		CHEMBL491871	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2268754	CHEMBL960828	Inhibition of Cdk1 at 10 uM	B	FC(F)(F)c1cc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)ccc1Cl		CHEMBL522133	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2268755	CHEMBL960828	Inhibition of Cdk1 at 10 uM	B	c1ccc(-c2cn(-c3ccc4[nH]ncc4c3)nn2)c(NCc2ccncc2)c1		CHEMBL516645	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2268756	CHEMBL960828	Inhibition of Cdk1 at 10 uM	B	c1ccc(-c2cn(-c3ccc4ccccc4n3)nn2)c(NCc2ccncc2)c1		CHEMBL461605	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2268757	CHEMBL960828	Inhibition of Cdk1 at 10 uM	B	CC(C)(C)c1ccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)cc1		CHEMBL461392	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2268758	CHEMBL960828	Inhibition of Cdk1 at 10 uM	B	CC(C)(C)c1cccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)c1		CHEMBL461391	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2268759	CHEMBL960828	Inhibition of Cdk1 at 10 uM	B	CC(C)c1cccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)c1		CHEMBL518652	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2268760	CHEMBL960828	Inhibition of Cdk1 at 10 uM	B	FC(F)(F)Oc1ccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)cc1		CHEMBL491681	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2268761	CHEMBL960828	Inhibition of Cdk1 at 10 uM	B	FC(F)(F)c1ccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)cc1		CHEMBL522304	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2268762	CHEMBL960828	Inhibition of Cdk1 at 10 uM	B	Clc1ccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)cc1		CHEMBL491680	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2268763	CHEMBL960828	Inhibition of Cdk1 at 10 uM	B	FC(F)(F)Oc1cccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)c1		CHEMBL491502	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2268764	CHEMBL960828	Inhibition of Cdk1 at 10 uM	B	FC(F)(F)c1cccc(-n2cc(-c3ccccc3NCc3ccccn3)nn2)c1		CHEMBL523133	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2268765	CHEMBL960828	Inhibition of Cdk1 at 10 uM	B	FC(F)(F)c1cccc(-n2cc(-c3ccccc3NCc3cccnc3)nn2)c1		CHEMBL490969	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2268766	CHEMBL960828	Inhibition of Cdk1 at 10 uM	B	FC(F)(F)c1cccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)c1		CHEMBL490968	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2268767	CHEMBL960828	Inhibition of Cdk1 at 10 uM	B	Clc1cccc(-n2cc(-c3ccccc3NCc3ccccn3)nn2)c1		CHEMBL523301	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2268768	CHEMBL960828	Inhibition of Cdk1 at 10 uM	B	Clc1cccc(-n2cc(-c3ccccc3NCc3cccnc3)nn2)c1		CHEMBL489329	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2298840	CHEMBL1017186	Inhibition of human CDK1	B	NC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(CN2CCCCC2)cc1)c1ccccc1		CHEMBL497949	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	2298865	CHEMBL1017186	Inhibition of human CDK1	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	2298866	CHEMBL1017186	Inhibition of human CDK1	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(CN(C)C(=O)N(C)C)cc1)c1ccccc1		CHEMBL525203	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	2341419	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(N3CCN(C(=O)Cc4c[nH]c5ccccc45)CC3)ncn2)c1		CHEMBL524898	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2341459	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	CN(C)CC(C)(C)CNC(=O)c1cccc(Nc2nccc(Nc3ccc4ncsc4c3)n2)c1		CHEMBL501459	=	Inhibition	%	5.0	CHEMBL308	Homo sapiens	INH	%	5.0
	2341500	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	Nc1nc(N2CCOCC2)cc(N2CCC(C(=O)NCCc3ccc(O)cc3)CC2)n1		CHEMBL501728	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2341541	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	O=C(NCCc1ccc(O)cc1)c1cccc(Nc2nccc(Nc3ccc4ncsc4c3)n2)c1		CHEMBL499617	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2341582	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	O=C(c1nc(SCc2ccc(Cl)cc2)n2ccccc12)N1CCN(c2cc(Nc3cccc(Br)c3)ncn2)CC1		CHEMBL501200	=	Inhibition	%	8.0	CHEMBL308	Homo sapiens	INH	%	8.0
	2341623	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	Nc1nc(Nc2ccc3ncsc3c2)cc(N2CCC[C@H]2C(=O)N[C@@H](CO)c2ccccc2)n1		CHEMBL525070	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2341664	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	Nc1nc(Nc2ccc3ncsc3c2)cc(N2CCC[C@H]2C(=O)NCCc2cccc(I)c2)n1		CHEMBL501463	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2341705	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	O=C(NC1Cc2ccccc2C1)c1cccc(Nc2ccnc(N3CCN(c4ccccc4)CC3)n2)c1		CHEMBL499624	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2341746	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)NCc4ccc(N(C)C)cc4)c3)ncn2)c1		CHEMBL502826	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2341787	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(Nc3ccc(CC(=O)Nc4ccc5ncsc5c4)cc3)ncn2)c1		CHEMBL502827	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2341828	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	COc1ccc(NC(=O)Cc2ccc(Nc3cc(N(C)c4cccc(C)c4)ncn3)cc2)cn1		CHEMBL526914	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2341869	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	Cc1cccc(Nc2nccc(Nc3cccc(C(=O)NCc4ccc(N(C)C)cc4)c3)n2)c1		CHEMBL501471	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2341910	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	O=C(NCc1cccnc1)c1cccc(-c2ccc(Nc3ccc4ncsc4c3)nn2)c1		CHEMBL501182	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2341951	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)N4CCCC5CCCCC54)c3)ncn2)c1		CHEMBL499606	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2341992	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	COc1cccc(Nc2cc(Nc3cccc(C(=O)N(C)CCc4ccccn4)c3)nc(N)n2)c1		CHEMBL499865	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2342033	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	Cc1cccc(Nc2nccc(Nc3cccc(C(=O)N(C)CCc4ccccn4)c3)n2)c1		CHEMBL499866	=	Inhibition	%	1.0	CHEMBL308	Homo sapiens	INH	%	1.0
	2342074	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	O=C(CN1CCN(c2ncnc3c2CN(Cc2ccccc2)CC3)CC1)Nc1cc(F)ccc1F		CHEMBL520451	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2342115	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	O=C(NCc1ccncc1)c1cccc(Nc2cc(Nc3cccc(Br)c3)ncn2)c1		CHEMBL482513	=	Inhibition	%	1.0	CHEMBL308	Homo sapiens	INH	%	1.0
	2342156	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	Cc1cccc(Nc2cc(Nc3cccc(C(=O)N(CC(C)O)CC(C)O)c3)ncn2)c1		CHEMBL483318	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2342197	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)NCCCn4ccnc4)c3)ncn2)c1		CHEMBL520971	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2342238	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)N(C)CCc4ccccn4)c3)ncn2)c1		CHEMBL521469	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2342279	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	CC(=O)N1CCN(C(=O)c2cccc(Nc3cc(N(C)c4cccc(C)c4)ncn3)c2)CC1		CHEMBL521478	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2342320	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)NCc4ccncc4)c3)ncn2)c1		CHEMBL483506	=	Inhibition	%	7.0	CHEMBL308	Homo sapiens	INH	%	7.0
	2342361	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	CN(CCc1ccccn1)C(=O)c1cccc(Nc2nccc(Nc3ccc4ncsc4c3)n2)c1		CHEMBL483507	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2342402	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	COc1cccc(Nc2cc(Nc3cccc(C(=O)NCCCn4ccnc4)c3)nc(N)n2)c1		CHEMBL520980	=	Inhibition	%	2.0	CHEMBL308	Homo sapiens	INH	%	2.0
	2342443	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	COC[C@@H]1CCCN1C(=O)[C@@H]1CCCN1c1cc(Nc2cccc(OC)c2)nc(N)n1		CHEMBL519962	=	Inhibition	%	5.0	CHEMBL308	Homo sapiens	INH	%	5.0
	2342484	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	COc1cccc(Nc2cc(N3CCC[C@H]3C(=O)NCCN3CCCCC3)nc(N)n2)c1		CHEMBL526526	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2342525	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	O=C(COc1ccccc1)N1CCN(c2nccc(Nc3ccc4ncsc4c3)n2)CC1		CHEMBL482488	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2342798	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	O=C(NC[C@@H]1CCCO1)c1cccc(Nc2nccc(Nc3ccc4ncsc4c3)n2)c1		CHEMBL500661	=	Inhibition	%	11.0	CHEMBL308	Homo sapiens	INH	%	11.0
	2342831	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	Clc1ccc2sc(CN3CCN(c4ncnc5c4CN(Cc4ccccc4)CC5)CC3)cc2c1		CHEMBL483710	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2343106	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	Nc1nc(Nc2ccccc2)cc(N2CCC(C(=O)NCCc3ccccn3)CC2)n1		CHEMBL521002	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2343130	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	CC(=O)CCCCC(=O)N1CCN(c2nccc(Oc3cccc(C)c3)n2)CC1		CHEMBL484713	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2343152	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	COc1ccc(-c2noc(CN3CCN(c4cc(Nc5cccc(O)c5)ncn4)CC3)n2)cc1		CHEMBL483715	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2343176	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	Cc1cccc(Oc2ccnc(N3CCN(CC(=O)Nc4cccc5c4CCCC5)CC3)n2)c1		CHEMBL520512	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2343200	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(N3CCN(CC(=O)Nc4nc(-c5ccccc5)cs4)CC3)ncn2)c1		CHEMBL519534	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2343224	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	Nc1nc(Nc2ccc(C(=O)NCCc3ccncc3)cc2)cc(N2CCOCC2)n1		CHEMBL485524	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2343248	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	Cc1cccc(Nc2nccc3c2CN(C(=O)c2cc(C)n(C)c2C)CC3)c1		CHEMBL519146	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2343272	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	Cc1cc(C(=O)N2CCN(c3ncnc4c3CN(Cc3ccccc3)CC4)CC2)c(C)n1C		CHEMBL482710	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2343633	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	Nc1nc(N2CCOCC2)cc(N2CCC(C(=O)NCc3cccs3)CC2)n1		CHEMBL482910	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2343691	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	COc1cccc(Nc2cc(N3CCC[C@H]3C(=O)NCCc3ccc(O)cc3)nc(N)n2)c1		CHEMBL483518	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2343715	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	Cc1cccc(Oc2ccnc(N3CCC[C@H]3C(=O)NCc3cccnc3)n2)c1		CHEMBL482717	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2343737	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	COC(=O)C(CO)NC(=O)[C@@H]1CCCN1c1nccc(Oc2cccc(C)c2)n1		CHEMBL519310	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2343759	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	Cc1cccc(Oc2ccnc(N3CCN(C(=O)c4c(C)noc4C)CC3)n2)c1		CHEMBL482721	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2343781	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	CN(C)CC(C)(C)CNC(=O)C1CCN(c2cc(N3CCOCC3)nc(N)n2)CC1		CHEMBL519311	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2343803	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	Cc1cccc(Oc2ccnc(N3CCC[C@H]3C(=O)NCCCn3ccnc3)n2)c1		CHEMBL482722	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2343824	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	O=C(c1nc(SCc2ccc(Cl)cc2)n2ccccc12)N1CCN(c2ncnc3c2CN(Cc2ccccc2)CC3)CC1		CHEMBL446637	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2343846	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	CN(C)c1ccc(C(=O)N2CCN(c3ncnc4c3CN(Cc3ccccc3)CC4)CC2)c2ccccc12		CHEMBL520331	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2343868	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	Cc1cccc(Nc2ncnc3c2CN(C(=O)c2ccc(N(C)C)c4ccccc24)CC3)c1		CHEMBL484324	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2343890	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	COC[C@@H]1CCCN1C(=O)C1CCCN1c1cc(Nc2cccc(Br)c2)ncn1		CHEMBL484521	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2343912	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	COC[C@@H]1CCCN1C(=O)[C@@H]1CCCN1c1nccc(Nc2ccccc2)n1		CHEMBL519349	=	Inhibition	%	3.0	CHEMBL308	Homo sapiens	INH	%	3.0
	2343934	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	CN(C)CC(C)(C)CNC(=O)[C@@H]1CCCN1c1nccc(Nc2ccccc2)n1		CHEMBL521000	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2343955	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	O=C(C1CCN(c2nccc(Nc3ccccc3)n2)CC1)N1CC[C@@H](O)C1		CHEMBL484706	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2343977	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)N(CC(C)C)CC(C)C)c3)ncn2)c1		CHEMBL484707	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2343999	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	CN(CCc1ccccn1)C(=O)[C@@H]1CCCN1c1nccc(Nc2ccccc2)n1		CHEMBL521479	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2344022	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	CN(CCCn1ccnc1)C(=O)[C@@H]1CCCN1c1nccc(Nc2ccccc2)n1		CHEMBL519658	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2344732	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	Cc1cccc(CN2CCN(c3cc(N(C)c4cccc(C)c4)ncn3)CC2)c1		CHEMBL446087	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2344752	CHEMBL953379	Inhibition of CDK1 at 10 uM by HTRF assay relative to control	B	Cc1ccc(CN2CCN(c3nccc(C(C#N)c4ccccn4)n3)CC2)cc1		CHEMBL521145	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2356966	CHEMBL958263	Inhibition of CDK1 at 1 uM relative to control	B	Cc1ccn(-c2cccc(C(F)(F)F)c2)c(=O)c1-c1ccc2nc(N)ncc2c1		CHEMBL504805	>	Inhibition	%	50.0	CHEMBL308	Homo sapiens	INH	%	50.0
	2373125	CHEMBL981692	Inhibition of CDK1 at 100 uM	B	O=C1NCc2cccc(-c3ccc[nH]3)c21		CHEMBL491045	=	Inhibition	%	63.0	CHEMBL308	Homo sapiens	INH	%	63.0
	2373148	CHEMBL981689	Inhibition of CDK1	B	O=C1NCc2cccc(-c3cc4cc(OCc5ccccc5)ccc4[nH]3)c21		CHEMBL484678	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	2373149	CHEMBL981689	Inhibition of CDK1	B	O=C1NCc2cccc(-c3cc4ccccc4[nH]3)c21		CHEMBL482621	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	2373150	CHEMBL981689	Inhibition of CDK1	B	O=C1NCc2cccc(-c3cc4cc(O)ccc4[nH]3)c21		CHEMBL443338	=	IC50	nM	13300.0	CHEMBL308	Homo sapiens	IC50	uM	13.3
	2373151	CHEMBL981689	Inhibition of CDK1	B	COc1ccc2[nH]c(-c3cccc4c3C(=O)NC4)cc2c1		CHEMBL520975	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	2373152	CHEMBL981689	Inhibition of CDK1	B	O=C1NCc2cccc(-c3cc4cc(OCCN5CCOCC5)ccc4[nH]3)c21		CHEMBL483451	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	2373153	CHEMBL981689	Inhibition of CDK1	B	O=C1NCc2cccc(-c3cc4cc(OCCCN5CCCCC5)ccc4[nH]3)c21		CHEMBL485081	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	2373154	CHEMBL981689	Inhibition of CDK1	B	O=C1NCc2cccc(-c3cc4cc(OCCN5CCCCC5)ccc4[nH]3)c21		CHEMBL484876	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	2373155	CHEMBL981689	Inhibition of CDK1	B	O=C1NCc2cccc(-c3cc4cc(OCCCO)ccc4[nH]3)c21		CHEMBL449663	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	2373156	CHEMBL981689	Inhibition of CDK1	B	O=C1NCc2cccc(-c3cc4cc(OCCCN5CCC(O)CC5)ccc4[nH]3)c21		CHEMBL522601	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	2373157	CHEMBL981689	Inhibition of CDK1	B	CCN1CCN(CCCOc2ccc3[nH]c(-c4cccc5c4C(=O)NC5)cc3c2)CC1		CHEMBL489820	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	2373158	CHEMBL981689	Inhibition of CDK1	B	CN1Cc2cccc(-c3cccn3C(=O)OC(C)(C)C)c2C1=O		CHEMBL491243	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	2373159	CHEMBL981692	Inhibition of CDK1 at 100 uM	B	CN1Cc2cccc(-c3ccc[nH]3)c2C1=O		CHEMBL523308	=	Inhibition	%	24.0	CHEMBL308	Homo sapiens	INH	%	24.0
	2373160	CHEMBL981692	Inhibition of CDK1 at 100 uM	B	CC(C)(C)OC(=O)n1cccc1-c1cccc2c1C(=O)NC2		CHEMBL521779	<	Inhibition	%	10.0	CHEMBL308	Homo sapiens	INH	%	10.0
	2411857	CHEMBL987694	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(Nc2nc3ncnc(Nc4c(F)cccc4F)c3s2)cc1		CHEMBL513716	=	IC50	nM	19800.0	CHEMBL308	Homo sapiens	IC50	uM	19.8
	2486588	CHEMBL994194	Inhibition of Cdc2	B	CCn1c2cc(Cl)c(O)cc2c(=O)c2c(=O)o[nH]c21		CHEMBL523823	>	Ki	nM	8910.0	CHEMBL308	Homo sapiens	Ki	uM	8.91
	2503167	CHEMBL946655	Inhibition of CDK1	B	CC(C)n1cnc2ccc3nc(C(=N)NCCN(C)C)sc3c2c1=O		CHEMBL210229	=	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	2503174	CHEMBL946655	Inhibition of CDK1	B	CCOC(=N)c1nc2ccc3ncn(CC)c(=O)c3c2s1		CHEMBL506669	=	IC50	nM	50000.0	CHEMBL308	Homo sapiens	IC50	uM	50.0
	2503175	CHEMBL946655	Inhibition of CDK1	B	CCOC(=N)c1nc2ccc3ncn(C(C)C)c(=O)c3c2s1		CHEMBL510863	=	IC50	nM	13000.0	CHEMBL308	Homo sapiens	IC50	uM	13.0
	2503176	CHEMBL946655	Inhibition of CDK1	B	CC(C)n1cnc2ccc3nc(C(=N)NCc4ccccc4)sc3c2c1=O		CHEMBL461739	=	IC50	nM	9000.0	CHEMBL308	Homo sapiens	IC50	uM	9.0
	2503177	CHEMBL946655	Inhibition of CDK1	B	CC(C)n1cnc2ccc3nc(C(=N)OCc4ccccc4)sc3c2c1=O		CHEMBL453129	=	IC50	nM	150.0	CHEMBL308	Homo sapiens	IC50	uM	0.15
Not Active	2527114	CHEMBL984141	Inhibition of CDK1 at => 3 ug/mL	B	COc1c(NC(=O)Nc2ccc(-c3ccc(CN4CCOCC4)nc3)c3ccccc23)cc(C(C)(C)C)cc1NS(C)(=O)=O		CHEMBL451523		Activity			CHEMBL308	Homo sapiens	Activity		
Active	2568946	CHEMBL975447	Inhibition of CDK1 in human HCT116 cells assessed as PP1-alpha(Thr320) phosphorylation	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813		Activity			CHEMBL308	Homo sapiens	Activity		
	2586206	CHEMBL1018124	Inhibition of CDK1	B	Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C		CHEMBL488436	=	IC50	nM	62.0	CHEMBL308	Homo sapiens	IC50	uM	0.062
	2586207	CHEMBL1018124	Inhibition of CDK1	B	Cc1ncc(-c2ccnc(Nc3ccc(C(=O)N4CCN(C)CC4)cc3)n2)n1C(C)C		CHEMBL455467	=	IC50	nM	71.0	CHEMBL308	Homo sapiens	IC50	uM	0.071
	2586208	CHEMBL1018124	Inhibition of CDK1	B	Cc1ncc(-c2nc(Nc3ccc(C(=O)N4CCN(C)CC4)cc3)ncc2F)n1C(C)C		CHEMBL451462	=	IC50	nM	130.0	CHEMBL308	Homo sapiens	IC50	uM	0.13
	2586209	CHEMBL1018124	Inhibition of CDK1	B	Cc1ncc(-c2ccnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3)n2)n1C(C)C		CHEMBL455468	=	IC50	nM	180.0	CHEMBL308	Homo sapiens	IC50	uM	0.18
	2586210	CHEMBL1018124	Inhibition of CDK1	B	Cc1ncc(-c2nc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3)ncc2F)n1C(C)C		CHEMBL507722	=	IC50	nM	50.0	CHEMBL308	Homo sapiens	IC50	uM	0.05
	2586211	CHEMBL1018124	Inhibition of CDK1	B	Cc1ncc(-c2ccnc(Nc3ccc(C(=O)NC4CCN(C)CC4)c(F)c3)n2)n1C(C)C		CHEMBL453895	=	IC50	nM	150.0	CHEMBL308	Homo sapiens	IC50	uM	0.15
	2586212	CHEMBL1018124	Inhibition of CDK1	B	Cc1ncc(-c2nc(Nc3ccc(C(=O)NC4CCN(C)CC4)c(F)c3)ncc2F)n1C(C)C		CHEMBL509406	=	IC50	nM	12.0	CHEMBL308	Homo sapiens	IC50	uM	0.012
	2586213	CHEMBL1018124	Inhibition of CDK1	B	Cc1ncc(-c2ccnc(Nc3ccc(C(=O)NCCN(C)C)c(F)c3)n2)n1C(C)C		CHEMBL453629	=	IC50	nM	29.0	CHEMBL308	Homo sapiens	IC50	uM	0.029
	2586214	CHEMBL1018124	Inhibition of CDK1	B	Cc1ncc(-c2nc(Nc3ccc(C(=O)NCCN(C)C)c(F)c3)ncc2F)n1C(C)C		CHEMBL462385	<	IC50	nM	1.0	CHEMBL308	Homo sapiens	IC50	uM	0.001
	2586215	CHEMBL1018124	Inhibition of CDK1	B	Cc1ncc(-c2nc(Nc3ccc(C(=O)N4CC[C@H](N(C)C)C4)cc3)ncc2F)n1C(C)C		CHEMBL460102	=	IC50	nM	11.0	CHEMBL308	Homo sapiens	IC50	uM	0.011
	2586216	CHEMBL1018124	Inhibition of CDK1	B	Cc1ncc(-c2nc(Nc3ccc(C(=O)N4CC[C@@H](N(C)C)C4)cc3)ncc2F)n1C(C)C		CHEMBL460103	=	IC50	nM	11.0	CHEMBL308	Homo sapiens	IC50	uM	0.011
	2586217	CHEMBL1018124	Inhibition of CDK1	B	Cc1ncc(-c2nc(Nc3ccc(C(=O)N4CCCN(C)CC4)cc3)ncc2F)n1C(C)C		CHEMBL462192	=	IC50	nM	5.0	CHEMBL308	Homo sapiens	IC50	uM	0.005
	2586218	CHEMBL1018124	Inhibition of CDK1	B	CCCN(C)[C@H]1CCN(C(=O)c2ccc(Nc3nccc(-c4cnc(C)n4C(C)C)n3)cc2)C1		CHEMBL518826	=	IC50	nM	120.0	CHEMBL308	Homo sapiens	IC50	uM	0.12
	2586219	CHEMBL1018124	Inhibition of CDK1	B	Cc1ncc(-c2ccnc(Nc3ccc(C(=O)N4CC[C@H](NC5CC5)C4)cc3)n2)n1C(C)C		CHEMBL460086	=	IC50	nM	100.0	CHEMBL308	Homo sapiens	IC50	uM	0.1
	2586220	CHEMBL1018124	Inhibition of CDK1	B	CN[C@H]1CCN(C(=O)c2ccc(Nc3nccc(-c4cnc(C)n4C(C)C)n3)cc2)C1		CHEMBL460087	=	IC50	nM	9.0	CHEMBL308	Homo sapiens	IC50	uM	0.009
	2586221	CHEMBL1018124	Inhibition of CDK1	B	CN[C@H]1CCN(C(=O)c2ccc(Nc3ncc(F)c(-c4cnc(C)n4C(C)C)n3)cc2)C1		CHEMBL455657	=	IC50	nM	2.0	CHEMBL308	Homo sapiens	IC50	uM	0.002
	2602483	CHEMBL1034905	Inhibition of CDK1 at 10 uM by HTRF assay	B	O=C(Nc1cccc(C(F)(F)F)c1)c1nscc1NCc1ccncc1		CHEMBL515880	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2602809	CHEMBL1034905	Inhibition of CDK1 at 10 uM by HTRF assay	B	O=C(Nc1cccc(Br)c1)c1nscc1NCc1ccc2ccccc2n1		CHEMBL458532	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2602810	CHEMBL1034905	Inhibition of CDK1 at 10 uM by HTRF assay	B	O=C(Nc1cccc(Br)c1)c1nscc1NCc1cnoc1		CHEMBL512380	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2602811	CHEMBL1034905	Inhibition of CDK1 at 10 uM by HTRF assay	B	O=C(Nc1cccc(C(F)(F)F)c1)c1nscc1NCc1ccnc2ccccc12		CHEMBL458531	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2602812	CHEMBL1034905	Inhibition of CDK1 at 10 uM by HTRF assay	B	O=C(Nc1cccc(Br)c1)c1nscc1NCc1ccnc2ccccc12		CHEMBL517399	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2602813	CHEMBL1034905	Inhibition of CDK1 at 10 uM by HTRF assay	B	O=C(Nc1cccc(Br)c1)c1nscc1NCCc1ccc2c(c1)OCO2		CHEMBL462528	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2602814	CHEMBL1034905	Inhibition of CDK1 at 10 uM by HTRF assay	B	O=C(Nc1cccc(C(F)(F)F)c1)c1nscc1NCCc1ccc2c(c1)OCO2		CHEMBL462527	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2602815	CHEMBL1034905	Inhibition of CDK1 at 10 uM by HTRF assay	B	O=C(Nc1cccc(C(F)(F)F)c1)c1nscc1NCc1ccc(F)c(F)c1		CHEMBL518204	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2602816	CHEMBL1034905	Inhibition of CDK1 at 10 uM by HTRF assay	B	O=C(NCc1ccc2c(c1)OCO2)c1nscc1NCc1ccncc1		CHEMBL462315	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2602817	CHEMBL1034905	Inhibition of CDK1 at 10 uM by HTRF assay	B	Cc1ccc(NC(=O)c2nscc2NCc2ccncc2)c(F)c1		CHEMBL460191	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2602818	CHEMBL1034905	Inhibition of CDK1 at 10 uM by HTRF assay	B	Cc1cc(NC(=O)c2nscc2NCc2ccncc2)ccc1C(F)(F)F		CHEMBL512863	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2602819	CHEMBL1034905	Inhibition of CDK1 at 10 uM by HTRF assay	B	Cc1ccc(NC(=O)c2nscc2NCc2ccncc2)cc1C(F)(F)F		CHEMBL470441	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2602820	CHEMBL1034905	Inhibition of CDK1 at 10 uM by HTRF assay	B	O=C(Nc1ccc(Cl)c(Cl)c1)c1nscc1NCc1ccncc1		CHEMBL470440	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2602821	CHEMBL1034905	Inhibition of CDK1 at 10 uM by HTRF assay	B	O=C(Nc1ccc(C(F)(F)F)c(Cl)c1)c1nscc1NCc1ccncc1		CHEMBL512862	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2602822	CHEMBL1034905	Inhibition of CDK1 at 10 uM by HTRF assay	B	O=C(Nc1ccc(Cl)c(C(F)(F)F)c1)c1nscc1NCc1ccncc1		CHEMBL473268	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2602823	CHEMBL1034905	Inhibition of CDK1 at 10 uM by HTRF assay	B	O=C(NC1=CC2C=NNC2C=C1)c1nscc1NCc1ccncc1		CHEMBL443921	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2602824	CHEMBL1034905	Inhibition of CDK1 at 10 uM by HTRF assay	B	O=C(Nc1ccc2ccccc2n1)c1nscc1NCc1ccncc1		CHEMBL474709	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2602825	CHEMBL1034905	Inhibition of CDK1 at 10 uM by HTRF assay	B	O=C(Nc1ccccc1Br)c1nscc1NCc1ccncc1		CHEMBL509737	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2602826	CHEMBL1034905	Inhibition of CDK1 at 10 uM by HTRF assay	B	O=C(Nc1ccc(Br)cc1)c1nscc1NCc1ccncc1		CHEMBL473288	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2602827	CHEMBL1034905	Inhibition of CDK1 at 10 uM by HTRF assay	B	O=C(Nc1cccc(Br)c1)c1nscc1NCc1ccncc1		CHEMBL473287	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2602828	CHEMBL1034905	Inhibition of CDK1 at 10 uM by HTRF assay	B	O=C(Nc1ccc(Cl)cc1)c1nscc1NCc1ccncc1		CHEMBL475709	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2602829	CHEMBL1034905	Inhibition of CDK1 at 10 uM by HTRF assay	B	CC(C)(C)c1ccc(NC(=O)c2nscc2NCc2ccncc2)cc1		CHEMBL475708	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2602830	CHEMBL1034905	Inhibition of CDK1 at 10 uM by HTRF assay	B	CC(C)(C)c1cccc(NC(=O)c2nscc2NCc2ccncc2)c1		CHEMBL475510	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2602831	CHEMBL1034905	Inhibition of CDK1 at 10 uM by HTRF assay	B	O=C(Nc1ccc(OC(F)(F)F)cc1)c1nscc1NCc1ccncc1		CHEMBL516243	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2602832	CHEMBL1034905	Inhibition of CDK1 at 10 uM by HTRF assay	B	O=C(Nc1cccc(OC(F)(F)F)c1)c1nscc1NCc1ccncc1		CHEMBL475509	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2602833	CHEMBL1034905	Inhibition of CDK1 at 10 uM by HTRF assay	B	O=C(Nc1ccc(C(F)(F)F)cc1)c1nscc1NCc1ccccn1		CHEMBL474494	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2602834	CHEMBL1034905	Inhibition of CDK1 at 10 uM by HTRF assay	B	O=C(Nc1ccc(C(F)(F)F)cc1)c1nscc1NCc1cccnc1		CHEMBL474293	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2602835	CHEMBL1034905	Inhibition of CDK1 at 10 uM by HTRF assay	B	O=C(Nc1ccc(C(F)(F)F)cc1)c1nscc1NCc1ccncc1		CHEMBL475704	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2602836	CHEMBL1034905	Inhibition of CDK1 at 10 uM by HTRF assay	B	O=C(Nc1cccc(C(F)(F)F)c1)c1nscc1NCc1ccccn1		CHEMBL475703	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2602837	CHEMBL1034905	Inhibition of CDK1 at 10 uM by HTRF assay	B	O=C(Nc1cccc(C(F)(F)F)c1)c1nscc1NCc1cccnc1		CHEMBL514986	<	Inhibition	%	30.0	CHEMBL308	Homo sapiens	INH	%	30.0
	2613489	CHEMBL1024806	Inhibition of CDK1	B	COc1ccc(-n2cnc3ccc(-c4nnc(SCc5cccc(C#N)c5)o4)cc32)cc1		CHEMBL516640	=	IC50	nM	4600.0	CHEMBL308	Homo sapiens	IC50	uM	4.6
	2620343	CHEMBL1036687	Inhibition of CDK1 at 100 nM	B	CCn1sc(=O)n(Cc2ccccc2)c1=O		CHEMBL26241	=	Inhibition	%	15.0	CHEMBL308	Homo sapiens	INH	%	15.0
	2620344	CHEMBL1036687	Inhibition of CDK1 at 100 nM	B	O=c1sn(-c2ccccc2)c(=O)n1CCCl		CHEMBL449063	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	2620345	CHEMBL1036687	Inhibition of CDK1 at 100 nM	B	CCOC(=O)Cn1sc(=O)n(-c2cccc(C(=O)OCC)c2)c1=O		CHEMBL458636	=	Inhibition	%	18.0	CHEMBL308	Homo sapiens	INH	%	18.0
	2620346	CHEMBL1036687	Inhibition of CDK1 at 100 nM	B	CCOC(=O)Cn1sc(=O)n(-c2ccc(C(=O)OCC)cc2)c1=O		CHEMBL458857	=	Inhibition	%	12.0	CHEMBL308	Homo sapiens	INH	%	12.0
	2620347	CHEMBL1036687	Inhibition of CDK1 at 100 nM	B	O=c1sn(CCc2ccccc2)c(=O)n1Cc1ccc(F)cc1		CHEMBL512208	=	Inhibition	%	20.0	CHEMBL308	Homo sapiens	INH	%	20.0
	2620348	CHEMBL1036687	Inhibition of CDK1 at 100 nM	B	CCOC(=O)Cn1sc(=O)n(CC(=O)N2CCCCC2)c1=O		CHEMBL458210	=	Inhibition	%	15.0	CHEMBL308	Homo sapiens	INH	%	15.0
	2696659	CHEMBL1051604	Inhibition of CDK1 assessed as Rb (ser780) biotinylated peptide phosphorylation at 100 uM by DELFIA assay	B	CCOC(=O)c1cnc2[nH]ncc2c1N1CCOC(CN)C1		CHEMBL560056	=	Inhibition	%	3.0	CHEMBL308	Homo sapiens	INH	%	3.0
	2696660	CHEMBL1051604	Inhibition of CDK1 assessed as Rb (ser780) biotinylated peptide phosphorylation at 100 uM by DELFIA assay	B	NCC1CN(c2c(Br)cnc3[nH]ncc23)CCO1		CHEMBL559781	=	Inhibition	%	37.0	CHEMBL308	Homo sapiens	INH	%	37.0
	2696661	CHEMBL1051604	Inhibition of CDK1 assessed as Rb (ser780) biotinylated peptide phosphorylation at 100 uM by DELFIA assay	B	NCC1CN(c2c(-c3ccsc3)cnc3[nH]ncc23)CCO1		CHEMBL562715	=	Inhibition	%	48.0	CHEMBL308	Homo sapiens	INH	%	48.0
	2696662	CHEMBL1051604	Inhibition of CDK1 assessed as Rb (ser780) biotinylated peptide phosphorylation at 100 uM by DELFIA assay	B	NC[C@@H]1CN(c2c(-c3ccccc3)cnc3[nH]ncc23)CCO1		CHEMBL554900	=	Inhibition	%	43.0	CHEMBL308	Homo sapiens	INH	%	43.0
	2696663	CHEMBL1051605	Inhibition of CDK1 assessed as Rb (ser780) biotinylated peptide phosphorylation by DELFIA assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	18.0	CHEMBL308	Homo sapiens	IC50	nM	18.0
	2701551	CHEMBL1061559	Inhibition of CDK2	B	COc1ccc2sc3c(c2c1)NC[C@@H](C)NC3=O		CHEMBL99780	=	IC50	nM	12.0	CHEMBL308	Homo sapiens	IC50	uM	0.012
	2701552	CHEMBL1061559	Inhibition of CDK2	B	C[C@@H]1CNc2c(sc3ccc4occc4c23)C(=O)N1		CHEMBL557318	=	IC50	nM	1.0	CHEMBL308	Homo sapiens	IC50	uM	0.001
	2701553	CHEMBL1061559	Inhibition of CDK2	B	C[C@@H]1CNc2c(sc3ccc4c(c23)CCO4)C(=O)N1		CHEMBL562754	=	IC50	nM	5.0	CHEMBL308	Homo sapiens	IC50	uM	0.005
	2701554	CHEMBL1061559	Inhibition of CDK2	B	C[C@@H]1CNc2c(sc3ccc4ncccc4c23)C(=O)N1		CHEMBL561334	=	IC50	nM	0.8	CHEMBL308	Homo sapiens	IC50	uM	0.0008
	2701555	CHEMBL1061559	Inhibition of CDK2	B	C[C@@H]1CNc2c(sc3ccc4oc(-c5ccccc5)cc4c23)C(=O)N1		CHEMBL562194	=	IC50	nM	250.0	CHEMBL308	Homo sapiens	IC50	uM	0.25
	2701556	CHEMBL1061559	Inhibition of CDK2	B	C[C@@H]1CNc2c(sc3ccc4nc(Cl)ccc4c23)C(=O)N1		CHEMBL556392	=	IC50	nM	25.0	CHEMBL308	Homo sapiens	IC50	uM	0.025
	2701557	CHEMBL1061559	Inhibition of CDK2	B	C[C@@H]1CNc2c(sc3ccc4nc(-c5ccccc5)ccc4c23)C(=O)N1		CHEMBL564076	=	IC50	nM	200.0	CHEMBL308	Homo sapiens	IC50	uM	0.2
	2701558	CHEMBL1061559	Inhibition of CDK2	B	C[C@@H]1CNc2c(sc3ccc4nc(-c5ccncc5)ccc4c23)C(=O)N1		CHEMBL552339	=	IC50	nM	390.0	CHEMBL308	Homo sapiens	IC50	uM	0.39
	2701559	CHEMBL1061559	Inhibition of CDK2	B	C[C@@H]1CNc2c(sc3ccc4nc(-c5cccnc5)ccc4c23)C(=O)N1		CHEMBL560075	=	IC50	nM	6330.0	CHEMBL308	Homo sapiens	IC50	uM	6.33
	2701560	CHEMBL1061559	Inhibition of CDK2	B	C[C@@H]1CNc2c(sc3ccc4nc(-c5cncnc5)ccc4c23)C(=O)N1		CHEMBL549585	=	IC50	nM	10800.0	CHEMBL308	Homo sapiens	IC50	uM	10.8
	2701561	CHEMBL1061559	Inhibition of CDK2	B	COc1ccccc1-c1ccc2c(ccc3sc4c(c32)NC[C@@H](C)NC4=O)n1		CHEMBL562137	=	IC50	nM	2730.0	CHEMBL308	Homo sapiens	IC50	uM	2.73
	2701562	CHEMBL1061559	Inhibition of CDK2	B	COc1cccc(-c2ccc3c(ccc4sc5c(c43)NC[C@@H](C)NC5=O)n2)c1		CHEMBL563307	=	IC50	nM	2040.0	CHEMBL308	Homo sapiens	IC50	uM	2.04
	2701563	CHEMBL1061559	Inhibition of CDK2	B	C[C@@H]1CNc2c(sc3ccc4nc(-c5ccccc5F)ccc4c23)C(=O)N1		CHEMBL554286	=	IC50	nM	10900.0	CHEMBL308	Homo sapiens	IC50	uM	10.9
	2701564	CHEMBL1061559	Inhibition of CDK2	B	Cc1ccccc1-c1ccc2c(ccc3sc4c(c32)NC[C@@H](C)NC4=O)n1		CHEMBL562606	=	IC50	nM	2210.0	CHEMBL308	Homo sapiens	IC50	uM	2.21
	2701565	CHEMBL1061559	Inhibition of CDK2	B	Cc1ccncc1-c1ccc2c(ccc3sc4c(c32)NC[C@@H](C)NC4=O)n1		CHEMBL549915	=	IC50	nM	7920.0	CHEMBL308	Homo sapiens	IC50	uM	7.92
	2701734	CHEMBL1063345	Inhibition of CDK2	B	COc1ccc2sc3c(c2c1)NCCNC3=O		CHEMBL319171	=	IC50	nM	160.0	CHEMBL308	Homo sapiens	IC50	uM	0.16
	2701737	CHEMBL1063345	Inhibition of CDK2	B	COc1ccc2sc3c(c2c1)NC[C@@H](C)NC3=O		CHEMBL99780	=	IC50	nM	12.0	CHEMBL308	Homo sapiens	IC50	uM	0.012
	2701740	CHEMBL1063345	Inhibition of CDK2	B	COc1ccc2sc3c(c2c1)NC[C@H](C)NC3=O		CHEMBL100818	=	IC50	nM	260.0	CHEMBL308	Homo sapiens	IC50	uM	0.26
	2701745	CHEMBL1063345	Inhibition of CDK2	B	COc1ccc2sc3c(c2c1)NC[C@@H](CO)NC3=O		CHEMBL553397	=	IC50	nM	25.0	CHEMBL308	Homo sapiens	IC50	uM	0.025
	2701748	CHEMBL1063345	Inhibition of CDK2	B	COc1ccc2sc3c(c2c1)SCCNC3=O		CHEMBL319170	=	IC50	nM	150.0	CHEMBL308	Homo sapiens	IC50	uM	0.15
	2701751	CHEMBL1063345	Inhibition of CDK2	B	COc1ccc2sc3c(c2c1)CCCNC3=O		CHEMBL571897	=	IC50	nM	360.0	CHEMBL308	Homo sapiens	IC50	uM	0.36
	2701754	CHEMBL1063345	Inhibition of CDK2	B	COc1ccc2sc3c(c2c1)NC[C@@H](CN)NC3=O		CHEMBL555205	=	IC50	nM	146.0	CHEMBL308	Homo sapiens	IC50	uM	0.146
	2701757	CHEMBL1063345	Inhibition of CDK2	B	CCNC[C@@H]1CNc2c(sc3ccc(OC)cc23)C(=O)N1		CHEMBL550060	=	IC50	nM	3100.0	CHEMBL308	Homo sapiens	IC50	uM	3.1
	2701760	CHEMBL1063345	Inhibition of CDK2	B	CCCNC[C@@H]1CNc2c(sc3ccc(OC)cc23)C(=O)N1		CHEMBL560737	=	IC50	nM	2600.0	CHEMBL308	Homo sapiens	IC50	uM	2.6
	2701763	CHEMBL1063345	Inhibition of CDK2	B	COc1ccc2sc3c(c2c1)NC[C@@H](CNCc1ccccc1)NC3=O		CHEMBL551534	=	IC50	nM	2700.0	CHEMBL308	Homo sapiens	IC50	uM	2.7
	2701768	CHEMBL1063345	Inhibition of CDK2	B	COc1ccc2sc3c(c2c1)NC[C@@H](CN(C)Cc1ccccc1)NC3=O		CHEMBL562002	=	IC50	nM	3170.0	CHEMBL308	Homo sapiens	IC50	uM	3.17
	2701771	CHEMBL1063345	Inhibition of CDK2	B	C[C@@H]1CNc2c(sc3ccc(O)cc23)C(=O)N1		CHEMBL559487	=	IC50	nM	26.0	CHEMBL308	Homo sapiens	IC50	uM	0.026
	2701774	CHEMBL1063345	Inhibition of CDK2	B	COc1cccc(COc2ccc3sc4c(c3c2)NC[C@@H](C)NC4=O)c1		CHEMBL541448	=	IC50	nM	64.0	CHEMBL308	Homo sapiens	IC50	uM	0.064
	2701777	CHEMBL1063345	Inhibition of CDK2	B	C[C@@H]1CNc2c(sc3ccc(OCC4CC4)cc23)C(=O)N1		CHEMBL563672	=	IC50	nM	52.0	CHEMBL308	Homo sapiens	IC50	uM	0.052
	2701780	CHEMBL1063345	Inhibition of CDK2	B	COCCOc1ccc2sc3c(c2c1)NC[C@@H](C)NC3=O		CHEMBL559411	=	IC50	nM	81.0	CHEMBL308	Homo sapiens	IC50	uM	0.081
	2701783	CHEMBL1063345	Inhibition of CDK2	B	CC(C)COc1ccc2sc3c(c2c1)NC[C@@H](C)NC3=O		CHEMBL563308	=	IC50	nM	11.0	CHEMBL308	Homo sapiens	IC50	uM	0.011
	2701786	CHEMBL1063345	Inhibition of CDK2	B	COC(=O)COc1ccc2sc3c(c2c1)NC[C@@H](C)NC3=O		CHEMBL559881	=	IC50	nM	3090.0	CHEMBL308	Homo sapiens	IC50	uM	3.09
	2924030	CHEMBL1038774	Inhibition of C-terminal 6xHis-tagged CDK1 by [gamma-33-P]ATP based assay	B	Cc1ccc(-c2ccc3occ(-c4ccc([S@+](C)[O-])cc4)c3c2)o1		CHEMBL574588	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	nM	10000.0
	2924031	CHEMBL1038774	Inhibition of C-terminal 6xHis-tagged CDK1 by [gamma-33-P]ATP based assay	B	CC[S@+]([O-])c1ccc(-c2coc3ccc(-c4ccc(C)o4)cc23)cc1		CHEMBL574613	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	nM	10000.0
	2938523	CHEMBL1041342	Inhibition of CDK1 at 1 uM	B	Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1		CHEMBL583042	=	Inhibition	%	7.0	CHEMBL308	Homo sapiens	INH	%	7.0
	2943957	CHEMBL1039603	Inhibition of CDK1	B	Cc1c(I)c(=O)n(C2CCCC2)c2nc(Nc3ccc(N4CCNCC4)cc3)ncc12		CHEMBL190460	>	IC50	nM	360.0	CHEMBL308	Homo sapiens	IC50	nM	360.0
	3084385	CHEMBL1072664	Inhibition of CDC2	B	NCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL590109	=	IC50	nM	320.0	CHEMBL308	Homo sapiens	IC50	uM	0.32
	3084407	CHEMBL1072686	Inhibition of CDC4	B	NCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL590109	=	IC50	nM	3600.0	CHEMBL308	Homo sapiens	IC50	uM	3.6
	3088560	CHEMBL1049485	Inhibition of CDK1	B	CN(C)CCOc1ccc2c(c1)CCn1nc(-c3ccc(Oc4ccccc4)cc3)c(C(N)=O)c1N2		CHEMBL591325	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	nM	10000.0
	3088626	CHEMBL1049500	Inhibition of CDK1	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)[nH]c(C(=O)c2c(F)cccc2F)c1N		CHEMBL589630	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	nM	10000.0
	3089490	CHEMBL1067350	Inhibition of CDK1	B	Cc1c(Nc2c(C#N)cncc2/C=C/CCN2CCC[C@@H](N)C2)ccc2[nH]ccc12		CHEMBL606245	=	IC50	nM	26000.0	CHEMBL308	Homo sapiens	IC50	nM	26000.0
	3091547	CHEMBL1067149	Inhibition of CDC2	B	O=C1Nc2cc3c(O)cccc3c3c4c(cc1c23)OCO4		CHEMBL609040	=	IC50	nM	214.0	CHEMBL308	Homo sapiens	IC50	nM	214.0
	3091548	CHEMBL1067149	Inhibition of CDC2	B	COc1c(O)cc2c3c(cc4ccc(O)cc4c13)NC2=O		CHEMBL388956	=	IC50	nM	200.0	CHEMBL308	Homo sapiens	IC50	nM	200.0
	3091549	CHEMBL1067149	Inhibition of CDC2	B	COc1ccc2nc3[nH]nc(C)c3c(OC)c2c1		CHEMBL603097	=	IC50	nM	200.0	CHEMBL308	Homo sapiens	IC50	nM	200.0
	3094274	CHEMBL1073145	Inhibition of CDC2	B	COc1c(O)cc2c3c(cc4ccc(O)cc4c13)NC2=O		CHEMBL388956	=	IC50	nM	214.0	CHEMBL308	Homo sapiens	IC50	nM	214.0
	3104133	CHEMBL1066415	Inhibition of recombinant CDK1 by IMAP assay	B	C[C@@H](Oc1ccc2ncccc2c1)c1c(Cl)ccc(F)c1Cl		CHEMBL600795	>	IC50	nM	50000.0	CHEMBL308	Homo sapiens	IC50	uM	50.0
	3104180	CHEMBL1066415	Inhibition of recombinant CDK1 by IMAP assay	B	C[C@@H](Oc1ccc2ncc(C3CC3C(N)=O)cc2c1)c1c(Cl)ccc(F)c1Cl		CHEMBL602472	>	IC50	nM	50000.0	CHEMBL308	Homo sapiens	IC50	uM	50.0
	3104231	CHEMBL1066415	Inhibition of recombinant CDK1 by IMAP assay	B	C[C@@H](Oc1ccc2ncc(/C=C/C(N)=O)cc2c1)c1c(Cl)ccc(F)c1Cl		CHEMBL602471	>	IC50	nM	50000.0	CHEMBL308	Homo sapiens	IC50	uM	50.0
	3186274	CHEMBL1111500	Inhibition of CDK1	B	CCC(CO)Nc1nc(Nc2cccc(-c3ccccn3)c2)c2ncn(C(C)C)c2n1		CHEMBL1080583	=	IC50	nM	220.0	CHEMBL308	Homo sapiens	IC50	nM	220.0
	3186451	CHEMBL1113276	Inhibition of Cdk1 at 20 uM	B	CCCC(=O)Nc1n[nH]c2cc(Cl)c(-c3ccccc3)cc12		CHEMBL1095040	=	Inhibition	%	95.0	CHEMBL308	Homo sapiens	INH	%	95.0
	3186458	CHEMBL1113301	Inhibition of Cdk1	B	CCCC(=O)Nc1n[nH]c2c(F)c(Cl)c(-c3ccccc3)cc12		CHEMBL1086427	=	IC50	nM	2500.0	CHEMBL308	Homo sapiens	IC50	nM	2500.0
	3186459	CHEMBL1113301	Inhibition of Cdk1	B	CCCC(=O)Nc1n[nH]c2cc(Cl)c(-c3ccccc3)cc12		CHEMBL1095040	=	IC50	nM	100.0	CHEMBL308	Homo sapiens	IC50	nM	100.0
	3196272	CHEMBL1102008	Inhibition of CDK1	B	N[C@H](CNc1ncc(-c2ccc3c(c2)CC(=O)N3)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081831	=	IC50	nM	250.0	CHEMBL308	Homo sapiens	IC50	uM	0.25
	3202392	CHEMBL1108602	Inhibition of CDK1	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	IC50	nM	320.0	CHEMBL308	Homo sapiens	IC50	uM	0.32
	3202395	CHEMBL1108602	Inhibition of CDK1	B	O=Nc1c(-c2c(O)[nH]c3c(Br)cccc23)[nH]c2ccccc12		CHEMBL373834	=	IC50	nM	22000.0	CHEMBL308	Homo sapiens	IC50	uM	22.0
	3213889	CHEMBL1114037	Inhibition of CDC2 at 5 uM	B	O=C(Nc1ccccc1Cl)c1cnc2ccc(C3CCNCC3)cn12.O=C(O)C(=O)O		CHEMBL1077739	=	Inhibition	%	-1.0	CHEMBL308	Homo sapiens	INH	%	-1.0
	3219998	CHEMBL1115847	Inhibition of CDK1	B	CN1C[C@@H]2C[C@H]1CN2c1ccc(-c2ccnc3c(-c4cccc(O)c4)c(-c4ccncc4)nn23)cc1		CHEMBL1087650	=	IC50	nM	28400.0	CHEMBL308	Homo sapiens	IC50	uM	28.4
	3240792	CHEMBL1109655	Inhibition of CDC2	B	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)c1		CHEMBL1090360	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	uM	1.0
	3251262	CHEMBL1110585	Inhibition of CDK1	B	Cn1cc(/C=C2\Oc3cccc(O)c3C2=O)c2c(-c3ccc(C(=O)NCCO)cc3)ccnc21		CHEMBL1092754	=	IC50	nM	39.2	CHEMBL308	Homo sapiens	IC50	nM	39.2
	3260502	CHEMBL1109837	Inhibition of CDK1	B	O=C(Nc1cccc(-c2ccnc3cc(-c4ccncc4)nn23)c1)c1cccc(C(F)(F)F)c1		CHEMBL1089082	>	IC50	nM	50000.0	CHEMBL308	Homo sapiens	IC50	uM	50.0
	3264366	CHEMBL1104635	Inhibition of CDK1	B	CC(C)(C)OC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(N)cc4)nc32)CC1		CHEMBL1095627	>	IC50	nM	50000.0	CHEMBL308	Homo sapiens	IC50	uM	50.0
	3271031	CHEMBL1104635	Inhibition of CDK1	B	COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(N)cc4)nc32)CC1		CHEMBL1095626	>	IC50	nM	50000.0	CHEMBL308	Homo sapiens	IC50	uM	50.0
	3305001	CHEMBL1119480	Inhibition of CDK1	B	Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL482967	>	Ki	nM	10000.0	CHEMBL308	Homo sapiens	Ki	nM	10000.0
	3305002	CHEMBL1119480	Inhibition of CDK1	B	Cc1nc(C)c(-c2ccnc(Nc3ccc(N4CCN(S(C)(=O)=O)CC4)cc3)n2)s1		CHEMBL1083484	>	Ki	nM	10000.0	CHEMBL308	Homo sapiens	Ki	nM	10000.0
	3305003	CHEMBL1119480	Inhibition of CDK1	B	CC(=O)N1CCN(c2ccc(Nc3nccc(-c4sc(C)nc4C)n3)cc2)CC1		CHEMBL1083786	=	Ki	nM	1894.0	CHEMBL308	Homo sapiens	Ki	nM	1894.0
	3305004	CHEMBL1119480	Inhibition of CDK1	B	CNc1nc(C)c(-c2ccnc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3)n2)s1		CHEMBL1083785	=	Ki	nM	851.0	CHEMBL308	Homo sapiens	Ki	nM	851.0
	3305005	CHEMBL1119480	Inhibition of CDK1	B	CC(=O)N1CCN(c2ccc(Nc3nccc(-c4sc(N)nc4C)n3)cc2)CC1		CHEMBL1084969	>	Ki	nM	10000.0	CHEMBL308	Homo sapiens	Ki	nM	10000.0
	3305006	CHEMBL1119480	Inhibition of CDK1	B	CCNc1nc(C)c(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)s1		CHEMBL1084630	>	Ki	nM	10000.0	CHEMBL308	Homo sapiens	Ki	nM	10000.0
	3305007	CHEMBL1119480	Inhibition of CDK1	B	CNc1nc(C)c(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)s1		CHEMBL1084629	=	Ki	nM	3925.0	CHEMBL308	Homo sapiens	Ki	nM	3925.0
	3305008	CHEMBL1119480	Inhibition of CDK1	B	Cc1nc(C)c(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)s1		CHEMBL1085626	>	Ki	nM	10000.0	CHEMBL308	Homo sapiens	Ki	nM	10000.0
	3305009	CHEMBL1119480	Inhibition of CDK1	B	CCNc1nc(C)c(-c2ccnc(Nc3ccc(CNC(C)=O)cc3)n2)s1		CHEMBL1084715	=	Ki	nM	240.0	CHEMBL308	Homo sapiens	Ki	nM	240.0
	3305010	CHEMBL1119480	Inhibition of CDK1	B	CCNc1nc(C)c(-c2ccnc(Nc3cc(OC)c(OC)c(OC)c3)n2)s1		CHEMBL1086088	=	Ki	nM	1224.0	CHEMBL308	Homo sapiens	Ki	nM	1224.0
	3305011	CHEMBL1119480	Inhibition of CDK1	B	CNc1nc(C)c(-c2ccnc(Nc3cc(OC)c(OC)c(OC)c3)n2)s1		CHEMBL1083152	=	Ki	nM	367.0	CHEMBL308	Homo sapiens	Ki	nM	367.0
	3305012	CHEMBL1119480	Inhibition of CDK1	B	COc1cc(Nc2nccc(-c3sc(C)nc3C)n2)cc(OC)c1OC		CHEMBL1083151	=	Ki	nM	706.0	CHEMBL308	Homo sapiens	Ki	nM	706.0
	3305013	CHEMBL1119480	Inhibition of CDK1	B	Cc1nc(C)c(-c2ccnc(Nc3ccc(N)cc3)n2)s1		CHEMBL1084454	=	Ki	nM	769.0	CHEMBL308	Homo sapiens	Ki	nM	769.0
	3305014	CHEMBL1119480	Inhibition of CDK1	B	CNc1ccc(Nc2nccc(-c3sc(C)nc3C)n2)cc1		CHEMBL1083150	=	Ki	nM	909.0	CHEMBL308	Homo sapiens	Ki	nM	909.0
	3305015	CHEMBL1119480	Inhibition of CDK1	B	Cc1nc(C)c(-c2ccnc(Nc3ccc(N(C)C)cc3)n2)s1		CHEMBL46817	=	Ki	nM	2520.0	CHEMBL308	Homo sapiens	Ki	nM	2520.0
	3305016	CHEMBL1119480	Inhibition of CDK1	B	Cc1nc(N)sc1-c1ccnc(Nc2cccc([N+](=O)[O-])c2)n1		CHEMBL298445	=	Ki	nM	80.0	CHEMBL308	Homo sapiens	Ki	nM	80.0
	3407684	CHEMBL1219736	Inhibition of CDC2 at 1 uM by radiometric method	B	CCOC(=O)CCc1c(/C=C2\C(=O)Nc3ccc(NS(=O)(=O)c4ccccc4)cc32)[nH]c2c1C(=O)CCC2		CHEMBL1215218	=	Inhibition	%	33.0	CHEMBL308	Homo sapiens	INH	%	33.0
	3407685	CHEMBL1219736	Inhibition of CDC2 at 1 uM by radiometric method	B	CN(C)CCCc1c(/C=C2\C(=O)Nc3ccc(NS(=O)(=O)c4ccccc4)cc32)[nH]c2c1C(=O)CCC2		CHEMBL1215346	=	Inhibition	%	12.0	CHEMBL308	Homo sapiens	INH	%	12.0
Active	3418654	CHEMBL1226575	Effect on Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25C interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay	B	Cc1ccc(S(=O)(=O)/C=C/C#N)cc1		CHEMBL403183		Activity			CHEMBL308	Homo sapiens	Activity		
Active	3418656	CHEMBL1226575	Effect on Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25C interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay	B	O=C1Nc2ncccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL1082552		Activity			CHEMBL308	Homo sapiens	Activity		
Active	3418657	CHEMBL1226576	Effect on Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25A interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay	B	CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1		CHEMBL672		Activity			CHEMBL308	Homo sapiens	Activity		
Active	3418661	CHEMBL1226575	Effect on Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25C interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay	B	CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1		CHEMBL565		Activity			CHEMBL308	Homo sapiens	Activity		
Active	3418662	CHEMBL1226576	Effect on Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25A interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay	B	CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1		CHEMBL565		Activity			CHEMBL308	Homo sapiens	Activity		
Active	3418666	CHEMBL1226575	Effect on Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25C interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay	B	C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1		CHEMBL43064		Activity			CHEMBL308	Homo sapiens	Activity		
Active	3418667	CHEMBL1226576	Effect on Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25A interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay	B	C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1		CHEMBL43064		Activity			CHEMBL308	Homo sapiens	Activity		
Active	3418671	CHEMBL1226575	Effect on Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25C interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay	B	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1		CHEMBL104		Activity			CHEMBL308	Homo sapiens	Activity		
Active	3418672	CHEMBL1226576	Effect on Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25A interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay	B	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1		CHEMBL104		Activity			CHEMBL308	Homo sapiens	Activity		
Active	3418676	CHEMBL1226575	Effect on Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25C interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay	B	O=C1C=C2C(=CCOC2O)O1		CHEMBL294018		Activity			CHEMBL308	Homo sapiens	Activity		
Active	3418677	CHEMBL1226576	Effect on Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25A interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay	B	O=C1C=C2C(=CCOC2O)O1		CHEMBL294018		Activity			CHEMBL308	Homo sapiens	Activity		
Active	3418681	CHEMBL1226575	Effect on Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25C interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay	B	C=C(C)[C@H]1Cc2c(ccc3c2O[C@@H]2COc4cc(OC)c(OC)cc4[C@@H]2C3=O)O1		CHEMBL429023		Activity			CHEMBL308	Homo sapiens	Activity		
Active	3418682	CHEMBL1226576	Effect on Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25A interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay	B	C=C(C)[C@H]1Cc2c(ccc3c2O[C@@H]2COc4cc(OC)c(OC)cc4[C@@H]2C3=O)O1		CHEMBL429023		Activity			CHEMBL308	Homo sapiens	Activity		
Active	3418686	CHEMBL1226575	Effect on Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25C interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay	B	CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21		CHEMBL809		Activity			CHEMBL308	Homo sapiens	Activity		
Active	3418687	CHEMBL1226576	Effect on Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25A interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay	B	CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21		CHEMBL809		Activity			CHEMBL308	Homo sapiens	Activity		
Active	3418707	CHEMBL1226584	Inhibition of Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25C interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay	B	CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1		CHEMBL672		Inhibition	%		CHEMBL308	Homo sapiens	INH		
Active	3418709	CHEMBL1226584	Inhibition of Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25C interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay	B	CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1		CHEMBL565		Inhibition	%		CHEMBL308	Homo sapiens	INH		
Active	3419709	CHEMBL1226575	Effect on Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25C interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay	B	CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1		CHEMBL672		Activity			CHEMBL308	Homo sapiens	Activity		
	3420187	CHEMBL1226914	Inhibition of cdk1	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	IC50	nM	30.0	CHEMBL308	Homo sapiens	IC50	nM	30.0
	3420220	CHEMBL1226914	Inhibition of cdk1	B	O=C1NCCc2[nH]c(-c3ccncc3)cc21		CHEMBL225519	=	IC50	nM	250.0	CHEMBL308	Homo sapiens	IC50	nM	250.0
	3425369	CHEMBL1228396	Inhibition of CDK1	B	Cc1cc2n[nH]c(=O)n2c2cc(-c3cccs3)ccc12	Non standard unit for type	CHEMBL1223524	>	INH	uM	100.0	CHEMBL308	Homo sapiens	INH	uM	100.0
	3425376	CHEMBL1228396	Inhibition of CDK1	B	Cc1cc2n[nH]c(=O)n2c2cc(-c3ccc[nH]3)ccc12	Non standard unit for type	CHEMBL1223526	=	INH	uM	46.9	CHEMBL308	Homo sapiens	INH	uM	46.9
	3425383	CHEMBL1228396	Inhibition of CDK1	B	Cc1cc2n[nH]c(=O)n2c2cc(-c3cn[nH]c3)ccc12	Non standard unit for type	CHEMBL1223528	=	INH	uM	0.24	CHEMBL308	Homo sapiens	INH	uM	0.24
	3438056	CHEMBL1246064	Inhibition of CDK1	B	O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12		CHEMBL50	=	IC50	nM	450.0	CHEMBL308	Homo sapiens	IC50	uM	0.45
	3438057	CHEMBL1246064	Inhibition of CDK1	B	CCN(CCO)CCCNc1ccnc2cc(Cl)ccc12		CHEMBL1243003	=	IC50	nM	830.0	CHEMBL308	Homo sapiens	IC50	uM	0.83
	3438058	CHEMBL1246064	Inhibition of CDK1	B	COC(=O)c1cc(NC(C)=O)ccc1S(=O)(=O)c1ccc(NC(C)=O)cc1C(=O)OC		CHEMBL1243004	=	IC50	nM	910.0	CHEMBL308	Homo sapiens	IC50	uM	0.91
	3438059	CHEMBL1246064	Inhibition of CDK1	B	OCCNC(=S)Nc1ccc(C(F)(F)F)cc1		CHEMBL1240760	=	IC50	nM	1400.0	CHEMBL308	Homo sapiens	IC50	uM	1.4
	3438060	CHEMBL1246064	Inhibition of CDK1	B	Cc1cc2[nH]c(=S)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2cc1C		CHEMBL1243037	=	IC50	nM	2100.0	CHEMBL308	Homo sapiens	IC50	uM	2.1
	3438061	CHEMBL1246064	Inhibition of CDK1	B	OCCSC(=S)Nc1ccc(Cl)c(Cl)c1		CHEMBL1240761	=	IC50	nM	2500.0	CHEMBL308	Homo sapiens	IC50	uM	2.5
	3438062	CHEMBL1246064	Inhibition of CDK1	B	O=C(NCCCO)c1cc(Cl)ccc1O		CHEMBL1240762	=	IC50	nM	2530.0	CHEMBL308	Homo sapiens	IC50	uM	2.53
	3438063	CHEMBL1246064	Inhibition of CDK1	B	OCCN(CCO)Cc1cc(Cl)c2cccnc2c1O		CHEMBL1240763	=	IC50	nM	3230.0	CHEMBL308	Homo sapiens	IC50	uM	3.23
	3438064	CHEMBL1246064	Inhibition of CDK1	B	O=Cc1cc(CCCCCCc2ccc(O)c(C=O)c2)ccc1O		CHEMBL1243038	=	IC50	nM	4900.0	CHEMBL308	Homo sapiens	IC50	uM	4.9
	3438065	CHEMBL1246064	Inhibition of CDK1	B	C[C@@H](COc1ccccc1)N[C@@H](C)[C@@H](O)c1ccc(O)cc1		CHEMBL1243039	=	IC50	nM	2900.0	CHEMBL308	Homo sapiens	IC50	uM	2.9
	3438066	CHEMBL1246064	Inhibition of CDK1	B	COc1cc(OC)nc(NC(=O)NS(=O)(=O)c2cc(NC=O)ccc2C(=O)N(C)C)n1		CHEMBL1243071	=	IC50	nM	3600.0	CHEMBL308	Homo sapiens	IC50	uM	3.6
	3439148	CHEMBL1247981	Inhibition of CDK1 by HTRF assay	B	CNc1nccc(-c2cccnc2Oc2ccc(NC(=O)c3ccccc3Nc3ccccc3)cc2)n1		CHEMBL1243200	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	nM	1000.0
	3441509	CHEMBL1244092	Inhibition of human CDK1	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	nmol/L	10000.0
	3446974	CHEMBL1250280	Inhibition of CDK1	B	Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc21		CHEMBL280074	=	IC50	nM	7000.0	CHEMBL308	Homo sapiens	IC50	uM	7.0
	3446975	CHEMBL1250280	Inhibition of CDK1	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	=	IC50	nM	450.0	CHEMBL308	Homo sapiens	IC50	uM	0.45
	3446976	CHEMBL1250280	Inhibition of CDK1	B	CCNc1cc(N[C@H]2CC[C@@H](O)CC2)nc(Nc2ccc3c(ccn3Cc3ccccc3)c2)n1		CHEMBL1242367	>	IC50	nM	50000.0	CHEMBL308	Homo sapiens	IC50	uM	50.0
	3446977	CHEMBL1250280	Inhibition of CDK1	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	IC50	nM	30.0	CHEMBL308	Homo sapiens	IC50	uM	0.03
	3446978	CHEMBL1250280	Inhibition of CDK1	B	CCCCOc1c(C(=O)c2c(F)cc(F)cc2F)c[nH]c2nncc1-2		CHEMBL79049	=	IC50	nM	20.0	CHEMBL308	Homo sapiens	IC50	uM	0.02
	3446979	CHEMBL1250280	Inhibition of CDK1	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	IC50	nM	55.0	CHEMBL308	Homo sapiens	IC50	uM	0.055
	3446980	CHEMBL1250280	Inhibition of CDK1	B	O=C1C(c2c(O)[nH]c3ccc(S(=O)(=O)O)cc23)=Nc2ccccc21		CHEMBL1207227	=	IC50	nM	40.0	CHEMBL308	Homo sapiens	IC50	uM	0.04
	3446981	CHEMBL1250280	Inhibition of CDK1	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	IC50	nM	35.0	CHEMBL308	Homo sapiens	IC50	uM	0.035
	3446982	CHEMBL1250280	Inhibition of CDK1	B	O=C(Nc1cc(CN[C@H]2Cc3ccc(Cl)cc3C2)n[nH]1)Nc1cccc2c1[C@@H]1CCCN1C2=O		CHEMBL336242	=	IC50	nM	120.0	CHEMBL308	Homo sapiens	IC50	uM	0.12
	3446983	CHEMBL1250280	Inhibition of CDK1	B	O=C(Nc1ccccn1)Nc1cccc2c1[C@H]1CCCN1C2=O		CHEMBL141247	=	IC50	nM	1800.0	CHEMBL308	Homo sapiens	IC50	uM	1.8
	3446984	CHEMBL1250280	Inhibition of CDK1	B	COC(=O)[C@@]1(Cc2ccc(O)c(CC=C(C)C)c2)OC(=O)C(O)=C1c1ccc(O)cc1		CHEMBL1242973	=	IC50	nM	600.0	CHEMBL308	Homo sapiens	IC50	uM	0.6
	3446985	CHEMBL1250280	Inhibition of CDK1	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(Oc4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL133498	=	IC50	nM	130.0	CHEMBL308	Homo sapiens	IC50	uM	0.13
	3446986	CHEMBL1250280	Inhibition of CDK1	B	NC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(=O)(=O)NCCOCCO)cc1)C(=O)N2		CHEMBL1242832	=	IC50	nM	2800.0	CHEMBL308	Homo sapiens	IC50	uM	2.8
	3446987	CHEMBL1250280	Inhibition of CDK1	B	c1ccc2c(c1)Cc1c-2n[nH]c1-c1ccncc1		CHEMBL1234009	=	IC50	nM	1600.0	CHEMBL308	Homo sapiens	IC50	uM	1.6
	3446988	CHEMBL1250280	Inhibition of CDK1	B	Cc1nc2ccccn2c1-c1ccnc(Nc2ccc(OCC(O)CN(C)C)cc2)n1		CHEMBL102926	=	IC50	nM	5.0	CHEMBL308	Homo sapiens	IC50	uM	0.005
	3446989	CHEMBL1250280	Inhibition of CDK1	B	Nc1nc(N)c(N=O)c(=O)[nH]1		CHEMBL291324	=	IC50	nM	6.0	CHEMBL308	Homo sapiens	IC50	uM	0.006
	3446990	CHEMBL1250280	Inhibition of CDK1	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nc(OCc2ccccc2)c1N=O		CHEMBL1241661	=	IC50	nM	2900.0	CHEMBL308	Homo sapiens	IC50	uM	2.9
	3446991	CHEMBL1250280	Inhibition of CDK1	B	Nc1nc2ccc(C(=O)c3c(F)cccc3Cl)cc2n1Cc1c(F)cccc1F		CHEMBL1241662	=	IC50	nM	104.0	CHEMBL308	Homo sapiens	IC50	uM	0.104
	3446992	CHEMBL1250280	Inhibition of CDK1	B	O=C(Nc1cc(C2CCC2)c[nH]1)Nc1cccc2ccncc12		CHEMBL1241758	=	IC50	nM	55.0	CHEMBL308	Homo sapiens	IC50	uM	0.055
	3446993	CHEMBL1250280	Inhibition of CDK1	B	CN(C)CCNS(=O)(=O)c1ccc(Nc2cccc(-c3cnc4ccccn34)c2)cc1		CHEMBL1241849	=	IC50	nM	15.0	CHEMBL308	Homo sapiens	IC50	uM	0.015
	3446994	CHEMBL1250280	Inhibition of CDK1	B	O=C(Cc1ccc2ccccc2c1)Nc1cc(C2CC2)n[nH]1		CHEMBL115220	=	IC50	nM	279.0	CHEMBL308	Homo sapiens	IC50	uM	0.279
	3446995	CHEMBL1250280	Inhibition of CDK1	B	CC1(C)CC2(C)Nc3cc(-c4ccc5c(c4)NC4(C)CC(C)(C)NC(=S)N54)ccc3N2C(=S)N1		CHEMBL1241935	=	IC50	nM	5000.0	CHEMBL308	Homo sapiens	IC50	uM	5.0
	3446996	CHEMBL1250280	Inhibition of CDK1	B	FC(F)(F)c1cnc(Nc2ccc3[nH]cnc3c2)nc1Nc1ccccc1Cl		CHEMBL194721	=	IC50	nM	1.0	CHEMBL308	Homo sapiens	IC50	uM	0.001
	3457251	CHEMBL1246099	Inhibition of GST-tagged recombinant CDK1 after 20 mins by autoradiography	B	O=C(O)c1ccc(C(=O)/C(=C\c2ccc(F)c([N+](=O)[O-])c2)SCc2ccc(Br)cc2)cc1		CHEMBL1242482	>	IC50	nM	50000.0	CHEMBL308	Homo sapiens	IC50	uM	50.0
Dose-dependent effect	3526188	CHEMBL1273685	Inhibition of CDC2 phosphorylation at threonine 161 in human A549 cells after 24 hrs by Western blot analysis	B	COc1cc(O)c(C(=O)/C=C/c2cccc(OC)c2OO)c(OC)c1		CHEMBL1271582		Inhibition	%		CHEMBL308	Homo sapiens	INH		
Dose-dependent effect	3526189	CHEMBL1273686	Inhibition of CDC2 phosphorylation at tyrosine 15 in human A549 cells after 24 hrs by Western blot analysis	B	COc1cc(O)c(C(=O)/C=C/c2cccc(OC)c2OO)c(OC)c1		CHEMBL1271582		Inhibition	%		CHEMBL308	Homo sapiens	INH		
Not Active	5190294	CHEMBL1663407	Inhibition of CDK1 at 10 uM by cell-based assay	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165		Inhibition	%		CHEMBL308	Homo sapiens	INH		
Active	5294116	CHEMBL1695260	Inhibition of CDK1	B	c1ccc(-c2nnc(Nc3ccc4c(c3)OCCO4)o2)c(NCc2ccncc2)c1		CHEMBL1087218		Inhibition	%		CHEMBL308	Homo sapiens	INH		
Active	5294117	CHEMBL1695260	Inhibition of CDK1	B	c1cnc(NCc2ccc3ncccc3c2)c(-c2nnc(Nc3ccc4c(c3)OCCO4)o2)c1		CHEMBL1688352		Inhibition	%		CHEMBL308	Homo sapiens	INH		
Not Active	6150859	CHEMBL1764769	Inhibition of CDK1	B	C[C@H]1C(=O)N(c2ccc(S(=O)(=O)C(F)(F)F)cc2)C(=O)N1Cc1ccnc2ccccc12		CHEMBL1738841		Inhibition	%		CHEMBL308	Homo sapiens	INH		
	6167007	CHEMBL1768893	Inhibition of CDK1	B	CNc1cncc(-c2c[nH]c(=O)c(NC(=O)c3ccc(N4CCC[C@H]4CN4CCCC4)cc3)c2)n1		CHEMBL1765781	>	Ki	nM	1000.0	CHEMBL308	Homo sapiens	Ki	uM	1.0
	6173448	CHEMBL1768220	Inhibition of CDK1 at 25 uM by TR-FRET assay	B	NC(=O)c1ccsc1NC(=O)Cc1csc2ccccc12		CHEMBL1767254	=	Inhibition	%	3.0	CHEMBL308	Homo sapiens	INH	%	3.0
	6231471	CHEMBL1787305	Inhibition of CDK1	B	O=C(c1ccco1)N1N=C(c2cccnc2)CC1c1ccccc1O		CHEMBL1779593	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
Active	6274467	CHEMBL1805552	Inhibition of CDK1-mediated phosphorylation of PP1a at Thr320 in human HCT116 cells after 4 hrs by immunoblotting analysis	B	CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12		CHEMBL1234833		Inhibition	%		CHEMBL308	Homo sapiens	INH		
Active	6274468	CHEMBL1805553	Inhibition of CDK1-mediated phosphorylation of PP1a at Thr320 in human HCT116 cells after 24 hrs by immunoblotting analysis	B	CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12		CHEMBL1234833		Inhibition	%		CHEMBL308	Homo sapiens	INH		
Not Active	6274471	CHEMBL1805556	Inhibition of CDK1-mediated phosphorylation of RB protein in human HCT116 cells after 4 hrs by immunoblotting analysis	B	CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12		CHEMBL1234833		Inhibition	%		CHEMBL308	Homo sapiens	INH		
Not Active	6274482	CHEMBL1805567	Inhibition of CDK1-mediated phosphorylation of RNA pol3 in human HCT116 cells after 4 hrs by immunoblotting analysis	B	CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12		CHEMBL1234833		Inhibition	%		CHEMBL308	Homo sapiens	INH		
	6282053	CHEMBL1804255	Inhibition of CDK1 in presence of 100 uM ATP	B	Nc1nccc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)n1		CHEMBL1800449	=	IC50	nM	15.0	CHEMBL308	Homo sapiens	IC50	uM	0.015
	6282055	CHEMBL1804255	Inhibition of CDK1 in presence of 100 uM ATP	B	Nc1nc(NC2CCCC2)cc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)n1		CHEMBL1800464	=	IC50	nM	19.0	CHEMBL308	Homo sapiens	IC50	uM	0.019
	6282056	CHEMBL1804255	Inhibition of CDK1 in presence of 100 uM ATP	B	Cc1cc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)nc(N)n1		CHEMBL1800450	=	IC50	nM	20.0	CHEMBL308	Homo sapiens	IC50	uM	0.02
	6282057	CHEMBL1804255	Inhibition of CDK1 in presence of 100 uM ATP	B	Nc1nc(NC2CCCCC2)cc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)n1		CHEMBL1800465	=	IC50	nM	20.0	CHEMBL308	Homo sapiens	IC50	uM	0.02
	6282059	CHEMBL1804255	Inhibition of CDK1 in presence of 100 uM ATP	B	Nc1nc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)cc(C2CCCC2)n1		CHEMBL1800455	=	IC50	nM	23.0	CHEMBL308	Homo sapiens	IC50	uM	0.023
	6282060	CHEMBL1804255	Inhibition of CDK1 in presence of 100 uM ATP	B	CCc1cc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)nc(N)n1		CHEMBL1800451	=	IC50	nM	31.0	CHEMBL308	Homo sapiens	IC50	uM	0.031
	6282061	CHEMBL1804255	Inhibition of CDK1 in presence of 100 uM ATP	B	Nc1nc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)cc(C2CCCCCC2)n1		CHEMBL1800457	=	IC50	nM	31.0	CHEMBL308	Homo sapiens	IC50	uM	0.031
	6282064	CHEMBL1804255	Inhibition of CDK1 in presence of 100 uM ATP	B	Nc1nc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)cc(C2CCCCC2)n1		CHEMBL1800456	=	IC50	nM	45.0	CHEMBL308	Homo sapiens	IC50	uM	0.045
	6282070	CHEMBL1804255	Inhibition of CDK1 in presence of 100 uM ATP	B	CC(C)c1cc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)nc(N)n1		CHEMBL1800452	=	IC50	nM	94.0	CHEMBL308	Homo sapiens	IC50	uM	0.094
	6282072	CHEMBL1804255	Inhibition of CDK1 in presence of 100 uM ATP	B	Nc1nc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)cc(C2CCCNC2)n1		CHEMBL1800458	=	IC50	nM	220.0	CHEMBL308	Homo sapiens	IC50	uM	0.22
	6282074	CHEMBL1804255	Inhibition of CDK1 in presence of 100 uM ATP	B	CCCCCCc1cc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)nc(N)n1		CHEMBL1800453	=	IC50	nM	260.0	CHEMBL308	Homo sapiens	IC50	uM	0.26
	6282075	CHEMBL1804255	Inhibition of CDK1 in presence of 100 uM ATP	B	CN(C)c1cc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)nc(N)n1		CHEMBL1800460	=	IC50	nM	280.0	CHEMBL308	Homo sapiens	IC50	uM	0.28
	6282078	CHEMBL1804255	Inhibition of CDK1 in presence of 100 uM ATP	B	Nc1nc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)cc(C2CCNCC2)n1		CHEMBL1800459	=	IC50	nM	340.0	CHEMBL308	Homo sapiens	IC50	uM	0.34
	6282082	CHEMBL1804255	Inhibition of CDK1 in presence of 100 uM ATP	B	CN1CCN(c2cc(-c3cc(N4C[C@H](O)[C@@H](O)C4)ccc3O)nc(N)n2)CC1		CHEMBL1800462	=	IC50	nM	420.0	CHEMBL308	Homo sapiens	IC50	uM	0.42
	6282089	CHEMBL1804255	Inhibition of CDK1 in presence of 100 uM ATP	B	Nc1nc(NCCN2CCOCC2)cc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)n1		CHEMBL1800463	=	IC50	nM	790.0	CHEMBL308	Homo sapiens	IC50	uM	0.79
	6282098	CHEMBL1804255	Inhibition of CDK1 in presence of 100 uM ATP	B	Nc1nc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)cc(N2CCOCC2)n1		CHEMBL1800461	=	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	uM	1.0
	6282110	CHEMBL1804255	Inhibition of CDK1 in presence of 100 uM ATP	B	Nc1nccc(-c2cc(N3CCOCC3)ccc2O)n1		CHEMBL1800218	=	IC50	nM	2240.0	CHEMBL308	Homo sapiens	IC50	uM	2.24
	6282112	CHEMBL1804255	Inhibition of CDK1 in presence of 100 uM ATP	B	Nc1nccc(-c2cc(N3CCC(O)C3)ccc2O)n1		CHEMBL1800448	=	IC50	nM	2990.0	CHEMBL308	Homo sapiens	IC50	uM	2.99
	6282121	CHEMBL1804255	Inhibition of CDK1 in presence of 100 uM ATP	B	Nc1nccc(-c2cc(N3CCS(=O)(=O)CC3)ccc2O)n1		CHEMBL1800219	=	IC50	nM	7500.0	CHEMBL308	Homo sapiens	IC50	uM	7.5
	6282122	CHEMBL1804255	Inhibition of CDK1 in presence of 100 uM ATP	B	CCC1CCN(c2ccc(O)c(-c3ccnc(N)n3)c2)CC1		CHEMBL1800217	=	IC50	nM	7940.0	CHEMBL308	Homo sapiens	IC50	uM	7.94
	6282123	CHEMBL1804255	Inhibition of CDK1 in presence of 100 uM ATP	B	Nc1nccc(-c2cc(N3CCC(O)CC3)ccc2O)n1		CHEMBL1800447	=	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	6282130	CHEMBL1804255	Inhibition of CDK1 in presence of 100 uM ATP	B	Nc1nccc(-c2cc(N3CCCCC3)ccc2O)n1		CHEMBL1800216	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	6282131	CHEMBL1804255	Inhibition of CDK1 in presence of 100 uM ATP	B	Nc1nccc(-c2cc(N3CCC(=O)CC3)ccc2O)n1		CHEMBL1800446	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	6282132	CHEMBL1804255	Inhibition of CDK1 in presence of 100 uM ATP	B	Nc1nc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)cc(C2CC2)n1		CHEMBL1800454	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
Active	6282152	CHEMBL1804260	Binding affinity to human CDK1 ATP-binding site at 0.5 mM after 24 hrs by X-ray crystallography	B	CC(C)c1cc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)nc(N)n1		CHEMBL1800452		Activity			CHEMBL308	Homo sapiens	Activity		
	6315023	CHEMBL1815312	Inhibition of CDK1	B	O=C1Nc2ccccc2/C1=C1/Nc2ccccc2C1=O		CHEMBL1276127	=	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	6356162	CHEMBL1831549	Inhibition of CDK1	B	Nc1nccc(-c2c[nH]c3cccc(O)c23)n1		CHEMBL50498	=	IC50	nM	2500.0	CHEMBL308	Homo sapiens	IC50	uM	2.5
	6386353	CHEMBL1839862	Inhibition of recombinant CDK1	B	CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1.O=P(O)(O)O		CHEMBL1834657	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	7849680	CHEMBL1912415	Inhibition of CDK1	B	Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1		CHEMBL303958	=	Ki	nM	2500.0	CHEMBL308	Homo sapiens	Ki	uM	2.5
	7991165	CHEMBL1937317	Inhibition of CDK1	B	CN1CCC(COc2ccc3c(Nc4ccc(NC(=O)Nc5cccc(F)c5)cc4)ncnc3c2)CC1		CHEMBL1934327	=	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	nM	10000.0
	8003416	CHEMBL1944415	Inhibition of human CDC2 in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM	B	C[C@H]1COc2c(NCCCn3cccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23		CHEMBL1940980	<	Inhibition	%	35.0	CHEMBL308	Homo sapiens	INH	%	35.0
	8003417	CHEMBL1944415	Inhibition of human CDC2 in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM	B	C[C@H]1COc2c(NCCCn3cccn3)c(F)c(N)c3c(=O)c(C#N)cn1c23		CHEMBL1940981	<	Inhibition	%	35.0	CHEMBL308	Homo sapiens	INH	%	35.0
	8003418	CHEMBL1944415	Inhibition of human CDC2 in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM	B	C[C@H]1COc2c(NCCCc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23		CHEMBL1940987	<	Inhibition	%	35.0	CHEMBL308	Homo sapiens	INH	%	35.0
	8003419	CHEMBL1944415	Inhibition of human CDC2 in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM	B	C[C@H]1COc2c(NCCCc3ccccn3)c(F)c(N)c3c(=O)c(C#N)cn1c23		CHEMBL1940990	<	Inhibition	%	35.0	CHEMBL308	Homo sapiens	INH	%	35.0
	8039310	CHEMBL1953284	Inhibition of CDK1	B	COc1ccc(C(=O)NC[C@@H](O)CO)cc1/C=C/c1ccc(Cl)cc1		CHEMBL1949788	>	IC50	nM	50000.0	CHEMBL308	Homo sapiens	IC50	uM	50.0
	8039311	CHEMBL1953284	Inhibition of CDK1	B	COc1ccc(C(=O)NC[C@H](O)CO)cc1/C=C/c1ccc(Cl)cc1		CHEMBL1949789	>	IC50	nM	50000.0	CHEMBL308	Homo sapiens	IC50	uM	50.0
Not Determined	8052236	CHEMBL1961112	Inhibition of CDK1 assessed as residual activity at 5 uM	B	CS(=O)(=O)Nc1ccc(CCNC(=O)c2ccc(O)c3[nH]c(-c4ccc(F)cc4F)nc23)cc1		CHEMBL1957948		Activity			CHEMBL308	Homo sapiens	Activity		
	8052237	CHEMBL1961112	Inhibition of CDK1 assessed as residual activity at 5 uM	B	O=C(O)COc1cccc(CCCNC(=O)c2ccc(O)c3[nH]c(-c4ccc(Cl)cc4)nc23)c1		CHEMBL1957953	=	Activity	%	90.9	CHEMBL308	Homo sapiens	Activity	%	90.9
Not Determined	8052238	CHEMBL1961112	Inhibition of CDK1 assessed as residual activity at 5 uM	B	O=C(NCCCn1cnc(Cl)c1Cl)c1ccc(O)c2[nH]c(-c3ccc(Cl)cc3Cl)nc12		CHEMBL1957955		Activity			CHEMBL308	Homo sapiens	Activity		
	8052239	CHEMBL1961112	Inhibition of CDK1 assessed as residual activity at 5 uM	B	O=C(NCCCn1ccnc1)c1ccc(O)c2[nH]c(-c3ccc(F)c(Cl)c3)nc12		CHEMBL1957956	=	Activity	%	71.3	CHEMBL308	Homo sapiens	Activity	%	71.3
	8052240	CHEMBL1961112	Inhibition of CDK1 assessed as residual activity at 5 uM	B	CCN1CCN(C(=O)c2ccc(CCNC(=O)c3ccc(O)c4[nH]c(-c5cccs5)nc34)cc2)CC1		CHEMBL1957958	=	Activity	%	70.4	CHEMBL308	Homo sapiens	Activity	%	70.4
	8052241	CHEMBL1961112	Inhibition of CDK1 assessed as residual activity at 5 uM	B	O=C(NCCCn1cnc(Cl)c1Cl)c1ccc(O)c2[nH]c(-c3ccco3)nc12		CHEMBL1957960	=	Activity	%	65.2	CHEMBL308	Homo sapiens	Activity	%	65.2
	8061290	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	1.68	CHEMBL308	Homo sapiens	Inhibition	%	1.68
	8061467	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	14.76	CHEMBL308	Homo sapiens	Inhibition	%	14.76
	8061798	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	2.52	CHEMBL308	Homo sapiens	Inhibition	%	2.52
	8061989	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	4.27	CHEMBL308	Homo sapiens	Inhibition	%	4.27
	8062329	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	1.15	CHEMBL308	Homo sapiens	Inhibition	%	1.15
	8062491	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	43.66	CHEMBL308	Homo sapiens	Inhibition	%	43.66
	8062715	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	1.97	CHEMBL308	Homo sapiens	Inhibition	%	1.97
	8062813	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	1.88	CHEMBL308	Homo sapiens	Inhibition	%	1.88
	8063169	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	3.12	CHEMBL308	Homo sapiens	Inhibition	%	3.12
	8063336	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	0.45	CHEMBL308	Homo sapiens	Inhibition	%	0.45
	8063560	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	0.2	CHEMBL308	Homo sapiens	Inhibition	%	0.2
	8063668	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	0.26	CHEMBL308	Homo sapiens	Inhibition	%	0.26
	8063850	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	7.4	CHEMBL308	Homo sapiens	Inhibition	%	7.4
	8064074	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	1.58	CHEMBL308	Homo sapiens	Inhibition	%	1.58
	8064189	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	4.4	CHEMBL308	Homo sapiens	Inhibition	%	4.4
	8064399	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	0.38	CHEMBL308	Homo sapiens	Inhibition	%	0.38
	8064623	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	0.19	CHEMBL308	Homo sapiens	Inhibition	%	0.19
	8064761	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	8.02	CHEMBL308	Homo sapiens	Inhibition	%	8.02
	8065151	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	0.44	CHEMBL308	Homo sapiens	Inhibition	%	0.44
	8065267	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	2.49	CHEMBL308	Homo sapiens	Inhibition	%	2.49
	8065666	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	3.23	CHEMBL308	Homo sapiens	Inhibition	%	3.23
	8065781	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	0.43	CHEMBL308	Homo sapiens	Inhibition	%	0.43
	8066005	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	0.67	CHEMBL308	Homo sapiens	Inhibition	%	0.67
	8066215	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	1.84	CHEMBL308	Homo sapiens	Inhibition	%	1.84
	8066351	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	29.89	CHEMBL308	Homo sapiens	Inhibition	%	29.89
	8066575	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	69.06	CHEMBL308	Homo sapiens	Inhibition	%	69.06
	8066741	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	4.03	CHEMBL308	Homo sapiens	Inhibition	%	4.03
	8066865	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	1.34	CHEMBL308	Homo sapiens	Inhibition	%	1.34
	8067089	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	2.26	CHEMBL308	Homo sapiens	Inhibition	%	2.26
	8067264	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	0.69	CHEMBL308	Homo sapiens	Inhibition	%	0.69
	8067609	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	0.74	CHEMBL308	Homo sapiens	Inhibition	%	0.74
	8067819	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	2.9	CHEMBL308	Homo sapiens	Inhibition	%	2.9
	8068178	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	91.34	CHEMBL308	Homo sapiens	Inhibition	%	91.34
	8068342	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	2.78	CHEMBL308	Homo sapiens	Inhibition	%	2.78
	8068691	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	-0.03	CHEMBL308	Homo sapiens	Inhibition	%	-0.03
	8068865	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	2.29	CHEMBL308	Homo sapiens	Inhibition	%	2.29
	8069214	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	1.96	CHEMBL308	Homo sapiens	Inhibition	%	1.96
	8069509	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	79.31	CHEMBL308	Homo sapiens	Inhibition	%	79.31
	8069670	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	17.05	CHEMBL308	Homo sapiens	Inhibition	%	17.05
	8070020	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	-0.31	CHEMBL308	Homo sapiens	Inhibition	%	-0.31
	8070192	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	0.99	CHEMBL308	Homo sapiens	Inhibition	%	0.99
	8070416	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	2.01	CHEMBL308	Homo sapiens	Inhibition	%	2.01
	8070541	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	-0.07	CHEMBL308	Homo sapiens	Inhibition	%	-0.07
	8070839	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	95.29	CHEMBL308	Homo sapiens	Inhibition	%	95.29
	8070996	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	1.08	CHEMBL308	Homo sapiens	Inhibition	%	1.08
	8071220	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	1.91	CHEMBL308	Homo sapiens	Inhibition	%	1.91
	8071346	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	0.3	CHEMBL308	Homo sapiens	Inhibition	%	0.3
	8071743	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	0.89	CHEMBL308	Homo sapiens	Inhibition	%	0.89
	8071868	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	2.01	CHEMBL308	Homo sapiens	Inhibition	%	2.01
	8072092	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	0.44	CHEMBL308	Homo sapiens	Inhibition	%	0.44
	8072182	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	2.66	CHEMBL308	Homo sapiens	Inhibition	%	2.66
	8072563	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	1.24	CHEMBL308	Homo sapiens	Inhibition	%	1.24
	8072688	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	2.06	CHEMBL308	Homo sapiens	Inhibition	%	2.06
	8072912	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	0.2	CHEMBL308	Homo sapiens	Inhibition	%	0.2
	8073079	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	5.15	CHEMBL308	Homo sapiens	Inhibition	%	5.15
	8073428	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	3.26	CHEMBL308	Homo sapiens	Inhibition	%	3.26
	8073547	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	3.51	CHEMBL308	Homo sapiens	Inhibition	%	3.51
	8073780	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	0.7	CHEMBL308	Homo sapiens	Inhibition	%	0.7
	8074004	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	1.45	CHEMBL308	Homo sapiens	Inhibition	%	1.45
	8074156	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	1.72	CHEMBL308	Homo sapiens	Inhibition	%	1.72
	8074510	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	1.91	CHEMBL308	Homo sapiens	Inhibition	%	1.91
	8074667	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	-0.31	CHEMBL308	Homo sapiens	Inhibition	%	-0.31
	8075018	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	1.38	CHEMBL308	Homo sapiens	Inhibition	%	1.38
	8075129	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	23.41	CHEMBL308	Homo sapiens	Inhibition	%	23.41
	8075353	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	0.43	CHEMBL308	Homo sapiens	Inhibition	%	0.43
	8075590	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	2.0	CHEMBL308	Homo sapiens	Inhibition	%	2.0
	8075731	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	0.24	CHEMBL308	Homo sapiens	Inhibition	%	0.24
	8076097	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	0.65	CHEMBL308	Homo sapiens	Inhibition	%	0.65
	8076245	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	-0.43	CHEMBL308	Homo sapiens	Inhibition	%	-0.43
	8076469	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	0.36	CHEMBL308	Homo sapiens	Inhibition	%	0.36
	8076603	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	4.94	CHEMBL308	Homo sapiens	Inhibition	%	4.94
	8076929	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	2.72	CHEMBL308	Homo sapiens	Inhibition	%	2.72
	8077176	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	4.13	CHEMBL308	Homo sapiens	Inhibition	%	4.13
	8077304	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	2.57	CHEMBL308	Homo sapiens	Inhibition	%	2.57
	8077528	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	0.88	CHEMBL308	Homo sapiens	Inhibition	%	0.88
	8077679	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	3.45	CHEMBL308	Homo sapiens	Inhibition	%	3.45
	8078046	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	1.62	CHEMBL308	Homo sapiens	Inhibition	%	1.62
	8078185	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	10.89	CHEMBL308	Homo sapiens	Inhibition	%	10.89
	8078511	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	0.23	CHEMBL308	Homo sapiens	Inhibition	%	0.23
	8078761	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	4.92	CHEMBL308	Homo sapiens	Inhibition	%	4.92
	8079101	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	1.11	CHEMBL308	Homo sapiens	Inhibition	%	1.11
	8079259	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	0.5	CHEMBL308	Homo sapiens	Inhibition	%	0.5
	8079625	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	0.66	CHEMBL308	Homo sapiens	Inhibition	%	0.66
	8079764	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	51.74	CHEMBL308	Homo sapiens	Inhibition	%	51.74
	8079988	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	1.73	CHEMBL308	Homo sapiens	Inhibition	%	1.73
	8080093	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	2.04	CHEMBL308	Homo sapiens	Inhibition	%	2.04
	8080345	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	36.94	CHEMBL308	Homo sapiens	Inhibition	%	36.94
	8080684	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	0.67	CHEMBL308	Homo sapiens	Inhibition	%	0.67
	8080848	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	3.21	CHEMBL308	Homo sapiens	Inhibition	%	3.21
	8081072	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	0.24	CHEMBL308	Homo sapiens	Inhibition	%	0.24
	8081207	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	0.48	CHEMBL308	Homo sapiens	Inhibition	%	0.48
	8081575	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	6.31	CHEMBL308	Homo sapiens	Inhibition	%	6.31
	8081678	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	0.73	CHEMBL308	Homo sapiens	Inhibition	%	0.73
	8081902	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	7.55	CHEMBL308	Homo sapiens	Inhibition	%	7.55
	8081930	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	75.5	CHEMBL308	Homo sapiens	Inhibition	%	75.5
	8082154	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	5.2	CHEMBL308	Homo sapiens	Inhibition	%	5.2
	8082267	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	1.75	CHEMBL308	Homo sapiens	Inhibition	%	1.75
	8082664	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	2.44	CHEMBL308	Homo sapiens	Inhibition	%	2.44
	8082787	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	0.42	CHEMBL308	Homo sapiens	Inhibition	%	0.42
	8083167	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	20.46	CHEMBL308	Homo sapiens	Inhibition	%	20.46
	8083490	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	1.04	CHEMBL308	Homo sapiens	Inhibition	%	1.04
	8083744	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	24.46	CHEMBL308	Homo sapiens	Inhibition	%	24.46
	8083854	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	0.23	CHEMBL308	Homo sapiens	Inhibition	%	0.23
	8084078	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	2.0	CHEMBL308	Homo sapiens	Inhibition	%	2.0
	8084263	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	61.28	CHEMBL308	Homo sapiens	Inhibition	%	61.28
	8084381	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	1.39	CHEMBL308	Homo sapiens	Inhibition	%	1.39
	8084605	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	0.49	CHEMBL308	Homo sapiens	Inhibition	%	0.49
	8084766	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	66.71	CHEMBL308	Homo sapiens	Inhibition	%	66.71
	8085088	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	3.4	CHEMBL308	Homo sapiens	Inhibition	%	3.4
	8085344	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	3.83	CHEMBL308	Homo sapiens	Inhibition	%	3.83
	8085676	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	0.37	CHEMBL308	Homo sapiens	Inhibition	%	0.37
	8085865	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	80.46	CHEMBL308	Homo sapiens	Inhibition	%	80.46
	8086204	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	1.95	CHEMBL308	Homo sapiens	Inhibition	%	1.95
	8086366	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	7.05	CHEMBL308	Homo sapiens	Inhibition	%	7.05
	8086689	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	0.77	CHEMBL308	Homo sapiens	Inhibition	%	0.77
	8086900	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	-1.13	CHEMBL308	Homo sapiens	Inhibition	%	-1.13
	8087124	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	-0.82	CHEMBL308	Homo sapiens	Inhibition	%	-0.82
	8087282	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	2.88	CHEMBL308	Homo sapiens	Inhibition	%	2.88
	8087620	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%		CHEMBL308	Homo sapiens	Inhibition	%	
	8087758	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	3.35	CHEMBL308	Homo sapiens	Inhibition	%	3.35
	8088124	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	1.24	CHEMBL308	Homo sapiens	Inhibition	%	1.24
	8088272	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	0.06	CHEMBL308	Homo sapiens	Inhibition	%	0.06
	8088624	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	-0.28	CHEMBL308	Homo sapiens	Inhibition	%	-0.28
	8088941	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	0.59	CHEMBL308	Homo sapiens	Inhibition	%	0.59
	8089069	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	-0.34	CHEMBL308	Homo sapiens	Inhibition	%	-0.34
	8089293	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	0.53	CHEMBL308	Homo sapiens	Inhibition	%	0.53
	8089441	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	28.69	CHEMBL308	Homo sapiens	Inhibition	%	28.69
	8089785	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	0.87	CHEMBL308	Homo sapiens	Inhibition	%	0.87
	8089965	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	0.47	CHEMBL308	Homo sapiens	Inhibition	%	0.47
	8090354	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	0.55	CHEMBL308	Homo sapiens	Inhibition	%	0.55
	8090521	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	1.76	CHEMBL308	Homo sapiens	Inhibition	%	1.76
	8090884	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	-0.1	CHEMBL308	Homo sapiens	Inhibition	%	-0.1
	8091089	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	0.68	CHEMBL308	Homo sapiens	Inhibition	%	0.68
	8091450	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	2.18	CHEMBL308	Homo sapiens	Inhibition	%	2.18
	8091605	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	2.38	CHEMBL308	Homo sapiens	Inhibition	%	2.38
	8091945	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	0.64	CHEMBL308	Homo sapiens	Inhibition	%	0.64
	8092082	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	-3.4	CHEMBL308	Homo sapiens	Inhibition	%	-3.4
	8092306	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	-1.98	CHEMBL308	Homo sapiens	Inhibition	%	-1.98
	8092457	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	2.55	CHEMBL308	Homo sapiens	Inhibition	%	2.55
	8092605	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	-0.25	CHEMBL308	Homo sapiens	Inhibition	%	-0.25
	8092829	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	0.75	CHEMBL308	Homo sapiens	Inhibition	%	0.75
	8092958	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	2.69	CHEMBL308	Homo sapiens	Inhibition	%	2.69
	8093270	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	1.54	CHEMBL308	Homo sapiens	Inhibition	%	1.54
	8093634	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	-0.31	CHEMBL308	Homo sapiens	Inhibition	%	-0.31
	8093773	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	69.65	CHEMBL308	Homo sapiens	Inhibition	%	69.65
	8094117	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	0.32	CHEMBL308	Homo sapiens	Inhibition	%	0.32
	8094297	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	0.87	CHEMBL308	Homo sapiens	Inhibition	%	0.87
	8094696	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	1.39	CHEMBL308	Homo sapiens	Inhibition	%	1.39
	8094852	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	2.4	CHEMBL308	Homo sapiens	Inhibition	%	2.4
	8095216	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	5.09	CHEMBL308	Homo sapiens	Inhibition	%	5.09
	8095419	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	-4.99	CHEMBL308	Homo sapiens	Inhibition	%	-4.99
	8095784	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	7.53	CHEMBL308	Homo sapiens	Inhibition	%	7.53
	8095932	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	2.61	CHEMBL308	Homo sapiens	Inhibition	%	2.61
	8096156	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	6.2	CHEMBL308	Homo sapiens	Inhibition	%	6.2
	8096273	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	1.02	CHEMBL308	Homo sapiens	Inhibition	%	1.02
	8096636	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	1.22	CHEMBL308	Homo sapiens	Inhibition	%	1.22
	8096792	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	0.45	CHEMBL308	Homo sapiens	Inhibition	%	0.45
	8097163	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	1.12	CHEMBL308	Homo sapiens	Inhibition	%	1.12
	8097470	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	2.59	CHEMBL308	Homo sapiens	Inhibition	%	2.59
	8097844	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	-0.33	CHEMBL308	Homo sapiens	Inhibition	%	-0.33
	8097977	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	-2.2	CHEMBL308	Homo sapiens	Inhibition	%	-2.2
	8098201	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	0.34	CHEMBL308	Homo sapiens	Inhibition	%	0.34
	8098321	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	0.45	CHEMBL308	Homo sapiens	Inhibition	%	0.45
	8098501	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	2.16	CHEMBL308	Homo sapiens	Inhibition	%	2.16
	8098725	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	0.19	CHEMBL308	Homo sapiens	Inhibition	%	0.19
	8098910	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	1.85	CHEMBL308	Homo sapiens	Inhibition	%	1.85
	8099054	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	2.51	CHEMBL308	Homo sapiens	Inhibition	%	2.51
	8099278	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	1.71	CHEMBL308	Homo sapiens	Inhibition	%	1.71
	8099420	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	0.91	CHEMBL308	Homo sapiens	Inhibition	%	0.91
	8099614	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	0.15	CHEMBL308	Homo sapiens	Inhibition	%	0.15
	8099838	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	-0.22	CHEMBL308	Homo sapiens	Inhibition	%	-0.22
	8099985	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	4.4	CHEMBL308	Homo sapiens	Inhibition	%	4.4
	8100355	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	32.63	CHEMBL308	Homo sapiens	Inhibition	%	32.63
	8100471	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	1.41	CHEMBL308	Homo sapiens	Inhibition	%	1.41
	8100835	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	1.4	CHEMBL308	Homo sapiens	Inhibition	%	1.4
	8100995	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	2.26	CHEMBL308	Homo sapiens	Inhibition	%	2.26
	8101219	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	0.88	CHEMBL308	Homo sapiens	Inhibition	%	0.88
	8101361	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	0.44	CHEMBL308	Homo sapiens	Inhibition	%	0.44
	8101546	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	-3.45	CHEMBL308	Homo sapiens	Inhibition	%	-3.45
	8101770	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	-2.45	CHEMBL308	Homo sapiens	Inhibition	%	-2.45
	8101799	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	42.0	CHEMBL308	Homo sapiens	Inhibition	%	42.0
	8102023	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	74.15	CHEMBL308	Homo sapiens	Inhibition	%	74.15
	8102178	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	1.69	CHEMBL308	Homo sapiens	Inhibition	%	1.69
	8102533	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	0.99	CHEMBL308	Homo sapiens	Inhibition	%	0.99
	8102653	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	-0.26	CHEMBL308	Homo sapiens	Inhibition	%	-0.26
	8102877	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	0.04	CHEMBL308	Homo sapiens	Inhibition	%	0.04
	8103055	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	2.26	CHEMBL308	Homo sapiens	Inhibition	%	2.26
	8103251	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	2.55	CHEMBL308	Homo sapiens	Inhibition	%	2.55
	8103613	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	1.24	CHEMBL308	Homo sapiens	Inhibition	%	1.24
	8103763	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	2.22	CHEMBL308	Homo sapiens	Inhibition	%	2.22
	8104172	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	-0.02	CHEMBL308	Homo sapiens	Inhibition	%	-0.02
	8104320	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	8.17	CHEMBL308	Homo sapiens	Inhibition	%	8.17
	8104690	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	66.77	CHEMBL308	Homo sapiens	Inhibition	%	66.77
	8104804	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	0.28	CHEMBL308	Homo sapiens	Inhibition	%	0.28
	8105028	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	1.02	CHEMBL308	Homo sapiens	Inhibition	%	1.02
	8105168	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	1.32	CHEMBL308	Homo sapiens	Inhibition	%	1.32
	8105558	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	-1.71	CHEMBL308	Homo sapiens	Inhibition	%	-1.71
	8105696	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	6.1	CHEMBL308	Homo sapiens	Inhibition	%	6.1
	8105976	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	-0.4	CHEMBL308	Homo sapiens	Inhibition	%	-0.4
	8106365	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	-1.9	CHEMBL308	Homo sapiens	Inhibition	%	-1.9
	8106521	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	14.49	CHEMBL308	Homo sapiens	Inhibition	%	14.49
	8106874	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	5.32	CHEMBL308	Homo sapiens	Inhibition	%	5.32
	8107219	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	0.38	CHEMBL308	Homo sapiens	Inhibition	%	0.38
	8107391	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	0.9	CHEMBL308	Homo sapiens	Inhibition	%	0.9
	8107592	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	0.95	CHEMBL308	Homo sapiens	Inhibition	%	0.95
	8107816	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	3.39	CHEMBL308	Homo sapiens	Inhibition	%	3.39
	8107951	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	3.33	CHEMBL308	Homo sapiens	Inhibition	%	3.33
	8108109	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	0.69	CHEMBL308	Homo sapiens	Inhibition	%	0.69
	8108333	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	2.03	CHEMBL308	Homo sapiens	Inhibition	%	2.03
	8108508	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	Inhibition	%	0.0
	8108655	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	1.74	CHEMBL308	Homo sapiens	Inhibition	%	1.74
	8108879	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	3.79	CHEMBL308	Homo sapiens	Inhibition	%	3.79
	8109021	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	3.78	CHEMBL308	Homo sapiens	Inhibition	%	3.78
	8109359	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	1.08	CHEMBL308	Homo sapiens	Inhibition	%	1.08
	8109489	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	0.7	CHEMBL308	Homo sapiens	Inhibition	%	0.7
	8109713	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	1.05	CHEMBL308	Homo sapiens	Inhibition	%	1.05
	8109884	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	-2.15	CHEMBL308	Homo sapiens	Inhibition	%	-2.15
	8110016	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	0.36	CHEMBL308	Homo sapiens	Inhibition	%	0.36
	8110240	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	4.4	CHEMBL308	Homo sapiens	Inhibition	%	4.4
	8110295	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	0.31	CHEMBL308	Homo sapiens	Inhibition	%	0.31
	8110519	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	0.67	CHEMBL308	Homo sapiens	Inhibition	%	0.67
	8110685	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	1.74	CHEMBL308	Homo sapiens	Inhibition	%	1.74
	8110843	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	3.69	CHEMBL308	Homo sapiens	Inhibition	%	3.69
	8111067	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	2.18	CHEMBL308	Homo sapiens	Inhibition	%	2.18
	8111190	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	-1.03	CHEMBL308	Homo sapiens	Inhibition	%	-1.03
	8111541	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	-0.63	CHEMBL308	Homo sapiens	Inhibition	%	-0.63
	8111707	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	4.47	CHEMBL308	Homo sapiens	Inhibition	%	4.47
	8112136	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	5.05	CHEMBL308	Homo sapiens	Inhibition	%	5.05
	8112273	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	0.65	CHEMBL308	Homo sapiens	Inhibition	%	0.65
	8112665	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	1.33	CHEMBL308	Homo sapiens	Inhibition	%	1.33
	8112837	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	-0.72	CHEMBL308	Homo sapiens	Inhibition	%	-0.72
	8113213	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	3.65	CHEMBL308	Homo sapiens	Inhibition	%	3.65
	8113349	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	4.97	CHEMBL308	Homo sapiens	Inhibition	%	4.97
	8113697	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	3.9	CHEMBL308	Homo sapiens	Inhibition	%	3.9
	8114037	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	1.24	CHEMBL308	Homo sapiens	Inhibition	%	1.24
	8114213	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	1.34	CHEMBL308	Homo sapiens	Inhibition	%	1.34
	8114569	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	-1.09	CHEMBL308	Homo sapiens	Inhibition	%	-1.09
	8114845	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	0.28	CHEMBL308	Homo sapiens	Inhibition	%	0.28
	8115011	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	2.66	CHEMBL308	Homo sapiens	Inhibition	%	2.66
	8115400	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	-0.13	CHEMBL308	Homo sapiens	Inhibition	%	-0.13
	8115520	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	0.5	CHEMBL308	Homo sapiens	Inhibition	%	0.5
	8115744	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	-1.31	CHEMBL308	Homo sapiens	Inhibition	%	-1.31
	8115877	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	0.58	CHEMBL308	Homo sapiens	Inhibition	%	0.58
	8116036	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	37.21	CHEMBL308	Homo sapiens	Inhibition	%	37.21
	8116260	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	74.8	CHEMBL308	Homo sapiens	Inhibition	%	74.8
	8116463	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	2.33	CHEMBL308	Homo sapiens	Inhibition	%	2.33
	8116597	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	2.77	CHEMBL308	Homo sapiens	Inhibition	%	2.77
	8116821	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	2.52	CHEMBL308	Homo sapiens	Inhibition	%	2.52
	8116993	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	2.57	CHEMBL308	Homo sapiens	Inhibition	%	2.57
	8117164	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	1.35	CHEMBL308	Homo sapiens	Inhibition	%	1.35
	8117388	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	9.4	CHEMBL308	Homo sapiens	Inhibition	%	9.4
	8117546	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	2.4	CHEMBL308	Homo sapiens	Inhibition	%	2.4
	8117676	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	2.72	CHEMBL308	Homo sapiens	Inhibition	%	2.72
	8117900	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	3.96	CHEMBL308	Homo sapiens	Inhibition	%	3.96
	8118038	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	-1.46	CHEMBL308	Homo sapiens	Inhibition	%	-1.46
	8118378	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	2.31	CHEMBL308	Homo sapiens	Inhibition	%	2.31
	8118550	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	0.34	CHEMBL308	Homo sapiens	Inhibition	%	0.34
	8118910	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	1.41	CHEMBL308	Homo sapiens	Inhibition	%	1.41
	8119181	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	-0.88	CHEMBL308	Homo sapiens	Inhibition	%	-0.88
	8119340	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	11.37	CHEMBL308	Homo sapiens	Inhibition	%	11.37
	8119564	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	6.11	CHEMBL308	Homo sapiens	Inhibition	%	6.11
	8119731	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	-0.16	CHEMBL308	Homo sapiens	Inhibition	%	-0.16
	8120074	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	-0.06	CHEMBL308	Homo sapiens	Inhibition	%	-0.06
	8120213	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	1.21	CHEMBL308	Homo sapiens	Inhibition	%	1.21
	8120597	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	2.44	CHEMBL308	Homo sapiens	Inhibition	%	2.44
	8120798	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	2.34	CHEMBL308	Homo sapiens	Inhibition	%	2.34
	8121150	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	6.84	CHEMBL308	Homo sapiens	Inhibition	%	6.84
	8121322	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	0.31	CHEMBL308	Homo sapiens	Inhibition	%	0.31
	8121713	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	21.88	CHEMBL308	Homo sapiens	Inhibition	%	21.88
	8121876	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	4.32	CHEMBL308	Homo sapiens	Inhibition	%	4.32
	8122221	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	1.33	CHEMBL308	Homo sapiens	Inhibition	%	1.33
	8122359	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	2.42	CHEMBL308	Homo sapiens	Inhibition	%	2.42
	8122583	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	25.03	CHEMBL308	Homo sapiens	Inhibition	%	25.03
	8122703	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	-0.03	CHEMBL308	Homo sapiens	Inhibition	%	-0.03
	8122870	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	1.81	CHEMBL308	Homo sapiens	Inhibition	%	1.81
	8123094	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	-0.11	CHEMBL308	Homo sapiens	Inhibition	%	-0.11
	8123236	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	-4.16	CHEMBL308	Homo sapiens	Inhibition	%	-4.16
	8123514	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	-1.98	CHEMBL308	Homo sapiens	Inhibition	%	-1.98
	8123888	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	35.84	CHEMBL308	Homo sapiens	Inhibition	%	35.84
	8124055	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	-3.5	CHEMBL308	Homo sapiens	Inhibition	%	-3.5
	8124398	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	63.89	CHEMBL308	Homo sapiens	Inhibition	%	63.89
	8124537	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	2.01	CHEMBL308	Homo sapiens	Inhibition	%	2.01
	8124761	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	0.93	CHEMBL308	Homo sapiens	Inhibition	%	0.93
	8124926	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	4.08	CHEMBL308	Homo sapiens	Inhibition	%	4.08
	8125127	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	2.36	CHEMBL308	Homo sapiens	Inhibition	%	2.36
	8125481	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	33.28	CHEMBL308	Homo sapiens	Inhibition	%	33.28
	8125649	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	1.96	CHEMBL308	Homo sapiens	Inhibition	%	1.96
	8126037	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	3.89	CHEMBL308	Homo sapiens	Inhibition	%	3.89
	8126201	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	6.19	CHEMBL308	Homo sapiens	Inhibition	%	6.19
	8126540	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	4.55	CHEMBL308	Homo sapiens	Inhibition	%	4.55
	8126900	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	62.38	CHEMBL308	Homo sapiens	Inhibition	%	62.38
	8127022	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	1.88	CHEMBL308	Homo sapiens	Inhibition	%	1.88
	8127413	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	1.72	CHEMBL308	Homo sapiens	Inhibition	%	1.72
	8127555	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	-1.4	CHEMBL308	Homo sapiens	Inhibition	%	-1.4
	8127779	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	-0.24	CHEMBL308	Homo sapiens	Inhibition	%	-0.24
	8127843	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	-0.4	CHEMBL308	Homo sapiens	Inhibition	%	-0.4
	8128219	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	1.02	CHEMBL308	Homo sapiens	Inhibition	%	1.02
	8128386	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	0.55	CHEMBL308	Homo sapiens	Inhibition	%	0.55
	8128610	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	0.47	CHEMBL308	Homo sapiens	Inhibition	%	0.47
	8128729	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	79.25	CHEMBL308	Homo sapiens	Inhibition	%	79.25
	8129090	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	3.94	CHEMBL308	Homo sapiens	Inhibition	%	3.94
	8129261	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	0.53	CHEMBL308	Homo sapiens	Inhibition	%	0.53
	8129450	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	2.02	CHEMBL308	Homo sapiens	Inhibition	%	2.02
	8129674	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	2.37	CHEMBL308	Homo sapiens	Inhibition	%	2.37
	8129813	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	72.53	CHEMBL308	Homo sapiens	Inhibition	%	72.53
	8129974	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	4.59	CHEMBL308	Homo sapiens	Inhibition	%	4.59
	8130198	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	29.14	CHEMBL308	Homo sapiens	Inhibition	%	29.14
	8130370	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	22.64	CHEMBL308	Homo sapiens	Inhibition	%	22.64
	8130530	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	36.28	CHEMBL308	Homo sapiens	Inhibition	%	36.28
	8130754	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	68.07	CHEMBL308	Homo sapiens	Inhibition	%	68.07
	8130870	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	0.13	CHEMBL308	Homo sapiens	Inhibition	%	0.13
	8131233	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	2.0	CHEMBL308	Homo sapiens	Inhibition	%	2.0
	8131353	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	2.92	CHEMBL308	Homo sapiens	Inhibition	%	2.92
	8131577	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	-0.91	CHEMBL308	Homo sapiens	Inhibition	%	-0.91
	8131744	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	0.96	CHEMBL308	Homo sapiens	Inhibition	%	0.96
	8132109	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	4.91	CHEMBL308	Homo sapiens	Inhibition	%	4.91
	8132171	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	0.45	CHEMBL308	Homo sapiens	Inhibition	%	0.45
	8132395	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	-4.66	CHEMBL308	Homo sapiens	Inhibition	%	-4.66
	8132542	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	5.98	CHEMBL308	Homo sapiens	Inhibition	%	5.98
	8132934	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	3.2	CHEMBL308	Homo sapiens	Inhibition	%	3.2
	8133055	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	7.01	CHEMBL308	Homo sapiens	Inhibition	%	7.01
	8133417	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	1.67	CHEMBL308	Homo sapiens	Inhibition	%	1.67
	8133589	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	1.85	CHEMBL308	Homo sapiens	Inhibition	%	1.85
	8133993	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	5.28	CHEMBL308	Homo sapiens	Inhibition	%	5.28
	8134141	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	2.33	CHEMBL308	Homo sapiens	Inhibition	%	2.33
	8134525	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	1.06	CHEMBL308	Homo sapiens	Inhibition	%	1.06
	8134709	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	1.78	CHEMBL308	Homo sapiens	Inhibition	%	1.78
	8135093	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	3.71	CHEMBL308	Homo sapiens	Inhibition	%	3.71
	8135208	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	-1.68	CHEMBL308	Homo sapiens	Inhibition	%	-1.68
	8135432	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	0.28	CHEMBL308	Homo sapiens	Inhibition	%	0.28
	8135573	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	5.6	CHEMBL308	Homo sapiens	Inhibition	%	5.6
	8135918	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	-1.43	CHEMBL308	Homo sapiens	Inhibition	%	-1.43
	8136086	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	1.12	CHEMBL308	Homo sapiens	Inhibition	%	1.12
	8136454	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	0.2	CHEMBL308	Homo sapiens	Inhibition	%	0.2
	8136744	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	-4.18	CHEMBL308	Homo sapiens	Inhibition	%	-4.18
	8136879	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	-0.56	CHEMBL308	Homo sapiens	Inhibition	%	-0.56
	8137266	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	2.68	CHEMBL308	Homo sapiens	Inhibition	%	2.68
	8137386	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	36.31	CHEMBL308	Homo sapiens	Inhibition	%	36.31
	8137610	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	-3.38	CHEMBL308	Homo sapiens	Inhibition	%	-3.38
	8137758	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	8.73	CHEMBL308	Homo sapiens	Inhibition	%	8.73
	8137924	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	1.03	CHEMBL308	Homo sapiens	Inhibition	%	1.03
	8138148	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	1.65	CHEMBL308	Homo sapiens	Inhibition	%	1.65
	8138327	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	2.33	CHEMBL308	Homo sapiens	Inhibition	%	2.33
	8138475	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	6.06	CHEMBL308	Homo sapiens	Inhibition	%	6.06
	8138699	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	0.57	CHEMBL308	Homo sapiens	Inhibition	%	0.57
	8138857	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	1.75	CHEMBL308	Homo sapiens	Inhibition	%	1.75
	8139042	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	9.18	CHEMBL308	Homo sapiens	Inhibition	%	9.18
	8139266	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	2.76	CHEMBL308	Homo sapiens	Inhibition	%	2.76
	8139425	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	5.82	CHEMBL308	Homo sapiens	Inhibition	%	5.82
	8139763	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	1.7	CHEMBL308	Homo sapiens	Inhibition	%	1.7
	8139904	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	2.01	CHEMBL308	Homo sapiens	Inhibition	%	2.01
	8140251	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	2.95	CHEMBL308	Homo sapiens	Inhibition	%	2.95
	8140410	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	4.16	CHEMBL308	Homo sapiens	Inhibition	%	4.16
	8140634	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	-0.56	CHEMBL308	Homo sapiens	Inhibition	%	-0.56
	8140777	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	1.39	CHEMBL308	Homo sapiens	Inhibition	%	1.39
	8141079	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	0.08	CHEMBL308	Homo sapiens	Inhibition	%	0.08
	8141209	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	-1.08	CHEMBL308	Homo sapiens	Inhibition	%	-1.08
	8141433	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	-0.24	CHEMBL308	Homo sapiens	Inhibition	%	-0.24
	8141593	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	22.53	CHEMBL308	Homo sapiens	Inhibition	%	22.53
	8141936	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	1.17	CHEMBL308	Homo sapiens	Inhibition	%	1.17
	8142097	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	0.5	CHEMBL308	Homo sapiens	Inhibition	%	0.5
	8142489	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	2.12	CHEMBL308	Homo sapiens	Inhibition	%	2.12
	8142665	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	2.13	CHEMBL308	Homo sapiens	Inhibition	%	2.13
	8143038	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	2.57	CHEMBL308	Homo sapiens	Inhibition	%	2.57
	8143193	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	1.11	CHEMBL308	Homo sapiens	Inhibition	%	1.11
	8143604	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	1.43	CHEMBL308	Homo sapiens	Inhibition	%	1.43
	8143763	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	3.78	CHEMBL308	Homo sapiens	Inhibition	%	3.78
	8144101	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	-4.43	CHEMBL308	Homo sapiens	Inhibition	%	-4.43
	8144240	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	-1.04	CHEMBL308	Homo sapiens	Inhibition	%	-1.04
	8144464	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	2.5	CHEMBL308	Homo sapiens	Inhibition	%	2.5
	8144594	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	1.14	CHEMBL308	Homo sapiens	Inhibition	%	1.14
	8144971	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	1.19	CHEMBL308	Homo sapiens	Inhibition	%	1.19
	8145108	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	0.29	CHEMBL308	Homo sapiens	Inhibition	%	0.29
	8145421	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	1.02	CHEMBL308	Homo sapiens	Inhibition	%	1.02
	8145769	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	2.61	CHEMBL308	Homo sapiens	Inhibition	%	2.61
	8145930	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	0.58	CHEMBL308	Homo sapiens	Inhibition	%	0.58
	8146274	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	0.09	CHEMBL308	Homo sapiens	Inhibition	%	0.09
	8146434	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	1.38	CHEMBL308	Homo sapiens	Inhibition	%	1.38
	8146658	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	5.37	CHEMBL308	Homo sapiens	Inhibition	%	5.37
	8146825	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	3.02	CHEMBL308	Homo sapiens	Inhibition	%	3.02
	8146994	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	10.29	CHEMBL308	Homo sapiens	Inhibition	%	10.29
	8147218	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	42.61	CHEMBL308	Homo sapiens	Inhibition	%	42.61
	8147360	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	0.56	CHEMBL308	Homo sapiens	Inhibition	%	0.56
	8147513	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	1.87	CHEMBL308	Homo sapiens	Inhibition	%	1.87
	8147737	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	0.53	CHEMBL308	Homo sapiens	Inhibition	%	0.53
	8147924	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	1.54	CHEMBL308	Homo sapiens	Inhibition	%	1.54
	8148082	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	3.79	CHEMBL308	Homo sapiens	Inhibition	%	3.79
	8148306	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	2.77	CHEMBL308	Homo sapiens	Inhibition	%	2.77
	8148420	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	-2.83	CHEMBL308	Homo sapiens	Inhibition	%	-2.83
	8148783	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	4.39	CHEMBL308	Homo sapiens	Inhibition	%	4.39
	8148921	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	3.25	CHEMBL308	Homo sapiens	Inhibition	%	3.25
	8149145	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	1.41	CHEMBL308	Homo sapiens	Inhibition	%	1.41
	8149304	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	-3.13	CHEMBL308	Homo sapiens	Inhibition	%	-3.13
	8149438	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	1.65	CHEMBL308	Homo sapiens	Inhibition	%	1.65
	8149662	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	0.45	CHEMBL308	Homo sapiens	Inhibition	%	0.45
	8149760	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	-0.06	CHEMBL308	Homo sapiens	Inhibition	%	-0.06
	8150109	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	-5.04	CHEMBL308	Homo sapiens	Inhibition	%	-5.04
	8150269	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	3.72	CHEMBL308	Homo sapiens	Inhibition	%	3.72
	8150493	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	0.46	CHEMBL308	Homo sapiens	Inhibition	%	0.46
	8150613	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	3.86	CHEMBL308	Homo sapiens	Inhibition	%	3.86
	8151002	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	6.76	CHEMBL308	Homo sapiens	Inhibition	%	6.76
	8151165	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	0.88	CHEMBL308	Homo sapiens	Inhibition	%	0.88
	8151566	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	2.52	CHEMBL308	Homo sapiens	Inhibition	%	2.52
	8151704	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	4.07	CHEMBL308	Homo sapiens	Inhibition	%	4.07
	8152082	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	1.61	CHEMBL308	Homo sapiens	Inhibition	%	1.61
	8152270	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	2.24	CHEMBL308	Homo sapiens	Inhibition	%	2.24
	8152652	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	4.54	CHEMBL308	Homo sapiens	Inhibition	%	4.54
	8152766	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	0.39	CHEMBL308	Homo sapiens	Inhibition	%	0.39
	8152990	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	1.28	CHEMBL308	Homo sapiens	Inhibition	%	1.28
	8153129	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	1.26	CHEMBL308	Homo sapiens	Inhibition	%	1.26
	8153490	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	2.63	CHEMBL308	Homo sapiens	Inhibition	%	2.63
	8153647	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	-3.04	CHEMBL308	Homo sapiens	Inhibition	%	-3.04
	8154004	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	0.67	CHEMBL308	Homo sapiens	Inhibition	%	0.67
	8154101	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	-0.3	CHEMBL308	Homo sapiens	Inhibition	%	-0.3
	8154325	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	-0.3	CHEMBL308	Homo sapiens	Inhibition	%	-0.3
	8154451	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	-3.69	CHEMBL308	Homo sapiens	Inhibition	%	-3.69
	8154834	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	2.85	CHEMBL308	Homo sapiens	Inhibition	%	2.85
	8154954	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	0.05	CHEMBL308	Homo sapiens	Inhibition	%	0.05
	8155178	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	0.52	CHEMBL308	Homo sapiens	Inhibition	%	0.52
	8155354	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	1.22	CHEMBL308	Homo sapiens	Inhibition	%	1.22
	8155515	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	2.1	CHEMBL308	Homo sapiens	Inhibition	%	2.1
	8155739	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	2.14	CHEMBL308	Homo sapiens	Inhibition	%	2.14
	8155917	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	6.8	CHEMBL308	Homo sapiens	Inhibition	%	6.8
	8156055	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	0.34	CHEMBL308	Homo sapiens	Inhibition	%	0.34
	8156279	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	6.63	CHEMBL308	Homo sapiens	Inhibition	%	6.63
	8156491	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	0.77	CHEMBL308	Homo sapiens	Inhibition	%	0.77
	8156641	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	1.52	CHEMBL308	Homo sapiens	Inhibition	%	1.52
	8157008	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	66.19	CHEMBL308	Homo sapiens	Inhibition	%	66.19
	8157128	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	1.96	CHEMBL308	Homo sapiens	Inhibition	%	1.96
	8157352	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	6.87	CHEMBL308	Homo sapiens	Inhibition	%	6.87
	8157493	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	0.7	CHEMBL308	Homo sapiens	Inhibition	%	0.7
	8157847	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	3.22	CHEMBL308	Homo sapiens	Inhibition	%	3.22
	8158008	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	1.42	CHEMBL308	Homo sapiens	Inhibition	%	1.42
	8158258	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	1.69	CHEMBL308	Homo sapiens	Inhibition	%	1.69
	8158482	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	0.41	CHEMBL308	Homo sapiens	Inhibition	%	0.41
	8158640	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	2.14	CHEMBL308	Homo sapiens	Inhibition	%	2.14
	8158809	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	1.12	CHEMBL308	Homo sapiens	Inhibition	%	1.12
	8159033	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	7.47	CHEMBL308	Homo sapiens	Inhibition	%	7.47
	8159168	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	0.36	CHEMBL308	Homo sapiens	Inhibition	%	0.36
	8159512	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	-4.51	CHEMBL308	Homo sapiens	Inhibition	%	-4.51
	8159643	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	12.9	CHEMBL308	Homo sapiens	Inhibition	%	12.9
	8159867	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	0.12	CHEMBL308	Homo sapiens	Inhibition	%	0.12
	8160008	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	1.42	CHEMBL308	Homo sapiens	Inhibition	%	1.42
	8160145	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	4.8	CHEMBL308	Homo sapiens	Inhibition	%	4.8
	8160369	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	4.23	CHEMBL308	Homo sapiens	Inhibition	%	4.23
	8160519	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	0.17	CHEMBL308	Homo sapiens	Inhibition	%	0.17
	8160813	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	3.16	CHEMBL308	Homo sapiens	Inhibition	%	3.16
	8160963	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	-0.38	CHEMBL308	Homo sapiens	Inhibition	%	-0.38
	8161187	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	2.55	CHEMBL308	Homo sapiens	Inhibition	%	2.55
	8161330	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	71.32	CHEMBL308	Homo sapiens	Inhibition	%	71.32
	8161679	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	2.95	CHEMBL308	Homo sapiens	Inhibition	%	2.95
	8161817	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	6.83	CHEMBL308	Homo sapiens	Inhibition	%	6.83
	8162041	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	0.79	CHEMBL308	Homo sapiens	Inhibition	%	0.79
	8162171	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	20.84	CHEMBL308	Homo sapiens	Inhibition	%	20.84
	8162331	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	-2.5	CHEMBL308	Homo sapiens	Inhibition	%	-2.5
	8162555	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	-3.79	CHEMBL308	Homo sapiens	Inhibition	%	-3.79
	8162808	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%		CHEMBL308	Homo sapiens	Inhibition	%	
	8162956	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	40.67	CHEMBL308	Homo sapiens	Inhibition	%	40.67
	8163349	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	1.07	CHEMBL308	Homo sapiens	Inhibition	%	1.07
	8163483	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	1.18	CHEMBL308	Homo sapiens	Inhibition	%	1.18
	8163830	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	-4.05	CHEMBL308	Homo sapiens	Inhibition	%	-4.05
	8164188	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	2.76	CHEMBL308	Homo sapiens	Inhibition	%	2.76
	8164328	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	-0.29	CHEMBL308	Homo sapiens	Inhibition	%	-0.29
	8164707	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	83.78	CHEMBL308	Homo sapiens	Inhibition	%	83.78
	8164851	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	5.68	CHEMBL308	Homo sapiens	Inhibition	%	5.68
	8165145	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	1.79	CHEMBL308	Homo sapiens	Inhibition	%	1.79
	8165510	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	0.18	CHEMBL308	Homo sapiens	Inhibition	%	0.18
	8165653	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	92.92	CHEMBL308	Homo sapiens	Inhibition	%	92.92
	8166003	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	21.01	CHEMBL308	Homo sapiens	Inhibition	%	21.01
	8166365	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	9.28	CHEMBL308	Homo sapiens	Inhibition	%	9.28
	8166495	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	0.66	CHEMBL308	Homo sapiens	Inhibition	%	0.66
	8166820	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	3.05	CHEMBL308	Homo sapiens	Inhibition	%	3.05
	8167132	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	0.45	CHEMBL308	Homo sapiens	Inhibition	%	0.45
	8167273	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	69.5	CHEMBL308	Homo sapiens	Inhibition	%	69.5
	8167497	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	2.56	CHEMBL308	Homo sapiens	Inhibition	%	2.56
	8167661	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	5.24	CHEMBL308	Homo sapiens	Inhibition	%	5.24
	8167794	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	0.74	CHEMBL308	Homo sapiens	Inhibition	%	0.74
	8168018	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	1.27	CHEMBL308	Homo sapiens	Inhibition	%	1.27
	8168142	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	0.21	CHEMBL308	Homo sapiens	Inhibition	%	0.21
	8168507	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	1.5	CHEMBL308	Homo sapiens	Inhibition	%	1.5
	8168643	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	0.21	CHEMBL308	Homo sapiens	Inhibition	%	0.21
	8168867	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	0.37	CHEMBL308	Homo sapiens	Inhibition	%	0.37
	8169031	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	89.25	CHEMBL308	Homo sapiens	Inhibition	%	89.25
	8169173	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	0.29	CHEMBL308	Homo sapiens	Inhibition	%	0.29
	8169397	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	3.65	CHEMBL308	Homo sapiens	Inhibition	%	3.65
	8169477	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	5.38	CHEMBL308	Homo sapiens	Inhibition	%	5.38
	8169835	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	3.95	CHEMBL308	Homo sapiens	Inhibition	%	3.95
	8169980	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	-0.06	CHEMBL308	Homo sapiens	Inhibition	%	-0.06
	8170204	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	4.1	CHEMBL308	Homo sapiens	Inhibition	%	4.1
	8170329	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	0.2	CHEMBL308	Homo sapiens	Inhibition	%	0.2
	8170693	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	-0.87	CHEMBL308	Homo sapiens	Inhibition	%	-0.87
	8170828	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	2.64	CHEMBL308	Homo sapiens	Inhibition	%	2.64
	8171052	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	21.52	CHEMBL308	Homo sapiens	Inhibition	%	21.52
	8171249	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	0.71	CHEMBL308	Homo sapiens	Inhibition	%	0.71
	8171466	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	3.69	CHEMBL308	Homo sapiens	Inhibition	%	3.69
	8171831	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	6.04	CHEMBL308	Homo sapiens	Inhibition	%	6.04
	8171984	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	1.44	CHEMBL308	Homo sapiens	Inhibition	%	1.44
	8172340	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	1.63	CHEMBL308	Homo sapiens	Inhibition	%	1.63
	8172468	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	-0.93	CHEMBL308	Homo sapiens	Inhibition	%	-0.93
	8172692	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	-0.35	CHEMBL308	Homo sapiens	Inhibition	%	-0.35
	8172834	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	1.54	CHEMBL308	Homo sapiens	Inhibition	%	1.54
	8173194	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	1.15	CHEMBL308	Homo sapiens	Inhibition	%	1.15
	8173359	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	45.05	CHEMBL308	Homo sapiens	Inhibition	%	45.05
	8173724	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	-0.12	CHEMBL308	Homo sapiens	Inhibition	%	-0.12
	8173811	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	30.09	CHEMBL308	Homo sapiens	Inhibition	%	30.09
	8174035	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	76.11	CHEMBL308	Homo sapiens	Inhibition	%	76.11
	8174167	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	0.78	CHEMBL308	Homo sapiens	Inhibition	%	0.78
	8174539	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	-0.46	CHEMBL308	Homo sapiens	Inhibition	%	-0.46
	8174661	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	2.23	CHEMBL308	Homo sapiens	Inhibition	%	2.23
	8174885	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	0.57	CHEMBL308	Homo sapiens	Inhibition	%	0.57
	8175028	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	4.13	CHEMBL308	Homo sapiens	Inhibition	%	4.13
	8175388	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	64.04	CHEMBL308	Homo sapiens	Inhibition	%	64.04
	8175644	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	10.61	CHEMBL308	Homo sapiens	Inhibition	%	10.61
	8175807	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	0.25	CHEMBL308	Homo sapiens	Inhibition	%	0.25
	8176184	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	3.12	CHEMBL308	Homo sapiens	Inhibition	%	3.12
	8176333	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	32.98	CHEMBL308	Homo sapiens	Inhibition	%	32.98
	8176557	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	6.23	CHEMBL308	Homo sapiens	Inhibition	%	6.23
	8176689	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	8.12	CHEMBL308	Homo sapiens	Inhibition	%	8.12
	8177043	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	1.46	CHEMBL308	Homo sapiens	Inhibition	%	1.46
	8177185	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	-2.89	CHEMBL308	Homo sapiens	Inhibition	%	-2.89
	8177547	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	0.17	CHEMBL308	Homo sapiens	Inhibition	%	0.17
	8177711	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	81.76	CHEMBL308	Homo sapiens	Inhibition	%	81.76
	8177935	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	3.94	CHEMBL308	Homo sapiens	Inhibition	%	3.94
	8178075	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	1.23	CHEMBL308	Homo sapiens	Inhibition	%	1.23
	8178387	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	0.08	CHEMBL308	Homo sapiens	Inhibition	%	0.08
	8178514	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	3.13	CHEMBL308	Homo sapiens	Inhibition	%	3.13
	8178738	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	9.55	CHEMBL308	Homo sapiens	Inhibition	%	9.55
	8178887	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	1.27	CHEMBL308	Homo sapiens	Inhibition	%	1.27
	8179234	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	2.13	CHEMBL308	Homo sapiens	Inhibition	%	2.13
	8179378	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	31.45	CHEMBL308	Homo sapiens	Inhibition	%	31.45
	8179739	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	2.23	CHEMBL308	Homo sapiens	Inhibition	%	2.23
	8179996	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	1.44	CHEMBL308	Homo sapiens	Inhibition	%	1.44
	8180150	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	5.8	CHEMBL308	Homo sapiens	Inhibition	%	5.8
	8180374	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	-1.89	CHEMBL308	Homo sapiens	Inhibition	%	-1.89
	8180530	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	10.53	CHEMBL308	Homo sapiens	Inhibition	%	10.53
	8180902	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	33.93	CHEMBL308	Homo sapiens	Inhibition	%	33.93
	8181035	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	1.72	CHEMBL308	Homo sapiens	Inhibition	%	1.72
	8181390	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	0.68	CHEMBL308	Homo sapiens	Inhibition	%	0.68
	8181530	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	-3.31	CHEMBL308	Homo sapiens	Inhibition	%	-3.31
	8181754	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	0.9	CHEMBL308	Homo sapiens	Inhibition	%	0.9
	8181893	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	3.22	CHEMBL308	Homo sapiens	Inhibition	%	3.22
	8182280	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	8.07	CHEMBL308	Homo sapiens	Inhibition	%	8.07
	8182420	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	-0.65	CHEMBL308	Homo sapiens	Inhibition	%	-0.65
	8182736	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	-0.52	CHEMBL308	Homo sapiens	Inhibition	%	-0.52
	8183082	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	35.5	CHEMBL308	Homo sapiens	Inhibition	%	35.5
	8183231	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	-0.89	CHEMBL308	Homo sapiens	Inhibition	%	-0.89
	8183584	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	5.01	CHEMBL308	Homo sapiens	Inhibition	%	5.01
	8183726	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	71.26	CHEMBL308	Homo sapiens	Inhibition	%	71.26
	8183950	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	8.41	CHEMBL308	Homo sapiens	Inhibition	%	8.41
	8184086	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	8.04	CHEMBL308	Homo sapiens	Inhibition	%	8.04
	8184352	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	9.39	CHEMBL308	Homo sapiens	Inhibition	%	9.39
	8184723	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	1.88	CHEMBL308	Homo sapiens	Inhibition	%	1.88
	8184880	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	0.14	CHEMBL308	Homo sapiens	Inhibition	%	0.14
	8185253	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	0.28	CHEMBL308	Homo sapiens	Inhibition	%	0.28
	8185384	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	-1.86	CHEMBL308	Homo sapiens	Inhibition	%	-1.86
	8185608	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	-2.94	CHEMBL308	Homo sapiens	Inhibition	%	-2.94
	8185739	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	14.53	CHEMBL308	Homo sapiens	Inhibition	%	14.53
	8186102	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	5.76	CHEMBL308	Homo sapiens	Inhibition	%	5.76
	8186243	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	-0.93	CHEMBL308	Homo sapiens	Inhibition	%	-0.93
	8186631	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	1.56	CHEMBL308	Homo sapiens	Inhibition	%	1.56
	8186770	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	0.76	CHEMBL308	Homo sapiens	Inhibition	%	0.76
	8186994	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	0.42	CHEMBL308	Homo sapiens	Inhibition	%	0.42
	8187092	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	0.12	CHEMBL308	Homo sapiens	Inhibition	%	0.12
	8187440	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	5.27	CHEMBL308	Homo sapiens	Inhibition	%	5.27
	8187588	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	2.51	CHEMBL308	Homo sapiens	Inhibition	%	2.51
	8187812	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	-0.08	CHEMBL308	Homo sapiens	Inhibition	%	-0.08
	8187941	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	4.37	CHEMBL308	Homo sapiens	Inhibition	%	4.37
	8188308	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	42.54	CHEMBL308	Homo sapiens	Inhibition	%	42.54
	8188443	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	26.17	CHEMBL308	Homo sapiens	Inhibition	%	26.17
	8188667	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	64.05	CHEMBL308	Homo sapiens	Inhibition	%	64.05
	8188717	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	-0.15	CHEMBL308	Homo sapiens	Inhibition	%	-0.15
	8188941	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%		CHEMBL308	Homo sapiens	Inhibition	%	
	8189089	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	11.76	CHEMBL308	Homo sapiens	Inhibition	%	11.76
	8189245	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	0.65	CHEMBL308	Homo sapiens	Inhibition	%	0.65
	8189469	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	2.85	CHEMBL308	Homo sapiens	Inhibition	%	2.85
	8189618	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	2.88	CHEMBL308	Homo sapiens	Inhibition	%	2.88
	8189974	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	-2.94	CHEMBL308	Homo sapiens	Inhibition	%	-2.94
	8190106	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	3.53	CHEMBL308	Homo sapiens	Inhibition	%	3.53
	8190470	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	-0.45	CHEMBL308	Homo sapiens	Inhibition	%	-0.45
	8190607	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	2.75	CHEMBL308	Homo sapiens	Inhibition	%	2.75
	8190831	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	0.37	CHEMBL308	Homo sapiens	Inhibition	%	0.37
	8190995	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	3.2	CHEMBL308	Homo sapiens	Inhibition	%	3.2
	8191357	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	2.58	CHEMBL308	Homo sapiens	Inhibition	%	2.58
	8191453	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	1.3	CHEMBL308	Homo sapiens	Inhibition	%	1.3
	8191677	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	-0.29	CHEMBL308	Homo sapiens	Inhibition	%	-0.29
	8191799	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	41.19	CHEMBL308	Homo sapiens	Inhibition	%	41.19
	8192172	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	1.65	CHEMBL308	Homo sapiens	Inhibition	%	1.65
	8192301	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	1.08	CHEMBL308	Homo sapiens	Inhibition	%	1.08
	8192525	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	1.37	CHEMBL308	Homo sapiens	Inhibition	%	1.37
	8192669	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	1.72	CHEMBL308	Homo sapiens	Inhibition	%	1.72
	8193029	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	2.86	CHEMBL308	Homo sapiens	Inhibition	%	2.86
	8193301	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	0.65	CHEMBL308	Homo sapiens	Inhibition	%	0.65
	8193446	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	47.92	CHEMBL308	Homo sapiens	Inhibition	%	47.92
	8193827	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	7.45	CHEMBL308	Homo sapiens	Inhibition	%	7.45
	8193976	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	0.79	CHEMBL308	Homo sapiens	Inhibition	%	0.79
	8194331	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	0.59	CHEMBL308	Homo sapiens	Inhibition	%	0.59
	8194462	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	5.31	CHEMBL308	Homo sapiens	Inhibition	%	5.31
	8194686	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	1.77	CHEMBL308	Homo sapiens	Inhibition	%	1.77
	8194829	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	1.56	CHEMBL308	Homo sapiens	Inhibition	%	1.56
	8195186	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	1.31	CHEMBL308	Homo sapiens	Inhibition	%	1.31
	8195350	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	2.24	CHEMBL308	Homo sapiens	Inhibition	%	2.24
	8195713	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	0.21	CHEMBL308	Homo sapiens	Inhibition	%	0.21
	8196035	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	0.48	CHEMBL308	Homo sapiens	Inhibition	%	0.48
	8196152	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	3.12	CHEMBL308	Homo sapiens	Inhibition	%	3.12
	8196376	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	4.29	CHEMBL308	Homo sapiens	Inhibition	%	4.29
	8196526	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	-0.23	CHEMBL308	Homo sapiens	Inhibition	%	-0.23
	8196878	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	-2.79	CHEMBL308	Homo sapiens	Inhibition	%	-2.79
	8197019	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	7.81	CHEMBL308	Homo sapiens	Inhibition	%	7.81
	8197380	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	12.05	CHEMBL308	Homo sapiens	Inhibition	%	12.05
	8197655	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	0.73	CHEMBL308	Homo sapiens	Inhibition	%	0.73
	8197795	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	1.92	CHEMBL308	Homo sapiens	Inhibition	%	1.92
	8198019	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	6.22	CHEMBL308	Homo sapiens	Inhibition	%	6.22
	8198176	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	-2.26	CHEMBL308	Homo sapiens	Inhibition	%	-2.26
	8198314	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	2.89	CHEMBL308	Homo sapiens	Inhibition	%	2.89
	8198538	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	0.86	CHEMBL308	Homo sapiens	Inhibition	%	0.86
	8198668	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	4.09	CHEMBL308	Homo sapiens	Inhibition	%	4.09
	8199023	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	3.26	CHEMBL308	Homo sapiens	Inhibition	%	3.26
	8199171	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	-0.43	CHEMBL308	Homo sapiens	Inhibition	%	-0.43
	8199395	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	1.6	CHEMBL308	Homo sapiens	Inhibition	%	1.6
	8199529	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	0.35	CHEMBL308	Homo sapiens	Inhibition	%	0.35
	8199692	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	7.36	CHEMBL308	Homo sapiens	Inhibition	%	7.36
	8199916	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	0.41	CHEMBL308	Homo sapiens	Inhibition	%	0.41
	8200054	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	1.4	CHEMBL308	Homo sapiens	Inhibition	%	1.4
	8200382	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	0.56	CHEMBL308	Homo sapiens	Inhibition	%	0.56
	8200721	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	2.77	CHEMBL308	Homo sapiens	Inhibition	%	2.77
	8200871	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	1.56	CHEMBL308	Homo sapiens	Inhibition	%	1.56
	8201225	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	-0.17	CHEMBL308	Homo sapiens	Inhibition	%	-0.17
	8201360	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	-0.03	CHEMBL308	Homo sapiens	Inhibition	%	-0.03
	8201584	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	0.11	CHEMBL308	Homo sapiens	Inhibition	%	0.11
	8201717	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	0.98	CHEMBL308	Homo sapiens	Inhibition	%	0.98
	8201996	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	-0.13	CHEMBL308	Homo sapiens	Inhibition	%	-0.13
	8202360	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	0.71	CHEMBL308	Homo sapiens	Inhibition	%	0.71
	8202527	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	-3.55	CHEMBL308	Homo sapiens	Inhibition	%	-3.55
	8202876	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	-0.63	CHEMBL308	Homo sapiens	Inhibition	%	-0.63
	8203006	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	1.85	CHEMBL308	Homo sapiens	Inhibition	%	1.85
	8203230	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	8.16	CHEMBL308	Homo sapiens	Inhibition	%	8.16
	8203361	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	-2.06	CHEMBL308	Homo sapiens	Inhibition	%	-2.06
	8203731	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	1.53	CHEMBL308	Homo sapiens	Inhibition	%	1.53
	8203865	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	1.89	CHEMBL308	Homo sapiens	Inhibition	%	1.89
	8204255	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	3.26	CHEMBL308	Homo sapiens	Inhibition	%	3.26
	8204392	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	0.02	CHEMBL308	Homo sapiens	Inhibition	%	0.02
	8204616	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	1.83	CHEMBL308	Homo sapiens	Inhibition	%	1.83
	8204721	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	1.32	CHEMBL308	Homo sapiens	Inhibition	%	1.32
	8205060	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	15.83	CHEMBL308	Homo sapiens	Inhibition	%	15.83
	8205209	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	2.3	CHEMBL308	Homo sapiens	Inhibition	%	2.3
	8205433	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	21.66	CHEMBL308	Homo sapiens	Inhibition	%	21.66
	8205569	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	0.5	CHEMBL308	Homo sapiens	Inhibition	%	0.5
	8205932	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	-0.23	CHEMBL308	Homo sapiens	Inhibition	%	-0.23
	8206064	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	3.25	CHEMBL308	Homo sapiens	Inhibition	%	3.25
	8206340	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	2.0	CHEMBL308	Homo sapiens	Inhibition	%	2.0
	8206707	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%		CHEMBL308	Homo sapiens	Inhibition	%	
	8206887	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	1.58	CHEMBL308	Homo sapiens	Inhibition	%	1.58
	8207237	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	0.61	CHEMBL308	Homo sapiens	Inhibition	%	0.61
	8207591	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	24.24	CHEMBL308	Homo sapiens	Inhibition	%	24.24
	8207723	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	1.04	CHEMBL308	Homo sapiens	Inhibition	%	1.04
	8208092	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	13.92	CHEMBL308	Homo sapiens	Inhibition	%	13.92
	8208224	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	0.11	CHEMBL308	Homo sapiens	Inhibition	%	0.11
	8208448	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	1.79	CHEMBL308	Homo sapiens	Inhibition	%	1.79
	8208614	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	0.76	CHEMBL308	Homo sapiens	Inhibition	%	0.76
	8208971	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	1.19	CHEMBL308	Homo sapiens	Inhibition	%	1.19
	8209076	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	0.67	CHEMBL308	Homo sapiens	Inhibition	%	0.67
	8209300	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	2.37	CHEMBL308	Homo sapiens	Inhibition	%	2.37
	8209416	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	0.79	CHEMBL308	Homo sapiens	Inhibition	%	0.79
	8209790	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	0.48	CHEMBL308	Homo sapiens	Inhibition	%	0.48
	8209926	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	2.69	CHEMBL308	Homo sapiens	Inhibition	%	2.69
	8210291	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	0.76	CHEMBL308	Homo sapiens	Inhibition	%	0.76
	8210427	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	0.69	CHEMBL308	Homo sapiens	Inhibition	%	0.69
	8210651	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	5.0	CHEMBL308	Homo sapiens	Inhibition	%	5.0
	8210686	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	-3.13	CHEMBL308	Homo sapiens	Inhibition	%	-3.13
	8210910	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	-1.46	CHEMBL308	Homo sapiens	Inhibition	%	-1.46
	8211054	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	-0.15	CHEMBL308	Homo sapiens	Inhibition	%	-0.15
	8211224	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	2.19	CHEMBL308	Homo sapiens	Inhibition	%	2.19
	8211448	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	-0.04	CHEMBL308	Homo sapiens	Inhibition	%	-0.04
	8211571	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	2.18	CHEMBL308	Homo sapiens	Inhibition	%	2.18
	8211924	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	64.22	CHEMBL308	Homo sapiens	Inhibition	%	64.22
	8212056	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	2.03	CHEMBL308	Homo sapiens	Inhibition	%	2.03
	8212280	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	2.22	CHEMBL308	Homo sapiens	Inhibition	%	2.22
	8212421	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	0.08	CHEMBL308	Homo sapiens	Inhibition	%	0.08
	8212778	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	-0.13	CHEMBL308	Homo sapiens	Inhibition	%	-0.13
	8212948	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	2.25	CHEMBL308	Homo sapiens	Inhibition	%	2.25
	8213301	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	8.14	CHEMBL308	Homo sapiens	Inhibition	%	8.14
	8213629	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	0.08	CHEMBL308	Homo sapiens	Inhibition	%	0.08
	8213742	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	3.13	CHEMBL308	Homo sapiens	Inhibition	%	3.13
	8214113	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	5.13	CHEMBL308	Homo sapiens	Inhibition	%	5.13
	8214250	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	0.89	CHEMBL308	Homo sapiens	Inhibition	%	0.89
	8214474	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	6.45	CHEMBL308	Homo sapiens	Inhibition	%	6.45
	8214608	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	-3.61	CHEMBL308	Homo sapiens	Inhibition	%	-3.61
	8214984	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	5.08	CHEMBL308	Homo sapiens	Inhibition	%	5.08
	8215235	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	0.36	CHEMBL308	Homo sapiens	Inhibition	%	0.36
	8215388	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	1.15	CHEMBL308	Homo sapiens	Inhibition	%	1.15
	8215776	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	1.97	CHEMBL308	Homo sapiens	Inhibition	%	1.97
	8215895	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	-2.84	CHEMBL308	Homo sapiens	Inhibition	%	-2.84
	8216119	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	-2.45	CHEMBL308	Homo sapiens	Inhibition	%	-2.45
	8216238	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	-0.53	CHEMBL308	Homo sapiens	Inhibition	%	-0.53
	8216598	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	1.03	CHEMBL308	Homo sapiens	Inhibition	%	1.03
	8216736	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	4.52	CHEMBL308	Homo sapiens	Inhibition	%	4.52
	8217094	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	2.72	CHEMBL308	Homo sapiens	Inhibition	%	2.72
	8217268	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	0.18	CHEMBL308	Homo sapiens	Inhibition	%	0.18
	8217492	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	1.13	CHEMBL308	Homo sapiens	Inhibition	%	1.13
	8217623	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	1.59	CHEMBL308	Homo sapiens	Inhibition	%	1.59
	8217948	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	1.14	CHEMBL308	Homo sapiens	Inhibition	%	1.14
	8218063	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	1.59	CHEMBL308	Homo sapiens	Inhibition	%	1.59
	8218287	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	5.87	CHEMBL308	Homo sapiens	Inhibition	%	5.87
	8218414	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	44.66	CHEMBL308	Homo sapiens	Inhibition	%	44.66
	8218781	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	0.92	CHEMBL308	Homo sapiens	Inhibition	%	0.92
	8218912	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	1.29	CHEMBL308	Homo sapiens	Inhibition	%	1.29
	8219296	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	4.83	CHEMBL308	Homo sapiens	Inhibition	%	4.83
	8219546	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	2.84	CHEMBL308	Homo sapiens	Inhibition	%	2.84
	8219707	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	1.77	CHEMBL308	Homo sapiens	Inhibition	%	1.77
	8219931	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	3.58	CHEMBL308	Homo sapiens	Inhibition	%	3.58
	8220100	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	0.79	CHEMBL308	Homo sapiens	Inhibition	%	0.79
	8220453	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	0.77	CHEMBL308	Homo sapiens	Inhibition	%	0.77
	8220567	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	1.01	CHEMBL308	Homo sapiens	Inhibition	%	1.01
	8220929	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	3.82	CHEMBL308	Homo sapiens	Inhibition	%	3.82
	8221065	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	-3.89	CHEMBL308	Homo sapiens	Inhibition	%	-3.89
	8221289	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	3.98	CHEMBL308	Homo sapiens	Inhibition	%	3.98
	8221422	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	1.3	CHEMBL308	Homo sapiens	Inhibition	%	1.3
	8221811	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	0.46	CHEMBL308	Homo sapiens	Inhibition	%	0.46
	8221942	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	6.07	CHEMBL308	Homo sapiens	Inhibition	%	6.07
	8222264	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	0.64	CHEMBL308	Homo sapiens	Inhibition	%	0.64
	8222622	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	19.67	CHEMBL308	Homo sapiens	Inhibition	%	19.67
	8222740	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	77.15	CHEMBL308	Homo sapiens	Inhibition	%	77.15
	8223108	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	7.71	CHEMBL308	Homo sapiens	Inhibition	%	7.71
	8223237	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	0.28	CHEMBL308	Homo sapiens	Inhibition	%	0.28
	8223461	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	3.27	CHEMBL308	Homo sapiens	Inhibition	%	3.27
	8223622	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	1.89	CHEMBL308	Homo sapiens	Inhibition	%	1.89
	8223872	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	1.11	CHEMBL308	Homo sapiens	Inhibition	%	1.11
	8224258	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	-0.58	CHEMBL308	Homo sapiens	Inhibition	%	-0.58
	8224428	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	0.88	CHEMBL308	Homo sapiens	Inhibition	%	0.88
	8224787	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	1.61	CHEMBL308	Homo sapiens	Inhibition	%	1.61
	8224901	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	-0.73	CHEMBL308	Homo sapiens	Inhibition	%	-0.73
	8225125	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	1.81	CHEMBL308	Homo sapiens	Inhibition	%	1.81
	8225259	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	2.03	CHEMBL308	Homo sapiens	Inhibition	%	2.03
	8225621	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	0.17	CHEMBL308	Homo sapiens	Inhibition	%	0.17
	8225756	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	1.51	CHEMBL308	Homo sapiens	Inhibition	%	1.51
	8226138	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	1.3	CHEMBL308	Homo sapiens	Inhibition	%	1.3
	8226263	CHEMBL1962018	GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	0.61	CHEMBL308	Homo sapiens	Inhibition	%	0.61
	8226487	CHEMBL1962019	GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	2.58	CHEMBL308	Homo sapiens	Inhibition	%	2.58
active	9648361	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(-c2[nH]c(-c3ccnc(N)n3)cc2C(N)=O)c1C		CHEMBL1964290	=	Ki	nM	1000.0	CHEMBL308	Homo sapiens	pKi		6.0
inactive	9648362	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1ccc(CNc2c(Nc3ccncc3)c(=O)c2=O)c(OC)c1		CHEMBL2003768	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648363	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1ncnc2onc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL213505	=	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648364	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1ccc(OC)c(Nc2ccc3nnc(-c4ccccc4)n3n2)c1		CHEMBL1982880	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648365	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	N#CCOc1ccc(Nc2nc(Nc3cccc(S(N)(=O)=O)c3)ncc2Br)cc1		CHEMBL1987034	=	Ki	nM	25.12	CHEMBL308	Homo sapiens	pKi		7.6
inactive	9648366	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCCn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1993941	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648367	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1Cl		CHEMBL377383	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648368	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1		CHEMBL578061	=	Ki	nM	3981.07	CHEMBL308	Homo sapiens	pKi		5.4
active	9648369	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12		CHEMBL2005886	=	Ki	nM	6309.57	CHEMBL308	Homo sapiens	pKi		5.2
inactive	9648370	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL481491	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648371	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)cc1		CHEMBL1682345	=	Ki	nM	501.19	CHEMBL308	Homo sapiens	pKi		6.3
active	9648372	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(=O)Nc1c(C(N)=O)sc2ccc(Cl)c(Cl)c12		CHEMBL1973142	=	Ki	nM	794.33	CHEMBL308	Homo sapiens	pKi		6.1
inactive	9648373	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4nc(N)nc(N)c34)cc2)c1		CHEMBL1973145	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648374	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cccc(C(=O)Nc2cnc3[nH]cc(-c4ccccc4)c3c2)c1		CHEMBL1982924	=	Ki	nM	6309.57	CHEMBL308	Homo sapiens	pKi		5.2
active	9648375	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCCC(=O)Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccccc3)cc12		CHEMBL2005936	=	Ki	nM	199.53	CHEMBL308	Homo sapiens	pKi		6.7
active	9648376	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC1CCC(Nc2nccc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1966628	=	Ki	nM	6.31	CHEMBL308	Homo sapiens	pKi		8.2
inactive	9648377	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc(C(N)=O)c3)cc2)c1		CHEMBL1971141	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648378	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC1CCCCC1Nc1nccc(-c2c[nH]c3ncccc23)n1		CHEMBL1995813	=	Ki	nM	158.49	CHEMBL308	Homo sapiens	pKi		6.8
inactive	9648379	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1c(C)n(Cc2ccccc2)c2ccc(C(=O)Nc3nc[nH]n3)cc12		CHEMBL1979718	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648380	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(COCc1ccccc1)COc1cncc(C=Cc2ccncc2)c1		CHEMBL1993781	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648381	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCn1c2cc(Cl)c(O)cc2c(=O)c2c(=O)o[nH]c21		CHEMBL523823	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648382	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(O)c1ccccc1Nc1ccnc(Nc2ccc3cn[nH]c3c2)n1		CHEMBL244378	=	Ki	nM	79.43	CHEMBL308	Homo sapiens	pKi		7.1
active	9648383	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cc(F)cc13)CN(C(=O)N1CCCCC1)CC2		CHEMBL362558	=	Ki	nM	794.33	CHEMBL308	Homo sapiens	pKi		6.1
inactive	9648384	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(OCC(F)(F)F)nccn23)n1		CHEMBL2001957	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648385	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COCCNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1969372	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648386	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1ncnn2ccc(C(=O)Nc3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1990583	=	Ki	nM	15.85	CHEMBL308	Homo sapiens	pKi		7.8
active	9648387	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	OC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1986943	=	Ki	nM	39.81	CHEMBL308	Homo sapiens	pKi		7.4
inactive	9648388	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1nc2ccc(NS(=O)(=O)c3ccc(N)cc3)cc2nc1C		CHEMBL2006263	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648389	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	OC(COc1cncc(C=Cc2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL1993584	=	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648390	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCn1c(C)c(-c2ccnc(Nc3cccc(OC)c3)n2)sc1=O		CHEMBL1986263	=	Ki	nM	19.95	CHEMBL308	Homo sapiens	pKi		7.7
active	9648391	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CSc1c[nH]c2ncnc(NCCCO)c12		CHEMBL2000114	=	Ki	nM	3981.07	CHEMBL308	Homo sapiens	pKi		5.4
inactive	9648392	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648393	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(Nc1cnccn1)Nc1ccnc2c(F)cccc12		CHEMBL1975647	=	Ki	nM	398.11	CHEMBL308	Homo sapiens	pKi		6.4
inactive	9648394	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCC1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL1968380	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648395	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(NCc1ccccc1)Nc1ncc([N+](=O)[O-])s1		CHEMBL1964644	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648396	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(NCc1ccc(Cl)c(Cl)c1)Nc1ccc2[nH]ncc2c1		CHEMBL1981782	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648397	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CNC(=O)c1cc2c(-c3ccccc3F)n[nH]c2s1		CHEMBL1977681	=	Ki	nM	1995.26	CHEMBL308	Homo sapiens	pKi		5.7
inactive	9648398	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CNC(=O)C(C)n1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5ccc(C)cc5)cc4)csc23)cn1		CHEMBL1970142	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648399	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648400	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	OCCNc1cc2cc(-c3cccnc3)ccc2cn1		CHEMBL1990912	=	Ki	nM	501.19	CHEMBL308	Homo sapiens	pKi		6.3
inactive	9648401	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648402	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NS(=O)(=O)c1cccc(Nc2ncc3ccn(-c4ccccc4)c3n2)c1		CHEMBL1988163	=	Ki	nM	50.12	CHEMBL308	Homo sapiens	pKi		7.3
active	9648403	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cc(O)ccc1-n1c2cc(Cl)ccc2c(=O)c2c(N)nc(N)nc21		CHEMBL1995592	=	Ki	nM	630.96	CHEMBL308	Homo sapiens	pKi		6.2
active	9648404	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3I)cc12		CHEMBL1975128	=	Ki	nM	31.62	CHEMBL308	Homo sapiens	pKi		7.5
inactive	9648405	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C1CCCc2oc3cc(C(F)(F)F)ccc3c(=O)c21		CHEMBL2006493	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648406	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1ccc(OC)c(CNC(=O)c2cc(N)c(C#N)c(OC(C)C)n2)c1		CHEMBL1982541	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648407	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Clc1cc2nn[nH]c2cc1Cl		CHEMBL1996923	=	Ki	nM	316.23	CHEMBL308	Homo sapiens	pKi		6.5
inactive	9648408	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1ccc(CNc2c(Nc3ccncc3)c(=O)c2=O)cc1C		CHEMBL1983449	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648409	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=c1[nH]cnc2c1oc1ccc(Cl)cc12		CHEMBL1992323	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648410	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(Cl)nccn23)n1		CHEMBL1969735	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648411	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCc1nc2c(c3cc(OC)c(OC)cc13)C(=O)NC2=O		CHEMBL2003524	=	Ki	nM	3162.28	CHEMBL308	Homo sapiens	pKi		5.5
active	9648412	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1ccc2c(c1)C(=Cc1c[nH]cn1)C(=O)N2		CHEMBL2002649	=	Ki	nM	316.23	CHEMBL308	Homo sapiens	pKi		6.5
active	9648413	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCCn1c(C2CCNCC2)nc(-c2ccc(Cl)c(Cl)c2)c1-c1ccnc(NC2CCCCC2)n1		CHEMBL437747	=	Ki	nM	1000.0	CHEMBL308	Homo sapiens	pKi		6.0
inactive	9648414	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Brc1ccc2c(c1)-c1[nH]ncc1C2		CHEMBL1995172	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648415	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(NC(=O)Nc2ccc(-c3ccc4nccnc4c3N)cc2)c1		CHEMBL507936	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648416	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=S(=O)(NCCNCC=Cc1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL1987756	=	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648417	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCNS(C)(=O)=O)cnc(N)c34)cc2)c1		CHEMBL1994321	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648418	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C1NCCc2[nH]c(-c3ccnc(C=Cc4ccccc4)c3)cc21		CHEMBL1997129	=	Ki	nM	251.19	CHEMBL308	Homo sapiens	pKi		6.6
active	9648419	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4cccc(Cl)c4)c3)cc12		CHEMBL1974870	=	Ki	nM	39.81	CHEMBL308	Homo sapiens	pKi		7.4
inactive	9648420	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(=O)c1cc(Cl)cc2[nH]c(-c3ccc(C4CCCNC4)cc3F)nc12		CHEMBL1984788	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648421	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	FC(F)(F)c1ccc(-c2nnc3ccc(NC4CC4)nn23)cc1		CHEMBL451964	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648422	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(NC(=O)Cc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL1964307	=	Ki	nM	6309.57	CHEMBL308	Homo sapiens	pKi		5.2
inactive	9648423	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Fc1ccc(-c2nc3sccn3c2-c2ccncc2)cc1		CHEMBL2000508	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648424	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCCCNc1n[s+]([O-])nc1Nc1ccc(F)cc1		CHEMBL1971694	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648425	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL2001547	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648426	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1Cl		CHEMBL210928	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648427	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1ccc(-c2cncc(OCC(N)Cc3c[nH]c4ccccc34)c2)cc1C(=O)c1ccccc1F		CHEMBL1994361	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648428	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cc(NC(=O)CCNC(=O)Nc2nc(C)c(-c3ccc(-n4cccn4)cc3)s2)no1		CHEMBL1986603	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648429	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648430	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(COc1cncc(-c2cc3cnccc3s2)c1)Cc1c[nH]c2ccccc12		CHEMBL1972840	=	Ki	nM	2511.89	CHEMBL308	Homo sapiens	pKi		5.6
inactive	9648431	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CCO)c5)cnc(N)c34)cc2)cc1		CHEMBL1977148	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648432	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cc(C=C2SC(=O)NC2=O)ccc1O		CHEMBL2003286	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648433	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)ccn1		CHEMBL1992306	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648434	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(O)Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL2002165	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648435	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=c1[nH]cc(I)c2nc(-c3ccccc3)cn12		CHEMBL2001668	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648436	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1n[nH]c2c1C(c1ccccc1I)C(C#N)=C(N)O2		CHEMBL1979318	=	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648437	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NCCOc1cncc(C=Cc2ccncc2)c1		CHEMBL1989518	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648438	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1ncnc2scc(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL1998585	=	Ki	nM	6309.57	CHEMBL308	Homo sapiens	pKi		5.2
inactive	9648439	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cn1cncc1C(OCc1c(-c2ccc(OC(F)(F)F)cc2)cc(C#N)c(=O)n1C)c1ccc(C#N)cc1		CHEMBL127898	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648440	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CN(C(=O)C1CCCCC1)c1ccc2c(c1)nc(NC(=O)c1ccc(C#N)cc1)n2C		CHEMBL519697	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648441	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)c(F)c2)c1		CHEMBL2004934	=	Ki	nM	3162.28	CHEMBL308	Homo sapiens	pKi		5.5
active	9648442	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3I)cc12		CHEMBL1975128	=	Ki	nM	31.62	CHEMBL308	Homo sapiens	pKi		7.5
inactive	9648443	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(=O)C1CCCN(C(=O)c2cc(-c3ccc4[nH]ncc4c3)on2)C1		CHEMBL1970369	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648444	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C(C)C(=O)N(C)C)c5)cnc(N)c34)cc2)cc1		CHEMBL2001485	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648445	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648446	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CN(C)CCCOc1cc2c(c(-c3ccc(Nc4nc5ccccc5o4)cc3)c1)CNC2=O		CHEMBL1966425	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648447	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cc(NC(=O)Cc2ccc(-c3cccc4[nH]nc(N)c34)cc2)ccc1F		CHEMBL1984363	=	Ki	nM	3981.07	CHEMBL308	Homo sapiens	pKi		5.4
active	9648448	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CNC(=O)COc1ccc(Nc2nc(Nc3ccc(C)c(S(N)(=O)=O)c3)ncc2F)cc1		CHEMBL1978099	=	Ki	nM	501.19	CHEMBL308	Homo sapiens	pKi		6.3
active	9648449	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(=O)c1cccc2c1Nc1nnc(Cl)cc1C(=O)N2		CHEMBL1968070	=	Ki	nM	1584.89	CHEMBL308	Homo sapiens	pKi		5.8
active	9648450	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(=O)Nc1cccc(CNc2c(Nc3ccc4[nH]ncc4c3)c(=O)c2=O)c1		CHEMBL1988608	=	Ki	nM	501.19	CHEMBL308	Homo sapiens	pKi		6.3
inactive	9648451	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1ccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2)cc1C		CHEMBL184847	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648452	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CN(C)c1ccc(CNC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)cc1		CHEMBL1984367	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648453	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cccc13)CN(C(=O)N1CCOCC1)CC2		CHEMBL178737	=	Ki	nM	1000.0	CHEMBL308	Homo sapiens	pKi		6.0
active	9648454	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1n[nH]c2cnc(-c3cncc(OCC(N)Cc4cccc(C(F)(F)F)c4)c3)cc12		CHEMBL1998159	=	Ki	nM	31.62	CHEMBL308	Homo sapiens	pKi		7.5
inactive	9648455	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COCC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(C)nccn23)n1		CHEMBL1982563	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648456	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C1CCCN1Cc1ccc2c(c1)[nH]c(=O)c1cccn12		CHEMBL539474	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648457	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(COc1cncc(-c2ccc3[nH]c(=O)oc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL1987679	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648458	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5ccc(OC(F)F)cc5)cc4)csc23)cn1		CHEMBL1988387	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648459	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cccc(NC(=O)c2cnn3c(-c4ccccc4)ccnc23)c1		CHEMBL1997759	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648460	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(CNC(=O)c2cnn3c(-c4ccccc4)ccnc23)c1C		CHEMBL1994968	=	Ki	nM	2511.89	CHEMBL308	Homo sapiens	pKi		5.6
inactive	9648461	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)O)c5)cnc(N)c34)cc2)c1		CHEMBL1989708	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648462	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(Nc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1)c1ccccc1		CHEMBL1990288	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648463	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=c1[nH]c2cc(Cl)cc(Cl)c2c(-c2cc(Cl)ccc2O)c1O		CHEMBL1974803	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648464	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL1970074	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648465	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COCCN(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1986970	=	Ki	nM	501.19	CHEMBL308	Homo sapiens	pKi		6.3
inactive	9648466	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC1=NN(c2cccc(Br)c2)C(=O)C1=Cc1c(C)c(C#N)c2nc3ccccc3n2c1O		CHEMBL2005112	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648467	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=c1cc(-c2ccncc2)nc(NC2CCCCC2)[nH]1		CHEMBL1958401	=	Ki	nM	630.96	CHEMBL308	Homo sapiens	pKi		6.2
inactive	9648468	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCN(CC)CCOc1ccc(-c2nc3c(C(N)=O)cccc3[nH]2)cc1		CHEMBL1984044	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648469	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=c1[nH]c2cc(-c3ccccc3)cnc2[nH]1		CHEMBL2003456	=	Ki	nM	5011.87	CHEMBL308	Homo sapiens	pKi		5.3
active	9648470	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(F)cccc12		CHEMBL1966816	=	Ki	nM	125.89	CHEMBL308	Homo sapiens	pKi		6.9
active	9648471	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(=O)N1CCN(C2CCC(n3nc(-c4ccc(NC(=O)c5cc6ccccc6n5C)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL1972584	=	Ki	nM	1584.89	CHEMBL308	Homo sapiens	pKi		5.8
active	9648472	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(N)C1CCC(C(=O)Nc2ccnc3[nH]ccc23)CC1		CHEMBL2002992	=	Ki	nM	630.96	CHEMBL308	Homo sapiens	pKi		6.2
inactive	9648473	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	N#Cc1cnc(NC(=O)Nc2ccc3cc(C(=O)O)ccc3c2)cn1		CHEMBL560813	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648474	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCCOn1c2ccc(Cl)cc2c(=O)c2c(C)nn(C)c21		CHEMBL207253	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648475	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(=NNC(=O)c1nnn(-c2nonc2N)c1-c1ccccc1)c1ccco1		CHEMBL1890036	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648476	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1c(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc2n1C1CC(CN2CCCC2)C1		CHEMBL1968791	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648477	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C1CC(c2ccc(Cl)cc2Cl)Cc2nc3cc(Cl)ccc3c(O)c21		CHEMBL326282	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648478	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(Cl)c1-c1cccc2c(CCCOc3cccc4ccccc34)c(C(=O)NCCOCCOCCN)[nH]c12		CHEMBL2002682	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648479	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCOc1ccccc1C=NNC(=O)c1nnn(-c2nonc2N)c1N1CCCC1		CHEMBL1992732	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648480	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Fc1ccc(-c2nc3occn3c2-c2ccnc(NC3CCNCC3)n2)cc1		CHEMBL1971186	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648481	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(Cc1ccc(Cl)cc1)Nc1[nH]nc2c1CCC2		CHEMBL2003482	=	Ki	nM	1000.0	CHEMBL308	Homo sapiens	pKi		6.0
inactive	9648482	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN5CCCC5)cnc(N)c34)cc2)c1		CHEMBL1973211	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648483	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)Oc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1984700	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648484	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648485	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1c(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc2n1C1CCC(N2CCCC2)CC1		CHEMBL2007151	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648486	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1ccc(-c2cncc(OCC(N)Cc3c[nH]c4ccccc34)c2)cc1C(=O)c1ccccc1		CHEMBL1972125	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648487	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(Nc1ccc2[nH]ncc2c1)c1cccc(F)c1		CHEMBL1461728	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648488	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648489	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	c1cc2cc(-c3ccc4cn[nH]c4c3)cnc2[nH]1		CHEMBL1976134	=	Ki	nM	316.23	CHEMBL308	Homo sapiens	pKi		6.5
active	9648490	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1ccc(C(=O)Nc2c(C(N)=O)sc3ccc(Cl)c(Cl)c23)cc1		CHEMBL1965131	=	Ki	nM	1000.0	CHEMBL308	Homo sapiens	pKi		6.0
inactive	9648491	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NCCOc1cccc(Nc2ccnc(N)n2)c1		CHEMBL1995448	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648492	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccccc3)cc12		CHEMBL1972158	=	Ki	nM	316.23	CHEMBL308	Homo sapiens	pKi		6.5
active	9648493	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(O)c1cc2c(-c3cccc(F)c3)cncc2s1		CHEMBL1974457	=	Ki	nM	3162.28	CHEMBL308	Homo sapiens	pKi		5.5
active	9648494	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1		CHEMBL482767	=	Ki	nM	6309.57	CHEMBL308	Homo sapiens	pKi		5.2
active	9648495	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Oc1ccc(Nc2ncnc3scc(Cl)c23)cc1		CHEMBL2006580	=	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648496	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCOc1nc(C(=O)NCc2ccccc2S(N)(=O)=O)cc(N)c1Cl		CHEMBL2006581	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648497	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(c1cc(-c2ccc3[nH]ncc3c2)on1)N1CCCCC1		CHEMBL2006481	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648498	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCC#N)c2)n1		CHEMBL1979855	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648499	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1noc2cccc(-c3cccc(O)c3)c12		CHEMBL1970340	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648500	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)NC(=O)COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1		CHEMBL2005186	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648501	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCNc1nc2cc(Cl)c(OC)cc2nc1NCC		CHEMBL1995927	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648502	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NCC(O)C(O)Cn1cc(I)c2c(N)ncnc21		CHEMBL1975534	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648503	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NS(=O)(=O)c1cccc(Nc2ncc3ccn(Cc4ccccc4)c3n2)c1		CHEMBL1993424	=	Ki	nM	199.53	CHEMBL308	Homo sapiens	pKi		6.7
active	9648504	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1n[nH]c2c1C(c1ccccc1F)C1=C(CC(C)(C)CC1=O)N2		CHEMBL1966703	=	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648505	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)N(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1969561	=	Ki	nM	100.0	CHEMBL308	Homo sapiens	pKi		7.0
active	9648506	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(NCc1ccccc1)c1cccc(-c2cnc3[nH]ccc3c2)c1		CHEMBL1972142	=	Ki	nM	1995.26	CHEMBL308	Homo sapiens	pKi		5.7
active	9648507	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL1975121	=	Ki	nM	3162.28	CHEMBL308	Homo sapiens	pKi		5.5
inactive	9648508	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CN(C)c1cc2sncc2cc1NC(=O)C(=O)O		CHEMBL1997023	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648509	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cc(C)cc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1964687	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648510	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943	=	Ki	nM	6309.57	CHEMBL308	Homo sapiens	pKi		5.2
active	9648511	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(=O)c1cc2c(-c3ccc(Br)c(F)c3F)cncc2s1		CHEMBL1999918	=	Ki	nM	251.19	CHEMBL308	Homo sapiens	pKi		6.6
inactive	9648512	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCOc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)cc1		CHEMBL1974254	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648513	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1ccc(C(=O)N2c3ccccc3Sc3c(Cl)cncc32)cc1		CHEMBL1988537	=	Ki	nM	794.33	CHEMBL308	Homo sapiens	pKi		6.1
inactive	9648514	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)c(C)c2)c1		CHEMBL1969049	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648515	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1ccc(NC(=O)Nc2ccc(-c3coc4ncnc(N)c34)cc2)cc1		CHEMBL2005828	=	Ki	nM	5011.87	CHEMBL308	Homo sapiens	pKi		5.3
inactive	9648516	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(=O)Nc1cc(N)c(C#N)c(-c2ccc3ccccc3c2)n1		CHEMBL2002240	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648517	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCc1nc(-c2cccc(C)c2)c(-c2ccnc(NC(=O)c3ccccc3)c2)s1		CHEMBL363648	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648518	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1ccc(-n2nc(C)c3c(=O)c4cc(Cl)ccc4n(O)c32)cc1		CHEMBL1991143	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648519	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648520	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(=O)c1sc2c(Br)ccc(Cl)c2c1N		CHEMBL1998611	=	Ki	nM	501.19	CHEMBL308	Homo sapiens	pKi		6.3
inactive	9648521	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CN(C(=O)C1CCCCC1)c1ccc2c(c1)nc(NC(=O)c1ccc(C#N)cc1)n2CCC(N)=O		CHEMBL485556	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648522	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=c1c(NCc2ccc(Cl)c(Cl)c2)c(Nc2ccncc2)c1=O		CHEMBL1975900	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648523	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cc(C=C2SC(=S)NC2=O)ccc1O		CHEMBL1973098	=	Ki	nM	3981.07	CHEMBL308	Homo sapiens	pKi		5.4
active	9648524	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(NC(=O)CC)c3c2)cc1		CHEMBL1972221	=	Ki	nM	158.49	CHEMBL308	Homo sapiens	pKi		6.8
inactive	9648525	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CNC(=O)C=Cc1cnc(N)c2c(-c3cc(F)c4[nH]c(C)cc4c3)csc12		CHEMBL2006778	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648526	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cc(S(C)(=O)=O)c(OC)cc1CC(=O)Nc1cc(N)c(C#N)c(OC(C)C)n1		CHEMBL378627	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648527	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1c(F)cccc1F		CHEMBL1996979	=	Ki	nM	3981.07	CHEMBL308	Homo sapiens	pKi		5.4
inactive	9648528	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(=O)c1cccc2[nH]c(-c3ccc(C4CCCNC4)cc3F)nc12		CHEMBL1997025	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648529	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCc1cccc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1968406	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648530	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)csc12		CHEMBL1982476	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648531	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C1C(=NNc2cccc3c(=O)[nH][nH]c(=O)c23)C(c2ccccc2)=NN1c1ccccc1		CHEMBL1984274	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648532	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(NC(CO)Cc1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1998545	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648533	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1csc(NC(=O)c2sc3nc(-c4ccncc4)ccc3c2N)n1		CHEMBL1986869	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648534	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(Cl)c(Cl)ccc12		CHEMBL2006010	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648535	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Fc1ccc(-c2ncn(CCN3CCOCC3)c2-c2ccc3[nH]ncc3c2)cc1		CHEMBL1682558	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648536	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cn1c(NCC(N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O		CHEMBL1990496	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648537	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CS(=O)(=O)Nc1ccccc1-c1ccc2c(c1)Nc1ccccc1NC2=O		CHEMBL1975937	=	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648538	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1n[nH]c2cc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)ccc12		CHEMBL1997623	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648539	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NCCCOc1cc2c(c(-c3ccc(Nc4nc5ccc(Cl)cc5o4)cc3)c1)CNC2=O		CHEMBL2002479	=	Ki	nM	5011.87	CHEMBL308	Homo sapiens	pKi		5.3
active	9648540	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1c(NC2CCC(N)CC2)nc2ccnn2c1Nc1ccc(F)c(Cl)c1		CHEMBL1980371	=	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648541	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(=NNC(=N)N)c1cc(NC(=O)NCCCN(C)CCCNC(=O)Nc2cc(C(C)=NNC(=N)N)cc(C(C)=NNC(=N)N)c2)cc(C(C)=NNC(=N)N)c1		CHEMBL1993166	=	Ki	nM	1258.93	CHEMBL308	Homo sapiens	pKi		5.9
inactive	9648542	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(NCc1ccc(Cl)cc1)c1cc2c(-c3ccccc3)n[nH]c2s1		CHEMBL1967094	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648543	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(Nc1c(Nc2ccncc2)c(=O)c1=O)c1ccccc1		CHEMBL1966035	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9648544	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(NC(CO)c1cc(Cl)cc(Cl)c1)c1ccc(-c2ccncc2)cc1		CHEMBL2003341	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648545	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	c1ccc(-c2n[nH]cc2-c2ccncc2)cc1		CHEMBL1992644	=	Ki	nM	10000.0	CHEMBL308	Homo sapiens	pKi		5.0
inactive	9648546	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(NS(=O)(=O)c1ccc(NCCSc2ccc(O)cc2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(F)cc2)cc1		CHEMBL1992645	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9648547	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Oc1cccc(Nc2ncnc3scc(Cl)c23)c1		CHEMBL1982992	=	Ki	nM	5011.87	CHEMBL308	Homo sapiens	pKi		5.3
inactive	9652566	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(Nc1ccc(CO)cc1)c1cnn2c(-c3ccccc3)ccnc12		CHEMBL1974363	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652567	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cc(-c2ccccc2)n(-c2cc(NN=Cc3ccco3)ncn2)n1		CHEMBL1999590	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652568	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1F		CHEMBL1981079	=	Ki	nM	251.19	CHEMBL308	Homo sapiens	pKi		6.6
inactive	9652569	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCN(CC)CCCNc1cccc(-c2nc3c(C(N)=O)cccc3[nH]2)n1		CHEMBL1972276	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652570	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=c1c(NCc2ccc(Cl)cc2)c(Nc2ccncc2)c1=O		CHEMBL1980489	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652571	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCc4cccc(F)c4)cc2NC3=O)ccc1O		CHEMBL2000832	=	Ki	nM	79.43	CHEMBL308	Homo sapiens	pKi		7.1
inactive	9652572	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)c1		CHEMBL1967116	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652573	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1nn(C)c2c1c(=O)c1cc(Cl)ccc1n2OCC(C)C		CHEMBL1977814	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652574	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1nc2ccccn2c1-c1csc(Nc2ccc(O)cc2)n1		CHEMBL513846	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652575	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(NCc1ccc(Br)cc1)Nc1ccc2[nH]ncc2c1		CHEMBL1970709	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652576	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1Cl		CHEMBL1965660	=	Ki	nM	63.1	CHEMBL308	Homo sapiens	pKi		7.2
inactive	9652577	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1ccc(-c2cc3nccn3c(Nc3ccccc3C(N)=O)n2)cc1OC		CHEMBL1998112	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652578	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)n1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)cc21		CHEMBL1969126	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652579	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1ncnc2sc(Br)c(-c3ccc(NC(=O)Cc4cccc(Cl)c4)cc3)c12		CHEMBL1980896	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652580	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(=O)NC1CCN(c2nc3[nH]cc(C(=O)O)c(=O)c3c(C)c2F)C1		CHEMBL1975208	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652581	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)(C)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1		CHEMBL1970104	=	Ki	nM	398.11	CHEMBL308	Homo sapiens	pKi		6.4
inactive	9652582	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCCC4=O)c3)n2)c1		CHEMBL1991429	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652583	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(=O)c1cc2c(Oc3cccc(F)c3)cncc2s1		CHEMBL1964777	=	Ki	nM	3162.28	CHEMBL308	Homo sapiens	pKi		5.5
inactive	9652584	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)C(=O)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1971149	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652585	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1ccc2c(c1)NC(=O)c1ccccc1N2		CHEMBL1999714	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652586	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(Cc1ccccc1Cl)Nc1ccc2cn[nH]c2c1		CHEMBL1987533	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652587	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)(O)CNc1nccc(-c2c(-c3ccc(F)cc3F)nc3c(CC4CC4)nccn23)n1		CHEMBL1994040	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652588	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CNC1CC2OC(C)(C1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL1980995	=	Ki	nM	3.981	CHEMBL308	Homo sapiens	pKi		8.4
active	9652589	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(COc1cncc(-c2ccc3c(c2)CC(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL1967302	=	Ki	nM	5011.87	CHEMBL308	Homo sapiens	pKi		5.3
active	9652590	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cc2cnc3c(c2cc1OC)C(=O)NC3=O		CHEMBL1982506	=	Ki	nM	2511.89	CHEMBL308	Homo sapiens	pKi		5.6
inactive	9652591	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCN(CC)CCNC(=O)C=Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL2004716	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652592	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CN(C)CC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1		CHEMBL1968127	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652593	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cc(C)c(Cl)cc1NC(=O)Nc1cnc(C#N)cn1		CHEMBL1975233	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652594	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCCC(=O)Nc1n[nH]c2ccc(-c3cccc(F)c3F)cc12		CHEMBL1985406	=	Ki	nM	39.81	CHEMBL308	Homo sapiens	pKi		7.4
inactive	9652595	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cn1nc(C(F)(F)F)c2c(=O)c3cc(Cl)ccc3n(O)c21		CHEMBL207400	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652596	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cc(O)ccc1-n1cc(C(=O)NN)c(=O)c2ccc(-c3ccncc3)cc21		CHEMBL2000894	=	Ki	nM	1584.89	CHEMBL308	Homo sapiens	pKi		5.8
inactive	9652597	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1nsc2[nH]cc(C(=O)O)c(=O)c12		CHEMBL2002553	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652598	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1ccccc1NC(=O)Nc1ccc2c(c1)CCc1sc3ncnc(N)c3c1-2		CHEMBL1982135	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652599	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1ncnc2c1sc1ncnc(N)c12		CHEMBL1976090	=	Ki	nM	2511.89	CHEMBL308	Homo sapiens	pKi		5.6
inactive	9652600	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CNC(=O)C=Cc1cnc(N)c2c(-c3ccc4c(c3)OCO4)csc12		CHEMBL1993243	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652601	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	OCC(CO)Nc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL1992922	=	Ki	nM	398.11	CHEMBL308	Homo sapiens	pKi		6.4
inactive	9652602	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C1NCc2c1cccc2-c1ccc(Nc2nc3ccccc3o2)cc1		CHEMBL2004771	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652603	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2C1CC(CN2CCCC2)C1		CHEMBL1988370	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652604	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL1997597	=	Ki	nM	3981.07	CHEMBL308	Homo sapiens	pKi		5.4
inactive	9652605	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	S=c1[nH]nc2c3c4c(sc3n3c(=S)[nH]nc3n12)CCC4		CHEMBL1969537	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652606	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CN(C)CC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1976093	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652607	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(=O)Nc1cc(N)c(C#N)c(-c2ccccc2)n1		CHEMBL210032	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652608	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1nonc1-n1nnc(C(=O)NN=Cc2cccs2)c1-c1cccs1		CHEMBL1975256	=	Ki	nM	3162.28	CHEMBL308	Homo sapiens	pKi		5.5
active	9652609	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(NC(=O)Nc2ccc(-c3cnc4c(-c5cnn(C)c5)cnn4c3N)cc2)c1		CHEMBL508928	=	Ki	nM	6309.57	CHEMBL308	Homo sapiens	pKi		5.2
inactive	9652610	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cccc(-c2cc3c(=O)[nH]c4ccccc4n3c2)c1		CHEMBL1991356	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652611	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1ccc(C(=O)Nc2nc3ccc(Cl)cc3s2)c(OC)c1		CHEMBL1983309	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652612	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL2004892	=	Ki	nM	2511.89	CHEMBL308	Homo sapiens	pKi		5.6
inactive	9652613	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC1=NN(c2ccccc2)C(=O)C1=Cc1c(C)c(C#N)c2nc3ccccc3n2c1O		CHEMBL1999126	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652614	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)Oc1ccc(-c2noc(-c3ccc(NC4CCC(C(=O)O)C4)cc3)n2)cc1Cl		CHEMBL1997503	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652615	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(=O)c1cc2c(Oc3ccc(Br)cc3)cncc2s1		CHEMBL116070	=	Ki	nM	1584.89	CHEMBL308	Homo sapiens	pKi		5.8
inactive	9652616	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cc(C)c(C)c(OCCCc2c(C(=O)O)[nH]c3c(-c4ccccc4C)cccc23)c1		CHEMBL1990821	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652617	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(=O)c1cc(-c2cccc(N)c2)cc2cccnc12		CHEMBL1970314	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652618	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	OCCCn1cnc(-c2ccc(F)cc2)c1-c1ccncc1		CHEMBL2004871	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652619	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncn3)cc2)c1		CHEMBL2004872	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652620	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C1Nc2ccccc2Nc2ccccc21		CHEMBL1727312	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652621	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC1CCN(C(=O)CO)CC1N(C)c1ncnc2[nH]ccc12		CHEMBL1969879	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652622	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(Nc1cnccn1)Nc1ccnc2ccccc12		CHEMBL1981720	=	Ki	nM	79.43	CHEMBL308	Homo sapiens	pKi		7.1
inactive	9652623	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(N)COc1cnc(Cl)c(C=Cc2ccncc2)c1		CHEMBL1993548	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652624	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3nsc4ncnc(N)c34)cc2)c1		CHEMBL262433	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652625	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1ccc(-c2nn(C(C)(C)C)c3ncnc(N)c23)cc1		CHEMBL306380	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652626	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(NNC(=S)Nc1ccc(Cl)cc1)C(O)(c1ccccc1)c1ccccc1		CHEMBL1966722	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652627	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCCNC(C)=O)cc2NC3=O)ccc1O		CHEMBL1975500	=	Ki	nM	251.19	CHEMBL308	Homo sapiens	pKi		6.6
inactive	9652628	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4snc(N)c34)cc2)c1		CHEMBL1976328	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652629	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4ccnc(N)c34)cc2)c1		CHEMBL394619	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652630	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1ccc(Nc2nccc(Nc3c(NC(C)C(C)(C)C)c(=O)c3=O)n2)cc1OC		CHEMBL1964399	=	Ki	nM	251.19	CHEMBL308	Homo sapiens	pKi		6.6
inactive	9652631	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(O)c1c2c(nc3ccccc13)C(=C1CCCC1)CC2		CHEMBL1996831	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652632	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1ncnc2c1N=C(c1ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc1)CCN2		CHEMBL411903	=	Ki	nM	2511.89	CHEMBL308	Homo sapiens	pKi		5.6
inactive	9652633	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN)cnc(N)c34)cc2)c1		CHEMBL1965988	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652634	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C(O)C1		CHEMBL422897	=	Ki	nM	31.62	CHEMBL308	Homo sapiens	pKi		7.5
active	9652635	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1c(-c2ccc3[nH]nc(N)c3c2)nnn1Cc1ccccc1		CHEMBL1989646	=	Ki	nM	398.11	CHEMBL308	Homo sapiens	pKi		6.4
active	9652636	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	c1ccc(Cc2cc(-c3ccc4[nH]ncc4c3)on2)cc1		CHEMBL1682357	=	Ki	nM	2511.89	CHEMBL308	Homo sapiens	pKi		5.6
active	9652637	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C1NCCc2[nH]c(-c3ccncc3)cc21		CHEMBL225519	=	Ki	nM	630.96	CHEMBL308	Homo sapiens	pKi		6.2
inactive	9652638	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCOc1nc(C(=O)NCc2cccnc2)cc(N)c1C#N		CHEMBL209534	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652639	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1nccn2c(-c3ccnc(NCCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1978200	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652640	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652641	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CN(C)S(=O)(=O)c1ccccc1-c1ccc2c(c1)Nc1ccccc1NC2=O		CHEMBL2006631	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652642	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cc(C=C2SC(=Nc3ccccc3)NC2=O)ccc1O		CHEMBL1970522	=	Ki	nM	6309.57	CHEMBL308	Homo sapiens	pKi		5.2
inactive	9652643	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)c1		CHEMBL402846	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652644	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(Nc1n[nH]c2nc3ccccc3cc12)c1ccncc1		CHEMBL1990415	=	Ki	nM	251.19	CHEMBL308	Homo sapiens	pKi		6.6
inactive	9652645	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cn1nc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)cncc21		CHEMBL1964692	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652646	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(NC(CO)Cc1ccc(Cl)cc1)c1ccc(-c2ccncc2)cc1		CHEMBL1996931	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652647	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	FC(F)(F)c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)c(C(F)(F)F)c1		CHEMBL1964413	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652648	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(C(F)(F)F)ccc12		CHEMBL1973483	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652649	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)c(C)c1		CHEMBL1984432	=	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652650	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCCOc1nc(NC(C)=O)cc(N)c1C#N		CHEMBL1970735	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652651	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4ccccc4)cc3)c12		CHEMBL219722	=	Ki	nM	3981.07	CHEMBL308	Homo sapiens	pKi		5.4
inactive	9652652	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(c1cc(-c2ccc3[nH]ncc3c2)on1)N1CCCC(O)C1		CHEMBL1997340	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652653	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCOC(=O)C1=C(N)n2c(sc(=Cc3cccs3)c2=O)=C(C(N)=O)C1c1cccs1		CHEMBL2004365	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652654	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cccc(Nc2ncnc3ccccc23)c1		CHEMBL117697	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652655	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL482967	=	Ki	nM	398.11	CHEMBL308	Homo sapiens	pKi		6.4
inactive	9652656	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cn1cc(-c2ccncn2)c(-c2ccc(F)cc2)n1		CHEMBL1989474	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652657	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)c1		CHEMBL1090360	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652658	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(Nc1nc2ccccc2n1CCCO)c1cccc([N+](=O)[O-])c1		CHEMBL210887	=	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652659	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997	=	Ki	nM	794.33	CHEMBL308	Homo sapiens	pKi		6.1
inactive	9652660	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)c(C(F)(F)F)c2)c1		CHEMBL1971021	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652661	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4cccc(OC(F)(F)F)c4)c3)cc12		CHEMBL1965836	=	Ki	nM	100.0	CHEMBL308	Homo sapiens	pKi		7.0
active	9652662	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=c1[nH]cnc2c1sc1c(Cl)ccc(Cl)c12		CHEMBL583144	=	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652663	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(=O)c1cc2c(-c3ccc(F)cc3)cncc2s1		CHEMBL1974310	=	Ki	nM	1258.93	CHEMBL308	Homo sapiens	pKi		5.9
active	9652664	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1ccc2c(NC(=O)Nc3cccc(C(F)(F)F)n3)ccnc2c1		CHEMBL1982660	=	Ki	nM	630.96	CHEMBL308	Homo sapiens	pKi		6.2
active	9652665	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1ncnc2sc3c(c12)-c1ccc(NC(=O)Nc2ccccc2)cc1CC3		CHEMBL1994693	=	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652666	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(=O)c1cccc(-c2cnc3[nH]cc(-c4ccccc4)c3c2)c1		CHEMBL1982957	=	Ki	nM	63.1	CHEMBL308	Homo sapiens	pKi		7.2
active	9652667	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Ki	nM	1000.0	CHEMBL308	Homo sapiens	pKi		6.0
inactive	9652668	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(NNC(=S)Nc1ccc(F)cc1)C(O)(c1ccccc1)c1ccccc1		CHEMBL1975138	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652669	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1C#N		CHEMBL424872	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652670	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC1=NN(c2ccc(C(=O)O)cc2)C(=O)C1=Cc1c(C)c(C#N)c2nc3ccccc3n2c1O		CHEMBL2006836	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652671	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#Cc5cccnc5)cnc(N)c34)cc2)c1		CHEMBL1971947	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652672	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1c[nH]c(-c2cnc(NCCNc3ccc(C#N)cn3)nc2-c2ccc(Cl)cc2Cl)n1		CHEMBL412142	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652673	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652674	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cc2nnc(SCc3cn4ccccc4n3)n2c2ccccc12		CHEMBL1980704	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652675	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(=O)c1sc2ccc(Cl)c(Cl)c2c1NC(=O)c1ccc(Cl)cc1		CHEMBL2003271	=	Ki	nM	1258.93	CHEMBL308	Homo sapiens	pKi		5.9
inactive	9652676	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=c1[nH]c2sc3c(c2c2nc(-c4ccncc4)nn12)CCCC3		CHEMBL1966808	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652677	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)(C)c1n[nH]c2c1C(c1ccccc1F)C(C#N)=C(N)O2		CHEMBL2004447	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652678	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12		CHEMBL1983111	=	Ki	nM	39.81	CHEMBL308	Homo sapiens	pKi		7.4
active	9652679	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	OCCNc1cc2cc(-c3ccsc3)ccc2cn1		CHEMBL1973860	=	Ki	nM	3981.07	CHEMBL308	Homo sapiens	pKi		5.4
inactive	9652680	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(NCc1ccc(Cl)cc1)Nc1cccc2[nH]ncc12		CHEMBL1977713	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652681	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1n[nH]c2nnc(-c3ccccc3)c(-c3ccccc3)c12		CHEMBL260135	=	Ki	nM	794.33	CHEMBL308	Homo sapiens	pKi		6.1
inactive	9652682	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21		CHEMBL220241	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652683	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=S(=O)(O)c1ccc(NCc2ccc3c(c2)OCO3)c2c(O)cccc12		CHEMBL2004544	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652684	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=c1[nH]cc(I)c2nc(-c3cccc(Cl)c3)cn12		CHEMBL1982610	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652685	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(C2(c3cccc(C)c3)CC2C(=O)Nc2ccncc2)c1		CHEMBL1999496	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652686	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CSc1cnc2c(ccc3cnccc32)c1O		CHEMBL2006933	=	Ki	nM	125.89	CHEMBL308	Homo sapiens	pKi		6.9
inactive	9652687	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1ccc(-c2csc3c(C=Cc4nc5ccccc5[nH]4)cnc(N)c23)cc1		CHEMBL1988300	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652688	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1ccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)cc1OC		CHEMBL1991078	=	Ki	nM	39.81	CHEMBL308	Homo sapiens	pKi		7.4
inactive	9652689	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652690	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCCCNc1ccc2c3c(cccc13)C(=O)N(CCNCCO)C2=O		CHEMBL1987359	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652691	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(=NNC(=N)N)c1cc(NC(=O)c2cccc(C(=O)Nc3cc(C(C)=NNC(=N)N)cc(C(C)=NNC(=N)N)c3)c2)cc(C(C)=NNC(=N)N)c1		CHEMBL2000685	=	Ki	nM	158.49	CHEMBL308	Homo sapiens	pKi		6.8
active	9652692	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	=	Ki	nM	1258.93	CHEMBL308	Homo sapiens	pKi		5.9
active	9652693	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cc(CO)ccc4F)cc3)c12		CHEMBL1985311	=	Ki	nM	6309.57	CHEMBL308	Homo sapiens	pKi		5.2
inactive	9652694	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC1CSc2c(C(=O)O)c(=O)c3cc(F)c(N4CCC(N)C4)cc3n21		CHEMBL1989265	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652695	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1Cl		CHEMBL1965660	=	Ki	nM	63.1	CHEMBL308	Homo sapiens	pKi		7.2
inactive	9652696	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CNC1CCN(c2nc3[nH]cc(C(=O)O)c(=O)c3c(C)c2Br)C1		CHEMBL2004647	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652697	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C1NN=Cc2c[nH]c3cc(NC(=O)C4CC4c4ccccc4)cc1c23		CHEMBL1969502	=	Ki	nM	1000.0	CHEMBL308	Homo sapiens	pKi		6.0
inactive	9652698	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2C1CCC(N2CCCC2)CC1		CHEMBL1965910	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652699	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)Nc1c(-c2ccc3[nH]ncc3c2)nc2ncccn12		CHEMBL1682553	=	Ki	nM	1000.0	CHEMBL308	Homo sapiens	pKi		6.0
inactive	9652700	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(-c2c(-c3ccncc3)nc(NCC(N)Cc3ccccc3)n(C)c2=O)c1		CHEMBL1971430	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652701	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1ccc(C(=O)Nc2cnc3[nH]cc(-c4ccccc4)c3c2)cc1		CHEMBL1997764	=	Ki	nM	5011.87	CHEMBL308	Homo sapiens	pKi		5.3
inactive	9652702	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(NC(=O)Nc2ccc(-c3coc4ncnc(N)c34)cc2)c1		CHEMBL1983963	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652703	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1n[nH]c2ccc(-c3cncc(OCC(CN)Cc4ccccc4)c3)cc12		CHEMBL2000271	=	Ki	nM	316.23	CHEMBL308	Homo sapiens	pKi		6.5
inactive	9652704	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Oc1ccc(-c2n[nH]c(Nc3cccc(Cl)c3)c2-c2ccc(O)cc2)cc1		CHEMBL1985092	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652705	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1nonc1-n1nnc(C(=O)NN=Cc2cccs2)c1-c1ccccc1		CHEMBL2004692	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652706	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CNc1ncnc2c1N=C(c1ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc1)CCN2		CHEMBL1981410	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652707	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC1(O)CC(c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn23)C1		CHEMBL1996234	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652708	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1ccc(C=C2C(=O)ON=C2c2ccc(Br)cc2)cc1OC		CHEMBL1991434	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652709	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CN(C)c1cccc2c(S(=O)(=O)N(CCN)c3cncc(-c4ccc5cnccc5c4)c3)cccc12		CHEMBL1967544	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652710	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	N#Cc1ncc2nc1OCCCCCOc1cc(CCCO)c(Cl)cc1NC(=O)N2		CHEMBL223367	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652711	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C(O)C1		CHEMBL422897	=	Ki	nM	31.62	CHEMBL308	Homo sapiens	pKi		7.5
active	9652712	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(=O)c1cn(-c2ccc(O)cc2Cl)c2cc(-c3ccncc3)ccc2c1=O		CHEMBL340384	=	Ki	nM	630.96	CHEMBL308	Homo sapiens	pKi		6.2
inactive	9652713	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)(CO)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4n3CCC4)nn12		CHEMBL1996587	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652714	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CS(=O)(=O)NCCOc1cncc(-c2ccc3cnccc3c2)c1		CHEMBL1964804	=	Ki	nM	501.19	CHEMBL308	Homo sapiens	pKi		6.3
active	9652715	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1ccc(-c2cnc3c(Br)cnn3c2)cc1		CHEMBL443962	=	Ki	nM	251.19	CHEMBL308	Homo sapiens	pKi		6.6
active	9652716	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1ccc(C=C2SC(=Nc3ccccc3)NC2=O)cc1O		CHEMBL2000354	=	Ki	nM	6309.57	CHEMBL308	Homo sapiens	pKi		5.2
active	9652717	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)c1		CHEMBL1965507	=	Ki	nM	31.62	CHEMBL308	Homo sapiens	pKi		7.5
inactive	9652718	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cn1ncc2c1CCCC2=O		CHEMBL1981107	<	Ki	nM	19952.62	CHEMBL308	Homo sapiens	pKi		4.7
inactive	9652719	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652720	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCCC(=O)Nc1n[nH]c2nc3ccccc3cc12		CHEMBL1967564	=	Ki	nM	1000.0	CHEMBL308	Homo sapiens	pKi		6.0
active	9652721	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NCCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL592030	=	Ki	nM	31.62	CHEMBL308	Homo sapiens	pKi		7.5
active	9652722	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	OCCCNc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL2000071	=	Ki	nM	1000.0	CHEMBL308	Homo sapiens	pKi		6.0
inactive	9652723	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1ccc2c(NC(=O)Nc3cc(C(F)(F)F)ccn3)ccnc2c1		CHEMBL1979176	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652724	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1970317	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652725	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc2c(C)n1		CHEMBL2000408	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652726	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	N#Cc1ncc2nc1OCCCCOc1cc(NCc3cncs3)c(Cl)cc1NC(=O)N2		CHEMBL248757	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652727	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CN1CCC(C(=O)n2nc(N)c3cc(-c4cn(Cc5ccccc5)nn4)ccc32)CC1		CHEMBL1978014	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652728	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(Nc1cnccn1)Nc1ccnc2c(C(F)(F)F)cccc12		CHEMBL1994538	=	Ki	nM	1584.89	CHEMBL308	Homo sapiens	pKi		5.8
inactive	9652729	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCN(CC)C(=O)Nc1ccc2nc(-c3ccco3)c(-c3ccco3)nc2c1		CHEMBL1983195	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652730	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NCCCOc1cc2c(c(-c3ccc(Nc4nc5ccccc5o4)cc3)c1)CNC2=O		CHEMBL1975490	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652731	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL1964444	=	Ki	nM	501.19	CHEMBL308	Homo sapiens	pKi		6.3
inactive	9652732	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	OCCNc1cc2cc(-c3ccccc3)ccc2cn1		CHEMBL1989957	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652733	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(=O)Nc1cc(N)c(C#N)c(-c2ccsc2)n1		CHEMBL2006567	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652734	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Clc1csc2ncnc(Nc3ccccc3)c12		CHEMBL1986139	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652735	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(Cc1cccc2ccccc12)C(=O)Nc1cncc(C=Cc2ccncc2)c1		CHEMBL1985580	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652736	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(Cl)cccc12		CHEMBL1980540	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652737	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN(C)C)cnc(N)c34)cc2)c1		CHEMBL1979883	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652738	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COCCOC1CCC(n2nc(-c3ccc(Nc4nc5cc(C)cc(C)c5o4)cc3)c3c(N)ncnc32)CC1		CHEMBL1984162	=	Ki	nM	398.11	CHEMBL308	Homo sapiens	pKi		6.4
active	9652739	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Fc1cnc(Nc2ccccc2)nc1Nc1ccccc1		CHEMBL491758	=	Ki	nM	630.96	CHEMBL308	Homo sapiens	pKi		6.2
active	9652740	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCO)nc21		CHEMBL86066	=	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652741	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(Nc1c(Nc2ccncc2)c(=O)c1=O)C(C)(C)C		CHEMBL1986186	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652742	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	c1cc2[nH]ncc2cc1-c1cc(CN2CCCCC2)no1		CHEMBL1682360	=	Ki	nM	5011.87	CHEMBL308	Homo sapiens	pKi		5.3
active	9652743	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1n[nH]c2c1C(c1ccccc1Cl)C(C#N)=C(N)O2		CHEMBL1970189	=	Ki	nM	6309.57	CHEMBL308	Homo sapiens	pKi		5.2
active	9652744	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1ncnc2c1c(I)nn2C1CCC(O)CC1		CHEMBL1996791	=	Ki	nM	1995.26	CHEMBL308	Homo sapiens	pKi		5.7
active	9652745	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3c(C)sc4ncnc(N)c34)cc2)c1		CHEMBL371206	=	Ki	nM	6309.57	CHEMBL308	Homo sapiens	pKi		5.2
active	9652746	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1ccc(C=NNc2ncnc3c2[nH]c2ccccc23)cc1OC		CHEMBL1974664	=	Ki	nM	501.19	CHEMBL308	Homo sapiens	pKi		6.3
active	9652747	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)(C)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1		CHEMBL1970104	=	Ki	nM	398.11	CHEMBL308	Homo sapiens	pKi		6.4
active	9652748	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(NC(CO)c1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1974288	=	Ki	nM	5011.87	CHEMBL308	Homo sapiens	pKi		5.3
inactive	9652749	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4ncnc(N)c34)cc2)c1		CHEMBL196363	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652750	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1ccc(-c2cc3nccn3c(Nc3ncccc3C(N)=O)n2)cc1OC		CHEMBL1190711	=	Ki	nM	501.19	CHEMBL308	Homo sapiens	pKi		6.3
active	9652751	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1n[nH]c2cccc(-c3ccc(Br)cc3)c12		CHEMBL1990346	=	Ki	nM	3981.07	CHEMBL308	Homo sapiens	pKi		5.4
inactive	9652752	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCCC4)ccc3n2)c1		CHEMBL1968705	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652753	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)c1		CHEMBL404367	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652754	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)Cc1cc(-c2ccc3[nH]nc(N)c3c2)on1		CHEMBL1966343	=	Ki	nM	251.19	CHEMBL308	Homo sapiens	pKi		6.6
active	9652755	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1n[nH]c2ccc(-c3cncc(OCCN)c3)cc12		CHEMBL1967887	=	Ki	nM	630.96	CHEMBL308	Homo sapiens	pKi		6.2
active	9652756	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(=O)c1cccc(-c2cnc3[nH]ccc3c2)c1		CHEMBL2000568	=	Ki	nM	3981.07	CHEMBL308	Homo sapiens	pKi		5.4
active	9652757	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4ncnc(N)c34)cc2)cc1C		CHEMBL2000335	=	Ki	nM	316.23	CHEMBL308	Homo sapiens	pKi		6.5
inactive	9652758	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC1CSc2c(C(=O)O)c(=O)c3cc(F)c(N4CCC(N)C4)c(F)c3n21		CHEMBL1977604	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652759	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	=	Ki	nM	63.1	CHEMBL308	Homo sapiens	pKi		7.2
inactive	9652760	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cn1cc(-c2cnn3c(N)c(-c4ccc(NC(=O)Nc5cccc(C(F)(F)F)c5)cc4)cnc23)cn1		CHEMBL1988717	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652761	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(Nc2nc(NC3CCCCC3N)cnc2C(N)=O)c1		CHEMBL1974328	=	Ki	nM	3981.07	CHEMBL308	Homo sapiens	pKi		5.4
active	9652762	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Ki	nM	316.23	CHEMBL308	Homo sapiens	pKi		6.5
inactive	9652763	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652764	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(Nc1ccc2[nH]ncc2c1)c1ccc(Cl)cc1		CHEMBL1973808	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652765	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)Oc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL2000429	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652766	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1ccc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)cc1		CHEMBL1972576	=	Ki	nM	630.96	CHEMBL308	Homo sapiens	pKi		6.2
inactive	9652767	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(NN=Cc1ccc(Sc2nc3ccccc3[nH]2)o1)c1cccc([N+](=O)[O-])c1		CHEMBL1992555	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652768	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NCC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1990254	=	Ki	nM	1584.89	CHEMBL308	Homo sapiens	pKi		5.8
active	9652769	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Fc1ccc2c(c1)-c1n[nH]cc1CS2		CHEMBL1989069	=	Ki	nM	15848.93	CHEMBL308	Homo sapiens	pKi		4.8
active	9652770	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL1992342	=	Ki	nM	1995.26	CHEMBL308	Homo sapiens	pKi		5.7
inactive	9652771	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cc(Cl)ccc1NC(=S)NNC(=O)C(O)(c1ccccc1)c1ccccc1		CHEMBL1988173	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652772	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	C(=NNc1nc2ccccc2[nH]1)c1c[nH]c2ccccc12		CHEMBL535331	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652773	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	N#CC1=C(N)n2c(sc(=Cc3ccco3)c2=O)=C(C(N)=O)C1c1ccco1		CHEMBL1989805	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652774	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652775	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)Cn1c(N)nc2ccc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc21		CHEMBL1965423	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652776	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)=C(C)c1cccc2c(CCCOc3cccc(Cl)c3Cl)c(C(=O)O)[nH]c12		CHEMBL1982980	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652777	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCC(N)(C#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12)CC		CHEMBL1983025	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652778	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(NCc1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1977135	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652779	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C1NC(=S)SC1=C1C(=O)Nc2ccc(Br)cc21		CHEMBL2001920	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652780	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(=O)c1cc2c(-c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cncc2s1		CHEMBL2002322	=	Ki	nM	1000.0	CHEMBL308	Homo sapiens	pKi		6.0
active	9652781	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cc(Nc2ncc([N+](=O)[O-])c(Nc3ccccc3C(N)=O)n2)cc(OC)c1OC		CHEMBL1241473	=	Ki	nM	19.95	CHEMBL308	Homo sapiens	pKi		7.7
inactive	9652782	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CS(=O)(=O)N(Cc1ccc2[nH]c(=O)c3cccn3c2c1)C1CC1		CHEMBL1978448	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652783	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COC(=O)c1ccccc1-c1ccc2c(c1)Nc1ccccc1NC2=O		CHEMBL2004513	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652784	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NCCCOc1cncc(C=Cc2ccncc2)c1		CHEMBL1972258	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652785	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCN(CC)CC#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL2001257	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652786	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)(C)OC(=O)n1ncc2cc(Nc3c(NCc4ccc(Cl)cc4Cl)c(=O)c3=O)ccc21		CHEMBL2005548	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652787	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1ccc(CNc2c(Nc3ccc4[nH]ncc4c3)c(=O)c2=O)cc1		CHEMBL1992536	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652788	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1ccccc1-c1c(C(=O)O)n(CCCOc2cccc3ccccc23)c2ccccc12		CHEMBL1987793	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652789	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCN1CCN(CCCC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1		CHEMBL1992740	=	Ki	nM	1258.93	CHEMBL308	Homo sapiens	pKi		5.9
inactive	9652790	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	OCCCn1cnc(-c2ccccc2)c1-c1ccncc1		CHEMBL2002373	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652791	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1ccc(-c2cncc(OCC(N)Cc3c[nH]c4ccccc34)c2)cc1C(=O)c1cccc(Cl)c1		CHEMBL1973348	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652792	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2NCCCN)c1		CHEMBL2006188	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652793	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1ncnc2scc(-c3ccc(NC(=O)Nc4ccccc4)cc3)c12		CHEMBL1967531	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652794	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCCC(=O)Nc1nn(C(=O)CC)c2nc3ccccc3cc12		CHEMBL1970913	=	Ki	nM	501.19	CHEMBL308	Homo sapiens	pKi		6.3
active	9652795	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(NC(C)=O)c3c2)cc1		CHEMBL1973893	=	Ki	nM	398.11	CHEMBL308	Homo sapiens	pKi		6.4
inactive	9652796	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCOC(=O)c1cccc2[nH]c(-c3ccc(N4CCC(N)C4)cc3)nc12		CHEMBL1995736	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9652797	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652798	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cccc(C(C)NC(=O)c2cc(C)c(-c3ccc4[nH]nc(C)c4c3)s2)c1		CHEMBL1997534	=	Ki	nM	794.33	CHEMBL308	Homo sapiens	pKi		6.1
inactive	9652799	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1996500	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9652800	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(=O)Cn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL1985095	=	Ki	nM	1584.89	CHEMBL308	Homo sapiens	pKi		5.8
inactive	9656813	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)(O)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4n3CCC4)nn12		CHEMBL1998551	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656814	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4n3CCC4)nn12		CHEMBL1977374	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656815	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COCc1nnn(-c2nonc2N)c1C(=O)NN=C(C)c1ccc(O)cc1O		CHEMBL1991180	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656816	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)O)c5)cnc(N)c34)cc2)c1		CHEMBL1989708	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656817	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	c1cnc2nc(-c3ccc4[nH]ncc4c3)cn2c1		CHEMBL1682540	=	Ki	nM	1584.89	CHEMBL308	Homo sapiens	pKi		5.8
inactive	9656818	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1c(O)cccc1NC(=O)c1cnn2c(-c3ccccc3)ccnc12		CHEMBL1978656	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656819	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCc1c(-c2ccc(C(C)(C)O)cc2)[nH]c2nccnc12		CHEMBL1976420	=	Ki	nM	1995.26	CHEMBL308	Homo sapiens	pKi		5.7
inactive	9656820	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1ccc(CNc2c(Nc3ccncc3)c(=O)c2=O)cc1		CHEMBL1994864	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656821	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	N#Cc1ncc2nc1OCCCCCOc1cc(OCCO)c(Cl)cc1NC(=O)N2		CHEMBL413779	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656822	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CN1CCN(Cc2ccc3c(c2)Cc2c(-c4csc(C#CCOCC5CC5)c4)n[nH]c2-3)CC1		CHEMBL2002446	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656823	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=c1nc(-c2cc3c(Oc4ccc(I)cc4)cncc3s2)[nH]o1		CHEMBL497151	=	Ki	nM	6309.57	CHEMBL308	Homo sapiens	pKi		5.2
active	9656824	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NCC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1		CHEMBL246970	=	Ki	nM	1000.0	CHEMBL308	Homo sapiens	pKi		6.0
active	9656825	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CN(c1ccccc1-c1ccc2c(c1)Nc1ccccc1NC2=O)S(C)(=O)=O		CHEMBL1980497	=	Ki	nM	3981.07	CHEMBL308	Homo sapiens	pKi		5.4
active	9656826	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cc(O)ccc1-n1cc(C(N)=O)c(=O)c2ccc(-c3ccncc3)cc21		CHEMBL340921	=	Ki	nM	3981.07	CHEMBL308	Homo sapiens	pKi		5.4
inactive	9656827	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	N#Cc1ncc2nc1OCCCCCOc1cc(OCCCO)c(Cl)cc1NC(=O)N2		CHEMBL373598	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656828	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	N#Cc1ccc(NC(=O)Nc2ccnc3cc(C(F)(F)F)ccc23)nc1		CHEMBL1999718	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656829	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C1Nc2ccc3ncsc3c2C1=CNc1ccc(S(=O)(=O)Nc2ccccn2)cc1		CHEMBL1973540	=	Ki	nM	19.95	CHEMBL308	Homo sapiens	pKi		7.7
active	9656830	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C1Nc2ccccc2Nc2nnc(I)cc21		CHEMBL1977346	=	Ki	nM	1258.93	CHEMBL308	Homo sapiens	pKi		5.9
active	9656831	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3ccc4nccnc4c3N)cc2)c1		CHEMBL1971649	=	Ki	nM	1258.93	CHEMBL308	Homo sapiens	pKi		5.9
inactive	9656832	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc21		CHEMBL2003657	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656833	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656834	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	OCCNc1cc2cc(-c3ccncc3)ccc2cn1		CHEMBL1998435	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656835	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Clc1cc(-c2c[nH]c3ncccc23)nc(NC2CCCCC2)n1		CHEMBL2006439	=	Ki	nM	31.62	CHEMBL308	Homo sapiens	pKi		7.5
inactive	9656836	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)N(C(=O)Nc1ccc2nc(-c3ccco3)c(-c3ccco3)nc2c1)C(C)C		CHEMBL2006156	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656837	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1ccc(-c2ccc(NC(=O)Nc3cc(F)cc(F)c3)cc2)c2c(N)noc12		CHEMBL1969190	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656838	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1ccc(-c2ccc(NC(=O)Nc3cccc(Br)c3)cc2)c2c(N)n[nH]c12		CHEMBL1973937	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656839	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	=	Ki	nM	398.11	CHEMBL308	Homo sapiens	pKi		6.4
active	9656840	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	OC1CCC(Nc2cc(Cl)nc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1991674	=	Ki	nM	1000.0	CHEMBL308	Homo sapiens	pKi		6.0
active	9656841	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(=O)c1ccc(-c2c[nH]c3nccc(Cl)c23)cc1		CHEMBL1982711	=	Ki	nM	39.81	CHEMBL308	Homo sapiens	pKi		7.4
inactive	9656842	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	FC(F)(F)Oc1ccc(-c2ccc3[nH]cc(C4=CCNCC4)c3c2)cc1		CHEMBL1987982	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656843	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL1984842	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656844	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cn[nH]c5)cnc(N)c34)cc2)c1		CHEMBL1969102	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656845	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12		CHEMBL1682346	=	Ki	nM	316.23	CHEMBL308	Homo sapiens	pKi		6.5
inactive	9656846	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCN(CC)CC#Cc1ccc2c(c1)-c1[nH]nc(-c3ccc(C#N)nc3)c1C2		CHEMBL2007044	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656847	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CNC(=O)N1CCN(CCCOc2ccc3c(c2)-c2[nH]nc(-c4ccc(C#N)nc4)c2C3)CC1		CHEMBL2001998	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656848	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cc(C=C(C#N)c2nc3ccccc3[nH]2)c(Br)cc1O		CHEMBL1994241	=	Ki	nM	501.19	CHEMBL308	Homo sapiens	pKi		6.3
inactive	9656849	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CS(=O)(=O)Nc1cc2c(cc1Cl)NC(=O)Nc1cnc(C#N)c(n1)OCCCCCO2		CHEMBL223460	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656850	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1ccc(Cl)cc1		CHEMBL1998829	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656851	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Ki	nM	31.62	CHEMBL308	Homo sapiens	pKi		7.5
active	9656852	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cnc(Nc2cccc(S(N)(=O)=O)c2)nc1Nc1ccc(OCC(N)=O)cc1		CHEMBL1988838	=	Ki	nM	794.33	CHEMBL308	Homo sapiens	pKi		6.1
inactive	9656853	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCN1CCN(c2ccc(Nc3nccc(-c4c(-c5cccc(C(=O)Nc6ccccc6F)c5)nc5ccccn45)n3)cc2)CC1		CHEMBL1981725	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656854	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4[nH]ncc34)cc2)c1		CHEMBL375284	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656855	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COCCn1cc(-c2ccncn2)c(-c2ccc(Cl)cc2)n1		CHEMBL1982866	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656856	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL2005792	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656857	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	c1ccc(CSc2nc(-c3ccncc3)n[nH]2)cc1		CHEMBL1968926	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656858	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCOc1nc(C(=O)NCc2ccncc2)cc(N)c1C#N		CHEMBL1984206	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656859	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1c(-c2ccccc2)c2cc(Cl)ccc2[nH]c1=O		CHEMBL462120	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656860	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(Nc1c(Nc2ccncc2)c(=O)c1=O)C1CCCCC1		CHEMBL1991577	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656861	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1ncc(-c2ccoc2)c2scc(-c3ccc(NC(=O)Nc4ccccc4F)cc3)c12		CHEMBL1965570	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656862	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=c1[nH]c2sc3c(c2c2nc(-c4ccccc4)nn12)CCCC3		CHEMBL2007592	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656863	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1C#N		CHEMBL210963	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656864	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cncc2cccc(S(=O)(=O)N3CCCNCC3C)c12		CHEMBL1082440	=	Ki	nM	3162.28	CHEMBL308	Homo sapiens	pKi		5.5
inactive	9656865	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(CO)N1CCC(c2[nH]nc(-c3ccc(Cl)cc3F)c2-c2ccncn2)CC1		CHEMBL1614705	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656866	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CS(=O)(=O)c1ccc(-c2cncc3sc(C(N)=O)cc23)cc1		CHEMBL1972362	=	Ki	nM	794.33	CHEMBL308	Homo sapiens	pKi		6.1
inactive	9656867	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cccc(C(C)NC(=O)c2cnc(-c3ccncc3)s2)c1		CHEMBL1984633	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656868	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656869	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CNc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL2007372	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656870	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cccc(C(C)NC(=O)N2CC=C(c3c[nH]c4ncccc34)CC2)c1		CHEMBL1965845	=	Ki	nM	794.33	CHEMBL308	Homo sapiens	pKi		6.1
inactive	9656871	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1ccc(OC)c(NC(=O)c2cnn3c(-c4ccccc4)ccnc23)c1		CHEMBL1982167	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656872	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCCC4=O)c3)n2)c1)c1c(F)cccc1F		CHEMBL2006715	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656873	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(=O)c1cccc2[nH]c(-c3ccc(NC(=O)c4cccc(S(=O)(=O)N5CCOCC5)c4)cc3)nc12		CHEMBL1986597	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656874	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(=O)c1cc2c(-c3cccc(F)c3)cncc2s1		CHEMBL1971017	=	Ki	nM	199.53	CHEMBL308	Homo sapiens	pKi		6.7
inactive	9656875	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(=O)c1cccc2[nH]c(-c3ccncc3)nc12		CHEMBL1990482	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656876	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Fc1ccc(-c2nc3cnccn3c2-c2ccnc(NCC3CC3)n2)cc1		CHEMBL1990904	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656877	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL1975121	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656878	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(NCC1CCCCC1)c1cc2c(-c3ccccc3)n[nH]c2s1		CHEMBL2005475	=	Ki	nM	5011.87	CHEMBL308	Homo sapiens	pKi		5.3
inactive	9656879	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)c1		CHEMBL402846	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656880	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC1=NN(c2ccc(Cl)c(Cl)c2)C(=O)C1=Cc1c(C)c(C#N)c2nc3ccccc3n2c1O		CHEMBL1997349	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656881	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2C)c1		CHEMBL183844	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656882	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL220057	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656883	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	c1ccc(Nc2nc(-c3ccc4[nH]ncc4c3)cs2)cc1		CHEMBL1682545	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656884	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(COc1cncc(C=Cc2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL1974935	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656885	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cc(OC2CCCC2)c(NC(=O)Nc2cnc(C#N)cn2)cc1Cl		CHEMBL2001224	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656886	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656887	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)(O)Cc1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)nn12		CHEMBL1976732	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656888	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)(C)OC(=O)n1ncc2cc(Nc3c(NCc4ccc(S(N)(=O)=O)cc4)c(=O)c3=O)ccc21		CHEMBL1969506	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656889	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(NC(CO)c1ccccc1)N1CC=C(c2c[nH]c3ncccc23)CC1		CHEMBL1964937	=	Ki	nM	1995.26	CHEMBL308	Homo sapiens	pKi		5.7
inactive	9656890	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1		CHEMBL1980163	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656891	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL590109	=	Ki	nM	316.23	CHEMBL308	Homo sapiens	pKi		6.5
inactive	9656892	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cc(-c2nn(C3CCC(N4CCN(C(C)=O)CC4)CC3)c3ncnc(N)c23)ccc1NC(=O)c1cc2ccccc2n1C		CHEMBL1970879	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656893	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1c(C=O)c(O)n2c(nc3ccccc32)c1C#N		CHEMBL1989856	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656894	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	c1cnc2nc(-c3ccc4[nH]ncc4c3)c(NC3CCCCC3)n2c1		CHEMBL1682552	=	Ki	nM	1584.89	CHEMBL308	Homo sapiens	pKi		5.8
inactive	9656895	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656896	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cncc(C=Cc2ccncc2)c1		CHEMBL1972568	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656897	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CN1CCC1COc1cncc(CCc2ccncc2)c1		CHEMBL1996155	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656898	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4cccc(Cl)c4)c3)cc12		CHEMBL1974870	=	Ki	nM	39.81	CHEMBL308	Homo sapiens	pKi		7.4
inactive	9656899	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCCc1cc(-c2ccc3[nH]ncc3c2)on1		CHEMBL1682359	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656900	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cc(C)c(C=C2C(=O)Nc3ccccc32)[nH]1		CHEMBL2002702	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656901	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL1970903	=	Ki	nM	50.12	CHEMBL308	Homo sapiens	pKi		7.3
inactive	9656902	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(COc1cncc(C=Cc2ccncc2)c1)Cc1ccccc1		CHEMBL1991846	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656903	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(Nc2nccc(Nc3c(NC(C)C(C)(C)C)c(=O)c3=O)n2)c1		CHEMBL1969523	=	Ki	nM	398.11	CHEMBL308	Homo sapiens	pKi		6.4
active	9656904	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1n[nH]c2c1C(c1ccccc1Br)C(C#N)=C(N)O2		CHEMBL2005214	=	Ki	nM	5011.87	CHEMBL308	Homo sapiens	pKi		5.3
inactive	9656905	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)nn12		CHEMBL1988995	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656906	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(=O)N1CCC(Nc2nccc(-c3c(-c4ccc(F)cc4)nc4occn34)n2)CC1		CHEMBL1986781	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656907	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=c1nc(-c2ccc3[nH]ncc3c2)cc(-c2ccccc2)[nH]1		CHEMBL526133	=	Ki	nM	3162.28	CHEMBL308	Homo sapiens	pKi		5.5
inactive	9656908	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCOCC3)nc21		CHEMBL1230122	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656909	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C1NCc2c1cccc2-c1ccc(Nc2nc3ccccc3[nH]2)cc1		CHEMBL1979057	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656910	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cc(-c2ccc3c(c2)Nc2ccc(CCOc4ccc(N5CCOCC5)cc4)cc2NC3=O)ccc1OCC(O)CO		CHEMBL1981045	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656911	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COCCOCC#Cc1cc(-c2n[nH]c3c2C(=O)c2cc(CN4CCN(C)CC4)ccc2-3)cs1		CHEMBL387971	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656912	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	c1ccc(Cn2nnc(-c3ccc4[nH]ncc4c3)c2C2CC2)cc1		CHEMBL1975418	=	Ki	nM	39.81	CHEMBL308	Homo sapiens	pKi		7.4
inactive	9656913	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=c1[nH]c2ccc(Cl)cc2c(-c2ccccc2)c1C1=NNC(c2ccccc2)C1		CHEMBL1992796	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656914	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1999428	=	Ki	nM	5011.87	CHEMBL308	Homo sapiens	pKi		5.3
inactive	9656915	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	N#Cc1ncc2nc1OCCCCCOc1cc(OCC(O)CO)c(Cl)cc1NC(=O)N2		CHEMBL223257	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656916	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCN1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL1967560	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656917	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Ki	nM	6309.57	CHEMBL308	Homo sapiens	pKi		5.2
inactive	9656918	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(NC(=O)Nc2ccc(-c3noc4ncnc(N)c34)cc2)c1		CHEMBL211378	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656919	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN5CCOCC5)cnc(N)c34)cc2)c1		CHEMBL1982465	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656920	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(COc1cncc(-c2ccc3c(c2)C(=Cc2ccco2)C(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL2001751	=	Ki	nM	251.19	CHEMBL308	Homo sapiens	pKi		6.6
inactive	9656921	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(NCCCCCCNC(=O)NCc1cccnc1)NCc1cccnc1		CHEMBL2003420	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656922	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1ccccc1NC(=O)Nc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL1984586	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656923	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1c(O)ccc2c1CCCC2=NNC(=O)Cc1cccc2ccccc12		CHEMBL1972659	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656924	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	OC1CCN(c2ncnc3[nH]cc(-c4ccccc4)c23)CC1		CHEMBL1973395	=	Ki	nM	316.23	CHEMBL308	Homo sapiens	pKi		6.5
inactive	9656925	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1ccc(NC(=O)Nc2ccc(-c3cccc4onc(N)c34)cc2)cc1Cl		CHEMBL272453	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656926	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3C)cc2)c1		CHEMBL1970217	=	Ki	nM	1584.89	CHEMBL308	Homo sapiens	pKi		5.8
inactive	9656927	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C1Nc2ccccc2Nc2nnccc21		CHEMBL1971801	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656928	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C1Nc2ccccc2Nc2nnc(Cl)cc21		CHEMBL1968850	=	Ki	nM	794.33	CHEMBL308	Homo sapiens	pKi		6.1
inactive	9656929	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCOC(=O)c1ccc2[nH]c3c(c2c1)CCNC3=O		CHEMBL2005528	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656930	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2)c1		CHEMBL185569	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656931	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	c1cc2[nH]ncc2cc1-c1cn(CC2CCOCC2)nn1		CHEMBL1969843	=	Ki	nM	2511.89	CHEMBL308	Homo sapiens	pKi		5.6
active	9656932	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cc(-c2ccc3[nH]nc(C(=O)Nc4ccccc4)c3c2)ccc1O		CHEMBL2007002	=	Ki	nM	5011.87	CHEMBL308	Homo sapiens	pKi		5.3
inactive	9656933	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(Nc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1)c1ccccc1		CHEMBL1990288	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656934	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CN1CCC(NC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)CC1		CHEMBL1987007	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656935	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Clc1cc(-c2c[nH]c3ncccc23)cc(NCc2ccccc2)n1		CHEMBL1969588	=	Ki	nM	25.12	CHEMBL308	Homo sapiens	pKi		7.6
active	9656936	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cc(Nc2nccc(Nc3cc(C4CCCCC4)no3)n2)cc(OC)c1OC		CHEMBL1984711	=	Ki	nM	3981.07	CHEMBL308	Homo sapiens	pKi		5.4
active	9656937	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cc(Nc2ncc(F)c(NC3C4C=CC(C4)C3C(N)=O)n2)ccc1N1CCN(C)CC1		CHEMBL1967878	=	Ki	nM	1000.0	CHEMBL308	Homo sapiens	pKi		6.0
inactive	9656938	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cc(OC)c(Nc2ccc3nnc(-c4ccccc4)n3n2)cc1Cl		CHEMBL1990212	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656939	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NCC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1990254	=	Ki	nM	398.11	CHEMBL308	Homo sapiens	pKi		6.4
inactive	9656940	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCCCn1c(NC(=O)c2ccc(C#N)cc2)nc2cc(N(C)C(=O)C3CCCCC3)ccc21		CHEMBL484390	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656941	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=c1c(NCc2cccc(C(F)(F)F)c2)c(Nc2ccncc2)c1=O		CHEMBL1979252	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656942	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	c1ccc(Cc2cn(-c3ccc4[nH]ncc4c3)nn2)cc1		CHEMBL1682341	=	Ki	nM	630.96	CHEMBL308	Homo sapiens	pKi		6.2
inactive	9656943	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)(C)O)c5)cnc(N)c34)cc2)cc1		CHEMBL2004290	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656944	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccc(F)cc3)cc12		CHEMBL1986499	=	Ki	nM	501.19	CHEMBL308	Homo sapiens	pKi		6.3
inactive	9656945	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cccc(C=C2SC(=Nc3ccccc3)NC2=O)c1		CHEMBL1972937	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656946	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	C#Cc1cc2c(cc1OC)-c1[nH]nc(-c3ccc(C#N)nc3)c1C2		CHEMBL1972250	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656947	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=c1[nH]c2cnc(-n3cnc4ccc(F)cc43)nc2n1C1CCOc2c(F)cccc21		CHEMBL2000393	=	Ki	nM	2511.89	CHEMBL308	Homo sapiens	pKi		5.6
inactive	9656948	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COC(=O)c1cc2c(-c3cccc(F)c3)cncc2s1		CHEMBL2004072	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656949	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)c(C)c2)c1		CHEMBL2004311	=	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656950	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Brc1cnc2[nH]cc(-c3ccccc3)c2c1		CHEMBL1992634	=	Ki	nM	398.11	CHEMBL308	Homo sapiens	pKi		6.4
inactive	9656951	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1242373	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656952	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCNNc1cc(C)c(C#N)c2nc3ccccc3n12		CHEMBL2000433	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656953	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	N#CC(=Cc1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL1974157	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656954	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Fc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL316264	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656955	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1ccc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1988075	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656956	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1991678	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656957	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1ncnc(Nc2cc(CNC(=O)C(F)(F)F)c(O)c(-c3ccc(Cl)cc3)c2)n1		CHEMBL2001239	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656958	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1ncnc2scc(C(=O)Nc3ccc(NC(=O)Nc4ccccc4)cc3)c12		CHEMBL1988594	=	Ki	nM	50.12	CHEMBL308	Homo sapiens	pKi		7.3
active	9656959	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1ncnc2c1c(I)nn2C1OC(CO)C(O)C1O		CHEMBL2001288	=	Ki	nM	6309.57	CHEMBL308	Homo sapiens	pKi		5.2
active	9656960	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1ncnc2c1N=C(c1ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc1)CCN2		CHEMBL260092	=	Ki	nM	630.96	CHEMBL308	Homo sapiens	pKi		6.2
inactive	9656961	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1		CHEMBL253969	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656962	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(NN=Cc1ccc(O)cc1O)Nc1cccc2nsnc12		CHEMBL1999811	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656963	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1n[nH]c2ncc(C#N)c(-c3ccccc3)c12		CHEMBL1965495	=	Ki	nM	501.19	CHEMBL308	Homo sapiens	pKi		6.3
active	9656964	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CSc1ccc2nc3c(c(Cl)c2c1)CCNC3=O		CHEMBL1985074	=	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656965	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1nc2ccc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc2n1CC1CC1		CHEMBL1982874	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656966	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NCCNS(=O)(=O)c1cccc(C(=O)Nc2ccc(-c3n[nH]c(=O)c4ccccc34)cc2)c1		CHEMBL2000481	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656967	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1		CHEMBL1173055	=	Ki	nM	2511.89	CHEMBL308	Homo sapiens	pKi		5.6
active	9656968	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CN(C)CC(=O)NC(COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL1991725	=	Ki	nM	5011.87	CHEMBL308	Homo sapiens	pKi		5.3
inactive	9656969	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4sncc34)cc2)c1		CHEMBL1992242	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656970	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCCOc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL2007296	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656971	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCOc1nc(NC(C)=O)cc(N)c1C#N		CHEMBL208637	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656972	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(O)c1ccccc1Nc1ccnc(Nc2ccc3[nH]ncc3c2)n1		CHEMBL396523	=	Ki	nM	79.43	CHEMBL308	Homo sapiens	pKi		7.1
inactive	9656973	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C1NC(=O)C(Nc2ccccc2)=C1Cl		CHEMBL2007138	<	Ki	nM	19952.62	CHEMBL308	Homo sapiens	pKi		4.7
active	9656974	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cc(C)cc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)c1		CHEMBL1970203	=	Ki	nM	79.43	CHEMBL308	Homo sapiens	pKi		7.1
inactive	9656975	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(c1cc(Cc2n[nH]c(=O)c3c2CCCC3)ccc1F)N1CCN(c2ncccn2)CC1		CHEMBL1986530	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656976	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(C=NNc2cc(N3CCOCC3)nc(OCCc3ccccn3)n2)c1		CHEMBL1965351	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656977	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=c1c(NCCc2ccc(Oc3ccccc3)cc2)c(Nc2ccncc2)c1=O		CHEMBL1999321	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656978	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CNC(=O)C=Cc1cnc(N)c2c(-c3ccc4sc(C)nc4c3)csc12		CHEMBL1968590	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656979	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cc(Nc2ncnc3ccc(-c4ccc(CN5CC6C(CO)C6C5)cc4)cc23)ccc1Oc1ccccc1		CHEMBL1999749	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656980	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCC1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCCCC4)cc3OC)nc2N1C1CCCC1		CHEMBL2005375	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656981	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Clc1ccc(-c2n[nH]cc2-c2ccncn2)cc1Cl		CHEMBL1984191	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656982	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CN1CCCC1COc1cncc(CCc2ccccc2)c1		CHEMBL1972183	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656983	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCN(C(C)=O)CC3)ccc2OC)ncc1Br		CHEMBL1971029	=	Ki	nM	39.81	CHEMBL308	Homo sapiens	pKi		7.4
inactive	9656984	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)Nc1n[nH]c2ccc(N)cc12		CHEMBL1995391	<	Ki	nM	19952.62	CHEMBL308	Homo sapiens	pKi		4.7
inactive	9656985	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)c12		CHEMBL394790	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656986	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C1NCCc2[nH]c(-c3ccnc(-c4ccccc4F)c3)cc21		CHEMBL226471	=	Ki	nM	3162.28	CHEMBL308	Homo sapiens	pKi		5.5
active	9656987	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1nc2c(sc3c(Br)ccc(Cl)c32)c(=O)o1		CHEMBL1974702	=	Ki	nM	6309.57	CHEMBL308	Homo sapiens	pKi		5.2
active	9656988	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CN(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1996111	=	Ki	nM	630.96	CHEMBL308	Homo sapiens	pKi		6.2
inactive	9656989	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1nccn2c(-c3ccnc(NCC4(O)CC4)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1965589	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656990	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(NCCCCCCNC(=O)Nc1cccnc1)Nc1cccnc1		CHEMBL1998193	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656991	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)O)s3)c2cc1OC		CHEMBL474432	=	Ki	nM	3981.07	CHEMBL308	Homo sapiens	pKi		5.4
active	9656992	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1nnc(-c2cc3c(Oc4ccc(C(F)(F)F)cc4)cncc3s2)o1		CHEMBL1988153	=	Ki	nM	630.96	CHEMBL308	Homo sapiens	pKi		6.2
active	9656993	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(=O)N1CCN(C2CCC(n3nc(-c4ccc(NC(=O)c5cc6ccccc6n5C)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL1972584	=	Ki	nM	1584.89	CHEMBL308	Homo sapiens	pKi		5.8
active	9656994	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	N#Cc1ccc2[nH]c(O)c(-c3ccc(CN4CCOCC4)cn3)c2c1		CHEMBL1969664	=	Ki	nM	1995.26	CHEMBL308	Homo sapiens	pKi		5.7
active	9656995	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(=O)c1cc2c(-c3ccccc3)cncc2s1		CHEMBL1999556	=	Ki	nM	630.96	CHEMBL308	Homo sapiens	pKi		6.2
inactive	9656996	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CNC(=O)c1ccccc1Sc1ccc2c(C=Cc3ccccn3)n[nH]c2c1		CHEMBL1988437	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9656997	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NCCC(C(=O)Nc1ccc2[nH]ncc2c1)c1ccc(Cl)c(Cl)c1		CHEMBL1998121	=	Ki	nM	6309.57	CHEMBL308	Homo sapiens	pKi		5.2
inactive	9656998	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CC(C)(C)N)cnc(N)c34)cc2)c1		CHEMBL1979577	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9656999	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(CC4CC4)nccn23)n1		CHEMBL1991800	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9657000	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cc(-c2ccc3c(c2)Nc2ccc(CCOc4ccc(N5CCOCC5)cc4)cc2NC3=O)ccc1CC#N		CHEMBL1985566	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9657001	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCC(CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL52387	=	Ki	nM	1258.93	CHEMBL308	Homo sapiens	pKi		5.9
inactive	9657002	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1nn(-c2ccccc2)c2c1c(=O)c1cc(Cl)ccc1n2O		CHEMBL379835	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9657003	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cn1cc(C(CN)c2cncc(C=Cc3ccncc3)c2)c2ccccc21		CHEMBL1979357	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9657004	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	N#Cc1ncc2nc1OCC(O)C(O)COc1ccc(Cl)cc1NC(=O)N2		CHEMBL1980802	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9657005	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=c1c(NCc2ccc(Cl)cc2Cl)c(Nc2ccc3[nH]ncc3c2)c1=O		CHEMBL1979554	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9657006	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCCCOc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL1996817	=	Ki	nM	251.19	CHEMBL308	Homo sapiens	pKi		6.6
inactive	9657007	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1nonc1-n1nnc(C(=O)NN=Cc2ccncc2)c1-c1ccccc1		CHEMBL1419458	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9657008	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCOc1nc(C(=O)NCc2ccc(S(N)(=O)=O)cc2)cc(N)c1C#N		CHEMBL2004355	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9657009	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O		CHEMBL483158	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9657010	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCn1c2cc(Cl)c(F)cc2c(=O)c2c(=O)o[nH]c21		CHEMBL468280	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9657011	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cc(C)c2oc(Nc3ccc(-c4cccc(C(N)=O)c4N)cc3F)nc2c1		CHEMBL1990884	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9657012	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCN(CC)CCNC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(F)cc32)c1C		CHEMBL1990885	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9657013	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL256835	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9657014	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CN(c1ccccc1CNc1nc(N)nc2[nH]ccc12)S(C)(=O)=O		CHEMBL1970006	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9657015	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(C(F)(F)F)cccc12		CHEMBL1980142	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9657016	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CN(C)CCCC(=O)Nc1n[nH]c2nnc(-c3cccc(F)c3F)cc12		CHEMBL41783	=	Ki	nM	794.33	CHEMBL308	Homo sapiens	pKi		6.1
inactive	9657017	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1c(-c2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)ccc2nccnc12		CHEMBL2004438	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9657018	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cccc2c1Nc1cc(Nc3ccncc3)ccc1C(=O)N2		CHEMBL2006276	=	Ki	nM	630.96	CHEMBL308	Homo sapiens	pKi		6.2
inactive	9657019	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1ccc(-c2ccc(NC(=O)Nc3cccc(Br)c3)cc2)c2c(N)noc12		CHEMBL271381	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9657020	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1ccc(C(=O)Nc2c(C#N)sc3ccc(Cl)c(Cl)c23)cc1		CHEMBL2006785	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9657021	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)cc1		CHEMBL1982466	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9657022	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1		CHEMBL249697	=	Ki	nM	3981.07	CHEMBL308	Homo sapiens	pKi		5.4
active	9657023	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cc(-c2ccc3c(c2)Nc2ccc([N+](=O)[O-])cc2NC3=O)ccc1O		CHEMBL1995740	=	Ki	nM	6.31	CHEMBL308	Homo sapiens	pKi		8.2
active	9657024	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(O)c1cc2c(-c3ccccc3)cncc2s1		CHEMBL1996390	=	Ki	nM	3162.28	CHEMBL308	Homo sapiens	pKi		5.5
active	9657025	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	OC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1986943	=	Ki	nM	39.81	CHEMBL308	Homo sapiens	pKi		7.4
inactive	9657026	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC1CCN(C(=O)CC#N)CC1N(C)c1ncnc2[nH]ccc12		CHEMBL234085	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9657027	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1995832	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9657028	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1n[nH]c2sc(C(=O)NCCc3ccc(Cl)cc3)cc12		CHEMBL1998414	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9657029	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Oc1ccc(Nc2[nH]nc(-c3ccc(O)cc3)c2-c2ccc(O)cc2)cc1		CHEMBL1969042	=	Ki	nM	1995.26	CHEMBL308	Homo sapiens	pKi		5.7
active	9657030	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cc(C=C(C#N)c2nc3cc(C)ccc3[nH]2)c(Br)cc1O		CHEMBL2000345	=	Ki	nM	794.33	CHEMBL308	Homo sapiens	pKi		6.1
active	9657031	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1ccccc1		CHEMBL1999931	=	Ki	nM	5.012	CHEMBL308	Homo sapiens	pKi		8.3
inactive	9657032	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=c1[nH]sc2c1c(=O)c1cc(F)c(NCc3ccccc3)c(F)c1n2C1CC1		CHEMBL1991640	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9657033	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1ccc(CNc2ccc3nnc(-c4ccccc4)n3n2)cc1		CHEMBL1375418	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9657034	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Ki	nM	15.85	CHEMBL308	Homo sapiens	pKi		7.8
active	9657035	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1[nH]c(C=C2C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL2007064	=	Ki	nM	5011.87	CHEMBL308	Homo sapiens	pKi		5.3
active	9657036	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COC(C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL1981047	=	Ki	nM	3162.28	CHEMBL308	Homo sapiens	pKi		5.5
active	9657037	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4ccc(Cl)c(Cl)c4)c3)cc12		CHEMBL1991063	=	Ki	nM	50.12	CHEMBL308	Homo sapiens	pKi		7.3
active	9657038	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cccc(C(CN)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL1976240	=	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9657039	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1ccc(-c2ccc(NC(=O)Nc3ccc(F)c(C)c3)cc2)c2c(N)noc12		CHEMBL1979093	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9657040	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=c1[nH]c2sccc2c2nc(-c3ccncc3)nn12		CHEMBL1968151	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9657041	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Clc1ccc(CNc2ccc3nnc(-c4ccccc4)n3n2)cc1		CHEMBL1381197	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9657042	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cccc(CNC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)c1		CHEMBL1987009	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9657043	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4ccccc4)c3)cc12		CHEMBL2002726	=	Ki	nM	158.49	CHEMBL308	Homo sapiens	pKi		6.8
inactive	9657044	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(Nc1cnccn1)Nc1ccnc2cc(C(F)(F)F)ccc12		CHEMBL2003817	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9657045	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1nnc(-c2cc3c(Oc4ccc(Cl)cc4)cncc3s2)o1		CHEMBL1994830	=	Ki	nM	251.19	CHEMBL308	Homo sapiens	pKi		6.6
active	9657046	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COCCOC1CCC(n2nc(-c3ccc(Nc4nc5cc(C)cc(Cl)c5o4)cc3)c3c(N)ncnc32)CC1		CHEMBL1987054	=	Ki	nM	1258.93	CHEMBL308	Homo sapiens	pKi		5.9
inactive	9657047	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1ncc(-c2ccncc2)c2scc(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL1970083	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9661063	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C1NCCc2[nH]c(-c3ccnc(-c4cnc5ccccc5c4)c3)cc21		CHEMBL226403	=	Ki	nM	3981.07	CHEMBL308	Homo sapiens	pKi		5.4
inactive	9661064	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cc(C)ccc4F)cc3)csc12		CHEMBL2005631	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661065	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1ncc(C=CC(=O)NCCCn2ccnc2)c2scc(-c3ccc(Br)cc3)c12		CHEMBL1994938	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9661066	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL1825138	=	Ki	nM	5011.87	CHEMBL308	Homo sapiens	pKi		5.3
active	9661067	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCCC(=O)Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12		CHEMBL1977223	=	Ki	nM	3.981	CHEMBL308	Homo sapiens	pKi		8.4
inactive	9661068	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)(C)C(=O)Oc1ccc2c(c1)nc(NC(=O)c1cccc([N+](=O)[O-])c1)n2CCCO		CHEMBL1236126	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661069	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NCCCNS(=O)(=O)c1cccc(C(=O)Nc2ccc(-c3n[nH]c(=O)c4ccccc34)cc2)c1		CHEMBL1966279	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9661070	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Clc1cc(NC2CCCCC2)nc(-c2c[nH]c3ncccc23)n1		CHEMBL1997846	=	Ki	nM	3162.28	CHEMBL308	Homo sapiens	pKi		5.5
inactive	9661071	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)Cn1c(N)nc2c(F)cc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc21		CHEMBL2004419	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9661072	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(=NNC(=N)N)c1cc(NC(=O)NCCCCCCNC(=O)Nc2cc(C(C)=NNC(=N)N)cc(C(C)=NNC(=N)N)c2)cc(C(C)=NNC(=N)N)c1		CHEMBL1991728	=	Ki	nM	630.96	CHEMBL308	Homo sapiens	pKi		6.2
active	9661073	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(=O)c1cc2c(-c3ccc(F)cc3F)cncc2s1		CHEMBL1975787	=	Ki	nM	316.23	CHEMBL308	Homo sapiens	pKi		6.5
active	9661074	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cc(C=C(C#N)c2n[nH]c(N)c2C#N)ccc1O		CHEMBL2002407	=	Ki	nM	630.96	CHEMBL308	Homo sapiens	pKi		6.2
inactive	9661075	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(Nc1ccc2cn[nH]c2c1)c1ccc(Cl)cc1		CHEMBL1972489	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661076	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Brc1ccc2[nH]nc(-c3ccccc3)c2c1		CHEMBL1994074	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9661077	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1ccc(Nc2nc3ccc([N+](=O)[O-])cc3[nH]2)nc1		CHEMBL1992937	=	Ki	nM	398.11	CHEMBL308	Homo sapiens	pKi		6.4
inactive	9661078	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(Cl)ccc1O		CHEMBL536151	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661079	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(Nc1cccc(N2CCOCC2)n1)Nc1ccnc2c(C(F)(F)F)cccc12		CHEMBL1972119	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661080	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CN(C)C(=O)Nc1ccc2nc(-c3ccco3)c(-c3ccco3)nc2c1		CHEMBL1986328	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661081	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL95692	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661082	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)c1		CHEMBL1090356	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9661083	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(Nc1cnccn1)Nc1ccnc2ccc(C(F)(F)F)cc12		CHEMBL1976455	=	Ki	nM	63.1	CHEMBL308	Homo sapiens	pKi		7.2
inactive	9661084	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(C=Cc3ccccc3)n2)n[nH]1		CHEMBL1983923	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661085	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661086	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	c1ccc(CNc2nc3ccc(-c4ccncc4)cc3s2)cc1		CHEMBL1983534	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661087	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=c1c(NCc2ccccc2F)c(Nc2ccncc2)c1=O		CHEMBL1982361	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661088	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCOC(=O)C1=c2sc(=Cc3ccco3)c(=O)n2C(N)=C(C#N)C1c1ccco1		CHEMBL1999112	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661089	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	OCCC(Nc1nc2ccc(-c3ccncc3)cc2s1)c1ccccc1		CHEMBL1982122	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661090	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(Nc1ccc(-c2cccc3sncc23)cc1)Nc1ccc(F)c(C(F)(F)F)c1		CHEMBL2000801	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661091	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	c1ccc(CNc2nc(-c3ccc4[nH]ncc4c3)cs2)cc1		CHEMBL1682546	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661092	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1991395	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661093	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CN1CCN(c2cccc(Nc3nccc(-c4c(C(N)=O)nc5ccccn45)n3)c2)CC1		CHEMBL1971245	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661094	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL1987648	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9661095	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCOC(=O)c1cn(-c2ccc(O)cc2C)c2cc(-c3ccncc3)ccc2c1=O		CHEMBL1996780	=	Ki	nM	3981.07	CHEMBL308	Homo sapiens	pKi		5.4
active	9661096	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(NCc1ccccc1)c1cccc(-c2cnc3[nH]ccc3c2)c1		CHEMBL1972142	=	Ki	nM	1995.26	CHEMBL308	Homo sapiens	pKi		5.7
inactive	9661097	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1ncc(-c2ccoc2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1966514	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9661098	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCCCCCCCCCCCOc1ccc(NC(=N)N)cc1NC(=N)N		CHEMBL1980715	=	Ki	nM	3981.07	CHEMBL308	Homo sapiens	pKi		5.4
active	9661099	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1cccc(F)c1		CHEMBL2003638	=	Ki	nM	10.0	CHEMBL308	Homo sapiens	pKi		8.0
active	9661100	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	N#Cc1ccc2nc(N)n(-c3nc(-c4ccccc4)cs3)c2c1		CHEMBL1996066	=	Ki	nM	1995.26	CHEMBL308	Homo sapiens	pKi		5.7
active	9661101	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC(COc1cncc(-c2cc3ccncc3s2)c1)Cc1c[nH]c2ccccc12		CHEMBL1966524	=	Ki	nM	158.49	CHEMBL308	Homo sapiens	pKi		6.8
inactive	9661102	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=c1c2c([nH]c3cc(-c4ccco4)nn13)CSC2		CHEMBL1972152	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9661103	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cc(C(=O)O)ccc4F)cc3)c12		CHEMBL1993722	=	Ki	nM	3981.07	CHEMBL308	Homo sapiens	pKi		5.4
inactive	9661104	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=c1[nH]c2sc3c(c2c2nc(-c4cccnc4)nn12)CCCC3		CHEMBL1970806	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661105	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1nc(COc2ccccc2Cl)sc1-c1ccnc(N)n1		CHEMBL1375640	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661106	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	N#Cc1ccc(-c2n[nH]c3c2Cc2ccc(OCCN4CCOCC4)cc2-3)cn1		CHEMBL249282	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9661107	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)(C)NC(=O)c1ccc2nc3[nH]c4ccccc4c3nc2c1		CHEMBL1969264	=	Ki	nM	1995.26	CHEMBL308	Homo sapiens	pKi		5.7
inactive	9661108	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	N#Cc1c(O)[nH]c(=O)c2c(=N)oc3ccc(Cl)cc3c12		CHEMBL1973711	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661109	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CN1CCN(CCCNc2cccc(-c3nc4c(C(N)=O)cccc4[nH]3)n2)CC1		CHEMBL2006237	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661110	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)(C(N)=O)n1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1967720	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661111	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NC1C2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)CC12		CHEMBL1624529	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661112	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1nccn2c(C3CC(CN4CCCC4)C3)nc(-c3cccc(OCc4ccccc4)c3)c12		CHEMBL1991138	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661113	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(NC(CO)Cc1ccccc1)c1ccc(-c2ccncc2)cc1F		CHEMBL1969755	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661114	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)csc12		CHEMBL1979516	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9661115	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(N)C1CCC(C(=O)Nc2ccncc2)CC1		CHEMBL1994526	=	Ki	nM	6309.57	CHEMBL308	Homo sapiens	pKi		5.2
inactive	9661116	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(O)c1ccc(N2C(=O)c3ccccc3C2=O)cc1O		CHEMBL1972820	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661117	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	NNc1cc(N2CCOCC2)nc(OCCc2ccccn2)n1		CHEMBL1996208	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661118	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)OC1=NNC(=O)C1=Cc1c[nH]c2ccccc12		CHEMBL1989029	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9661119	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CSc1ccccc1CNc1ncc([N+](=O)[O-])c(NCC2CCC(CN)CC2)n1		CHEMBL392642	=	Ki	nM	251.19	CHEMBL308	Homo sapiens	pKi		6.6
inactive	9661120	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9661121	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CN(C)CC(=O)Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12		CHEMBL1965631	=	Ki	nM	100.0	CHEMBL308	Homo sapiens	pKi		7.0
active	9661122	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1ccccc1NC(=O)Nc1ccc(NC(=O)c2csc3ncnc(N)c23)cc1		CHEMBL1980144	=	Ki	nM	398.11	CHEMBL308	Homo sapiens	pKi		6.4
active	9661123	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3F)cc2OC)c1		CHEMBL1991188	=	Ki	nM	794.33	CHEMBL308	Homo sapiens	pKi		6.1
inactive	9661124	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)(CO)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)nn12		CHEMBL1972849	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661125	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCOc1nc(C(=O)NCc2ccccc2S(N)(=O)=O)cc(N)c1C#N		CHEMBL377408	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661126	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661127	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL231209	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661128	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)(C)OC(=O)n1cc(-c2cncn2C2CCCCC2)c2ccccc21		CHEMBL1975357	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661129	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(Br)c4)cc3)c12		CHEMBL1976220	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661130	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1ccc(C(=O)Nc2ccon2)cc1Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL259922	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661131	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CN1CCN(C2CCC(n3cc(-c4ccc(Oc5ccccc5)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL1997617	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661132	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(CCN)nccn23)n1		CHEMBL1982383	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661133	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CCCCn1c(NC(=O)c2cccc(C#N)c2)nc2cc(N(C)C(=O)C3CCCCC3)ccc21		CHEMBL1969301	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661134	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CSc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17370	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661135	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4ccccc4C(F)(F)F)cc3)c12		CHEMBL1987910	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661136	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1ccc2c(NC(=O)Nc3cccc(Br)n3)ccnc2c1		CHEMBL1983932	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661137	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1980297	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9661138	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	c1ccc2c(c1)nnn2Cc1cn(-c2ccc3[nH]ncc3c2)nn1		CHEMBL1966069	=	Ki	nM	2511.89	CHEMBL308	Homo sapiens	pKi		5.6
inactive	9661139	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661140	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cc2cc(-c3csc4c(-c5cccc(S(C)(=O)=O)c5)cnc(N)c34)ccc2[nH]1		CHEMBL1997822	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661141	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1cc(OCC2CCC(C(=O)O)C2)c(NC(=O)Nc2cnc(C#N)cn2)cc1Cl		CHEMBL1991285	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9661142	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(O)c1ccccc1Nc1ccnc(Nc2cccc(O)c2)n1		CHEMBL243088	=	Ki	nM	501.19	CHEMBL308	Homo sapiens	pKi		6.3
inactive	9661143	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cc(-c2ccc3c(c2)NC(=O)c2ccc(-c4ccccc4NS(C)(=O)=O)cc2N3)cc(OC)c1OC		CHEMBL1984038	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9661144	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1cccc(F)c1F		CHEMBL1974416	=	Ki	nM	3162.28	CHEMBL308	Homo sapiens	pKi		5.5
inactive	9661145	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	CSc1nn(-c2ccccn2)c(N)c1C(N)=O		CHEMBL2004615	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
inactive	9661146	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	Cc1nn(C)c(C)c1-c1cccc2c(CCCOc3cccc4ccccc34)c(C(=O)O)[nH]c12		CHEMBL1984039	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
active	9661147	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2		CHEMBL1980391	=	Ki	nM	794.33	CHEMBL308	Homo sapiens	pKi		6.1
inactive	9661148	CHEMBL1963819	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC2	F	O=C(c1cccc(-c2cnc3[nH]ccc3c2)c1)N1CCOCC1		CHEMBL1997872	<	Ki	nM	7943.28	CHEMBL308	Homo sapiens	pKi		5.1
	10837524	CHEMBL2013813	Inhibition of CDK1	B	O=C1N=C(NCc2cccs2)S/C1=C\c1ccc2ncccc2c1		CHEMBL393929	=	IC50	nM	19.0	CHEMBL308	Homo sapiens	IC50	uM	0.019
	10837525	CHEMBL2013813	Inhibition of CDK1	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	10837526	CHEMBL2013813	Inhibition of CDK1	B	CC(C)n1ncc2cnc(Nc3cc(C(N)=O)n(C)c3)nc21		CHEMBL2012308	=	IC50	nM	160.0	CHEMBL308	Homo sapiens	IC50	uM	0.16
	10837527	CHEMBL2013813	Inhibition of CDK1	B	Cn1cc(Nc2ncc3cnn(C4CCC5(CC5)C4)c3n2)cc1C(N)=O		CHEMBL2012309	=	IC50	nM	50.0	CHEMBL308	Homo sapiens	IC50	uM	0.05
	10837528	CHEMBL2013813	Inhibition of CDK1	B	Cn1cc(Nc2ncc3cnn(C4C5CC6CC(C5)CC4C6)c3n2)cc1C(N)=O		CHEMBL2012397	=	IC50	nM	38.0	CHEMBL308	Homo sapiens	IC50	uM	0.038
	10837529	CHEMBL2013813	Inhibition of CDK1	B	Cn1cc(Nc2ncc3cnn([C@H]4CC[C@H]5CCC[C@@H]45)c3n2)cc1C(N)=O		CHEMBL2012398	=	IC50	nM	16.0	CHEMBL308	Homo sapiens	IC50	uM	0.016
	10837530	CHEMBL2013813	Inhibition of CDK1	B	Cn1cc(Nc2ncc3cnn(C4CCCCCC4)c3n2)cc1C(N)=O		CHEMBL2012399	=	IC50	nM	15.0	CHEMBL308	Homo sapiens	IC50	uM	0.015
	10837531	CHEMBL2013813	Inhibition of CDK1	B	Cn1cc(Nc2ncc3cnn(C4CCC5(CC4)CC5)c3n2)cc1C(N)=O		CHEMBL2012400	=	IC50	nM	19.0	CHEMBL308	Homo sapiens	IC50	uM	0.019
	10837532	CHEMBL2013813	Inhibition of CDK1	B	Cn1cc(Nc2ncc3cnn(C4CCC(C)(C)CC4)c3n2)cc1C(N)=O		CHEMBL2012401	=	IC50	nM	24.0	CHEMBL308	Homo sapiens	IC50	uM	0.024
	10837533	CHEMBL2013813	Inhibition of CDK1	B	Cn1cc(Nc2ncc3cnn([C@H]4C[C@@H]5C[C@@H]5C4)c3n2)cc1C(N)=O		CHEMBL2012402	=	IC50	nM	24.0	CHEMBL308	Homo sapiens	IC50	uM	0.024
	10837534	CHEMBL2013813	Inhibition of CDK1	B	Cn1cc(Nc2ncc3cnn([C@@H]4CC[C@H]5CCC[C@H]54)c3n2)cc1C(N)=O		CHEMBL2012403	=	IC50	nM	13.0	CHEMBL308	Homo sapiens	IC50	uM	0.013
	10837535	CHEMBL2013813	Inhibition of CDK1	B	CN(C)C(=O)[C@@H]1CCCN1C(=O)c1cc(Nc2ncc3cnn([C@H]4C[C@@H]5C[C@@H]5C4)c3n2)cn1C		CHEMBL2012404	=	IC50	nM	1700.0	CHEMBL308	Homo sapiens	IC50	uM	1.7
	10837536	CHEMBL2013813	Inhibition of CDK1	B	CNC[C@@H]1CCCN1C(=O)c1cc(Nc2ncc3cnn([C@H]4C[C@@H]5C[C@@H]5C4)c3n2)cn1C		CHEMBL2012405	=	IC50	nM	1200.0	CHEMBL308	Homo sapiens	IC50	uM	1.2
	10837537	CHEMBL2013813	Inhibition of CDK1	B	C[C@@H]1CCCN1C(=O)c1cc(Nc2ncc3cnn([C@H]4C[C@@H]5C[C@@H]5C4)c3n2)cn1C		CHEMBL2012406	=	IC50	nM	40.0	CHEMBL308	Homo sapiens	IC50	uM	0.04
	10837538	CHEMBL2013813	Inhibition of CDK1	B	Cn1cc(Nc2ncc3cnn([C@H]4C[C@@H]5C[C@@H]5C4)c3n2)cc1C(=O)N1CCCC1		CHEMBL2012407	=	IC50	nM	41.0	CHEMBL308	Homo sapiens	IC50	uM	0.041
	10837539	CHEMBL2013813	Inhibition of CDK1	B	Cn1cc(Nc2ncc3cnn([C@H]4C[C@@H]5C[C@@H]5C4)c3n2)cc1C(=O)N1CCC[C@H]1C(N)=O		CHEMBL2012408	=	IC50	nM	10.0	CHEMBL308	Homo sapiens	IC50	uM	0.01
	10837540	CHEMBL2013813	Inhibition of CDK1	B	Cn1cc(Nc2ncc3cnn([C@H]4C[C@@H]5C[C@@H]5C4)c3n2)cc1C(=O)N1CCC[C@H]1CO		CHEMBL2012409	=	IC50	nM	10.0	CHEMBL308	Homo sapiens	IC50	uM	0.01
	10837541	CHEMBL2013813	Inhibition of CDK1	B	Cn1cc(Nc2ncc3cnn([C@H]4C[C@@H]5C[C@@H]5C4)c3n2)cc1C(=O)N1CCC[C@H]1CN1CCCC1		CHEMBL2012410	=	IC50	nM	47.0	CHEMBL308	Homo sapiens	IC50	uM	0.047
	10837542	CHEMBL2013813	Inhibition of CDK1	B	COC[C@@H]1CCCN1C(=O)c1cc(Nc2ncc3cnn([C@H]4C[C@@H]5C[C@@H]5C4)c3n2)cn1C		CHEMBL2012411	=	IC50	nM	22.0	CHEMBL308	Homo sapiens	IC50	uM	0.022
	10837543	CHEMBL2013813	Inhibition of CDK1	B	Cn1cc(Nc2ncc3cnn([C@H]4C[C@@H]5C[C@@H]5C4)c3n2)cc1C(=O)N1CCC[C@H]1CN1CCOCC1		CHEMBL2012412	=	IC50	nM	21.0	CHEMBL308	Homo sapiens	IC50	uM	0.021
	10837544	CHEMBL2013813	Inhibition of CDK1	B	Cn1cc(Nc2ncc3cnn([C@H]4C[C@@H]5C[C@@H]5C4)c3n2)cc1C(=O)N1CCC[C@@H]1CO		CHEMBL2012413	=	IC50	nM	150.0	CHEMBL308	Homo sapiens	IC50	uM	0.15
	10837545	CHEMBL2013813	Inhibition of CDK1	B	COC[C@H]1CCCN1C(=O)c1cc(Nc2ncc3cnn([C@H]4C[C@@H]5C[C@@H]5C4)c3n2)cn1C		CHEMBL2012414	=	IC50	nM	150.0	CHEMBL308	Homo sapiens	IC50	uM	0.15
	10837546	CHEMBL2013813	Inhibition of CDK1	B	Cn1cc(Nc2ncc3cnn([C@H]4C[C@@H]5C[C@@H]5C4)c3n2)cc1C(=O)N1CCC[C@@H]1CN1CCOCC1		CHEMBL2012415	=	IC50	nM	390.0	CHEMBL308	Homo sapiens	IC50	uM	0.39
	10838179	CHEMBL2015883	Inhibition of CDK1	B	C[C@H]1C/C=C/[C@@H](O)[C@@H](O)CC/C=C/c2cc(O)cc(O)c2C(=O)O1		CHEMBL1173442	=	IC50	nM	6000.0	CHEMBL308	Homo sapiens	IC50	uM	6.0
	10867514	CHEMBL2027271	Inhibition of CDK1 at 2 uM	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	10890727	CHEMBL2032823	Inhibition of CDK1	B	CN1CCN(C(=O)c2cc(Nc3ncc4cc(/C=N/O)n(C5CCCC5)c4n3)cn2C)CC1		CHEMBL2029900	=	IC50	nM	3.0	CHEMBL308	Homo sapiens	IC50	uM	0.003
	10890728	CHEMBL2032823	Inhibition of CDK1	B	CN1CCN(C(=O)c2cc(Nc3ncc4cc(C#N)n(C5CCCC5)c4n3)cn2C)CC1		CHEMBL2029901	=	IC50	nM	6.0	CHEMBL308	Homo sapiens	IC50	uM	0.006
	10890729	CHEMBL2032823	Inhibition of CDK1	B	CN1CCN(C(=O)c2cc(Nc3ncc4ccn(C5CCCC5)c4n3)cn2C)CC1		CHEMBL2029902	=	IC50	nM	240.0	CHEMBL308	Homo sapiens	IC50	uM	0.24
	10890730	CHEMBL2032823	Inhibition of CDK1	B	CN1CCN(C(=O)c2cc(Nc3ncc4cc(C(N)=O)n(C5CCCC5)c4n3)cn2C)CC1		CHEMBL2029903	=	IC50	nM	500.0	CHEMBL308	Homo sapiens	IC50	uM	0.5
	10890731	CHEMBL2032823	Inhibition of CDK1	B	CNCc1cc2cnc(Nc3cc(C(=O)N4CCN(C)CC4)n(C)c3)nc2n1C1CCCC1		CHEMBL2029904	=	IC50	nM	700.0	CHEMBL308	Homo sapiens	IC50	uM	0.7
	10890732	CHEMBL2032823	Inhibition of CDK1	B	CC(O)c1cc2cnc(Nc3cc(C(=O)N4CCN(C)CC4)n(C)c3)nc2n1C1CCCC1		CHEMBL2029905	=	IC50	nM	1100.0	CHEMBL308	Homo sapiens	IC50	uM	1.1
	10890733	CHEMBL2032823	Inhibition of CDK1	B	CN1CCN(C(=O)c2cc(Nc3ncc4cc(CO)n(C5CCCC5)c4n3)cn2C)CC1		CHEMBL2029906	=	IC50	nM	1300.0	CHEMBL308	Homo sapiens	IC50	uM	1.3
	10890734	CHEMBL2032823	Inhibition of CDK1	B	CN1CCN(C(=O)c2cc(Nc3ncc4cc(C(=O)O)n(C5CCCC5)c4n3)cn2C)CC1		CHEMBL2029907	=	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	10890735	CHEMBL2032823	Inhibition of CDK1	B	CN1CCN(C(=O)c2cc(Nc3ncc4cc(-c5cnco5)n(C5CCCC5)c4n3)cn2C)CC1		CHEMBL2029908	=	IC50	nM	28.0	CHEMBL308	Homo sapiens	IC50	uM	0.028
	10890736	CHEMBL2032823	Inhibition of CDK1	B	CN1CCN(C(=O)c2cc(Nc3ncc4cc(-c5cnn(C)c5)n(C5CCCC5)c4n3)cn2C)CC1		CHEMBL2029909	=	IC50	nM	180.0	CHEMBL308	Homo sapiens	IC50	uM	0.18
	10890737	CHEMBL2032823	Inhibition of CDK1	B	CN1CCN(C(=O)c2cc(Nc3ncc4cc(-c5cncn5C)n(C5CCCC5)c4n3)cn2C)CC1		CHEMBL2029910	=	IC50	nM	200.0	CHEMBL308	Homo sapiens	IC50	uM	0.2
	10890738	CHEMBL2032823	Inhibition of CDK1	B	Cc1c(-c2cc3cnc(Nc4cc(C(=O)N5CCN(C)CC5)n(C)c4)nc3n2C2CCCC2)cnn1C		CHEMBL2029911	=	IC50	nM	330.0	CHEMBL308	Homo sapiens	IC50	uM	0.33
	10890739	CHEMBL2032823	Inhibition of CDK1	B	CC(C)CCn1cc(-c2cc3cnc(Nc4cc(C(=O)N5CCN(C)CC5)n(C)c4)nc3n2C2CCCC2)cn1		CHEMBL2029912	=	IC50	nM	1400.0	CHEMBL308	Homo sapiens	IC50	uM	1.4
	10890740	CHEMBL2032823	Inhibition of CDK1	B	CN1CCN(C(=O)c2cc(Nc3ncc4cc(-c5ccnn5C)n(C5CCCC5)c4n3)cn2C)CC1		CHEMBL2029913	=	IC50	nM	1700.0	CHEMBL308	Homo sapiens	IC50	uM	1.7
	10890741	CHEMBL2032823	Inhibition of CDK1	B	CN1CCN(C(=O)c2cc(Nc3ncc4cc(-c5cnn(Cc6ccccc6)c5)n(C5CCCC5)c4n3)cn2C)CC1		CHEMBL2029914	=	IC50	nM	2000.0	CHEMBL308	Homo sapiens	IC50	uM	2.0
Active	10911625	CHEMBL2039882	Inhibition of CDC2 phosphorylation at Tyr15 in human Hep3B cells at 160 uM after 18 hrs by Western blotting analysis	B	CCC(C)[C@@H]1NC(=O)[C@@H](Cc2ccccc2)n2c1nc1c(c2=O)C=CC=CO1		CHEMBL1802135		Inhibition	%		CHEMBL308	Homo sapiens	INH		
	10978302	CHEMBL2065346	Inhibition of CDC2	B	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1ccccc1		CHEMBL1999931	=	Ki	nM	5.012	CHEMBL308	Homo sapiens	pKi		8.3
	10978303	CHEMBL2065346	Inhibition of CDC2	B	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1cccc(Cl)c1		CHEMBL1983595	<	Ki	nM	10000.0	CHEMBL308	Homo sapiens	pKi		5.0
	10978304	CHEMBL2065346	Inhibition of CDC2	B	O[C@H]1CC[C@H](Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL2062936	=	Ki	nM	39.81	CHEMBL308	Homo sapiens	pKi		7.4
	10978305	CHEMBL2065346	Inhibition of CDC2	B	CN(C)[C@H]1CC[C@H](Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL2062937	<	Ki	nM	10000.0	CHEMBL308	Homo sapiens	pKi		5.0
	11018498	CHEMBL2091527	Inhibition of CDK1 at 10 uM	B	Nc1n[nH]c2nc(Nc3cccc(NC(=O)Nc4ccc(F)c(Cl)c4)c3)ncc12		CHEMBL2089212	=	Inhibition	%	42.0	CHEMBL308	Homo sapiens	INH	%	42.0
Not Determined	12075963	CHEMBL2161546	Inhibition of CDK1	B	CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4ccc(C)c(S(N)(=O)=O)c4)n3)ccn2)cc1		CHEMBL2158860		IC50			CHEMBL308	Homo sapiens	IC50		
Not Determined	12075964	CHEMBL2161546	Inhibition of CDK1	B	CN1CCN(c2cc(-c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccn2)CC1		CHEMBL2158856		IC50			CHEMBL308	Homo sapiens	IC50		
Not Determined	12075965	CHEMBL2161546	Inhibition of CDK1	B	c1ccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)cc1		CHEMBL2158852		IC50			CHEMBL308	Homo sapiens	IC50		
Not Determined	12075966	CHEMBL2161546	Inhibition of CDK1	B	N#Cc1cccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)c1		CHEMBL2158851		IC50			CHEMBL308	Homo sapiens	IC50		
Not Determined	12075967	CHEMBL2161546	Inhibition of CDK1	B	COc1cccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)c1		CHEMBL2158850		IC50			CHEMBL308	Homo sapiens	IC50		
Not Determined	12075968	CHEMBL2161546	Inhibition of CDK1	B	FC(F)(F)c1cccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)c1		CHEMBL2158849		IC50			CHEMBL308	Homo sapiens	IC50		
Not Determined	12075969	CHEMBL2161546	Inhibition of CDK1	B	NS(=O)(=O)c1ccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)cc1		CHEMBL2158847		IC50			CHEMBL308	Homo sapiens	IC50		
Not Determined	12075970	CHEMBL2161546	Inhibition of CDK1	B	Clc1ccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)cc1		CHEMBL2158846		IC50			CHEMBL308	Homo sapiens	IC50		
	12075992	CHEMBL2161546	Inhibition of CDK1	B	OCCCNc1cc(-c2ccnc(Nc3cccc(Cl)c3)n2)ccn1		CHEMBL300389	<	IC50	nM	5.2	CHEMBL308	Homo sapiens	IC50	uM	0.0052
	12076009	CHEMBL2161546	Inhibition of CDK1	B	CCN(CC)S(=O)(=O)c1cc(Nc2nccc(-c3ccnc(-c4ccc(NC(=O)NC)cc4)c3)n2)ccc1Cl		CHEMBL2158866	=	IC50	nM	32000.0	CHEMBL308	Homo sapiens	IC50	uM	32.0
	12076011	CHEMBL2161546	Inhibition of CDK1	B	CCN(CC)S(=O)(=O)c1cc(Nc2nccc(-c3ccnc(-c4ccc(NC(=O)NC)cc4)c3)n2)ccc1C		CHEMBL2158863	=	IC50	nM	14000.0	CHEMBL308	Homo sapiens	IC50	uM	14.0
	12076692	CHEMBL2161546	Inhibition of CDK1	B	CCN(CC)S(=O)(=O)c1cccc(Nc2nccc(-c3ccnc(-c4ccc(NC(=O)NC)cc4)c3)n2)c1		CHEMBL2158011	=	IC50	nM	3200.0	CHEMBL308	Homo sapiens	IC50	uM	3.2
	12076698	CHEMBL2161546	Inhibition of CDK1	B	CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4ccc(Cl)c(S(=O)(=O)N(C)C)c4)n3)ccn2)cc1		CHEMBL2158865	=	IC50	nM	1400.0	CHEMBL308	Homo sapiens	IC50	uM	1.4
	12076699	CHEMBL2161546	Inhibition of CDK1	B	CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4ccc(C)c(S(=O)(=O)N(C)C)c4)n3)ccn2)cc1		CHEMBL2158861	=	IC50	nM	1200.0	CHEMBL308	Homo sapiens	IC50	uM	1.2
	12076708	CHEMBL2161546	Inhibition of CDK1	B	CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4ccc(Cl)c(S(=O)(=O)NC)c4)n3)ccn2)cc1		CHEMBL2158864	=	IC50	nM	320.0	CHEMBL308	Homo sapiens	IC50	uM	0.32
	12076713	CHEMBL2161546	Inhibition of CDK1	B	CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4ccc(C)c(S(=O)(=O)NC)c4)n3)ccn2)cc1		CHEMBL2158862	=	IC50	nM	230.0	CHEMBL308	Homo sapiens	IC50	uM	0.23
	12076714	CHEMBL2161546	Inhibition of CDK1	B	CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4cccc(S(=O)(=O)NC)c4)n3)ccn2)cc1		CHEMBL2158859	=	IC50	nM	210.0	CHEMBL308	Homo sapiens	IC50	uM	0.21
	12076723	CHEMBL2161546	Inhibition of CDK1	B	NS(=O)(=O)c1cccc(Nc2nccc(-c3ccnc(N4C5CCC4COC5)c3)n2)c1		CHEMBL2158854	=	IC50	nM	100.0	CHEMBL308	Homo sapiens	IC50	uM	0.1
	12076724	CHEMBL2161546	Inhibition of CDK1	B	Cc1cccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)c1		CHEMBL2158848	=	IC50	nM	100.0	CHEMBL308	Homo sapiens	IC50	uM	0.1
	12076735	CHEMBL2161546	Inhibition of CDK1	B	CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccn2)cc1		CHEMBL2158858	=	IC50	nM	62.0	CHEMBL308	Homo sapiens	IC50	uM	0.062
	12076739	CHEMBL2161546	Inhibition of CDK1	B	NS(=O)(=O)c1cccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)c1		CHEMBL2158845	=	IC50	nM	55.0	CHEMBL308	Homo sapiens	IC50	uM	0.055
	12076742	CHEMBL2161546	Inhibition of CDK1	B	NS(=O)(=O)c1cccc(Nc2nccc(-c3ccnc(N4CC5CCC(C4)O5)c3)n2)c1		CHEMBL2158855	=	IC50	nM	48.0	CHEMBL308	Homo sapiens	IC50	uM	0.048
	12076747	CHEMBL2161546	Inhibition of CDK1	B	NS(=O)(=O)c1cccc(Nc2nccc(-c3ccnc(N4CCCCC4)c3)n2)c1		CHEMBL2158857	=	IC50	nM	36.0	CHEMBL308	Homo sapiens	IC50	uM	0.036
	12076748	CHEMBL2161546	Inhibition of CDK1	B	Clc1cccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)c1		CHEMBL2158844	=	IC50	nM	35.0	CHEMBL308	Homo sapiens	IC50	uM	0.035
	12076762	CHEMBL2161546	Inhibition of CDK1	B	NS(=O)(=O)c1cccc(Nc2nccc(-c3ccnc(NCCCO)c3)n2)c1		CHEMBL2158843	=	IC50	nM	12.0	CHEMBL308	Homo sapiens	IC50	uM	0.012
	12076767	CHEMBL2161546	Inhibition of CDK1	B	CCN(CC)c1cc(-c2ccnc(Nc3cccc(S(N)(=O)=O)c3)n2)ccn1		CHEMBL2158853	=	IC50	nM	7.4	CHEMBL308	Homo sapiens	IC50	uM	0.0074
	12100982	CHEMBL2173149	Inhibition of human CDK1	B	O=C(CBr)N(c1ccccc1)S(=O)(=O)c1cc(Cl)sc1Cl		CHEMBL1171238	>	IC50	nM	20000.0	CHEMBL308	Homo sapiens	IC50	uM	20.0
Not Determined	12152276	CHEMBL2188995	Inhibition of CDK1	B	O=C(Nc1ccc(O)cn1)Nc1cccc2c1C1CCCCN1C2=O		CHEMBL2180845		IC50			CHEMBL308	Homo sapiens	IC50		
Not Determined	12152277	CHEMBL2188995	Inhibition of CDK1	B	O=C(Nc1cccc2c1C1CCCCN1C2=O)Nc1ncccc1O		CHEMBL2180844		IC50			CHEMBL308	Homo sapiens	IC50		
Not Determined	12152278	CHEMBL2188995	Inhibition of CDK1	B	O=C(Nc1ccc(-c2ccccc2)cn1)Nc1cccc2c1C1CCCCN1C2=O		CHEMBL2180843		IC50			CHEMBL308	Homo sapiens	IC50		
Not Determined	12152279	CHEMBL2188995	Inhibition of CDK1	B	O=C(Nc1cccc(N2CCCCC2)n1)Nc1cccc2c1C1CCCCN1C2=O		CHEMBL2180859		IC50			CHEMBL308	Homo sapiens	IC50		
Not Determined	12152280	CHEMBL2188995	Inhibition of CDK1	B	COc1cccnc1NC(=O)Nc1cccc2c1C1CCCCN1C2=O		CHEMBL2180858		IC50			CHEMBL308	Homo sapiens	IC50		
Not Determined	12152281	CHEMBL2188995	Inhibition of CDK1	B	O=C(Nc1cccc2c1C1CCCCN1C2=O)Nc1nc(Cl)c(Cl)c(Cl)c1Cl		CHEMBL2180857		IC50			CHEMBL308	Homo sapiens	IC50		
Not Determined	12152282	CHEMBL2188995	Inhibition of CDK1	B	O=C(Nc1cccc2c1C1CCCCN1C2=O)Nc1ncc(F)cc1F		CHEMBL2180856		IC50			CHEMBL308	Homo sapiens	IC50		
Not Determined	12152283	CHEMBL2188995	Inhibition of CDK1	B	O=C(Nc1cccc(F)n1)Nc1cccc2c1C1CCCCN1C2=O		CHEMBL2180855		IC50			CHEMBL308	Homo sapiens	IC50		
Not Determined	12152284	CHEMBL2188995	Inhibition of CDK1	B	O=C(Nc1cc(Br)ccn1)Nc1cccc2c1C1CCCCN1C2=O		CHEMBL2180854		IC50			CHEMBL308	Homo sapiens	IC50		
Not Determined	12152285	CHEMBL2188995	Inhibition of CDK1	B	O=C(Nc1ccc(Br)cn1)Nc1cccc2c1C1CCCCN1C2=O		CHEMBL2180853		IC50			CHEMBL308	Homo sapiens	IC50		
Not Determined	12152286	CHEMBL2188995	Inhibition of CDK1	B	O=C(Nc1cccc(Br)n1)Nc1cccc2c1C1CCCCN1C2=O		CHEMBL2180852		IC50			CHEMBL308	Homo sapiens	IC50		
	12152287	CHEMBL2188995	Inhibition of CDK1	B	O=C(Nc1ccccn1)Nc1cccc2c1C1CCCCN1C2=O		CHEMBL2180862	=	IC50	nM	75.0	CHEMBL308	Homo sapiens	IC50	uM	0.075
Active	12174712	CHEMBL2210607	Activation of CDK1 in human Jurkat T cells overexpressing Bcl2 assessed as increase in p-histone H3 Ser-10 level at 7.5 to 30 ug/ml by Western blot analysis	B	CCOC(C)(C)/C=C1/C=C(C(=O)O)C(O)CO1		CHEMBL2203686		Activity			CHEMBL308	Homo sapiens	Activity		
Active	12174713	CHEMBL2210608	Activation of CDK1 in human Jurkat T cells overexpressing Neo assessed as increase in p-histone H3 Ser-10 level at 7.5 to 30 ug/ml by Western blot analysis	B	CCOC(C)(C)/C=C1/C=C(C(=O)O)C(O)CO1		CHEMBL2203686		Activity			CHEMBL308	Homo sapiens	Activity		
Active	12174716	CHEMBL2211019	Activation of CDK1 in human Jurkat T cells overexpressing Bcl2 assessed as increase in p-CDK1 Thr-161 level at 7.5 to 30 ug/ml by Western blot analysis	B	CCOC(C)(C)/C=C1/C=C(C(=O)O)C(O)CO1		CHEMBL2203686		Activity			CHEMBL308	Homo sapiens	Activity		
Active	12174717	CHEMBL2211020	Activation of CDK1 in human Jurkat T cells overexpressing Neo assessed as increase in p-CDK1 Thr-161 level at 7.5 to 30 ug/ml by Western blot analysis	B	CCOC(C)(C)/C=C1/C=C(C(=O)O)C(O)CO1		CHEMBL2203686		Activity			CHEMBL308	Homo sapiens	Activity		
Active	12174718	CHEMBL2211021	Activation of CDK1 in human Jurkat T cells overexpressing Bcl2 assessed as decrease in p-CDK1 Tyr-15 level at 7.5 to 30 ug/ml by Western blot analysis	B	CCOC(C)(C)/C=C1/C=C(C(=O)O)C(O)CO1		CHEMBL2203686		Activity			CHEMBL308	Homo sapiens	Activity		
Active	12174719	CHEMBL2211022	Activation of CDK1 in human Jurkat T cells overexpressing Neo assessed as decrease in p-CDK1 Tyr-15 level at 7.5 to 30 ug/ml by Western blot analysis	B	CCOC(C)(C)/C=C1/C=C(C(=O)O)C(O)CO1		CHEMBL2203686		Activity			CHEMBL308	Homo sapiens	Activity		
	12175184	CHEMBL2210710	Inhibition of CDK1	B	CN(c1ccc(F)c(NC(=O)c2cccc(OC(C)(C)C#N)c2Cl)c1)c1ccc2nc(NC(=O)C3CC3)sc2n1		CHEMBL2204532	=	IC50	nM	3700.0	CHEMBL308	Homo sapiens	IC50	nM	3700.0
	12183913	CHEMBL2211052	Inhibition of CDC2	B	CC(C)(C)NS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1		CHEMBL2205766	<	IC50	nM	10000.0	CHEMBL308	Homo sapiens	pIC50		5.0
	12187422	CHEMBL2216272	Inhibition of CDK1	B	COc1cc(Nc2cnc(C#N)c(O[C@H](C)CN(C)C)n2)ncc1-c1cnn(C)c1		CHEMBL2203843	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	12187423	CHEMBL2216272	Inhibition of CDK1	B	CNc1cc(Nc2cnc(C#N)c(O[C@H](C)CN(C)C)n2)ncc1-c1cnn(C)c1		CHEMBL2204592	=	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	12187424	CHEMBL2216272	Inhibition of CDK1	B	COC(=O)c1cnc(Nc2cnc(C#N)cn2)cc1NCC1CCNCC1		CHEMBL1928692	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	12187425	CHEMBL2216272	Inhibition of CDK1	B	C[C@H](CN(C)C)Oc1nc(Nc2cc3cccc(Cl)c3cn2)cnc1C#N		CHEMBL1928705	=	IC50	nM	7500.0	CHEMBL308	Homo sapiens	IC50	uM	7.5
	12187786	CHEMBL2208531	Inhibition of CDK1	B	O=S1(=O)NCCCNc2nc(ncc2Br)Nc2cccc1c2		CHEMBL1235529	=	IC50	nM	20.0	CHEMBL308	Homo sapiens	IC50	nM	20.0
	12187789	CHEMBL2208531	Inhibition of CDK1	B	C[C@@H]1C[C@H]2CN1CCn1nc3c(cccc3c1O)-c1nc3c(cccc3nc1O)O2		CHEMBL215803	=	IC50	nM	1.0	CHEMBL308	Homo sapiens	IC50	nM	1.0
	12187790	CHEMBL2208531	Inhibition of CDK1	B	N#CCNc1nc(Nc2ccccc2)ncc1Br		CHEMBL2203628	=	IC50	nM	100.0	CHEMBL308	Homo sapiens	IC50	nM	100.0
	12621665	CHEMBL2319813	Inhibition of human recombinant CDK1 using histone H1 as substrate and [gamma33P]-ATP after 15 mins by scintillation counting	B	CC1=C(O)[C@@H](C/C(C)=C/CCC(C)/C=C/C=C(\C)CCCc2ccoc2)OC1=O		CHEMBL464381	<	IC50	nM	100000.0	CHEMBL308	Homo sapiens	pIC50		4.0
	12621688	CHEMBL2319813	Inhibition of human recombinant CDK1 using histone H1 as substrate and [gamma33P]-ATP after 15 mins by scintillation counting	B	CC1=C(O)[C@@H](C/C(C)=C/CCC(C)/C=C/C=C(\C)CCCc2ccoc2)OC1=O		CHEMBL464381	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	12622854	CHEMBL2321001	Inhibition of CDK1 (unknown origin)	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	=	Ki	nM	480.0	CHEMBL308	Homo sapiens	Ki	nM	480.0
	12622856	CHEMBL2321001	Inhibition of CDK1 (unknown origin)	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	Ki	nM	70.0	CHEMBL308	Homo sapiens	Ki	nM	70.0
	12622862	CHEMBL2321001	Inhibition of CDK1 (unknown origin)	B	CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4)oc23)[C@@H]1CO.Cl		CHEMBL4296686	<	Ki	nM	100.0	CHEMBL308	Homo sapiens	Ki	nM	100.0
Active	13372545	CHEMBL2405061	Inhibition of CDK1 in human G361 cells sensitized with nocodazole assessed as PP1alpha phosphorylation at Thr320 at 640 nM after 8 hrs by immunoblotting analysis	B	NC1CCC(Nc2nc(NCc3ccc(-c4ccccc4O)nc3)c3ncn(C4CCCC4)c3n2)CC1		CHEMBL2402946		Inhibition	%		CHEMBL308	Homo sapiens	INH		
Active	13372556	CHEMBL2405068	Inhibition of CDK1 in human G361 cells sensitized with nocodazole assessed as PP1alpha phosphorylation at Thr320 at 640 nM after 4 hrs by immunoblotting analysis	B	NC1CCC(Nc2nc(NCc3ccc(-c4ccccc4O)nc3)c3ncn(C4CCCC4)c3n2)CC1		CHEMBL2402946		Inhibition	%		CHEMBL308	Homo sapiens	INH		
	13373991	CHEMBL2406224	Inhibition of human recombinant CDK1	B	Nc1ccccc1CNc1nc(NC2CCC(N)CC2)nc2c1ncn2C1CCCC1		CHEMBL2402948	=	IC50	nM	93.0	CHEMBL308	Homo sapiens	IC50	nM	93.0
	13373992	CHEMBL2406224	Inhibition of human recombinant CDK1	B	NC1CCC(Nc2nc(NCc3cc(Cl)ccc3O)c3ncn(C4CCCC4)c3n2)CC1		CHEMBL2402947	=	IC50	nM	23.0	CHEMBL308	Homo sapiens	IC50	nM	23.0
	13373993	CHEMBL2406224	Inhibition of human recombinant CDK1	B	NC1CCC(Nc2nc(NCc3ccc(-c4ccccc4O)nc3)c3ncn(C4CCCC4)c3n2)CC1		CHEMBL2402946	=	IC50	nM	46.8	CHEMBL308	Homo sapiens	IC50	nM	46.8
	13373994	CHEMBL2406224	Inhibition of human recombinant CDK1	B	NC1CCC(Nc2nc(NCc3ccc(-c4ccccc4O)cc3)c3ncn(C4CCCC4)c3n2)CC1		CHEMBL2402945	=	IC50	nM	777.0	CHEMBL308	Homo sapiens	IC50	nM	777.0
	13373995	CHEMBL2406224	Inhibition of human recombinant CDK1	B	CC(C)(O)CNc1nc(NCc2ccc(-c3ccco3)nc2)c2ncn(C3CCCC3)c2n1		CHEMBL2403099	=	IC50	nM	555.0	CHEMBL308	Homo sapiens	IC50	nM	555.0
	13373996	CHEMBL2406224	Inhibition of human recombinant CDK1	B	OC1CCC(Nc2nc(NCc3ccc(-c4ccco4)nc3)c3ncn(C4CCCC4)c3n2)CC1		CHEMBL2403098	=	IC50	nM	215.0	CHEMBL308	Homo sapiens	IC50	nM	215.0
	13373997	CHEMBL2406224	Inhibition of human recombinant CDK1	B	NC1CCC(Nc2nc(NCc3ccc(-c4ccsc4)nc3)c3ncn(C4CCCC4)c3n2)CC1		CHEMBL2403097	=	IC50	nM	169.0	CHEMBL308	Homo sapiens	IC50	nM	169.0
	13373998	CHEMBL2406224	Inhibition of human recombinant CDK1	B	NC1CCC(Nc2nc(NCc3ccc(-c4cccs4)nc3)c3ncn(C4CCCC4)c3n2)CC1		CHEMBL2403096	=	IC50	nM	49.0	CHEMBL308	Homo sapiens	IC50	nM	49.0
	13373999	CHEMBL2406224	Inhibition of human recombinant CDK1	B	NC1CCC(Nc2nc(NCc3ccc(-c4ccoc4)nc3)c3ncn(C4CCCC4)c3n2)CC1		CHEMBL2403095	=	IC50	nM	66.0	CHEMBL308	Homo sapiens	IC50	nM	66.0
	13374000	CHEMBL2406224	Inhibition of human recombinant CDK1	B	NC1CCC(Nc2nc(NCc3ccc(-c4ccco4)nc3)c3ncn(C4CCCC4)c3n2)CC1		CHEMBL2403094	=	IC50	nM	50.0	CHEMBL308	Homo sapiens	IC50	nM	50.0
	13374001	CHEMBL2406224	Inhibition of human recombinant CDK1	B	NC1CCC(Nc2nc(NCc3ccc(-c4cccc(F)c4)nc3)c3ncn(C4CCCC4)c3n2)CC1		CHEMBL2403093	=	IC50	nM	77.0	CHEMBL308	Homo sapiens	IC50	nM	77.0
	13374002	CHEMBL2406224	Inhibition of human recombinant CDK1	B	COc1ccccc1-c1ccc(CNc2nc(NC3CCC(N)CC3)nc3c2ncn3C2CCCC2)cn1		CHEMBL2403092	=	IC50	nM	118.0	CHEMBL308	Homo sapiens	IC50	nM	118.0
	13374003	CHEMBL2406224	Inhibition of human recombinant CDK1	B	Nc1ccccc1-c1ccc(CNc2nc(NC3CCC(N)CC3)nc3c2ncn3C2CCCC2)cn1		CHEMBL2403091	=	IC50	nM	100.0	CHEMBL308	Homo sapiens	IC50	nM	100.0
	13374004	CHEMBL2406224	Inhibition of human recombinant CDK1	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	=	IC50	nM	2421.0	CHEMBL308	Homo sapiens	IC50	nM	2421.0
	13374005	CHEMBL2406224	Inhibition of human recombinant CDK1	B	CC[C@H](CO)Nc1nc(NCc2ccc(-c3ccccn3)cc2)c2ncn(C3CCCC3)c2n1		CHEMBL2402949	=	IC50	nM	90.0	CHEMBL308	Homo sapiens	IC50	nM	90.0
	13374006	CHEMBL2406224	Inhibition of human recombinant CDK1	B	N[C@H]1CC[C@H](Nc2nc(NCc3ccccc3)c3ncn(C4CCCC4)c3n2)CC1		CHEMBL150261	=	IC50	nM	52.0	CHEMBL308	Homo sapiens	IC50	nM	52.0
	13374007	CHEMBL2406224	Inhibition of human recombinant CDK1	B	NC1CCC(Nc2nc(NCc3ccc(-c4ccccc4)cc3)c3ncn(C4CCCC4)c3n2)CC1		CHEMBL2402952	=	IC50	nM	232.0	CHEMBL308	Homo sapiens	IC50	nM	232.0
	13374008	CHEMBL2406224	Inhibition of human recombinant CDK1	B	Nc1ccccc1-c1ccc(CNc2nc(NC3CCC(N)CC3)nc3c2ncn3C2CCCC2)cc1		CHEMBL2402953	=	IC50	nM	152.0	CHEMBL308	Homo sapiens	IC50	nM	152.0
	13374009	CHEMBL2406224	Inhibition of human recombinant CDK1	B	COc1ccccc1-c1ccc(CNc2nc(NC3CCC(N)CC3)nc3c2ncn3C2CCCC2)cc1		CHEMBL2402954	=	IC50	nM	301.0	CHEMBL308	Homo sapiens	IC50	nM	301.0
	13374010	CHEMBL2406224	Inhibition of human recombinant CDK1	B	NC1CCC(Nc2nc(NCc3ccc(-c4cccc(F)c4)cc3)c3ncn(C4CCCC4)c3n2)CC1		CHEMBL2403083	=	IC50	nM	422.0	CHEMBL308	Homo sapiens	IC50	nM	422.0
	13374011	CHEMBL2406224	Inhibition of human recombinant CDK1	B	NC1CCC(Nc2nc(NCc3ccc(-c4ccco4)cc3)c3ncn(C4CCCC4)c3n2)CC1		CHEMBL2403084	=	IC50	nM	148.0	CHEMBL308	Homo sapiens	IC50	nM	148.0
	13374012	CHEMBL2406224	Inhibition of human recombinant CDK1	B	NC1CCC(Nc2nc(NCc3ccc(-c4ccoc4)cc3)c3ncn(C4CCCC4)c3n2)CC1		CHEMBL2403085	=	IC50	nM	202.0	CHEMBL308	Homo sapiens	IC50	nM	202.0
	13374013	CHEMBL2406224	Inhibition of human recombinant CDK1	B	NC1CCC(Nc2nc(NCc3ccc(-c4cccs4)cc3)c3ncn(C4CCCC4)c3n2)CC1		CHEMBL2403086	=	IC50	nM	119.0	CHEMBL308	Homo sapiens	IC50	nM	119.0
	13374014	CHEMBL2406224	Inhibition of human recombinant CDK1	B	NC1CCC(Nc2nc(NCc3ccc(-c4ccsc4)cc3)c3ncn(C4CCCC4)c3n2)CC1		CHEMBL2403087	=	IC50	nM	183.0	CHEMBL308	Homo sapiens	IC50	nM	183.0
	13374015	CHEMBL2406224	Inhibition of human recombinant CDK1	B	NC1CCC(Nc2nc(NCc3ccc(-n4cccn4)cc3)c3ncn(C4CCCC4)c3n2)CC1		CHEMBL2403088	=	IC50	nM	58.0	CHEMBL308	Homo sapiens	IC50	nM	58.0
	13374016	CHEMBL2406224	Inhibition of human recombinant CDK1	B	CC(C)(O)CNc1nc(NCc2ccc(-c3ccco3)cc2)c2ncn(C3CCCC3)c2n1		CHEMBL2403089	>	IC50	nM	999.0	CHEMBL308	Homo sapiens	IC50	nM	999.0
	13374017	CHEMBL2406224	Inhibition of human recombinant CDK1	B	NC1CCC(Nc2nc(NCc3ccc(-c4ccccc4)nc3)c3ncn(C4CCCC4)c3n2)CC1		CHEMBL2403090	=	IC50	nM	184.0	CHEMBL308	Homo sapiens	IC50	nM	184.0
	13446092	CHEMBL2427323	Inhibition of CDK1 (unknown origin) using histone H1 as substrate after 10 mins in presence of [gamma-32P]-ATP	B	COc1ccc(NC(=S)NC(=O)c2cn(-c3ccccc3)nc2-c2ccc(OC)cc2)cc1		CHEMBL2426395	=	IC50	nM	522.0	CHEMBL308	Homo sapiens	IC50	nM	522.0
	13446093	CHEMBL2427323	Inhibition of CDK1 (unknown origin) using histone H1 as substrate after 10 mins in presence of [gamma-32P]-ATP	B	COc1ccc(NC(=S)NC(=O)c2cn(-c3ccccc3)nc2-c2ccc(F)cc2)cc1		CHEMBL2426391	=	IC50	nM	569.0	CHEMBL308	Homo sapiens	IC50	nM	569.0
	13446094	CHEMBL2427323	Inhibition of CDK1 (unknown origin) using histone H1 as substrate after 10 mins in presence of [gamma-32P]-ATP	B	COc1ccc(NC(=S)NC(=O)c2cn(-c3ccccc3)nc2-c2ccc(Cl)cc2)cc1		CHEMBL2426387	=	IC50	nM	571.0	CHEMBL308	Homo sapiens	IC50	nM	571.0
	13446095	CHEMBL2427323	Inhibition of CDK1 (unknown origin) using histone H1 as substrate after 10 mins in presence of [gamma-32P]-ATP	B	COc1ccc(NC(=S)NC(=O)c2cn(-c3ccccc3)nc2-c2ccc(C)cc2)cc1		CHEMBL2426383	=	IC50	nM	584.0	CHEMBL308	Homo sapiens	IC50	nM	584.0
	13446096	CHEMBL2427323	Inhibition of CDK1 (unknown origin) using histone H1 as substrate after 10 mins in presence of [gamma-32P]-ATP	B	COc1ccc(NC(=S)NC(=O)c2cn(-c3ccccc3)nc2-c2ccccc2)cc1		CHEMBL2426399	=	IC50	nM	610.0	CHEMBL308	Homo sapiens	IC50	nM	610.0
Active	13466851	CHEMBL2432710	Reduction in CDC2 phosphorylation at Tyr15 in human PC3 cell cytoplasm at 1 uM after 24 hrs by immunofluorescence assay	B	CC1=C(CO)C(=O)O[C@H]([C@@H](C)[C@H]2CC[C@H]3[C@@H]4C[C@H]5O[C@]56[C@@H](O)C=CC(=O)[C@]6(C)[C@H]4CC[C@@]32C)C1		CHEMBL1221986		Activity			CHEMBL308	Homo sapiens	Activity		
Active	13466854	CHEMBL2432724	Reduction in CDC2 phosphorylation at Tyr15 in human PC3 cells at 1 uM after 12 to 24 hrs by Western blotting analysis	B	CC1=C(CO)C(=O)O[C@H]([C@@H](C)[C@H]2CC[C@H]3[C@@H]4C[C@H]5O[C@]56[C@@H](O)C=CC(=O)[C@]6(C)[C@H]4CC[C@@]32C)C1		CHEMBL1221986		Activity			CHEMBL308	Homo sapiens	Activity		
	13475355	CHEMBL2439767	Inhibition of wild type human CDK1 by high throughput ATP-[33P] radiolabeled assay	B	CN1CCN(Cc2ccc(-c3cnc4[nH]cc(-c5ccc6[nH]ccc6c5)c4c3)cc2)CC1		CHEMBL2436978	=	IC50	nM	1125.0	CHEMBL308	Homo sapiens	IC50	nM	1125.0
	13836308	CHEMBL3090916	Inhibition of CDK-1 (unknown origin) after 90 mins by TR-FRET/IMAP fluorescence polarization assay	B	CNS(=O)(=O)Nc1cccc(Cc2c(C)c3cc(Cl)c(OC(=O)N(C)C)cc3oc2=O)c1		CHEMBL3086065	>	IC50	nM	50000.0	CHEMBL308	Homo sapiens	IC50	uM	50.0
Not Active	13859804	CHEMBL3101308	Inhibition of active state of CDK1 (unknown origin) at 1 uM	B	COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(Cl)c3)ccc2n1		CHEMBL3099755		Inhibition	%		CHEMBL308	Homo sapiens	INH		
Active	13864308	CHEMBL3102640	Decrease of cdc2 protein phosphorylation at Tyr15 in human HeLa cells at 10 to 100 nM after 24 to 48 hrs by Western blot analysis	B	COc1cc(C(=O)c2cc3cc(N)cc(OC)c3s2)cc(OC)c1OC		CHEMBL3099862		Activity			CHEMBL308	Homo sapiens	Activity		
	13914203	CHEMBL3118312	Inhibition of His-6-tagged CDK1 (unknown origin) expressed in baculovirus-infected insect cells using histone H1 as substrate after 1 hr by by liquid scintillation counting in presence of [gamma-33P]ATP	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	IC50	nM	40.0	CHEMBL308	Homo sapiens	IC50	uM	0.04
Not Active	13950888	CHEMBL3129551	Inhibition of human CDK1 at 10 uM	B	C[C@@H]1NC(c2ccc(Br)cc2)=Nc2nc3ccccn3c2C1=O		CHEMBL3125580		Inhibition	%		CHEMBL308	Homo sapiens	INH		
	14750888	CHEMBL3299296	Inhibition of CDK1 (unknown origin) assessed as inhibition of phosphate incorporation into substrate in presence of radiolabeled ATP	B	CC1(C)C=Cc2c(cc(O)c3c(=O)c4cccc(O)c4[nH]c23)O1		CHEMBL452220	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	14750889	CHEMBL3299296	Inhibition of CDK1 (unknown origin) assessed as inhibition of phosphate incorporation into substrate in presence of radiolabeled ATP	B	Cn1c2c(O)cccc2c(=O)c2c3occc3c3c(c21)C=CC(C)(C)O3		CHEMBL3297831	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	14750890	CHEMBL3299296	Inhibition of CDK1 (unknown origin) assessed as inhibition of phosphate incorporation into substrate in presence of radiolabeled ATP	B	Cn1c2c(O)cccc2c(=O)c2c3c(c4c(c21)C=CC(C)(C)O4)C=C(O)C(C)(C)O3		CHEMBL3297830	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	14750891	CHEMBL3299296	Inhibition of CDK1 (unknown origin) assessed as inhibition of phosphate incorporation into substrate in presence of radiolabeled ATP	B	COc1c(O)ccc2c(=O)c3c(O)cc4c(c3[nH]c12)C=CC(C)(C)O4		CHEMBL3297832	=	IC50	nM	5300.0	CHEMBL308	Homo sapiens	IC50	uM	5.3
	14750892	CHEMBL3299296	Inhibition of CDK1 (unknown origin) assessed as inhibition of phosphate incorporation into substrate in presence of radiolabeled ATP	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	IC50	nM	320.0	CHEMBL308	Homo sapiens	IC50	uM	0.32
	14980848	CHEMBL3372970	Inhibition of CDK1 (unknown origin) in presence of 1 mM ATP	B	CN(Cc1ccccc1)C(=O)c1ccc(S(=O)(=O)Nc2ccccc2)cc1		CHEMBL3355482	>	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	14994857	CHEMBL3371900	Inhibition of CDK1 (unknown origin) at 100 uM	B	CCCCCCCCCCCC(=O)NNC(=O)C1Sc2ccccc2N(Cc2ccccc2)C1=O		CHEMBL3358803	=	Inhibition	%	36.0	CHEMBL308	Homo sapiens	INH	%	36.0
	15013918	CHEMBL3364477	Inhibition of CDK1 (unknown origin)	B	c1ccc2[nH]c(-c3cc[nH]n3)nc2c1		CHEMBL495758	=	IC50	nM	28000.0	CHEMBL308	Homo sapiens	IC50	uM	28.0
	15013919	CHEMBL3364477	Inhibition of CDK1 (unknown origin)	B	O=C(Nc1c[nH]nc1-c1nc2ccccc2[nH]1)c1ccccc1		CHEMBL522891	=	IC50	nM	52.0	CHEMBL308	Homo sapiens	IC50	uM	0.052
	15075107	CHEMBL3376325	Inhibition of Cdk1 (unknown origin) at 1 uM	B	CS(=O)(=O)c1ccc(-c2cc3c(Nc4ccncc4)ncnn3c2)cc1		CHEMBL3326761	=	Inhibition	%	81.0	CHEMBL308	Homo sapiens	INH	%	81.0
	15075113	CHEMBL3376325	Inhibition of Cdk1 (unknown origin) at 1 uM	B	CC(C)(O)Cn1cc(-c2ccc(-c3cc4c(Nc5ccncc5)ncnn4c3)cc2)cn1		CHEMBL3326802	=	Inhibition	%	98.0	CHEMBL308	Homo sapiens	INH	%	98.0
	15101433	CHEMBL3380806	Inhibition of human CDK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1O		CHEMBL3343033	>	IC50	nM	30000.0	CHEMBL308	Homo sapiens	IC50	uM	30.0
	15101434	CHEMBL3380806	Inhibition of human CDK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)nc(C)nc2cc1O		CHEMBL3343034	>	IC50	nM	30000.0	CHEMBL308	Homo sapiens	IC50	uM	30.0
	15101435	CHEMBL3380806	Inhibition of human CDK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCO		CHEMBL3343037	>	IC50	nM	30000.0	CHEMBL308	Homo sapiens	IC50	uM	30.0
	15101436	CHEMBL3380806	Inhibition of human CDK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCC(=O)O		CHEMBL3343038	>	IC50	nM	30000.0	CHEMBL308	Homo sapiens	IC50	uM	30.0
	15101437	CHEMBL3380806	Inhibition of human CDK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCC(N)=O		CHEMBL3343039	>	IC50	nM	30000.0	CHEMBL308	Homo sapiens	IC50	uM	30.0
	15101438	CHEMBL3380806	Inhibition of human CDK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)nc(N)nc2cc1O		CHEMBL3343040	>	IC50	nM	30000.0	CHEMBL308	Homo sapiens	IC50	uM	30.0
	15101439	CHEMBL3380806	Inhibition of human CDK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)nc(NCCc3ccccn3)nc2cc1O		CHEMBL3343042	>	IC50	nM	30000.0	CHEMBL308	Homo sapiens	IC50	uM	30.0
	15101440	CHEMBL3380806	Inhibition of human CDK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	COc1cc(C(=O)Nc2ccc(NC(=O)c3ccccn3)cc2)ccc1O		CHEMBL3343044	>	IC50	nM	30000.0	CHEMBL308	Homo sapiens	IC50	uM	30.0
	15101441	CHEMBL3380806	Inhibition of human CDK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	O=C(Nc1ccc(NC(=O)c2ccccn2)cc1)c1ccc(O)c([N+](=O)[O-])c1		CHEMBL3343045	>	IC50	nM	30000.0	CHEMBL308	Homo sapiens	IC50	uM	30.0
	15101442	CHEMBL3380806	Inhibition of human CDK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	COc1cc(C(=O)Nc2ccc(NC(=O)c3ccccc3)cc2)ccc1O		CHEMBL3343046	>	IC50	nM	30000.0	CHEMBL308	Homo sapiens	IC50	uM	30.0
	15101443	CHEMBL3380806	Inhibition of human CDK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	COc1cc(C(=O)Nc2ccc(NC(=O)c3ccccc3)cc2)c(N)cc1O		CHEMBL3343047	>	IC50	nM	30000.0	CHEMBL308	Homo sapiens	IC50	uM	30.0
	15101444	CHEMBL3380806	Inhibition of human CDK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	COc1cc(C(=O)Nc2ccc(NC(=O)c3ccccc3)cc2)ccc1OCC(=O)O		CHEMBL3343048	>	IC50	nM	30000.0	CHEMBL308	Homo sapiens	IC50	uM	30.0
	15101445	CHEMBL3380806	Inhibition of human CDK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	COc1cc(C(=O)Nc2ccc(NC(=O)c3ccccn3)cc2)cc(-c2c[nH]c(=O)[nH]c2=O)c1		CHEMBL3341771	>	IC50	nM	30000.0	CHEMBL308	Homo sapiens	IC50	uM	30.0
	15101446	CHEMBL3380806	Inhibition of human CDK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	O=C(Nc1ccc(NC(=O)c2ccccn2)cc1)c1cccc(-c2c[nH]c(=O)[nH]c2=O)c1		CHEMBL3343051	>	IC50	nM	30000.0	CHEMBL308	Homo sapiens	IC50	uM	30.0
	15101447	CHEMBL3380806	Inhibition of human CDK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	COc1ccc(C(=O)Nc2ccc(NC(=O)c3ccccn3)cc2)cc1-c1c[nH]c(=O)[nH]c1=O		CHEMBL3343052	>	IC50	nM	30000.0	CHEMBL308	Homo sapiens	IC50	uM	30.0
	15101448	CHEMBL3380806	Inhibition of human CDK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	COc1cc(C(=O)Nc2ccc(NC(=O)c3ccccn3)cc2)cc(N2CCC(=O)NC2=O)c1		CHEMBL3343055	>	IC50	nM	30000.0	CHEMBL308	Homo sapiens	IC50	uM	30.0
	15101449	CHEMBL3380806	Inhibition of human CDK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	COc1cc(C(=O)Nc2ccc(NC(=O)C3CCCCN3)cc2)cc(-c2c[nH]c(=O)[nH]c2=O)c1		CHEMBL3343057	>	IC50	nM	30000.0	CHEMBL308	Homo sapiens	IC50	uM	30.0
	15101450	CHEMBL3380806	Inhibition of human CDK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	CCNC(=O)Nc1ccc(NC(=O)c2cc(OC)cc(-c3c[nH]c(=O)[nH]c3=O)c2)cc1		CHEMBL3343058	>	IC50	nM	30000.0	CHEMBL308	Homo sapiens	IC50	uM	30.0
	15228583	CHEMBL3420888	Inhibition of CDC2 kinase (unknown origin) using histone H1 and [32P]-ATP	B	O=C(Cn1c2ccc(Br)cc2c2nc3ccccc3nc21)NNC(=S)NC1CCCCC1		CHEMBL1973716	=	IC50	nM	70000.0	CHEMBL308	Homo sapiens	IC50	uM	70.0
	15753801	CHEMBL3630468	Inhibition of human CDK1 by kinase inhibition assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	4.9	CHEMBL308	Homo sapiens	IC50	10'-8M	0.49
	15753826	CHEMBL3630458	Inhibition of human CDK1 at 10 uM by kinase inhibition assay	B	COc1ccc(Nc2ncc3c(n2)-c2ccccc2SC3)cc1		CHEMBL3628537	=	Inhibition	%	84.8	CHEMBL308	Homo sapiens	INH	%	84.8
	15753902	CHEMBL3630458	Inhibition of human CDK1 at 10 uM by kinase inhibition assay	B	COc1ccc2c(c1)SCc1cnc(-c3ccccc3)nc1-2		CHEMBL481789	=	Inhibition	%	-4.2	CHEMBL308	Homo sapiens	INH	%	-4.2
	15753961	CHEMBL3630458	Inhibition of human CDK1 at 10 uM by kinase inhibition assay	B	Clc1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2SC3)cc1		CHEMBL3628818	=	Inhibition	%	-3.2	CHEMBL308	Homo sapiens	INH	%	-3.2
284319	16258105	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CNC(=O)c1cc2cnc(Nc3ccc(C(=O)N4C[C@@H]5C[C@H]4CN5)cn3)nc2n1C1CCCC1		CHEMBL3691567	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284399	16259080	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4C[C@@]5(CCCNCC5)OC4=O)cn3)nc2n1C1CCCC1		CHEMBL3691642	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284368	16259257	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CCC5COCC(C4)N5)cn3)nc2n1C1CCCC1		CHEMBL3691614	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284427	16259742	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4C[C@H]5CC[C@@H](CC4=O)N5)cn3)nc2n1C1CCCCC1		CHEMBL3691669	=	IC50	nM	13338.0	CHEMBL308	Homo sapiens	IC50	nM	13338.0
218151	16260138	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CCOC(=O)N=S(C)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)[C@H](C)O)n2)cc1		CHEMBL3648085	=	IC50	nM	16.0	CHEMBL308	Homo sapiens	IC50	nM	16.0
284356	16260162	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CCC(C4)N5C(=O)C4CCCN4)cn3)nc2n1C1CCCC1		CHEMBL3691603	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284371	16260217	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CC5CC5(N)C4)cn3)nc2n1C1CCCC1		CHEMBL3691617	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284416	16261282	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CC5CCC(CC4=O)N5)cn3)nc2n1C1CCCC1		CHEMBL3691659	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
267690	16262061	CHEMBL3707754	Kinase Assay: The compounds from the examples below were investigated for their CDK2/cyclin E, CDK1/cyclin B, CDK4/cyclin D1 and CDK7/cyclin H, ERK-2, and PKA inhibitory activity. His6-tagged recombinant human cyclin-dependent kinases CDK1/cyclin B1, CDK2/cyclin E, CDK4 and CDK7/cyclin H were expressed in sf9 cells using a baculovirus expression system. Recombinant cyclin D1 was expressed in E. coli. Proteins were purified by metal chelate affinity chromatography to greater than 90% homogeneity. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins, recombinant active ERK-2 (Upstate Biotechnology), or cyclic AMP-dependent kinase (PKA) catalytic subunit (Calbiochem Cat. 539487). Assays were performed in assay buffer (25 mM beta -glycerophosphate, 20 mM MOPS, 5 mM EGTA, 1 mM DTT, 1 mM Na3VO3, pH 7.4), into which were added 2-4 ug of active enzyme with appropriate substrates (purified histone H1 for CDK2, recombinant GST-retinoblastoma protein (residues 773-928) for CDK4.	B	CC[C@H](Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1)C(C)(C)O		CHEMBL1922212	=	IC50	nM	4400.0	CHEMBL308	Homo sapiens	IC50	nM	4400.0
284367	16262321	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CCC(C4)O5)cn3)nc2n1C1CCCC1		CHEMBL3691613	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284375	16262341	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CCC(C4)N5)cn3)nc2n1[C@H]1CC[C@H](C(C)(C)C)CC1		CHEMBL3691580	=	IC50	nM	3812.0	CHEMBL308	Homo sapiens	IC50	nM	3812.0
284361	16262540	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CC4CN5)cn3)nc2n1C1CCCCC1		CHEMBL3691608	=	IC50	nM	10377.0	CHEMBL308	Homo sapiens	IC50	nM	10377.0
11798	16262932	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CC(C)(O)CSc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br		CHEMBL3648128	=	IC50	nM	55.0	CHEMBL308	Homo sapiens	IC50	nM	55.0
294721	16262959	CHEMBL3705691	Enzyme Inhibition Assay: The tests are carried out as follows: the enzyme to be assayed was purified, for example by affinity chromatography on agarose beads. The catalytic activity was measured using radiolabeled ATP, at a standard final concentration. The test compounds were added at various concentrations making it possible to establish dose-response curves (activity of the enzyme as a function of the concentration).	B	COc1ccc2nc3c(cc2c1)C(O)CC1CC(=O)C([Si](C)(C)C)=C31		CHEMBL3651156	=	IC50	nM	1700.0	CHEMBL308	Homo sapiens	IC50	nM	1700.0
284298	16263778	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CC4CN5)cn3)nc2n1C1CCCCCC1		CHEMBL3691546	=	IC50	nM	4671.5	CHEMBL308	Homo sapiens	IC50	nM	4671.5
284433	16264140	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CC(=O)N1[C@H]2CC[C@@H]1CC(=O)N(c1ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc1)C2		CHEMBL3691675	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
308344	16264912	CHEMBL3705885	In Vitro Kinase Inhibition Assay: In vitro kinase assay analysis may be performed using standard techniques described in the art. These techniques are also used by commercial services providers in order to offer in vitro kinase activity assay services, e.g. the assays offered by Millipore Inc. (worldwide website www(dot)millipore.com), ProQinase GmbH (worldwide website www(dot)proqinase.de) and others. All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50ul reaction volume. The reaction mixture was pipetted in four steps in the following order: 20ul of assay buffer (standard buffer),5ul of ATP solution (in H2O, 5 ul of test compound (in 10% DMSO), 10ul of substrate/10ul of enzyme solution (premixed)The assay for all enzymes contained 60 mM HEPES-NaOH (pH 7.5), 3 mM MgCl2, 3 mM MnCl2, 3uM Na-Orthovanadate, 1.2 mM DTT, 50 ug/ml PEG2000, 1 uM [33P]-ATP (approx. 5x1005 cpm per well).	B	COc1cc(F)ccc1-c1ccnc(NC(=O)[C@H]2CCC[C@@H](NC(C)=O)C2)c1		CHEMBL3673434	=	IC50	nM	94.0	CHEMBL308	Homo sapiens	IC50	nM	94.0
284313	16265211	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CCC(C4)N5)cn3)nc2n1C1CCCC1		CHEMBL3691561	=	IC50	nM	13206.0	CHEMBL308	Homo sapiens	IC50	nM	13206.0
284304	16265536	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CNC(C5)C4)cn3)nc2n1C1CCCC1		CHEMBL3691552	=	IC50	nM	7101.0	CHEMBL308	Homo sapiens	IC50	nM	7101.0
284422	16266936	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CC5CCC(CC4=O)N5)cn3)nc2n1-c1ccccc1		CHEMBL3691664	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284430	16266964	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4C[C@H]5CC[C@@H](CC4=O)N5)cn3)nc2n1C1CCC1		CHEMBL3691672	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284407	16267073	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCC5(CCCN5)C4=O)cn3)nc2n1C1CCCC1		CHEMBL3691650	=	IC50	nM	13280.5	CHEMBL308	Homo sapiens	IC50	nM	13280.5
8167	16267186	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CCS(=N)(=O)c1ccc(Nc2ncc(Br)c(N[C@@H](C)[C@H](C)O)n2)cc1		CHEMBL3648122	=	IC50	nM	11.0	CHEMBL308	Homo sapiens	IC50	nM	11.0
284411	16267371	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN5CCCC5C4)cn3)nc2n1C1CCCC1		CHEMBL3691654	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284328	16267390	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CCC(C4)C5O)cn3)nc2n1C1CCCC1		CHEMBL3691576	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
8572	16267551	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CCS(=N)(=O)c1ccc(Nc2ncc(Br)c(N[C@@H](C)C(C)(C)O)n2)cc1		CHEMBL3648124	=	IC50	nM	68.0	CHEMBL308	Homo sapiens	IC50	nM	68.0
218121	16267942	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	C[C@@H](Nc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br)C(C)(C)O		CHEMBL3648072	=	IC50	nM	10.0	CHEMBL308	Homo sapiens	IC50	nM	10.0
284366	16267983	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CCC(C4)N5)nn3)nc2n1C1CCCC1		CHEMBL3691581	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
218158	16268040	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CCC(C)Sc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br		CHEMBL3648100	=	IC50	nM	97.0	CHEMBL308	Homo sapiens	IC50	nM	97.0
284428	16268375	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CC5CCC(CC4=O)N5)cn3)nc2n1C1CCC1		CHEMBL3691670	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284303	16268590	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CC(=O)N1C2CCC1CN(C(=O)c1ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCCCC5)c4n3)nc1)C2		CHEMBL3691551	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284340	16268878	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CCC(C4)N5C)cn3)nc2n1C1CCCC1		CHEMBL3691587	=	IC50	nM	12815.0	CHEMBL308	Homo sapiens	IC50	nM	12815.0
218128	16269028	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CCOC(=O)N=S(C)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)C(C)(C)O)n2)cc1		CHEMBL3648084	=	IC50	nM	27.0	CHEMBL308	Homo sapiens	IC50	nM	27.0
218145	16269663	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	C[C@H](O)[C@@H](C)Nc1nc(Nc2ccc(S(=O)(CC=O)=NS(=O)(=O)CC[Si](C)(C)C)cc2)ncc1Br		CHEMBL3648080	=	IC50	nM	170.0	CHEMBL308	Homo sapiens	IC50	nM	170.0
284351	16270517	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CCC(C4)N5)cn3)nc2n1C1CCN(C2CC2)CC1		CHEMBL3691598	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284392	16271162	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN5CCCC5C4=O)cn3)nc2n1C1CCCCC1		CHEMBL3691635	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284369	16271323	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CCC(C4)N5)cn3)nc2n1C1C[C@H]2CC[C@@H]1C2		CHEMBL3691615	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284435	16272756	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4C[C@@H]5CC[C@H](CC4=O)N5C)cn3)nc2n1C1CCCC1		CHEMBL3691677	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284335	16273036	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4[C@H]5CNC[C@@H]4COC5)cn3)nc2n1C1CCCC1		CHEMBL3691583	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
6391	16273172	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	COc1cc(Nc2ncc(Br)c(N[C@H](C)C(C)(C)O)n2)ccc1S(C)(=N)=O		CHEMBL3648115	=	IC50	nM	2.0	CHEMBL308	Homo sapiens	IC50	nM	2.0
9784	16273730	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	Cc1cc(Nc2ncc(Br)c(N[C@@H](C)C(C)(C)O)n2)ccc1S(C)(=N)=O		CHEMBL3648125	=	IC50	nM	9.0	CHEMBL308	Homo sapiens	IC50	nM	9.0
284386	16275237	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4C[C@@H]5CNC[C@@H]5CC4=O)cn3)nc2n1C1CCCC1		CHEMBL3691629	=	IC50	nM	25059.0	CHEMBL308	Homo sapiens	IC50	nM	25059.0
6383	16275316	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CN=S(C)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)[C@@H](C)O)n2)cc1OC		CHEMBL3648113	=	IC50	nM	7.0	CHEMBL308	Homo sapiens	IC50	nM	7.0
218138	16275739	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CCS(=N)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)C(C)(C)O)n2)cc1		CHEMBL3648123	=	IC50	nM	8.0	CHEMBL308	Homo sapiens	IC50	nM	8.0
284334	16275812	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN1CC2(C)CN(C(=O)c3ccc(Nc4ncc5cc(C(=O)N(C)C)n(C6CCCC6)c5n4)nc3)CC(C)(C1)C2O		CHEMBL3691582	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284393	16275834	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN5CCCCC5C4=O)cn3)nc2n1C1CCCC1		CHEMBL3691636	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284350	16275852	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CCC(C4)N5)cn3)nc2n1C1CCC1		CHEMBL3691597	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284362	16276170	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CCC(C4)N5)cn3)nc2n1-c1ccc(C(C)(C)C#N)cc1		CHEMBL3691609	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284439	16277247	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN5CCC[C@H]5C4=O)cn3)nc2n1C1CCCC1		CHEMBL3691681	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
218126	16277288	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	COc1cc(Nc2ncc(Br)c(O[C@H](C)[C@H](C)O)n2)ccc1S(C)(=N)=O		CHEMBL3648082	=	IC50	nM	5.0	CHEMBL308	Homo sapiens	IC50	nM	5.0
284355	16277389	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CCC(C4)N5C(=O)CN)cn3)nc2n1C1CCCC1		CHEMBL3691602	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
267682	16277509	CHEMBL3707754	Kinase Assay: The compounds from the examples below were investigated for their CDK2/cyclin E, CDK1/cyclin B, CDK4/cyclin D1 and CDK7/cyclin H, ERK-2, and PKA inhibitory activity. His6-tagged recombinant human cyclin-dependent kinases CDK1/cyclin B1, CDK2/cyclin E, CDK4 and CDK7/cyclin H were expressed in sf9 cells using a baculovirus expression system. Recombinant cyclin D1 was expressed in E. coli. Proteins were purified by metal chelate affinity chromatography to greater than 90% homogeneity. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins, recombinant active ERK-2 (Upstate Biotechnology), or cyclic AMP-dependent kinase (PKA) catalytic subunit (Calbiochem Cat. 539487). Assays were performed in assay buffer (25 mM beta -glycerophosphate, 20 mM MOPS, 5 mM EGTA, 1 mM DTT, 1 mM Na3VO3, pH 7.4), into which were added 2-4 ug of active enzyme with appropriate substrates (purified histone H1 for CDK2, recombinant GST-retinoblastoma protein (residues 773-928) for CDK4.	B	CC[C@H](Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1)[C@@H](C)O		CHEMBL1922219	=	IC50	nM	2200.0	CHEMBL308	Homo sapiens	IC50	nM	2200.0
284309	16277580	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CC5(N)C4)cn3)nc2n1C1CCCC1		CHEMBL3691557	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
267689	16278222	CHEMBL3707754	Kinase Assay: The compounds from the examples below were investigated for their CDK2/cyclin E, CDK1/cyclin B, CDK4/cyclin D1 and CDK7/cyclin H, ERK-2, and PKA inhibitory activity. His6-tagged recombinant human cyclin-dependent kinases CDK1/cyclin B1, CDK2/cyclin E, CDK4 and CDK7/cyclin H were expressed in sf9 cells using a baculovirus expression system. Recombinant cyclin D1 was expressed in E. coli. Proteins were purified by metal chelate affinity chromatography to greater than 90% homogeneity. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins, recombinant active ERK-2 (Upstate Biotechnology), or cyclic AMP-dependent kinase (PKA) catalytic subunit (Calbiochem Cat. 539487). Assays were performed in assay buffer (25 mM beta -glycerophosphate, 20 mM MOPS, 5 mM EGTA, 1 mM DTT, 1 mM Na3VO3, pH 7.4), into which were added 2-4 ug of active enzyme with appropriate substrates (purified histone H1 for CDK2, recombinant GST-retinoblastoma protein (residues 773-928) for CDK4.	B	CC[C@@H](Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1)C(C)(C)O		CHEMBL1922123	=	IC50	nM	6200.0	CHEMBL308	Homo sapiens	IC50	nM	6200.0
267684	16278536	CHEMBL3707754	Kinase Assay: The compounds from the examples below were investigated for their CDK2/cyclin E, CDK1/cyclin B, CDK4/cyclin D1 and CDK7/cyclin H, ERK-2, and PKA inhibitory activity. His6-tagged recombinant human cyclin-dependent kinases CDK1/cyclin B1, CDK2/cyclin E, CDK4 and CDK7/cyclin H were expressed in sf9 cells using a baculovirus expression system. Recombinant cyclin D1 was expressed in E. coli. Proteins were purified by metal chelate affinity chromatography to greater than 90% homogeneity. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins, recombinant active ERK-2 (Upstate Biotechnology), or cyclic AMP-dependent kinase (PKA) catalytic subunit (Calbiochem Cat. 539487). Assays were performed in assay buffer (25 mM beta -glycerophosphate, 20 mM MOPS, 5 mM EGTA, 1 mM DTT, 1 mM Na3VO3, pH 7.4), into which were added 2-4 ug of active enzyme with appropriate substrates (purified histone H1 for CDK2, recombinant GST-retinoblastoma protein (residues 773-928) for CDK4.	B	CCC(O)[C@H](CC)Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1		CHEMBL1922209	=	IC50	nM	13000.0	CHEMBL308	Homo sapiens	IC50	nM	13000.0
284381	16278953	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CC5CNCC5CC4=O)cn3)nc2n1C1CCCCCC1		CHEMBL3691624	=	IC50	nM	4140.0	CHEMBL308	Homo sapiens	IC50	nM	4140.0
284360	16278959	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CCC(C4)N5)cn3)nc2n1C1CCCCC1		CHEMBL3691607	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284317	16279531	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4C5CCC4CNC5)cn3)nc2n1C1CCCC1		CHEMBL3691565	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
218153	16280010	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CC(O)CSc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br		CHEMBL3648101	=	IC50	nM	72.0	CHEMBL308	Homo sapiens	IC50	nM	72.0
284300	16280300	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CCC5(CC4)CNC5)cn3)nc2n1C1CCCCCC1		CHEMBL3691548	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
198666	16280346	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4C[C@@H]5CC[C@H](C4)N5C)cn3)nc2n1C1CCCC1		CHEMBL3691683	=	IC50	nM	44.0	CHEMBL308	Homo sapiens	IC50	nM	44.0
284302	16280864	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CCC4C5O)cn3)nc2n1C1CCCCCC1		CHEMBL3691550	=	IC50	nM	17590.0	CHEMBL308	Homo sapiens	IC50	nM	17590.0
6377	16281595	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	COc1cc(Nc2ncc(Br)c(N[C@H](C)[C@@H](C)O)n2)ccc1S(C)(=N)=O		CHEMBL3648111	=	IC50	nM	2.0	CHEMBL308	Homo sapiens	IC50	nM	2.0
218140	16282147	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	C[C@@H](Nc1nc(Nc2ccc(S(=N)(=O)CC3CC3)cc2)ncc1Br)C(C)(C)O		CHEMBL3648076	=	IC50	nM	5.0	CHEMBL308	Homo sapiens	IC50	nM	5.0
284374	16282152	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CCC(C4)N5)cn3)nc2n1[C@H]1CC[C@H](C(C)(C)C)CC1		CHEMBL3691580	=	IC50	nM	14016.0	CHEMBL308	Homo sapiens	IC50	nM	14016.0
218131	16282281	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CCOC(=O)N=S(=O)(CC)c1ccc(Nc2ncc(Br)c(O[C@H](C)[C@H](C)O)n2)cc1		CHEMBL3648092	=	IC50	nM	49.0	CHEMBL308	Homo sapiens	IC50	nM	49.0
284388	16282565	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CC5(CC6CCC(C5)N6)OC4=O)cn3)nc2n1C1CCCCC1		CHEMBL3691631	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
6396	16284008	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	C[C@H](Nc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br)C(C)(C)O		CHEMBL3648116	=	IC50	nM	5.0	CHEMBL308	Homo sapiens	IC50	nM	5.0
284423	16284645	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4C[C@@H]5CC[C@H](CC4=O)N5)cn3)nc2n1-c1ccccc1		CHEMBL3691665	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284325	16285176	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4C[C@@H]5C[C@H]4C[C@@H]5O)cn3)nc2n1C1CCCC1		CHEMBL3691573	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
218133	16285728	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CCOC(=O)N=S(=O)(CC)c1ccc(Nc2ncc(Br)c(N[C@H](C)C(C)(C)O)n2)cc1		CHEMBL3648088	=	IC50	nM	96.0	CHEMBL308	Homo sapiens	IC50	nM	96.0
218156	16286131	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CC(Sc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br)C(C)(C)O		CHEMBL3648104	=	IC50	nM	19.0	CHEMBL308	Homo sapiens	IC50	nM	19.0
218132	16286349	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CCOC(=O)N=S(=O)(CC)c1ccc(Nc2ncc(Br)c(N[C@@H](COC)[C@H](C)O)n2)cc1		CHEMBL3648086	=	IC50	nM	200.0	CHEMBL308	Homo sapiens	IC50	nM	200.0
284306	16286811	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4C[C@H]5CN[C@H](C5)C4)cn3)nc2n1C1CCCC1		CHEMBL3691554	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284341	16286845	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CN(Cc6ccccc6)CC(C4)O5)cn3)nc2n1C1CCCC1		CHEMBL3691588	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284365	16287046	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC[C@@H]5CC[C@H](C4)N5)cn3)nc2n1C1CCCC1		CHEMBL3691612	=	IC50	nM	12731.0	CHEMBL308	Homo sapiens	IC50	nM	12731.0
294720	16287190	CHEMBL3705691	Enzyme Inhibition Assay: The tests are carried out as follows: the enzyme to be assayed was purified, for example by affinity chromatography on agarose beads. The catalytic activity was measured using radiolabeled ATP, at a standard final concentration. The test compounds were added at various concentrations making it possible to establish dose-response curves (activity of the enzyme as a function of the concentration).	B	C[Si](C)(C)C1=C2c3nc4ccccc4cc3C(Cl)CC2CC1=O		CHEMBL3651155	=	IC50	nM	3600.0	CHEMBL308	Homo sapiens	IC50	nM	3600.0
284380	16287390	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4C[C@H]5CNC[C@H]5C4=O)cn3)nc2n1C1CCCC1		CHEMBL3691622	=	IC50	nM	20621.0	CHEMBL308	Homo sapiens	IC50	nM	20621.0
284434	16287638	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4C[C@H]5CC[C@@H](CC4=O)N5C)cn3)nc2n1C1CCCC1		CHEMBL3691676	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284349	16288134	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CCC(C4)N5)cn3)nc2n1-c1cccc(C(C)(C)C)c1		CHEMBL3691596	=	IC50	nM	1992.0	CHEMBL308	Homo sapiens	IC50	nM	1992.0
267688	16288473	CHEMBL3707754	Kinase Assay: The compounds from the examples below were investigated for their CDK2/cyclin E, CDK1/cyclin B, CDK4/cyclin D1 and CDK7/cyclin H, ERK-2, and PKA inhibitory activity. His6-tagged recombinant human cyclin-dependent kinases CDK1/cyclin B1, CDK2/cyclin E, CDK4 and CDK7/cyclin H were expressed in sf9 cells using a baculovirus expression system. Recombinant cyclin D1 was expressed in E. coli. Proteins were purified by metal chelate affinity chromatography to greater than 90% homogeneity. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins, recombinant active ERK-2 (Upstate Biotechnology), or cyclic AMP-dependent kinase (PKA) catalytic subunit (Calbiochem Cat. 539487). Assays were performed in assay buffer (25 mM beta -glycerophosphate, 20 mM MOPS, 5 mM EGTA, 1 mM DTT, 1 mM Na3VO3, pH 7.4), into which were added 2-4 ug of active enzyme with appropriate substrates (purified histone H1 for CDK2, recombinant GST-retinoblastoma protein (residues 773-928) for CDK4.	B	CC[C@H](Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1)C(O)C(C)(C)C		CHEMBL1922211	=	IC50	nM	21000.0	CHEMBL308	Homo sapiens	IC50	nM	21000.0
218149	16288597	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CCS(=N)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)[C@H](C)O)n2)cc1		CHEMBL3648095	=	IC50	nM	5.0	CHEMBL308	Homo sapiens	IC50	nM	5.0
284401	16289208	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CC5(CCCNC5)OC4=O)cn3)nc2n1C1CCCC1		CHEMBL3691644	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
218141	16289637	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	C[C@@H](Nc1nc(Nc2ccc(S(=O)(CC=O)=NS(=O)(=O)CC[Si](C)(C)C)cc2)ncc1Br)C(C)(C)O		CHEMBL3648079	=	IC50	nM	160.0	CHEMBL308	Homo sapiens	IC50	nM	160.0
284400	16289657	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4C[C@]5(CCCNCC5)OC4=O)cn3)nc2n1C1CCCC1		CHEMBL3691643	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284324	16290362	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CC(C)N1C2CCC1CN(C(=O)c1ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc1)C2		CHEMBL3691572	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284410	16290548	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN5CCCC5C4=O)cn3)nc2n1C1CCCC1		CHEMBL3691653	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
218143	16290599	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CCOC(=O)N=S(C)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)C(C)(C)O)n2)cc1C		CHEMBL3648090	=	IC50	nM	63.0	CHEMBL308	Homo sapiens	IC50	nM	63.0
218157	16290777	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CCC(Sc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br)C(C)(C)O		CHEMBL3648105	=	IC50	nM	91.0	CHEMBL308	Homo sapiens	IC50	nM	91.0
294718	16291247	CHEMBL3705691	Enzyme Inhibition Assay: The tests are carried out as follows: the enzyme to be assayed was purified, for example by affinity chromatography on agarose beads. The catalytic activity was measured using radiolabeled ATP, at a standard final concentration. The test compounds were added at various concentrations making it possible to establish dose-response curves (activity of the enzyme as a function of the concentration).	B	C[Si](C)(C)C1=C2c3nc4ccccc4cc3C(O)CC2CC1=O		CHEMBL3651154	=	IC50	nM	620.0	CHEMBL308	Homo sapiens	IC50	nM	620.0
218134	16291853	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CCOC(=O)N=S(C)(=O)c1ccc(Nc2ncc(Br)c(N[C@@H](COC)[C@H](C)O)n2)cc1		CHEMBL3648087	=	IC50	nM	110.0	CHEMBL308	Homo sapiens	IC50	nM	110.0
218130	16291865	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	C[C@@H](Nc1nc(Nc2ccc(S(=O)(=NS(=O)(=O)CC[Si](C)(C)C)C3CCCC3)cc2)ncc1Br)C(C)(C)O		CHEMBL3648077	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	nM	1000.0
8428	16292255	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CCS(=N)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)C(C)(C)O)n2)cc1		CHEMBL3648123	=	IC50	nM	45.0	CHEMBL308	Homo sapiens	IC50	nM	45.0
284377	16292457	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4C[C@H]5CNC[C@H]5C4=O)cn3)nc2n1C1CCCCCC1		CHEMBL3691620	=	IC50	nM	5316.0	CHEMBL308	Homo sapiens	IC50	nM	5316.0
284337	16293182	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4C[C@H]5[C@H](N)[C@H]5C4)cn3)nc2n1C1CCCC1		CHEMBL3691585	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
267686	16295055	CHEMBL3707754	Kinase Assay: The compounds from the examples below were investigated for their CDK2/cyclin E, CDK1/cyclin B, CDK4/cyclin D1 and CDK7/cyclin H, ERK-2, and PKA inhibitory activity. His6-tagged recombinant human cyclin-dependent kinases CDK1/cyclin B1, CDK2/cyclin E, CDK4 and CDK7/cyclin H were expressed in sf9 cells using a baculovirus expression system. Recombinant cyclin D1 was expressed in E. coli. Proteins were purified by metal chelate affinity chromatography to greater than 90% homogeneity. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins, recombinant active ERK-2 (Upstate Biotechnology), or cyclic AMP-dependent kinase (PKA) catalytic subunit (Calbiochem Cat. 539487). Assays were performed in assay buffer (25 mM beta -glycerophosphate, 20 mM MOPS, 5 mM EGTA, 1 mM DTT, 1 mM Na3VO3, pH 7.4), into which were added 2-4 ug of active enzyme with appropriate substrates (purified histone H1 for CDK2, recombinant GST-retinoblastoma protein (residues 773-928) for CDK4.	B	CC[C@H](Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1)C(O)C(C)C		CHEMBL1922210	=	IC50	nM	22000.0	CHEMBL308	Homo sapiens	IC50	nM	22000.0
284424	16295139	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4C[C@H]5CC[C@@H](CC4=O)N5)cn3)nc2n1-c1ccccc1		CHEMBL3691666	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284409	16295570	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCCC5(CCNCC5)C4=O)cn3)nc2n1C1CCCC1		CHEMBL3691652	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
218120	16295593	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	C=S(N)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)CO)n2)cc1		CHEMBL3648099	=	IC50	nM	79.0	CHEMBL308	Homo sapiens	IC50	nM	79.0
284373	16296280	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CC5CCC(N5)C4=O)cn3)nc2n1C1CCCCCC1		CHEMBL3691619	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284397	16296473	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CC5(CCCNCC5)OC4=O)cn3)nc2n1C1CCCC1		CHEMBL3691640	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
267687	16297831	CHEMBL3707754	Kinase Assay: The compounds from the examples below were investigated for their CDK2/cyclin E, CDK1/cyclin B, CDK4/cyclin D1 and CDK7/cyclin H, ERK-2, and PKA inhibitory activity. His6-tagged recombinant human cyclin-dependent kinases CDK1/cyclin B1, CDK2/cyclin E, CDK4 and CDK7/cyclin H were expressed in sf9 cells using a baculovirus expression system. Recombinant cyclin D1 was expressed in E. coli. Proteins were purified by metal chelate affinity chromatography to greater than 90% homogeneity. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins, recombinant active ERK-2 (Upstate Biotechnology), or cyclic AMP-dependent kinase (PKA) catalytic subunit (Calbiochem Cat. 539487). Assays were performed in assay buffer (25 mM beta -glycerophosphate, 20 mM MOPS, 5 mM EGTA, 1 mM DTT, 1 mM Na3VO3, pH 7.4), into which were added 2-4 ug of active enzyme with appropriate substrates (purified histone H1 for CDK2, recombinant GST-retinoblastoma protein (residues 773-928) for CDK4.	B	CC[C@@H](Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1)C(O)C(C)(C)C		CHEMBL1922122	=	IC50	nM	23000.0	CHEMBL308	Homo sapiens	IC50	nM	23000.0
284331	16298124	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CCC(C4)N5)cn3)nc2n1[C@@H]1C[C@H]2CC[C@@H]1C2		CHEMBL3691579	=	IC50	nM	12965.0	CHEMBL308	Homo sapiens	IC50	nM	12965.0
7972	16298995	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CCS(=N)(=O)c1ccc(Nc2ncc(Br)c(N[C@@H](COC)[C@H](C)O)n2)cc1		CHEMBL3648121	=	IC50	nM	44.0	CHEMBL308	Homo sapiens	IC50	nM	44.0
284405	16299190	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CC5CC4CN5)cn3)nc2n1C1CCCC1		CHEMBL3691648	=	IC50	nM	9170.0	CHEMBL308	Homo sapiens	IC50	nM	9170.0
218144	16299598	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	Cc1cc(Nc2ncc(Br)c(N[C@H](C)C(C)(C)O)n2)ccc1S(C)(=N)=O		CHEMBL3639469	=	IC50	nM	8.0	CHEMBL308	Homo sapiens	IC50	nM	8.0
284379	16299664	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4C[C@@H]5CNC[C@@H]5C4=O)cn3)nc2n1C1CCCC1		CHEMBL3691623	=	IC50	nM	10072.5	CHEMBL308	Homo sapiens	IC50	nM	10072.5
284318	16299682	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CNC(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CCC(C4)N5)cn3)nc2n1C1CCCC1		CHEMBL3691566	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
198662	16300936	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4C[C@@H]5CC[C@H](C4)N5)cn3)nc2n1C1CCCC1		CHEMBL3691684	=	IC50	nM	29.0	CHEMBL308	Homo sapiens	IC50	nM	29.0
284404	16300999	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4C[C@]5(CCCNC5)OC4=O)cn3)nc2n1C1CCCC1		CHEMBL3691647	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284316	16301572	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CCN5CCC[C@@H]5C4)cn3)nc2n1C1CCCC1		CHEMBL3691564	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
218160	16301764	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CC(C)(O)CSc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br		CHEMBL3648128	=	IC50	nM	55.0	CHEMBL308	Homo sapiens	IC50	nM	55.0
284352	16303667	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CCC(C4)N5)cn3)nc2n1C1CCN(C(C)(C)C)CC1		CHEMBL3691599	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284311	16304367	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4C[C@H]5C[C@@]5(N)C4)cn3)nc2n1C1CCCC1		CHEMBL3691559	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284420	16304649	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CC5CCC(C4)N5)nn3)nc2n1C1CCCCC1		CHEMBL3691662	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284342	16305592	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CNCC(C4)O5)cn3)nc2n1C1CCCC1		CHEMBL3691589	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284344	16306048	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5C[C@@H]4CN5)cn3)nc2n1C1CCCC1		CHEMBL3691591	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284299	16307206	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CCC(C4)N5)cn3)nc2n1C1CCCCCC1		CHEMBL3691547	=	IC50	nM	7065.0	CHEMBL308	Homo sapiens	IC50	nM	7065.0
284417	16307407	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4C[C@H]5CC[C@@H](CC4=O)N5)cn3)nc2n1C1CCCC1		CHEMBL3691660	=	IC50	nM	29281.0	CHEMBL308	Homo sapiens	IC50	nM	29281.0
284415	16307457	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCC5(CCCN5)C4=O)cn3)nc2n1C1CCCOC1		CHEMBL3691658	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
294722	16307600	CHEMBL3705691	Enzyme Inhibition Assay: The tests are carried out as follows: the enzyme to be assayed was purified, for example by affinity chromatography on agarose beads. The catalytic activity was measured using radiolabeled ATP, at a standard final concentration. The test compounds were added at various concentrations making it possible to establish dose-response curves (activity of the enzyme as a function of the concentration).	B	COc1cc2cc3c(nc2cc1OC)C1=C([Si](C)(C)C)C(=O)CC1CC3O		CHEMBL3651158	=	IC50	nM	1700.0	CHEMBL308	Homo sapiens	IC50	nM	1700.0
284370	16309264	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CCC(C4)N5)cn3)nc2n1[C@H]1C[C@@H]2CC[C@H]1C2		CHEMBL3691616	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
198660	16309621	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4C[C@@H]5CC[C@H](C4)N5C)cn3)nc2n1C1CCCC1		CHEMBL3691683	=	IC50	nM	17.5	CHEMBL308	Homo sapiens	IC50	nM	17.5
6374	16309725	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	C[C@H](O)[C@@H](C)Nc1nc(Nc2ccc(S(=N)(=O)CCO)cc2)ncc1Br		CHEMBL3648110	=	IC50	nM	5.0	CHEMBL308	Homo sapiens	IC50	nM	5.0
284394	16310004	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN5CCCCC5C4=O)cn3)nc2n1C1CCCCC1		CHEMBL3691637	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284323	16310117	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CCC(C4)N5CCO)cn3)nc2n1C1CCCC1		CHEMBL3691571	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284389	16310804	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN1C[C@H]2CN(c3ccc(Nc4ncc5cc(C(=O)N(C)C)n(C6CCCC6)c5n4)nc3)C(=O)[C@H]2C1		CHEMBL3691632	=	IC50	nM	14159.0	CHEMBL308	Homo sapiens	IC50	nM	14159.0
218125	16310812	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	COc1cc(Nc2ncc(Br)c(N[C@H](C)C(C)(C)O)n2)ccc1S(C)(=N)=O		CHEMBL3648115	=	IC50	nM	8.0	CHEMBL308	Homo sapiens	IC50	nM	8.0
6380	16311080	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	COc1cc(Nc2ncc(Br)c(N[C@H](C)[C@H](C)O)n2)ccc1S(C)(=N)=O		CHEMBL3648112	=	IC50	nM	3.0	CHEMBL308	Homo sapiens	IC50	nM	3.0
284338	16311340	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)C45C[C@H]6C[C@H](O)C[C@@H](C4)N65)cn3)nc2n1C1CCCC1		CHEMBL3639904	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284357	16311813	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CC(C)[C@@H](N)C(=O)N1C2CCC1CN(C(=O)c1ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc1)C2		CHEMBL3691604	=	IC50	nM	39910.0	CHEMBL308	Homo sapiens	IC50	nM	39910.0
284312	16312447	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CC5(N(C)C)C4)cn3)nc2n1C1CCCC1		CHEMBL3691560	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
218142	16313261	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	C[C@@H](Nc1nc(Nc2ccc(S(=N)(=O)C3CC3)cc2)ncc1Br)C(C)(C)O		CHEMBL3648074	=	IC50	nM	14.0	CHEMBL308	Homo sapiens	IC50	nM	14.0
218135	16313352	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CCOC(=O)N=S(C)(=O)c1ccc(Nc2ncc(Br)c(O[C@H](C)[C@H](C)O)n2)cc1		CHEMBL3648093	=	IC50	nM	21.0	CHEMBL308	Homo sapiens	IC50	nM	21.0
267681	16313645	CHEMBL3707754	Kinase Assay: The compounds from the examples below were investigated for their CDK2/cyclin E, CDK1/cyclin B, CDK4/cyclin D1 and CDK7/cyclin H, ERK-2, and PKA inhibitory activity. His6-tagged recombinant human cyclin-dependent kinases CDK1/cyclin B1, CDK2/cyclin E, CDK4 and CDK7/cyclin H were expressed in sf9 cells using a baculovirus expression system. Recombinant cyclin D1 was expressed in E. coli. Proteins were purified by metal chelate affinity chromatography to greater than 90% homogeneity. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins, recombinant active ERK-2 (Upstate Biotechnology), or cyclic AMP-dependent kinase (PKA) catalytic subunit (Calbiochem Cat. 539487). Assays were performed in assay buffer (25 mM beta -glycerophosphate, 20 mM MOPS, 5 mM EGTA, 1 mM DTT, 1 mM Na3VO3, pH 7.4), into which were added 2-4 ug of active enzyme with appropriate substrates (purified histone H1 for CDK2, recombinant GST-retinoblastoma protein (residues 773-928) for CDK4.	B	CC[C@@H](Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1)[C@H](C)O		CHEMBL1922218	=	IC50	nM	4900.0	CHEMBL308	Homo sapiens	IC50	nM	4900.0
284307	16314267	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CC(C4)N(CC(F)(F)F)C5)cn3)nc2n1C1CCCC1		CHEMBL3691555	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
218136	16314445	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CCOc1nc(Nc2ccc(S(=N)(=O)CC)cc2)ncc1Br		CHEMBL3648097	=	IC50	nM	200.0	CHEMBL308	Homo sapiens	IC50	nM	200.0
284421	16314726	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CC5CCC(CC4=O)N5)cn3)nc2n1-c1ccc(C(C)(C)C#N)cc1		CHEMBL3691663	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284345	16315004	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	Cc1nc(Nc2ncc3cc(C(=O)N(C)C)n(C4CCCC4)c3n2)ccc1C(=O)N1CC2CCC(C1)N2		CHEMBL3691592	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
218148	16315195	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CCOC(=O)N=S(=O)(CC)c1ccc(Nc2ncc(Br)c(N[C@H](C)[C@H](C)O)n2)cc1		CHEMBL3648089	=	IC50	nM	43.0	CHEMBL308	Homo sapiens	IC50	nM	43.0
284308	16316109	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CC(C4)N(C)C5)cn3)nc2n1C1CCCC1		CHEMBL3691556	=	IC50	nM	8439.0	CHEMBL308	Homo sapiens	IC50	nM	8439.0
284348	16316281	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CCC(C4)N5)cn3)nc2n1-c1ccc(C(C)(C)C)cc1		CHEMBL3691595	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284353	16316415	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CCC(C4)N5)cn3)nc2n1C(C)(C)C		CHEMBL3691600	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284403	16316622	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4C[C@@]5(CCCNC5)OC4=O)cn3)nc2n1C1CCCC1		CHEMBL3691646	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284429	16316780	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4C[C@@H]5CC[C@H](CC4=O)N5)cn3)nc2n1C1CCC1		CHEMBL3691671	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284310	16316867	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4C[C@@H]5C[C@]5(N)C4)cn3)nc2n1C1CCCC1		CHEMBL3914273	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
6363	16317601	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	C[C@@H](Nc1nc(Nc2ccc(S(=N)(=O)CCO)cc2)ncc1Br)C(C)(C)O		CHEMBL3648107	=	IC50	nM	7.0	CHEMBL308	Homo sapiens	IC50	nM	7.0
284320	16317854	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CCC[C@@H]5CCN[C@@H]5C4)cn3)nc2n1C1CCCC1		CHEMBL3691568	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
294719	16318459	CHEMBL3705691	Enzyme Inhibition Assay: The tests are carried out as follows: the enzyme to be assayed was purified, for example by affinity chromatography on agarose beads. The catalytic activity was measured using radiolabeled ATP, at a standard final concentration. The test compounds were added at various concentrations making it possible to establish dose-response curves (activity of the enzyme as a function of the concentration).	B	C[Si](C)(C)C1=C2c3nc4ccccc4cc3C(O)CC2CC1=O		CHEMBL3651154	=	IC50	nM	7800.0	CHEMBL308	Homo sapiens	IC50	nM	7800.0
284364	16319026	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5COCC(C4)N5)cn3)nc2n1C1CCCC1		CHEMBL3691611	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284396	16319280	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CC5(CC6CCC(C5)N6C)OC4=O)cn3)nc2n1C1CCCC1		CHEMBL3691639	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284339	16319774	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)C45C[C@H]6C[C@@H](O)C[C@@H](C4)N65)cn3)nc2n1C1CCCC1		CHEMBL3691586	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284333	16321485	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CCC(C4)N5)nn3)nc2n1C1CCCC1		CHEMBL3691581	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284314	16322020	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4C[C@@H]5CC4CN5)cn3)nc2n1C1CCCC1		CHEMBL3691562	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284326	16322104	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4C[C@@H]5C[C@H]4C[C@H]5O)cn3)nc2n1C1CCCC1		CHEMBL3691574	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
218154	16322164	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CC(O)C(C)Sc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br		CHEMBL3648102	=	IC50	nM	17.0	CHEMBL308	Homo sapiens	IC50	nM	17.0
218127	16323140	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	COc1cc(Nc2ncc(Br)c(N[C@H](C)[C@H](C)O)n2)ccc1S(C)(=N)=O		CHEMBL3648112	=	IC50	nM	2.0	CHEMBL308	Homo sapiens	IC50	nM	2.0
284406	16323480	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CC5CCC(C4)N5)cn3)nc2n1C1CCCC1		CHEMBL3691649	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284376	16324087	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4C[C@@H]5CNC[C@@H]5C4=O)cn3)nc2n1C1CCCCCC1		CHEMBL3691621	=	IC50	nM	2659.0	CHEMBL308	Homo sapiens	IC50	nM	2659.0
294723	16324207	CHEMBL3705691	Enzyme Inhibition Assay: The tests are carried out as follows: the enzyme to be assayed was purified, for example by affinity chromatography on agarose beads. The catalytic activity was measured using radiolabeled ATP, at a standard final concentration. The test compounds were added at various concentrations making it possible to establish dose-response curves (activity of the enzyme as a function of the concentration).	B	COc1ccc2cc3c(nc2c1)C1=C([Si](C)(C)C)C(=O)CC1CC3O		CHEMBL3651157	=	IC50	nM	1600.0	CHEMBL308	Homo sapiens	IC50	nM	1600.0
284315	16324617	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CCN5CCCC5C4)cn3)nc2n1C1CCCC1		CHEMBL3691563	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284432	16324792	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1CC(=O)N(c1ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc1)C2		CHEMBL3691674	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284346	16325235	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	Cc1cc(Nc2ncc3cc(C(=O)N(C)C)n(C4CCCC4)c3n2)ncc1C(O)N1CC2CCC(C1)N2		CHEMBL3691593	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
218124	16325621	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	C[C@H](CO)Nc1nc(Nc2ccc(S(C)(=O)=NS(=O)(=O)CC[Si](C)(C)C)cc2)ncc1Br		CHEMBL3648098	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	nM	1000.0
284437	16326631	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4C[C@H]5CC[C@@H](CC4=O)N5CC(F)(F)F)cn3)nc2n1C1CCCC1		CHEMBL3691679	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284343	16328249	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CCN5CCC4CC5)cn3)nc2n1C1CCCC1		CHEMBL3691590	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284408	16328356	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCC5(CCCN5C(=O)OC(C)(C)C)C4=O)cn3)nc2n1C1CCCC1		CHEMBL3691651	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
218152	16328358	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CN=S(C)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)[C@H](C)O)n2)cc1		CHEMBL3648083	=	IC50	nM	14.0	CHEMBL308	Homo sapiens	IC50	nM	14.0
284327	16328994	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CNCC5C4)cn3)nc2n1C1CCCC1		CHEMBL3691575	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284384	16329399	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CC5CNCC5CC4=O)cn3)nc2n1C1CCCC1		CHEMBL3691627	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284354	16330177	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CSCC[C@@H](N)C(=O)N1C2CCC1CN(C(=O)c1ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc1)C2		CHEMBL3691601	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284440	16330533	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN5CCC[C@@H]5C4=O)cn3)nc2n1C1CCCC1		CHEMBL3691682	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284412	16330598	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CC5(CC4=O)CC4CCC(C5)N4)cn3)nc2n1C1CCCC1		CHEMBL3691655	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
10953	16331291	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CC(C)Nc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br		CHEMBL3648126	=	IC50	nM	110.0	CHEMBL308	Homo sapiens	IC50	nM	110.0
284297	16331331	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4C[C@@H]5CNC[C@H](C4)C5O)cn3)nc2n1C1CCCCCC1		CHEMBL3691545	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284347	16331546	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CCCC(C4)N5)cn3)nc2n1C1CCCC1		CHEMBL3691594	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284301	16331581	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CCC(C4)C5(C)O)cn3)nc2n1C1CCCCCC1		CHEMBL3691549	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
218150	16332988	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	Cc1cc(Nc2ncc(Br)c(N[C@H](C)[C@H](C)O)n2)ccc1S(C)(=N)=O		CHEMBL3648096	=	IC50	nM	4.0	CHEMBL308	Homo sapiens	IC50	nM	4.0
11309	16333334	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CCC(CO)Sc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br		CHEMBL3648127	=	IC50	nM	49.0	CHEMBL308	Homo sapiens	IC50	nM	49.0
284395	16333868	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CC5(CC6CCC(C5)N6)OC4=O)cn3)nc2n1C1CCCC1		CHEMBL3691638	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284382	16334828	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4C[C@H]5CNC[C@H]5CC4=O)cn3)nc2n1C1CCCCCC1		CHEMBL3691625	=	IC50	nM	2511.0	CHEMBL308	Homo sapiens	IC50	nM	2511.0
284363	16335643	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CCC5CCC(C4)N5)cn3)nc2n1C1CCCC1		CHEMBL3691610	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
7305	16336136	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	COC[C@@H](Nc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br)[C@@H](C)O		CHEMBL3648118	=	IC50	nM	11.0	CHEMBL308	Homo sapiens	IC50	nM	11.0
284322	16336539	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CC(=O)N1C2CCC1CN(C(=O)c1ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc1)C2		CHEMBL3691570	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
9094	16337190	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	Cc1cc(Nc2ncc(Br)c(N[C@H](C)C(C)(C)O)n2)ccc1S(C)(=N)=O		CHEMBL3639469	=	IC50	nM	4.0	CHEMBL308	Homo sapiens	IC50	nM	4.0
284387	16337627	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN1C[C@H]2CN(c3ccc(Nc4ncc5cc(C(=O)N(C)C)n(C6CCCCCC6)c5n4)nc3)C(=O)C[C@H]2C1		CHEMBL3691630	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284378	16337738	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4C[C@H]5CNC[C@H]5C4=O)cn3)nc2n1C1CCCC1		CHEMBL3691622	=	IC50	nM	18028.0	CHEMBL308	Homo sapiens	IC50	nM	18028.0
218139	16338103	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	C[C@@H](Nc1nc(Nc2ccc(S(=N)(=O)C3CCCC3)cc2)ncc1Br)C(C)(C)O		CHEMBL3648078	=	IC50	nM	44.0	CHEMBL308	Homo sapiens	IC50	nM	44.0
284425	16338140	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CC5CCC(CC4=O)N5)cn3)nc2n1C1CCCCC1		CHEMBL3691667	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
308345	16338239	CHEMBL3705885	In Vitro Kinase Inhibition Assay: In vitro kinase assay analysis may be performed using standard techniques described in the art. These techniques are also used by commercial services providers in order to offer in vitro kinase activity assay services, e.g. the assays offered by Millipore Inc. (worldwide website www(dot)millipore.com), ProQinase GmbH (worldwide website www(dot)proqinase.de) and others. All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50ul reaction volume. The reaction mixture was pipetted in four steps in the following order: 20ul of assay buffer (standard buffer),5ul of ATP solution (in H2O, 5 ul of test compound (in 10% DMSO), 10ul of substrate/10ul of enzyme solution (premixed)The assay for all enzymes contained 60 mM HEPES-NaOH (pH 7.5), 3 mM MgCl2, 3 mM MnCl2, 3uM Na-Orthovanadate, 1.2 mM DTT, 50 ug/ml PEG2000, 1 uM [33P]-ATP (approx. 5x1005 cpm per well).	B	COc1cc(F)ccc1-c1ccnc(NC(=O)C2CCC(NC(C)=O)C2)c1		CHEMBL3673435	=	IC50	nM	1877.0	CHEMBL308	Homo sapiens	IC50	nM	1877.0
218147	16338534	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CCOC(=O)N=S(C)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)[C@H](C)O)n2)cc1C		CHEMBL3648091	=	IC50	nM	75.0	CHEMBL308	Homo sapiens	IC50	nM	75.0
284436	16338812	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CC(C)N1[C@H]2CC[C@@H]1CC(=O)N(c1ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc1)C2		CHEMBL3691678	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
218137	16339150	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CCS(=N)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](COC)[C@H](C)O)n2)cc1		CHEMBL3648094	=	IC50	nM	16.0	CHEMBL308	Homo sapiens	IC50	nM	16.0
267683	16339293	CHEMBL3707754	Kinase Assay: The compounds from the examples below were investigated for their CDK2/cyclin E, CDK1/cyclin B, CDK4/cyclin D1 and CDK7/cyclin H, ERK-2, and PKA inhibitory activity. His6-tagged recombinant human cyclin-dependent kinases CDK1/cyclin B1, CDK2/cyclin E, CDK4 and CDK7/cyclin H were expressed in sf9 cells using a baculovirus expression system. Recombinant cyclin D1 was expressed in E. coli. Proteins were purified by metal chelate affinity chromatography to greater than 90% homogeneity. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins, recombinant active ERK-2 (Upstate Biotechnology), or cyclic AMP-dependent kinase (PKA) catalytic subunit (Calbiochem Cat. 539487). Assays were performed in assay buffer (25 mM beta -glycerophosphate, 20 mM MOPS, 5 mM EGTA, 1 mM DTT, 1 mM Na3VO3, pH 7.4), into which were added 2-4 ug of active enzyme with appropriate substrates (purified histone H1 for CDK2, recombinant GST-retinoblastoma protein (residues 773-928) for CDK4.	B	CCC(O)[C@@H](CC)Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1		CHEMBL1922120	=	IC50	nM	12000.0	CHEMBL308	Homo sapiens	IC50	nM	12000.0
218129	16339508	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	C[C@H](CO)Nc1nc(Nc2ccc(S(=O)(CC3CC3)=NS(=O)(=O)CC[Si](C)(C)C)cc2)ncc1Br		CHEMBL3648075	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	nM	1000.0
284329	16339832	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CCC(C4)C5N(C)C)cn3)nc2n1C1CCCC1		CHEMBL3691577	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284419	16339850	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CNC(=O)c1cc2cnc(Nc3ccc(N4C[C@H]5CC[C@@H](CC4=O)N5C)cn3)nc2n1C1CCCC1		CHEMBL3691661	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284398	16339864	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN1CCCC2(CC1)CN(c1ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc1)C(=O)O2		CHEMBL3691641	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284336	16340573	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5(CNC5)C4)cn3)nc2n1C1CCCC1		CHEMBL3691584	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
6370	16341225	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	C[C@@H](O)[C@@H](C)Nc1nc(Nc2ccc(S(=N)(=O)CCO)cc2)ncc1Br		CHEMBL3648109	=	IC50	nM	3.0	CHEMBL308	Homo sapiens	IC50	nM	3.0
284438	16341507	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CC5COCC(CC4=O)N5)cn3)nc2n1C1CCCC1		CHEMBL3691680	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
294717	16342031	CHEMBL3705691	Enzyme Inhibition Assay: The tests are carried out as follows: the enzyme to be assayed was purified, for example by affinity chromatography on agarose beads. The catalytic activity was measured using radiolabeled ATP, at a standard final concentration. The test compounds were added at various concentrations making it possible to establish dose-response curves (activity of the enzyme as a function of the concentration).	B	C[Si](C)(C)C1=C2c3nc4ccccc4cc3C(O)CC2CC1=O		CHEMBL3651154	=	IC50	nM	650.0	CHEMBL308	Homo sapiens	IC50	nM	650.0
218155	16342430	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CCC(Sc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br)C(C)O		CHEMBL3648103	=	IC50	nM	22.0	CHEMBL308	Homo sapiens	IC50	nM	22.0
284332	16342688	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CCC(C4)N5)cn3)nc2n1[C@H]1CC[C@H](C(C)(C)C)CC1		CHEMBL3691580	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
7798	16343360	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CCS(=N)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](COC)[C@@H](C)O)n2)cc1		CHEMBL3648120	=	IC50	nM	15.0	CHEMBL308	Homo sapiens	IC50	nM	15.0
284358	16345370	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CCOC(=O)N1C2CCC1CN(C(=O)c1ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc1)C2		CHEMBL3691605	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
218122	16346410	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	C[C@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br		CHEMBL3648073	=	IC50	nM	13.0	CHEMBL308	Homo sapiens	IC50	nM	13.0
284402	16346629	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN1CCCC2(C1)CN(c1ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc1)C(=O)O2		CHEMBL3691645	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284359	16347109	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CCC(C4)N5)cn3)nc2n1C1CCCOC1		CHEMBL3691606	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
267685	16347291	CHEMBL3707754	Kinase Assay: The compounds from the examples below were investigated for their CDK2/cyclin E, CDK1/cyclin B, CDK4/cyclin D1 and CDK7/cyclin H, ERK-2, and PKA inhibitory activity. His6-tagged recombinant human cyclin-dependent kinases CDK1/cyclin B1, CDK2/cyclin E, CDK4 and CDK7/cyclin H were expressed in sf9 cells using a baculovirus expression system. Recombinant cyclin D1 was expressed in E. coli. Proteins were purified by metal chelate affinity chromatography to greater than 90% homogeneity. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins, recombinant active ERK-2 (Upstate Biotechnology), or cyclic AMP-dependent kinase (PKA) catalytic subunit (Calbiochem Cat. 539487). Assays were performed in assay buffer (25 mM beta -glycerophosphate, 20 mM MOPS, 5 mM EGTA, 1 mM DTT, 1 mM Na3VO3, pH 7.4), into which were added 2-4 ug of active enzyme with appropriate substrates (purified histone H1 for CDK2, recombinant GST-retinoblastoma protein (residues 773-928) for CDK4.	B	CC[C@@H](Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1)C(O)C(C)C		CHEMBL1922121	=	IC50	nM	20000.0	CHEMBL308	Homo sapiens	IC50	nM	20000.0
284426	16347347	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4C[C@@H]5CC[C@H](CC4=O)N5)cn3)nc2n1C1CCCCC1		CHEMBL3691668	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
218159	16347697	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CC(CO)Sc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br		CHEMBL3648106	=	IC50	nM	18.0	CHEMBL308	Homo sapiens	IC50	nM	18.0
284385	16347700	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4C[C@H]5CNC[C@H]5CC4=O)cn3)nc2n1C1CCCC1		CHEMBL3691628	=	IC50	nM	14105.5	CHEMBL308	Homo sapiens	IC50	nM	14105.5
284330	16347788	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CC(CO)N1C2CCC1CN(C(=O)c1ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc1)C2		CHEMBL3691578	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284414	16348354	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CC5(CC4=O)CC4CCC(C5)N4)cn3)nc2n1C1CCCOC1		CHEMBL3691657	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
218146	16348656	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	C[C@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(=O)(CCO)=NS(=O)(=O)CC[Si](C)(C)C)cc2)ncc1Br		CHEMBL3648081	=	IC50	nM	160.0	CHEMBL308	Homo sapiens	IC50	nM	160.0
284372	16348795	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CC5CCC(CC4=O)N5)nn3)nc2n1C1CCCC1		CHEMBL3691618	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
7503	16349496	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	COC[C@H](Nc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br)[C@H](C)O		CHEMBL3648119	=	IC50	nM	27.0	CHEMBL308	Homo sapiens	IC50	nM	27.0
284391	16349917	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4C(=O)CN5CCC4CC5)cn3)nc2n1C1CCCC1		CHEMBL3691634	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
218123	16350120	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	C[C@@H](O)[C@@H](C)Nc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br		CHEMBL3648071	=	IC50	nM	130.0	CHEMBL308	Homo sapiens	IC50	nM	130.0
284383	16350823	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4C[C@@H]5CNC[C@@H]5CC4=O)cn3)nc2n1C1CCCCCC1		CHEMBL3691626	=	IC50	nM	6483.0	CHEMBL308	Homo sapiens	IC50	nM	6483.0
284296	16351521	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4C[C@@H]5CNC[C@H](C4)C5O)cn3)nc2n1C1CCCC1		CHEMBL3691544	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
6366	16351886	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	C[C@H](Nc1nc(Nc2ccc(S(=N)(=O)CCO)cc2)ncc1Br)C(C)(C)O		CHEMBL3648108	=	IC50	nM	25.0	CHEMBL308	Homo sapiens	IC50	nM	25.0
284418	16352195	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CC5CCC(CC4=O)N5)cn3)nc2n1C1CCCC1		CHEMBL3691659	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
7279	16352680	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	C[C@H](O)[C@@H](C)Nc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br		CHEMBL3648117	=	IC50	nM	5.0	CHEMBL308	Homo sapiens	IC50	nM	5.0
6386	16353069	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CN=S(C)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)[C@H](C)O)n2)cc1OC		CHEMBL3648114	=	IC50	nM	15.0	CHEMBL308	Homo sapiens	IC50	nM	15.0
284321	16353832	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CC5CCC4C5O)cn3)nc2n1C1CCCC1		CHEMBL3691569	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284431	16354264	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4C[C@@H]5CC[C@H](CC4=O)N5S(C)(=O)=O)cn3)nc2n1C1CCCC1		CHEMBL3691673	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
284305	16354928	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4C[C@@H]5CN[C@@H](C5)C4)cn3)nc2n1C1CCCC1		CHEMBL3691553	=	IC50	nM	4137.0	CHEMBL308	Homo sapiens	IC50	nM	4137.0
284413	16354953	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CC5(CCNCC5)OC4=O)cn3)nc2n1C1CCCC1		CHEMBL3691656	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
198664	16355036	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4C[C@@H]5CC[C@H](C4)N5)cn3)nc2n1C1CCCC1		CHEMBL3691684	=	IC50	nM	23.0	CHEMBL308	Homo sapiens	IC50	nM	23.0
284390	16356058	CHEMBL3705854	IMAP-FP (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FP (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4C(=O)CN5CCC4CC5)cn3)nc2n1C1CCCCCC1		CHEMBL3691633	=	IC50	nM	10777.0	CHEMBL308	Homo sapiens	IC50	nM	10777.0
	16413418	CHEMBL3743726	Inhibition of CDC2 (unknown origin)	B	O=C(O)C1CN(Cc2ccc(OCc3ccc(Cl)c(Cl)c3)cc2)C1		CHEMBL3741589	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	16438255	CHEMBL3757183	Inhibition of CDK1 (unknown origin) using poly-GAT as substrate after 60 mins by TR-FRET assay	B	CC(C)n1ncc2cnc(Nc3cc(C(N)=O)n(C)c3)nc21		CHEMBL2012308	=	IC50	nM	24.0	CHEMBL308	Homo sapiens	IC50	uM	0.024
	16507272	CHEMBL3777410	Inhibition of CDK1 (unknown origin)	B	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL189963	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	16507273	CHEMBL3777410	Inhibition of CDK1 (unknown origin)	B	CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12		CHEMBL1801932	=	IC50	nM	14000.0	CHEMBL308	Homo sapiens	IC50	uM	14.0
	16507274	CHEMBL3777410	Inhibition of CDK1 (unknown origin)	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	=	IC50	nM	72.0	CHEMBL308	Homo sapiens	IC50	uM	0.072
	16507275	CHEMBL3777410	Inhibition of CDK1 (unknown origin)	B	CC(O)CNc1nc(NCc2ccc(-c3ccccn3)cc2)c2[nH]nc(C(C)C)c2n1		CHEMBL3774632	=	IC50	nM	777.0	CHEMBL308	Homo sapiens	IC50	uM	0.777
	16566135	CHEMBL3803165	Inhibition of CDK1 (unknown origin)	B	Nc1ncccc1-c1nc2ccccc2[nH]1		CHEMBL3797559	=	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	16566136	CHEMBL3803165	Inhibition of CDK1 (unknown origin)	B	Nc1ncc(-c2ccccc2)cc1-c1nc2ccccc2[nH]1		CHEMBL3799935	=	IC50	nM	160.0	CHEMBL308	Homo sapiens	IC50	uM	0.16
	16566137	CHEMBL3803165	Inhibition of CDK1 (unknown origin)	B	CN(C)C(=O)c1cccc(-c2cnc(N)c(-c3nc4ccccc4[nH]3)c2)c1		CHEMBL3797574	=	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	uM	1.0
	16566138	CHEMBL3803165	Inhibition of CDK1 (unknown origin)	B	CN(C)C(=O)c1cccc(-c2cnc(N)c(-c3nc4cccc(N5CCNCC5)c4[nH]3)c2)c1		CHEMBL3797828	=	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	uM	1.0
	16566139	CHEMBL3803165	Inhibition of CDK1 (unknown origin)	B	CN(C)C(=O)c1cccc(-c2cnc(N)c(-c3nc4cccc(N5CCNCC5)c4[nH]3)n2)c1		CHEMBL3798066	=	IC50	nM	1700.0	CHEMBL308	Homo sapiens	IC50	uM	1.7
	16566140	CHEMBL3803165	Inhibition of CDK1 (unknown origin)	B	CN(C)C(=O)c1cccc(-c2cnc(N)c(-c3nc4cccc(N5CCNCC5)c4n3C)n2)c1		CHEMBL3798762	=	IC50	nM	500.0	CHEMBL308	Homo sapiens	IC50	uM	0.5
	16566141	CHEMBL3803165	Inhibition of CDK1 (unknown origin)	B	C[C@H]1CN(c2cccc3nc(-c4nc(-c5cccc(C(=O)N(C)C)c5)cnc4N)n(C)c23)CCN1		CHEMBL3797873	=	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	uM	1.0
	16566142	CHEMBL3803165	Inhibition of CDK1 (unknown origin)	B	C[C@H]1CN(c2cccc3nc(-c4nc(-c5cc(C(=O)N(C)C)ccn5)cnc4N)n(C)c23)CCN1		CHEMBL3800585	>	IC50	nM	25000.0	CHEMBL308	Homo sapiens	IC50	uM	25.0
Not Active	16599636	CHEMBL3810780	Effect on CDK1 phosphorylation in human MCF7 cells after 6 hrs by Western blot analysis	B	COc1ccc(/C=C2/S/C(=N\c3nc4cc(-c5ccc(Cl)cc5)sc4s3)NC2=O)cc1		CHEMBL3809320		Activity			CHEMBL308	Homo sapiens	Activity		
Not Active	16599637	CHEMBL3810781	Effect on CDK1 phosphorylation in human MDA-MB-231 after 6 hrs by Western blot analysis	B	COc1ccc(/C=C2/S/C(=N\c3nc4cc(-c5ccc(Cl)cc5)sc4s3)NC2=O)cc1		CHEMBL3809320		Activity			CHEMBL308	Homo sapiens	Activity		
	16610777	CHEMBL3817692	Inhibition of CDK1 (unknown origin)	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	IC50	nM	30.0	CHEMBL308	Homo sapiens	IC50	uM	0.03
	16636709	CHEMBL3825310	Inhibition of CDK1 (unknown origin)	B	CC(=O)N1CCC(n2cc(Nc3ncc(Cl)c(-c4cnc5ccccn45)n3)cn2)CC1		CHEMBL3823659	=	IC50	nM	66.0	CHEMBL308	Homo sapiens	IC50	uM	0.066
	16636710	CHEMBL3825310	Inhibition of CDK1 (unknown origin)	B	Cc1nn(C2CCN(C(=O)[C@@H](C)O)CC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1		CHEMBL3823030	=	IC50	nM	430.0	CHEMBL308	Homo sapiens	IC50	uM	0.43
	16737085	CHEMBL3856515	Inhibition of recombinant CDK1 (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotinylated Histone H1 as substrate after 1 hr in presence of 33P-ATP by liquid scintillation counting analysis	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	=	IC50	nM	3.0	CHEMBL308	Homo sapiens	IC50	nmol/L	3.0
	16737095	CHEMBL3856510	Inhibition of CDK1 (unknown origin)	B	CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1		CHEMBL1944698	=	IC50	nM	3.0	CHEMBL308	Homo sapiens	IC50	nM	3.0
	16737096	CHEMBL3856510	Inhibition of CDK1 (unknown origin)	B	COc1ccccc1-c1cc(Nc2ccc(F)c(NS(C)(=O)=O)c2)ncn1		CHEMBL3895785	>	Ki	nM	1000.0	CHEMBL308	Homo sapiens	Ki	nM	1000.0
	16780373	CHEMBL3865326	Inhibition of CDK1 phosphorylation at Thr-161 residue in human MCF7 cells at 75 nM after 48 hrs by Western blot analysis relative to control	B	COc1ccc(/C=C2\N=C3C=CC=CN3C2=O)cc1		CHEMBL3910987	=	FC		2.0	CHEMBL308	Homo sapiens	FC		2.0
	16780394	CHEMBL3865290	Inhibition of CDK1 phosphorylation at Thr-161 residue in human MCF7 cells at 50 nM after 48 hrs by Western blot analysis relative to control	B	COc1ccc(/C=C2\N=C3C=CC=CN3C2=O)cc1		CHEMBL3910987	=	FC		1.2	CHEMBL308	Homo sapiens	FC		1.2
	16815451	CHEMBL3871612	Inhibition of CDK1 (unknown origin) at 1 uM	B	O=C(O)/C=C\C(=O)Nc1cccc(-c2n[nH]c3ccc(NS(=O)(=O)c4ccccc4)cc23)c1		CHEMBL3986609	=	Inhibition	%	21.0	CHEMBL308	Homo sapiens	INH	%	21.0
	16844137	CHEMBL3877183	Inhibition of CDK1 (unknown origin)	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	=	IC50	nM	3.0	CHEMBL308	Homo sapiens	IC50	nM	3.0
	16883318	CHEMBL3881054	Inhibition of CDK1 (unknown origin)	B	O=C(Nc1ccc(O)cc1)c1ccc2c(-c3nc4ccccc4[nH]3)n[nH]c2c1		CHEMBL392765	=	Ki	nM	24000.0	CHEMBL308	Homo sapiens	Ki	uM	24.0
	16883319	CHEMBL3881054	Inhibition of CDK1 (unknown origin)	B	C(=N/n1cccc1)\c1n[nH]c2cc(-c3ccncc3)ccc12		CHEMBL3894999	=	Ki	nM	146.0	CHEMBL308	Homo sapiens	Ki	uM	0.146
	16883320	CHEMBL3881054	Inhibition of CDK1 (unknown origin)	B	C(=C/c1n[nH]c2cc(-c3ccncc3)ccc12)\c1ccc2c(c1)OCO2		CHEMBL3930293	=	Ki	nM	66.0	CHEMBL308	Homo sapiens	Ki	uM	0.066
	16883321	CHEMBL3881054	Inhibition of CDK1 (unknown origin)	B	Fc1cccc(/C=C/c2n[nH]c3cc(-c4ccncc4)ccc23)c1		CHEMBL3932994	=	Ki	nM	390.0	CHEMBL308	Homo sapiens	Ki	uM	0.39
	16883409	CHEMBL3881053	Inhibition of CDK1 (unknown origin) at 1 uM	B	Oc1ccc(-c2ccc3c(/C=C/c4ccccc4)n[nH]c3c2)cc1O		CHEMBL3927984	=	Inhibition	%	93.0	CHEMBL308	Homo sapiens	INH	%	93.0
	16883410	CHEMBL3881053	Inhibition of CDK1 (unknown origin) at 1 uM	B	C(=C/c1n[nH]c2cc(-c3ccccc3)ccc12)\c1ccccc1		CHEMBL3943400		Inhibition	%		CHEMBL308	Homo sapiens	INH		
	16883411	CHEMBL3881053	Inhibition of CDK1 (unknown origin) at 1 uM	B	Oc1cccc(-c2ccc3c(/C=C/c4ccccc4)n[nH]c3c2)c1		CHEMBL3934652	=	Inhibition	%	77.0	CHEMBL308	Homo sapiens	INH	%	77.0
	16883412	CHEMBL3881053	Inhibition of CDK1 (unknown origin) at 1 uM	B	OCCOc1cc(-c2ccc3c(/C=C/c4ccccc4)n[nH]c3c2)ccc1O		CHEMBL3916120	=	Inhibition	%	85.0	CHEMBL308	Homo sapiens	INH	%	85.0
	16883413	CHEMBL3881053	Inhibition of CDK1 (unknown origin) at 1 uM	B	CCOc1cc(-c2ccc3c(/C=C/c4ccccc4)n[nH]c3c2)ccc1O		CHEMBL3976748	=	Inhibition	%	84.0	CHEMBL308	Homo sapiens	INH	%	84.0
	16883414	CHEMBL3881053	Inhibition of CDK1 (unknown origin) at 1 uM	B	C(=C/c1n[nH]c2cc(-c3ccnc4[nH]ncc34)ccc12)\c1ccccc1		CHEMBL3908396	=	Inhibition	%	39.0	CHEMBL308	Homo sapiens	INH	%	39.0
	16883415	CHEMBL3881053	Inhibition of CDK1 (unknown origin) at 1 uM	B	Clc1ccc(/C=C/c2n[nH]c3cc(-c4ccncc4)ccc23)cc1		CHEMBL3909445	=	Inhibition	%	56.0	CHEMBL308	Homo sapiens	INH	%	56.0
	16883416	CHEMBL3881053	Inhibition of CDK1 (unknown origin) at 1 uM	B	O=C(Nc1ccc(O)cc1)c1ccc2c(-c3nc4cc5ccccc5cc4[nH]3)n[nH]c2c1		CHEMBL3943067		Inhibition	%		CHEMBL308	Homo sapiens	INH		
	16883417	CHEMBL3881053	Inhibition of CDK1 (unknown origin) at 1 uM	B	O=C(Nc1ccc(O)cc1)c1ccc2c(-c3nc4ccc5ccccc5c4[nH]3)n[nH]c2c1		CHEMBL3959021		Inhibition	%		CHEMBL308	Homo sapiens	INH		
	16883418	CHEMBL3881053	Inhibition of CDK1 (unknown origin) at 1 uM	B	O=C(Nc1ccc(O)cc1)c1ccc2c(-c3nc4cc(F)c(F)cc4[nH]3)n[nH]c2c1		CHEMBL3949614	=	Inhibition	%	1.0	CHEMBL308	Homo sapiens	INH	%	1.0
	16883419	CHEMBL3881053	Inhibition of CDK1 (unknown origin) at 1 uM	B	FC(F)(F)Oc1cccc(/C=C/c2n[nH]c3cc(-c4ccncc4)ccc23)c1		CHEMBL3922865	=	Inhibition	%	6.0	CHEMBL308	Homo sapiens	INH	%	6.0
	16883420	CHEMBL3881053	Inhibition of CDK1 (unknown origin) at 1 uM	B	CC(C)(C)c1ccc2[nH]c(-c3n[nH]c4cc(C(=O)Nc5ccc(O)cc5)ccc34)nc2c1		CHEMBL3972710	=	Inhibition	%	3.0	CHEMBL308	Homo sapiens	INH	%	3.0
	16883421	CHEMBL3881053	Inhibition of CDK1 (unknown origin) at 1 uM	B	NC(=O)c1ccc2c(-c3nc4ccccc4[nH]3)n[nH]c2c1		CHEMBL3926148	=	Inhibition	%	13.0	CHEMBL308	Homo sapiens	INH	%	13.0
	16883422	CHEMBL3881053	Inhibition of CDK1 (unknown origin) at 1 uM	B	Fc1cccc(/C=C/c2n[nH]c3cc(-c4ccncc4)ccc23)c1F		CHEMBL3983182	=	Inhibition	%	7.0	CHEMBL308	Homo sapiens	INH	%	7.0
	16883423	CHEMBL3881053	Inhibition of CDK1 (unknown origin) at 1 uM	B	Fc1cc(F)cc(/C=C/c2n[nH]c3cc(-c4ccncc4)ccc23)c1		CHEMBL3901204	=	Inhibition	%	54.0	CHEMBL308	Homo sapiens	INH	%	54.0
	16883424	CHEMBL3881054	Inhibition of CDK1 (unknown origin)	B	C(=C/c1n[nH]c2cc(-c3ccncc3)ccc12)\c1ccccc1		CHEMBL3979164	=	Ki	nM	223.0	CHEMBL308	Homo sapiens	Ki	uM	0.223
	16883425	CHEMBL3881054	Inhibition of CDK1 (unknown origin)	B	C(=C/c1n[nH]c2cc(-c3ccnc4[nH]ccc34)ccc12)\c1ccccc1		CHEMBL3953845	=	Ki	nM	41.0	CHEMBL308	Homo sapiens	Ki	uM	0.041
	16883426	CHEMBL3881054	Inhibition of CDK1 (unknown origin)	B	Cc1cccc(/C=C/c2n[nH]c3cc(-c4ccncc4)ccc23)c1		CHEMBL3970483	=	Ki	nM	900.0	CHEMBL308	Homo sapiens	Ki	uM	0.9
	16883427	CHEMBL3881054	Inhibition of CDK1 (unknown origin)	B	COc1cccc(/C=C/c2n[nH]c3cc(-c4ccncc4)ccc23)c1		CHEMBL3927122	=	Ki	nM	593.0	CHEMBL308	Homo sapiens	Ki	uM	0.593
	16883428	CHEMBL3881054	Inhibition of CDK1 (unknown origin)	B	Fc1ccccc1/C=C/c1n[nH]c2cc(-c3ccncc3)ccc12		CHEMBL3945754	=	Ki	nM	1300.0	CHEMBL308	Homo sapiens	Ki	uM	1.3
	16883429	CHEMBL3881054	Inhibition of CDK1 (unknown origin)	B	COc1ccc2[nH]c(-c3n[nH]c4cc(C(=O)Nc5ccc(O)cc5)ccc34)nc2c1	Potential missing data	CHEMBL3931019		Ki			CHEMBL308	Homo sapiens	Ki		
	16897329	CHEMBL3882689	Inhibition of CDK1 (unknown origin) using kemptide as substrate measured after 2 hrs by kinase-Glo luminescent kinase assay	B	COc1cc2[nH]c3ncnc(N4CCN(C(=S)Nc5ccc(S(=O)(=O)Nc6ncccn6)cc5)CC4)c3c2cc1OC		CHEMBL456689	=	IC50	nM	22300.0	CHEMBL308	Homo sapiens	IC50	uM	22.3
11306	17601220	CHEMBL3707822	Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.	B	CS(=N)(=O)c1ccc(Nc2ncc(Br)c(Nc3ccccc3)n2)cc1		CHEMBL3940661	=	IC50	nM	160.0	CHEMBL308	Homo sapiens	IC50	nM	160.0
12926	17601253	CHEMBL3705517	Kinase Assay: CDK1/CycB (200 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C, the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.	B	C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(=O)(=O)C3CC3)cc2)ncc1C(F)(F)F		CHEMBL3644032	=	IC50	nM	8.0	CHEMBL308	Homo sapiens	IC50	nM	8.0
12935	17601257	CHEMBL3705517	Kinase Assay: CDK1/CycB (200 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C, the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.	B	C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(C)(=O)=O)cc2)ncc1C(F)(F)F		CHEMBL3644033	=	IC50	nM	4.0	CHEMBL308	Homo sapiens	IC50	nM	4.0
12979	17601261	CHEMBL3705517	Kinase Assay: CDK1/CycB (200 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C, the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.	B	C[C@@H](Oc1nc(Nc2ccc(S(C)(=O)=O)cc2)ncc1C(F)(F)F)C(C)(C)O		CHEMBL3644034	=	IC50	nM	9.0	CHEMBL308	Homo sapiens	IC50	nM	9.0
260725	17643253	CHEMBL3705517	Kinase Assay: CDK1/CycB (200 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C, the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.	B	C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(=O)(=O)C3CC3)cc2)ncc1C(F)(F)F		CHEMBL3644032	=	IC50	nM	16.0	CHEMBL308	Homo sapiens	IC50	nM	16.0
260726	17643254	CHEMBL3705517	Kinase Assay: CDK1/CycB (200 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C, the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.	B	C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(C)(=O)=O)cc2)ncc1C(F)(F)F		CHEMBL3644033	=	IC50	nM	9.0	CHEMBL308	Homo sapiens	IC50	nM	9.0
260727	17643255	CHEMBL3705517	Kinase Assay: CDK1/CycB (200 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C, the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.	B	C[C@@H](Oc1nc(Nc2ccc(S(C)(=O)=O)cc2)ncc1C(F)(F)F)C(C)(C)O		CHEMBL3644034	=	IC50	nM	32.0	CHEMBL308	Homo sapiens	IC50	nM	32.0
260728	17643256	CHEMBL3705517	Kinase Assay: CDK1/CycB (200 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C, the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.	B	C[C@@H](Oc1nc(Nc2ccc(S(=O)(=O)C3CC3)cc2)ncc1C(F)(F)F)C(C)(C)O		CHEMBL3644019	=	IC50	nM	36.0	CHEMBL308	Homo sapiens	IC50	nM	36.0
260729	17643257	CHEMBL3705517	Kinase Assay: CDK1/CycB (200 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C, the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.	B	C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(=O)(=O)c3ccccc3)cc2)ncc1C(F)(F)F		CHEMBL3644020	=	IC50	nM	41.0	CHEMBL308	Homo sapiens	IC50	nM	41.0
260730	17643258	CHEMBL3705517	Kinase Assay: CDK1/CycB (200 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C, the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.	B	C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(=O)(=O)C(F)F)cc2)ncc1C(F)(F)F		CHEMBL3644021	=	IC50	nM	24.0	CHEMBL308	Homo sapiens	IC50	nM	24.0
260731	17643259	CHEMBL3705517	Kinase Assay: CDK1/CycB (200 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C, the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.	B	C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(=O)(=O)C3CCCC3)cc2)ncc1C(F)(F)F		CHEMBL3644022	=	IC50	nM	23.0	CHEMBL308	Homo sapiens	IC50	nM	23.0
260732	17643260	CHEMBL3705517	Kinase Assay: CDK1/CycB (200 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C, the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.	B	C=CCS(=O)(=O)c1ccc(Nc2ncc(C(F)(F)F)c(O[C@H](C)C(C)(C)O)n2)cc1		CHEMBL3644023	=	IC50	nM	43.0	CHEMBL308	Homo sapiens	IC50	nM	43.0
260733	17643261	CHEMBL3705517	Kinase Assay: CDK1/CycB (200 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C, the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.	B	CC(C)S(=O)(=O)c1ccc(Nc2ncc(C(F)(F)F)c(O[C@H](C)[C@@H](C)O)n2)cc1		CHEMBL3644024	=	IC50	nM	12.0	CHEMBL308	Homo sapiens	IC50	nM	12.0
260734	17643262	CHEMBL3705517	Kinase Assay: CDK1/CycB (200 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C, the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.	B	C#CCS(=O)(=O)c1ccc(Nc2ncc(C(F)(F)F)c(O[C@H](C)C(C)(C)O)n2)cc1		CHEMBL3644025	=	IC50	nM	82.0	CHEMBL308	Homo sapiens	IC50	nM	82.0
260735	17643263	CHEMBL3705517	Kinase Assay: CDK1/CycB (200 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C, the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.	B	C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(=O)(=O)CCO)cc2)ncc1C(F)(F)F		CHEMBL3644026	=	IC50	nM	3.0	CHEMBL308	Homo sapiens	IC50	nM	3.0
260736	17643264	CHEMBL3705517	Kinase Assay: CDK1/CycB (200 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C, the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.	B	COC[C@@H](C)Oc1nc(Nc2ccc(S(C)(=O)=O)cc2)ncc1C(F)(F)F		CHEMBL3644027	=	IC50	nM	51.0	CHEMBL308	Homo sapiens	IC50	nM	51.0
260737	17643265	CHEMBL3705517	Kinase Assay: CDK1/CycB (200 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C, the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.	B	C#CCOc1nc(Nc2ccc(S(C)(=O)=O)cc2)ncc1C(F)(F)F		CHEMBL3644028	=	IC50	nM	130.0	CHEMBL308	Homo sapiens	IC50	nM	130.0
260738	17643266	CHEMBL3705517	Kinase Assay: CDK1/CycB (200 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C, the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.	B	CS(=O)(=O)c1ccc(Nc2ncc(C(F)(F)F)c(OCCC(F)(F)F)n2)cc1		CHEMBL3644029	=	IC50	nM	740.0	CHEMBL308	Homo sapiens	IC50	nM	740.0
260739	17643267	CHEMBL3705517	Kinase Assay: CDK1/CycB (200 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C, the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.	B	C=CCOc1nc(Nc2ccc(S(C)(=O)=O)cc2)ncc1C(F)(F)F		CHEMBL3644030	=	IC50	nM	280.0	CHEMBL308	Homo sapiens	IC50	nM	280.0
260740	17643268	CHEMBL3705517	Kinase Assay: CDK1/CycB (200 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C, the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.	B	CS(=O)(=O)c1ccc(Nc2ncc(C(F)(F)F)c(OC3CCCCC3)n2)cc1		CHEMBL3644031	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	nM	1000.0
286574	17668919	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccccn3)nc2n1C1CCCC1		CHEMBL3654234	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286575	17668920	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1		CHEMBL3545110	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286576	17668921	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CCN1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1		CHEMBL3658063	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286577	17668922	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CCF)CC4)cn3)nc2n1C1CCCC1		CHEMBL3658071	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286578	17668923	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CCO)CC4)cn3)nc2n1C1CCCC1		CHEMBL3654258	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286579	17668924	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	COCCN1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1		CHEMBL3654246	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286580	17668925	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CC(C)OCCN1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1		CHEMBL3658078	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286581	17668926	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CCOCCO)CC4)cn3)nc2n1C1CCCC1		CHEMBL3658021	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286582	17668927	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	C[C@@H](O)CN1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1		CHEMBL3658044	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286583	17668928	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	C[C@H](O)CN1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1		CHEMBL3658043	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286584	17668929	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CC(C)(C)O)CC4)cn3)nc2n1C1CCCC1		CHEMBL3658057	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286585	17668930	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CCCO)CC4)cn3)nc2n1C1CCCC1		CHEMBL3654253	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286586	17668931	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CC(O)CO)CC4)cn3)nc2n1C1CCCC1		CHEMBL3658031	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286587	17668932	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C[C@@H](O)CO)CC4)cn3)nc2n1C1CCCC1		CHEMBL3658033	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286588	17668933	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C[C@H](O)CO)CC4)cn3)nc2n1C1CCCC1		CHEMBL3654260	=	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286589	17668934	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C5CCCC5)CC4)cn3)nc2n1C1CCCC1		CHEMBL3658064	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286590	17668935	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CC(C)N1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1		CHEMBL3658050	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286591	17668936	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CC(CO)N1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1		CHEMBL3658024	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286592	17668937	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	COC(=O)C(C)N1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1		CHEMBL3658082	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286593	17668938	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CC(C(=O)O)N1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1		CHEMBL3658083	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286594	17668939	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CC5CCCCC5)CC4)cn3)nc2n1C1CCCC1		CHEMBL3658055	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286595	17668940	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CC(C)CN1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1		CHEMBL3658076	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286596	17668941	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CCC(C)CN1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1		CHEMBL3658080	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286597	17668942	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C(=O)CC5CCCCC5)CC4)cn3)nc2n1C1CCCC1		CHEMBL3658074	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286598	17668943	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CC(C)CCCN1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1		CHEMBL3658054	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286599	17668944	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CC(F)(F)F)CC4)cn3)nc2n1C1CCCC1		CHEMBL3654257	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286600	17668945	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CC(N)=O)CC4)cn3)nc2n1C1CCCC1		CHEMBL3654241	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286601	17668946	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CC#N)CC4)cn3)nc2n1C1CCCC1		CHEMBL3658069	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286602	17668947	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CCC#N)CC4)cn3)nc2n1C1CCCC1		CHEMBL3654240	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286603	17668948	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CC(=O)N1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1		CHEMBL3654238	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286604	17668949	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C(=O)C5CC5)CC4)cn3)nc2n1C1CCCC1		CHEMBL3654259	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286605	17668950	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C(=O)C5CCCCC5)CC4)cn3)nc2n1C1CCCC1		CHEMBL3654255	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286606	17668951	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C(=O)CC5CCCCC5)CC4)cn3)nc2n1C1CCCC1		CHEMBL3658074	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286607	17668952	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C(=O)CCC5CCCC5)CC4)cn3)nc2n1C1CCCC1		CHEMBL3658075	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286608	17668953	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C(=O)CN)CC4)cn3)nc2n1C1CCCC1		CHEMBL3654244	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286609	17668954	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)CC(=O)N1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1		CHEMBL3658073	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286610	17668955	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C(=O)N5CCCC5)CC4)cn3)nc2n1C1CCCC1		CHEMBL3654254	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286611	17668956	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C(=O)N5CCCCC5)CC4)cn3)nc2n1C1CCCC1		CHEMBL3658077	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286612	17668957	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C(=O)N5CCOCC5)CC4)cn3)nc2n1C1CCCC1		CHEMBL3658025	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286613	17668958	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	C[C@@H]1CN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CCN1C(=O)OC(C)(C)C		CHEMBL3654261	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286614	17668959	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	C[C@H]1CN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CCN1C(=O)OC(C)(C)C		CHEMBL3654262	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286615	17668960	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CC1CN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CCN1		CHEMBL3654251	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286616	17668961	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	C[C@@H]1CN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CCN1		CHEMBL3654248	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286617	17668962	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	C[C@@H]1CN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CCN1CCO		CHEMBL3658066	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286618	17668963	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	C[C@H]1CN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CCN1		CHEMBL3654249	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286619	17668964	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	C[C@H]1CN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CCN1CCO		CHEMBL3658067	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286620	17668965	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNC(C)(C)C4)cn3)nc2n1C1CCCC1		CHEMBL3658058	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286621	17668966	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CC1CN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC(C)N1		CHEMBL3654256	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286622	17668967	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNC(=O)C4)cn3)nc2n1C1CCCC1		CHEMBL3654236	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286623	17668968	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCCNCC4)cn3)nc2n1C1CCCC1		CHEMBL3654239	=	IC50	nM	14000.0	CHEMBL308	Homo sapiens	IC50	nM	14000.0
286624	17668969	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCC(N)C4)cn3)nc2n1C1CCCC1		CHEMBL3654245	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286625	17668970	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CC[C@H](O)C4)cn3)nc2n1C1CCCC1		CHEMBL3658026	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286626	17668971	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CC(O)C4)cn3)nc2n1C1CCCC1		CHEMBL3639531	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286627	17668972	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N(C)CCN)cn3)nc2n1C1CCCC1		CHEMBL3658046	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286628	17668973	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N(C)CCO)cn3)nc2n1C1CCCC1		CHEMBL3658068	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286629	17668974	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(CN4CC(O)C4)cn3)nc2n1C1CCCC1		CHEMBL3654242	=	IC50	nM	12000.0	CHEMBL308	Homo sapiens	IC50	nM	12000.0
286630	17668975	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(CN4CCN(S(C)(=O)=O)CC4)cn3)nc2n1C1CCCC1		CHEMBL3658022	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286631	17668976	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(CN4CCNCC4)cn3)nc2n1C1CCCC1		CHEMBL3658029	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286632	17668977	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN1CCN(Cc2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1		CHEMBL3658030	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286633	17668978	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CC1CN(Cc2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CCN1		CHEMBL3658041	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286634	17668979	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	C[C@H]1CN(Cc2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CCN1		CHEMBL3658042	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286635	17668980	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(CN4CCN(C)C(=O)C4)cn3)nc2n1C1CCCC1		CHEMBL3658047	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286636	17668981	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CC(=O)N1CCN(Cc2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1		CHEMBL3658048	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286637	17668982	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CC(C)N1CCN(Cc2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1		CHEMBL3658049	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286638	17668983	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(CN4CCN(C(=O)CN)CC4)cn3)nc2n1C1CCCC1		CHEMBL3658051	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286639	17668984	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(CN4CC5CCC(C4)N5)cn3)nc2n1C1CCCC1		CHEMBL3658059	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286640	17668985	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	C[C@H]1CN(Cc2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)C[C@@H](C)N1		CHEMBL3658060	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286641	17668986	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(CN4CCC(O)CC4)cn3)nc2n1C1CCCC1		CHEMBL3658061	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286642	17668987	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	COCCN1CCN(Cc2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1		CHEMBL3658062	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286643	17668988	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(CN4CCN(CCO)CC4)cn3)nc2n1C1CCCC1		CHEMBL3658070	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286644	17668989	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	C[C@H](CO)NCc1ccc(Nc2ncc3cc(C(=O)N(C)C)n(C4CCCC4)c3n2)nc1		CHEMBL3658052	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286645	17668990	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)NC4CCNCC4)cn3)nc2n1C1CCCC1		CHEMBL3654235	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286646	17668991	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N(C)C4CCNCC4)cn3)nc2n1C1CCCC1		CHEMBL3658040	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286647	17668992	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CCNCC4)cn3)nc2n1C1CCCC1		CHEMBL3658036	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286648	17668993	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CCN(CCO)CC4)cn3)nc2n1C1CCCC1		CHEMBL3658079	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286649	17668994	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CCC(N(C)C)CC4)cn3)nc2n1C1CCCC1		CHEMBL3658037	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286650	17668995	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CCC(O)CC4)cn3)nc2n1C1CCCC1		CHEMBL3658072	=	IC50	nM	13000.0	CHEMBL308	Homo sapiens	IC50	nM	13000.0
286651	17668996	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N(C)CCN)cn3)nc2n1C1CCCC1		CHEMBL3658028	=	IC50	nM	14800.0	CHEMBL308	Homo sapiens	IC50	nM	14800.0
286652	17668997	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCC(N(C)C)CC4)cn3)nc2n1C1CCCC1		CHEMBL3654237	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286653	17668998	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCC(O)CC4)cn3)nc2n1C1CCCC1		CHEMBL3654252	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286654	17668999	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCC(CCO)CC4)cn3)nc2n1C1CCCC1		CHEMBL3658023	=	IC50	nM	4700.0	CHEMBL308	Homo sapiens	IC50	nM	4700.0
286655	17669000	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C4CCNCC4)cn3)nc2n1C1CCCC1		CHEMBL3658039	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286656	17669001	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CC(C)N1CCC(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1		CHEMBL3658065	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286657	17669002	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(C4CCN(CCO)CC4)cn3)nc2n1C1CCCC1		CHEMBL3658081	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286658	17669003	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C(=O)OC(C)(C)C)CC4)nn3)nc2n1C1CCCC1		CHEMBL3658032	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286659	17669004	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)nn3)nc2n1C1CCCC1		CHEMBL3658053	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286660	17669005	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CC(C)N1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nn2)CC1		CHEMBL3658056	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286661	17669006	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CCO)CC4)nn3)nc2n1C1CCCC1		CHEMBL3639568	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286662	17669007	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3cnc(N4CCNCC4)cn3)nc2n1C1CCCC1		CHEMBL3658035	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286663	17669008	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3cnc(N4CCN(CCO)CC4)cn3)nc2n1C1CCCC1		CHEMBL3654247	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286664	17669009	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccccn3)nc2n1C1CCC(C)(O)CC1		CHEMBL3658027	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286665	17669010	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C1CCN(c2ccc(Nc3ncc4cc(C#N)n(C5CCCC5)c4n3)nc2)CC1		CHEMBL3658034	=	IC50	nM	2600.0	CHEMBL308	Homo sapiens	IC50	nM	2600.0
286666	17669011	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CNC(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1		CHEMBL3658045	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286667	17669012	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CNC(=O)c1cc2cnc(Nc3ccc(N4CCN(C(C)C)CC4)cn3)nc2n1C1CCCC1		CHEMBL3658038	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286668	17669013	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	c1ncc(-c2cc3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n2C2CCCC2)o1		CHEMBL3654243	=	IC50	nM	1300.0	CHEMBL308	Homo sapiens	IC50	nM	1300.0
286669	17669014	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	c1ncc(-c2cc3cnc(Nc4ccc(CN5CCNCC5)cn4)nc3n2C2CCCC2)o1		CHEMBL3654250	=	IC50	nM	1100.0	CHEMBL308	Homo sapiens	IC50	nM	1100.0
286670	17669015	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4=O)cn3)nc2n1C1CCCC1		CHEMBL3658084	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286671	17669016	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCOCC4)cn3)nc2n1C1CCCC1		CHEMBL3658085	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286771	17669116	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1	Outside typical range	CHEMBL3545110	=	IC50	nM	113000.0	CHEMBL308	Homo sapiens	IC50	nM	113000.0
286774	17669119	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CC(C)N1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1		CHEMBL3658050	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
286777	17669122	CHEMBL3705367	IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 uL volumes in the reaction solution, which is composed of 2 uL compound (in 20% DMSO), 8 uL CDK1/cyclin B in the 1x Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 uL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1x Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 uM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 uM ATP.All reactions were run at room temperature in black 384-well flat-bottom Costar plates (Corning, Cat. No. 3710) for 120 min then were quenched.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CCO)CC4)cn3)nc2n1C1CCCC1		CHEMBL3654258	>	IC50	nM	15000.0	CHEMBL308	Homo sapiens	IC50	nM	15000.0
Inactive	17888430	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(NCC(=O)O)c2)c(OC)c1		CHEMBL1241855	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888431	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO		CHEMBL1801204	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888432	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@@H]23)OCO4)cc(OC)c1OC		CHEMBL283120	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888433	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888434	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2Nc2ccc3nsnc3c2)cc1		CHEMBL3218575	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888435	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1		CHEMBL2403108	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888436	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1		CHEMBL1976040	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888437	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888438	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cccc(-c2nn3c(c2-c2ccnc4ccc(C(N)=O)cc24)CCC3)n1		CHEMBL2364611	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888439	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=Nc3cc(NC(=O)C(N)C4CCCCC4)cc4c3C2=CNNC4=O)cn1		CHEMBL3545137	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Active	17888440	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1		CHEMBL2105728	=	Kd	nM	1378.0	CHEMBL308	Homo sapiens	Kd apparent	nM	1378.0
Inactive	17888441	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888442	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1N=C(N)c2cn([C@@H]3O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL462018	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888443	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1		CHEMBL2001019	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888444	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1		CHEMBL2396661	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888445	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)NCc2cc(F)ccc2Oc2ccc3c(cnn3CCO)c2)cc1		CHEMBL3991932	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888446	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1		CHEMBL592445	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888447	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888448	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12		CHEMBL3408248	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888449	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1		CHEMBL1952329	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888450	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCNC(=O)C#Cc1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(CN(C)C)cc1)c1ccccc1		CHEMBL3699142	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888451	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2[nH]nc3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)c2sccc2n1		CHEMBL3128043	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888452	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888453	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1csc(-c2nnc(Nc3ccc(Oc4ncccc4-c4ccnc(N)n4)cc3)c3ccccc23)c1		CHEMBL2140408	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888454	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1		CHEMBL587723	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888455	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)C1(Cc2cccc(Nc3nccs3)n2)CCC(Oc2cccc(Cl)c2F)CC1		CHEMBL3182444	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Active	17888456	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1		CHEMBL1738757	=	Kd	nM	1070.0	CHEMBL308	Homo sapiens	Kd apparent	nM	1070.0
Inactive	17888457	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1		CHEMBL270995	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888458	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1		CHEMBL1983268	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888459	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1		CHEMBL460702	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888460	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(O)cc3)c2cc1OC		CHEMBL405130	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888461	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O		CHEMBL483158	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Active	17888462	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3688339	=	Kd	nM	288.0	CHEMBL308	Homo sapiens	Kd apparent	nM	288.0
Inactive	17888463	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3991931	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Active	17888464	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@@H]1CO.Cl		CHEMBL3991935	=	Kd	nM	4226.0	CHEMBL308	Homo sapiens	Kd apparent	nM	4226.0
Inactive	17888465	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888466	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(S(=O)(=O)N(C(C)=O)c2ccccc2/C=C/c2cc[n+]([O-])cc2)cc1		CHEMBL3991927	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888467	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1		CHEMBL3989868	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888468	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL3545154	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888469	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1		CHEMBL2103842	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888470	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21		CHEMBL1879463	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888471	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1		CHEMBL3545085	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888472	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888473	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888474	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1		CHEMBL2017974	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888475	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1		CHEMBL1822792	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888476	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL189963	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888477	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc2cc(-c3nc([C@H]4CC[C@H](C(=O)O)CC4)n4ncnc(N)c34)[nH]c12		CHEMBL3120215	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888478	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1		CHEMBL3544983	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888479	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1		CHEMBL3301622	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888480	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888481	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21		CHEMBL3334567	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888482	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F		CHEMBL3188267	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888483	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888484	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL507361	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888485	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1		CHEMBL3545308	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888486	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)n[nH]2)c2cccn2n1		CHEMBL575448	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888487	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1		CHEMBL1236682	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888488	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1		CHEMBL3039517	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888489	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OP(C)(C)=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL2103839	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888490	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccccc5)cc4F)c3s2)c1		CHEMBL254760	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888491	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21		CHEMBL3218576	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888492	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2ccc(-n3ncc(C(=O)c4cc5ccccc5[nH]4)c3N)cc2[nH]1		CHEMBL3907479	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888493	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888494	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCN(/C=C1/C(=O)O[C@H](COC)[C@@]2(C)C1=C(O)C(=O)C1=C2[C@H](OC(C)=O)C[C@]2(C)C(=O)CC[C@@H]12)CC=C		CHEMBL411907	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888495	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888496	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1		CHEMBL206834	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888497	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1		CHEMBL3301612	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888498	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1		CHEMBL2180604	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888499	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888500	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888501	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N[C@@H]1CCCN(c2c(/C=C3\SC(=O)NC3=O)cccc2-c2ccccc2)C1		CHEMBL2048872	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888502	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888503	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1		CHEMBL217092	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888504	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888505	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1		CHEMBL3545110	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888506	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888507	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1		CHEMBL3186534	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888508	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)[C@@H](c2cn3c4c(cccc24)CCC3)[C@@H]1c1c[nH]c2ccccc12		CHEMBL2103882	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888509	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888510	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12		CHEMBL1983111	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888511	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL3545360	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Active	17888512	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	=	Kd	nM	1406.0	CHEMBL308	Homo sapiens	Kd apparent	nM	1406.0
Uncertain	17888513	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C		CHEMBL488436	=	Kd	nM	1992.0	CHEMBL308	Homo sapiens	Kd apparent	nM	1992.0
Inactive	17888514	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(C(F)(F)c4ccc5ncccc5c4)n3n2)cn1		CHEMBL2133806	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888515	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(=O)c(-c2cc[nH]n2)cc2c(C)nc(N)nc21		CHEMBL3545366	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888516	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888517	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F		CHEMBL1229517	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888518	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888519	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc3c2cc1OCCCCCN(C)Cc1ccc(Br)cc1N3		CHEMBL3109738	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888520	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL2103830	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888521	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1.Cl		CHEMBL3991929	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888522	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888523	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1		CHEMBL3039525	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888524	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1C#CC(C)(C)N1CCN(C)CC1		CHEMBL2138625	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888525	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888526	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1		CHEMBL253969	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888527	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCC(=O)NO)cc23)c1		CHEMBL598797	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888528	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1		CHEMBL1088751	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888529	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888530	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1		CHEMBL1946170	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888531	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnn3c(N)c(Br)c([C@@H]4CCCNC4)nc23)cn1		CHEMBL2386889	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888532	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]ccc2cc(OC3CCNCC3)ccc12		CHEMBL1667969	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888533	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888534	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888535	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1		CHEMBL496102	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888536	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC[C@H](O)CO)c1ccncc1Nc1ccc(I)cc1F		CHEMBL2107832	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888537	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@](C)(Nc1ccnc(-c2c[nH]c3ncccc23)n1)C(=O)NCC(F)(F)F		CHEMBL3039513	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888538	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12		CHEMBL2220486	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888539	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12		CHEMBL1645462	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888540	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1		CHEMBL2110732	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888541	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)N[C@H]1CCCNC1		CHEMBL2041933	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888542	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL574737	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888543	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		CHEMBL3813873	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888544	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F		CHEMBL3264002	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888545	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1cc(-c2ccnc3[nH]c(-c4cccc(CN(C)C)c4)cc23)c(-c2ccc(NC(=O)N(C)C)cc2)n1		CHEMBL1090479	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888546	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888547	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1		CHEMBL372764	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888548	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888549	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1		CHEMBL1231124	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888550	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl		CHEMBL2219422	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888551	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888552	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1		CHEMBL1944698	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888553	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1908360	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888554	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1nccc1Nc1nccc(-c2ccn([C@H](CO)c3ccc(Cl)c(F)c3)c(=O)c2)n1		CHEMBL3544964	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888555	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc([C@@H](C)Nc2ccccc2C(=O)O)c2nc(N3CCOCC3)cc(=O)n2c1		CHEMBL2165191	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888556	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL3353410	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888557	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1		CHEMBL3545396	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888558	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C		CHEMBL1233528	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888559	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1		CHEMBL1078178	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Active	17888560	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C		CHEMBL1230607	=	Kd	nM	2565.0	CHEMBL308	Homo sapiens	Kd apparent	nM	2565.0
Active	17888561	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1		CHEMBL2028663	=	Kd	nM	364.0	CHEMBL308	Homo sapiens	Kd apparent	nM	364.0
Inactive	17888562	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888563	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)c(F)c(Nc2ccc(I)cc2F)c2c(=O)n(C[C@@H](O)CO)cnc21		CHEMBL1615025	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888564	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888565	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888566	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12		CHEMBL3426621	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888567	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1		CHEMBL2087361	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888568	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)c1cccc(-c2cc(C(=O)NC3CCN(C)CC3)c(C)c3[nH]c4ncc(C)cc4c23)c1		CHEMBL3544932	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888569	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(Cn2c(C)nc3c(C(=O)O)cc(N4CCOCC4)cc32)cccc1C(F)(F)F		CHEMBL3188551	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888570	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1		CHEMBL2079588	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Active	17888571	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	Kd	nM	1516.0	CHEMBL308	Homo sapiens	Kd apparent	nM	1516.0
Inactive	17888572	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1		CHEMBL2336325	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888573	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(N2CCN(C)CC2)cc1Nc1ncc2c(n1)-c1c(c(C(N)=O)nn1C)CC2		CHEMBL1094408	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888574	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888575	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC		CHEMBL2105717	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888576	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888577	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)Nc1cc(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)c(Cl)cn1		CHEMBL3590106	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888578	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O		CHEMBL3182621	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888579	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(Cl)ccc1O		CHEMBL536151	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Uncertain	17888580	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331	=	Kd	nM	2014.0	CHEMBL308	Homo sapiens	Kd apparent	nM	2014.0
Inactive	17888581	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21		CHEMBL1614725	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888582	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888583	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888584	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888585	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888586	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1		CHEMBL1088752	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888587	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CN(C(=O)c2cc3c(C(=O)C(=O)N(C)C)cn(C)c3cc2Cl)[C@H](C)CN1Cc1ccc(F)cc1		CHEMBL514201	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Active	17888588	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	=	Kd	nM	77.0	CHEMBL308	Homo sapiens	Kd apparent	nM	77.0
Inactive	17888589	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21		CHEMBL3187723	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888590	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1		CHEMBL482767	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888591	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888592	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O		CHEMBL1738797	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888593	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1		CHEMBL1079175	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888594	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1ccc(N(C(N)=O)c2c(F)cccc2F)nc1-c1ccc(F)cc1F		CHEMBL1090090	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888595	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888596	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888597	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1		CHEMBL571948	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888598	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1		CHEMBL2105759	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Active	17888599	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	=	Kd	nM	1228.0	CHEMBL308	Homo sapiens	Kd apparent	nM	1228.0
Inactive	17888600	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1		CHEMBL3545328	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888601	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1		CHEMBL3402762	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888602	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1		CHEMBL3545157	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Active	17888603	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	=	Kd	nM	3049.0	CHEMBL308	Homo sapiens	Kd apparent	nM	3049.0
Inactive	17888604	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21		CHEMBL3545215	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888605	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888606	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888607	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F		CHEMBL1236962	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Active	17888608	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	=	Kd	nM	1510.0	CHEMBL308	Homo sapiens	Kd apparent	nM	1510.0
Inactive	17888609	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888610	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888611	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc2o1		CHEMBL3991933	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888612	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(CCc2cc(NC(=O)c3ccc(N4CC(C)NC(C)C4)cc3)n[nH]2)cc(OC)c1		CHEMBL3184679	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888613	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1		CHEMBL2323775	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888614	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	c1cc(OCCN2CCCCC2)cc(-c2n[nH]c3ccc(-c4nnc[nH]4)cc23)c1		CHEMBL1614713	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Active	17888615	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	=	Kd	nM	1216.0	CHEMBL308	Homo sapiens	Kd apparent	nM	1216.0
Inactive	17888616	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC		CHEMBL2029988	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888617	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1		CHEMBL1091644	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888618	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325741	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888619	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888620	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888621	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL402548	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888622	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888623	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1		CHEMBL2103851	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888624	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL274654	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888625	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888626	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOCCO)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL1614766	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888627	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL1922094	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888628	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]c(C2CCCN2)nc2c1oc1ccc(Cl)cc12		CHEMBL3544944	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888629	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1		CHEMBL2103875	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888630	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O[C@H]1CC[C@H](Nc2ncc3nc(Nc4c(F)cc(F)cc4F)n([C@H]4CCOC4)c3n2)CC1		CHEMBL1950289	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888631	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888632	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1		CHEMBL2216870	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888633	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCc1c(-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)c(F)c2)c2c(N)ncnn2c1CN1CCOCC1		CHEMBL3991934	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888634	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12		CHEMBL1614710	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888635	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888636	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)/C(=C/c2ccc3nccc(-c4ccncc4)c3c2)S1		CHEMBL3544966	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888637	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL403989	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888638	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1		CHEMBL3301607	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888639	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1201182	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888640	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(C(=O)Nc2ccc(C(=O)N3CCN(C)CC3)cc2)nnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL2376648	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888641	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1		CHEMBL3348923	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888642	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl		CHEMBL3137336	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888643	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888644	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1		CHEMBL482968	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888645	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B			CHEMBL4084193	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888646	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2		CHEMBL564829	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888647	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3544960	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888648	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12		CHEMBL1171837	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888649	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2[C@H]1C[C@H](N2CCC2)C1		CHEMBL551064	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888650	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2c(O)nccc12)N1CCCNCC1		CHEMBL1233300	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888651	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888652	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1		CHEMBL3545307	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888653	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888654	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888655	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O		CHEMBL415049	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888656	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)CN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL2408045	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888657	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O		CHEMBL1289601	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888658	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc3[nH]ncc23)CC1		CHEMBL3545076	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888659	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(O)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL400402	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888660	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1		CHEMBL2146883	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888661	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1		CHEMBL495727	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888662	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCNCC3)c(C(F)(F)F)c2)c(=O)n4C)cn1		CHEMBL3218578	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888663	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCCO)CC3)c2=O)cn1		CHEMBL1234354	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888664	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1		CHEMBL2035187	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888665	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Active	17888666	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCCN1CCN(Cc2ccc(-c3n[nH]c4c3C(=O)c3c(NC(=O)NN5CCOCC5)cccc3-4)cc2)CC1		CHEMBL3545083	=	Kd	nM	1337.0	CHEMBL308	Homo sapiens	Kd apparent	nM	1337.0
Inactive	17888667	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888668	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1		CHEMBL571546	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888669	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888670	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888671	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL482967	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17888672	CHEMBL3991650	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(/C=C/c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1		CHEMBL1614707	>	Kd	nM	30000.0	CHEMBL308	Homo sapiens	Kd apparent	nM	30000.0
	18012408	CHEMBL4004228	Inhibition of CDK1 (unknown origin)	B	COc1cc2ncccc2cc1NC(=O)c1csc2cncnc12		CHEMBL3822972	>	IC50	nM	50000.0	CHEMBL308	Homo sapiens	IC50	uM	50.0
	18086033	CHEMBL4018653	Inhibition of CDK1 (unknown origin) by FRET assay	B	Cc1n[nH]c2ccc(-c3cc(N[C@@H](CO)c4ccccc4)cnc3-c3cc(Cl)ccc3O)cc12		CHEMBL4105329	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	nM	1000.0
	18086034	CHEMBL4018653	Inhibition of CDK1 (unknown origin) by FRET assay	B	OC[C@H](Nc1cnc(-c2cc(Cl)ccc2O)c(-c2ccc3cnccc3c2)c1)c1ccccc1		CHEMBL4067871	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	nM	1000.0
	18086035	CHEMBL4018653	Inhibition of CDK1 (unknown origin) by FRET assay	B	Cc1n[nH]c2ccc(-c3cc(N[C@@H](CO)c4ccccc4)cnc3-c3cc(F)ccc3O)cc12		CHEMBL4062877	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	nM	1000.0
	18086036	CHEMBL4018653	Inhibition of CDK1 (unknown origin) by FRET assay	B	Cc1n[nH]c2ccc(-c3cc(N[C@@H](CO)c4ccccc4)cnc3-c3ccc(F)cc3O)cc12		CHEMBL4075917	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	nM	1000.0
Not Active	18099889	CHEMBL4021796	Inhibition of CDK1 (unknown origin) at 61 uM	B	Cc1ccc(CNc2nc(N)nc3[nH]c4cc(C)c(O)cc4c23)cc1		CHEMBL4098682		Inhibition	%		CHEMBL308	Homo sapiens	INH		
	18105899	CHEMBL4022687	Inhibition of human CDC2 using biotin histone H1 peptide substrate after 1 hr by scintillation counting method	B	Nc1nc(NCCNc2ncc(-n3ccnc3)c(-c3ccc(Cl)cc3Cl)n2)ccc1[N+](=O)[O-]		CHEMBL3185148	=	IC50	nM	4000.0	CHEMBL308	Homo sapiens	IC50	uM	4.0
	18105900	CHEMBL4022687	Inhibition of human CDC2 using biotin histone H1 peptide substrate after 1 hr by scintillation counting method	B	Nc1nc(NCCNc2ncc(-c3ncc[nH]3)c(-c3ccc(Cl)cc3Cl)n2)ccc1[N+](=O)[O-]		CHEMBL1080901	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	18105901	CHEMBL4022687	Inhibition of human CDC2 using biotin histone H1 peptide substrate after 1 hr by scintillation counting method	B	Cc1c[nH]c(-c2cnc(NCCNc3ccc(C#N)cn3)nc2-c2ccc(Cl)cc2Cl)n1		CHEMBL412142	=	IC50	nM	8800.0	CHEMBL308	Homo sapiens	IC50	uM	8.8
	18153124	CHEMBL4034285	Inhibition of CDC2 Lysine 2 labelling site (unknown origin) at 10 uM	B	c1cc(-c2c[nH]c3cnccc23)ccn1		CHEMBL4084955	=	Inhibition	%	3.3	CHEMBL308	Homo sapiens	INH	%	3.3
	18153335	CHEMBL4034284	Inhibition of CDC2 Lysine 1 labelling site (unknown origin) at 10 uM	B	c1cc(-c2c[nH]c3cnccc23)ccn1		CHEMBL4084955	=	Inhibition	%	2.5	CHEMBL308	Homo sapiens	INH	%	2.5
Dose-dependent effect	18160662	CHEMBL4035832	Reduction in phosphorylated CDC2 level in human HeLa cells after 24 hrs by Western blot analysis	B	COc1cc([C@@H]2c3cc4c(cc3[C@H](OC(=O)NS(=O)(=O)N3CCOCC3)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OC		CHEMBL4089692		Activity			CHEMBL308	Homo sapiens	Activity		
	18211606	CHEMBL4045655	Inhibition of CDC2 labeling at conserved Lys2 (DLKPQNLLIDDKGTIK) in human PBMC at 1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1		CHEMBL3971067	=	Inhibition	%	12.6	CHEMBL308	Homo sapiens	INH	%	12.6
	18211619	CHEMBL4045654	Inhibition of CDC2 labeling at conserved Lys2 (DLKPQNLLIDDK) in human PBMC at 1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1		CHEMBL3971067	=	Inhibition	%	2.5	CHEMBL308	Homo sapiens	INH	%	2.5
	18211801	CHEMBL4045897	Inhibition of CDC2 labeling at conserved Lys2 (DLKPQNLLIDDK) in human PBMC at 0.1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1		CHEMBL3971067	=	Inhibition	%	13.1	CHEMBL308	Homo sapiens	INH	%	13.1
	18211802	CHEMBL4045898	Inhibition of CDC2 labeling at conserved Lys2 (DLKPQNLLIDDKGTIK) in human PBMC at 0.1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1		CHEMBL3971067	=	Inhibition	%	14.4	CHEMBL308	Homo sapiens	INH	%	14.4
	18274818	CHEMBL4118318	Inhibition of CDC2 in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled DLKPQNLLIDDK probe by mass-spectrometric analysis relative to control	B	C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1Cl		CHEMBL3883384	=	Inhibition	%	47.7	CHEMBL308	Homo sapiens	INH	%	47.7
	18274819	CHEMBL4118318	Inhibition of CDC2 in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled DLKPQNLLIDDK probe by mass-spectrometric analysis relative to control	B	C=CC(=O)Nc1ccccc1Oc1nc(Nc2cnn(CCOC)c2)ncc1Cl		CHEMBL3884839	=	Inhibition	%	33.1	CHEMBL308	Homo sapiens	INH	%	33.1
	18274820	CHEMBL4118318	Inhibition of CDC2 in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled DLKPQNLLIDDK probe by mass-spectrometric analysis relative to control	B	COc1cc(O)c2c(c1)/C=C/C[C@H](O)[C@H](O)C(=O)/C=C\C[C@H](C)OC2=O		CHEMBL1077979	=	Inhibition	%	46.6	CHEMBL308	Homo sapiens	INH	%	46.6
	18299190	CHEMBL4124402	Inhibition of CDK1 (unknown origin) expressed in baculovirus infected Sf9 insect cells using histone H1 as substrate after 1 hr by liquid scintillation counting analysis	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	=	IC50	nM	3.0	CHEMBL308	Homo sapiens	IC50	nM	3.0
Active	18367030	CHEMBL4142876	Activation of CDK1 in human A549 cells assessed as increase in CDK1 phosphorylation at Tyr15 residues at 100 nM after 24 hrs by western blot analysis	B	CO[C@@H]1[C@@H](O)[C@H](C)O[C@@H](O[C@H]2C[C@@H](O)[C@]3(C)[C@H]4CC[C@]5(C)[C@@H](C6=CC(=O)OC6)CC[C@]5(O)[C@@H]4CC[C@@H]3C2)[C@H]1O		CHEMBL4161504		Activity			CHEMBL308	Homo sapiens	Activity		
Active	18367239	CHEMBL4142935	Inhibition of cdc2 phosphorylation at Y15 in human HeLa cells at 0.1 to 1 uM after 24 to 48 hrs by Western blot analysis	B	CCn1ccc2c3c(=O)cc(-c4ccc5c(c4)OCO5)[nH]c3ccc21		CHEMBL4163970		Inhibition	%		CHEMBL308	Homo sapiens	INH		
	18460862	CHEMBL4180590	Inhibition of CDK1 (unknown origin) using U-light as substrate preincubated for 1 hr followed by EDTA addition measured after 1 hr by LANCE Ultra kinase assay	B	CCN1CCN(Cc2ccc(Nc3cc(-c4cc(F)c5nc(C)n(C(C)C)c5c4)ncn3)nc2)CC1		CHEMBL4214898	=	IC50	nM	411.9	CHEMBL308	Homo sapiens	IC50	nM	411.9
	18460863	CHEMBL4180590	Inhibition of CDK1 (unknown origin) using U-light as substrate preincubated for 1 hr followed by EDTA addition measured after 1 hr by LANCE Ultra kinase assay	B	CCN1CCN(Cc2ccc(Nc3cc(-c4cc(F)c5nc(C)n(C(C)C)c5c4)ccn3)nc2)CC1		CHEMBL4208198	=	IC50	nM	300.9	CHEMBL308	Homo sapiens	IC50	nM	300.9
	18460864	CHEMBL4180590	Inhibition of CDK1 (unknown origin) using U-light as substrate preincubated for 1 hr followed by EDTA addition measured after 1 hr by LANCE Ultra kinase assay	B	CCN1CCN(Cc2cnc(Nc3cc(-c4cc(F)c5nc(C)n(C(C)C)c5c4)ncn3)cn2)CC1		CHEMBL4208504	=	IC50	nM	135.5	CHEMBL308	Homo sapiens	IC50	nM	135.5
	18460865	CHEMBL4180590	Inhibition of CDK1 (unknown origin) using U-light as substrate preincubated for 1 hr followed by EDTA addition measured after 1 hr by LANCE Ultra kinase assay	B	CCN1CCN(Cc2cnc(Nc3cc(-c4cc(F)c5nc(C)n(C(C)C)c5c4)ccn3)cn2)CC1		CHEMBL4204030	=	IC50	nM	35.8	CHEMBL308	Homo sapiens	IC50	nM	35.8
	18460866	CHEMBL4180590	Inhibition of CDK1 (unknown origin) using U-light as substrate preincubated for 1 hr followed by EDTA addition measured after 1 hr by LANCE Ultra kinase assay	B	CCN1CCN(Cc2cnc(Nc3cc(-c4cc(F)c5nc(C)n(C(C)C)c5c4)c(F)cn3)cn2)CC1		CHEMBL4218267	=	IC50	nM	44.0	CHEMBL308	Homo sapiens	IC50	nM	44.0
	18460867	CHEMBL4180590	Inhibition of CDK1 (unknown origin) using U-light as substrate preincubated for 1 hr followed by EDTA addition measured after 1 hr by LANCE Ultra kinase assay	B	CCN1CCN(Cc2ccc(Nc3cc(-c4cc(F)c5nc(C)n(C(C)C)c5c4)ccn3)nn2)CC1		CHEMBL4205366	=	IC50	nM	800.9	CHEMBL308	Homo sapiens	IC50	nM	800.9
	18460868	CHEMBL4180590	Inhibition of CDK1 (unknown origin) using U-light as substrate preincubated for 1 hr followed by EDTA addition measured after 1 hr by LANCE Ultra kinase assay	B	CCN1CCN(Cc2ccc(Nc3cc(-c4cc(F)c5nc(C)n(C(C)C)c5c4)ncn3)nn2)CC1		CHEMBL4218705	=	IC50	nM	2429.5	CHEMBL308	Homo sapiens	IC50	nM	2429.5
	18460869	CHEMBL4180590	Inhibition of CDK1 (unknown origin) using U-light as substrate preincubated for 1 hr followed by EDTA addition measured after 1 hr by LANCE Ultra kinase assay	B	CCN1CCN(Cc2cnc(Nc3cc(-c4cc(F)c5nc(C)n(C(C)C)c5c4)ncn3)nc2)CC1		CHEMBL4213770	=	IC50	nM	20225.0	CHEMBL308	Homo sapiens	IC50	nM	20225.0
	18460870	CHEMBL4180590	Inhibition of CDK1 (unknown origin) using U-light as substrate preincubated for 1 hr followed by EDTA addition measured after 1 hr by LANCE Ultra kinase assay	B	CCN1CCN(Cc2ccc(Nc3cc(-c4cc(F)c5nc(C)n(C(C)C)c5c4)c(F)cn3)nn2)CC1		CHEMBL4211162	=	IC50	nM	1671.1	CHEMBL308	Homo sapiens	IC50	nM	1671.1
Not Determined	18460871	CHEMBL4180590	Inhibition of CDK1 (unknown origin) using U-light as substrate preincubated for 1 hr followed by EDTA addition measured after 1 hr by LANCE Ultra kinase assay	B	CCN1CCN(Cc2ncc(Nc3cc(-c4cc(F)c5nc(C)n(C(C)C)c5c4)ncn3)cn2)CC1		CHEMBL4206280		IC50			CHEMBL308	Homo sapiens	IC50		
Not Determined	18460872	CHEMBL4180590	Inhibition of CDK1 (unknown origin) using U-light as substrate preincubated for 1 hr followed by EDTA addition measured after 1 hr by LANCE Ultra kinase assay	B	CCN1CCN(Cc2cnc(Nc3ncnc(-c4cc(F)c5nc(C)n(C(C)C)c5c4)c3F)cn2)CC1		CHEMBL4206797		IC50			CHEMBL308	Homo sapiens	IC50		
	18460873	CHEMBL4180590	Inhibition of CDK1 (unknown origin) using U-light as substrate preincubated for 1 hr followed by EDTA addition measured after 1 hr by LANCE Ultra kinase assay	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	=	IC50	nM	1523.0	CHEMBL308	Homo sapiens	IC50	nM	1523.0
	18460874	CHEMBL4180590	Inhibition of CDK1 (unknown origin) using U-light as substrate preincubated for 1 hr followed by EDTA addition measured after 1 hr by LANCE Ultra kinase assay	B	Cc1nc2c(F)cc(-c3cc(Nc4cnc(CN5CCN(C(C)C)CC5)cn4)ncn3)cc2n1C(C)C		CHEMBL4202432	=	IC50	nM	97.2	CHEMBL308	Homo sapiens	IC50	nM	97.2
	18460875	CHEMBL4180590	Inhibition of CDK1 (unknown origin) using U-light as substrate preincubated for 1 hr followed by EDTA addition measured after 1 hr by LANCE Ultra kinase assay	B	Cc1nc2c(F)cc(-c3cc(Nc4cnc(CN5CCN(CC(F)(F)F)CC5)cn4)ncn3)cc2n1C(C)C		CHEMBL4214123	=	IC50	nM	150.0	CHEMBL308	Homo sapiens	IC50	nM	150.0
	18460876	CHEMBL4180590	Inhibition of CDK1 (unknown origin) using U-light as substrate preincubated for 1 hr followed by EDTA addition measured after 1 hr by LANCE Ultra kinase assay	B	COCCN1CCN(Cc2cnc(Nc3cc(-c4cc(F)c5nc(C)n(C(C)C)c5c4)ncn3)cn2)CC1		CHEMBL4214634	=	IC50	nM	139.7	CHEMBL308	Homo sapiens	IC50	nM	139.7
	18460877	CHEMBL4180590	Inhibition of CDK1 (unknown origin) using U-light as substrate preincubated for 1 hr followed by EDTA addition measured after 1 hr by LANCE Ultra kinase assay	B	Cc1nc2c(F)cc(-c3cc(Nc4cnc(CN5CCN(CC6CC6)CC5)cn4)ncn3)cc2n1C(C)C		CHEMBL4213557	=	IC50	nM	103.1	CHEMBL308	Homo sapiens	IC50	nM	103.1
	18460878	CHEMBL4180590	Inhibition of CDK1 (unknown origin) using U-light as substrate preincubated for 1 hr followed by EDTA addition measured after 1 hr by LANCE Ultra kinase assay	B	Cc1nc2c(F)cc(-c3cc(Nc4cnc(CN5CCN(C6CCCC6)CC5)cn4)ncn3)cc2n1C(C)C		CHEMBL4216534	=	IC50	nM	100.5	CHEMBL308	Homo sapiens	IC50	nM	100.5
	18460879	CHEMBL4180590	Inhibition of CDK1 (unknown origin) using U-light as substrate preincubated for 1 hr followed by EDTA addition measured after 1 hr by LANCE Ultra kinase assay	B	CCN1CCC(Cc2cnc(Nc3cc(-c4cc(F)c5nc(C)n(C(C)C)c5c4)ncn3)cn2)CC1		CHEMBL4207218	=	IC50	nM	133.8	CHEMBL308	Homo sapiens	IC50	nM	133.8
	18460880	CHEMBL4180590	Inhibition of CDK1 (unknown origin) using U-light as substrate preincubated for 1 hr followed by EDTA addition measured after 1 hr by LANCE Ultra kinase assay	B	CCN1CCC(C(C)c2cnc(Nc3cc(-c4cc(F)c5nc(C)n(C(C)C)c5c4)ncn3)cn2)CC1		CHEMBL4203994	=	IC50	nM	1413.0	CHEMBL308	Homo sapiens	IC50	nM	1413.0
	18460881	CHEMBL4180590	Inhibition of CDK1 (unknown origin) using U-light as substrate preincubated for 1 hr followed by EDTA addition measured after 1 hr by LANCE Ultra kinase assay	B	CCN1CCC(Oc2cnc(Nc3cc(-c4cc(F)c5nc(C)n(C(C)C)c5c4)ncn3)cn2)CC1		CHEMBL4208875	=	IC50	nM	230.7	CHEMBL308	Homo sapiens	IC50	nM	230.7
	18653727	CHEMBL4230040	Inhibition of CDK1 (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc(NC(=O)c3cccc(C(F)(F)F)c3)c2)c2c(N)ncnc21		CHEMBL3736320	=	Inhibition	%	6.0	CHEMBL308	Homo sapiens	INH	%	6.0
	18653728	CHEMBL4230040	Inhibition of CDK1 (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc3cc(-c4cccc(C(F)(F)F)c4)ncc23)c2c(N)ncnc21		CHEMBL4247506	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
Not Active	18659147	CHEMBL4231766	Inhibition of CDK1 (unknown origin)	B	Cn1cc2cnc(-c3ccccc3)cc2n1		CHEMBL4250369		Inhibition	%		CHEMBL308	Homo sapiens	INH		
Not Active	18659148	CHEMBL4231766	Inhibition of CDK1 (unknown origin)	B	c1ccc(-c2cc3nn(-c4ccccc4)cc3cn2)cc1		CHEMBL4246112		Inhibition	%		CHEMBL308	Homo sapiens	INH		
Not Active	18659149	CHEMBL4231766	Inhibition of CDK1 (unknown origin)	B	c1ccc(-n2cc3cnc(-c4ccsc4)cc3n2)cc1		CHEMBL4241650		Inhibition	%		CHEMBL308	Homo sapiens	INH		
Not Active	18659150	CHEMBL4231766	Inhibition of CDK1 (unknown origin)	B	c1ccc(-n2cc3cnc(C4CC4)cc3n2)cc1		CHEMBL4245887		Inhibition	%		CHEMBL308	Homo sapiens	INH		
Not Active	18659151	CHEMBL4231766	Inhibition of CDK1 (unknown origin)	B	CCCCc1cc2nn(-c3ccccc3)cc2cn1		CHEMBL4245428		Inhibition	%		CHEMBL308	Homo sapiens	INH		
Not Active	18659152	CHEMBL4231766	Inhibition of CDK1 (unknown origin)	B	CCCCCc1cc2nn(-c3ccccc3)cc2cn1		CHEMBL4249686		Inhibition	%		CHEMBL308	Homo sapiens	INH		
Not Active	18659153	CHEMBL4231766	Inhibition of CDK1 (unknown origin)	B	OCCc1cc2nn(-c3ccccc3)cc2cn1		CHEMBL4249222		Inhibition	%		CHEMBL308	Homo sapiens	INH		
Not Active	18659154	CHEMBL4231766	Inhibition of CDK1 (unknown origin)	B	c1ccc(-n2cc3cnccc3n2)cc1		CHEMBL4239140		Inhibition	%		CHEMBL308	Homo sapiens	INH		
Not Active	18659155	CHEMBL4231766	Inhibition of CDK1 (unknown origin)	B	Cc1nc(-c2ccccc2)cc2nn(-c3ccccc3)cc12		CHEMBL4238729		Inhibition	%		CHEMBL308	Homo sapiens	INH		
Not Active	18659156	CHEMBL4231766	Inhibition of CDK1 (unknown origin)	B	Cc1nc(-c2ccsc2)cc2nn(-c3ccccc3)cc12		CHEMBL4243069		Inhibition	%		CHEMBL308	Homo sapiens	INH		
Not Active	18659157	CHEMBL4231766	Inhibition of CDK1 (unknown origin)	B	Cc1nc(C2CC2)cc2nn(-c3ccccc3)cc12		CHEMBL4242452		Inhibition	%		CHEMBL308	Homo sapiens	INH		
Not Active	18659158	CHEMBL4231766	Inhibition of CDK1 (unknown origin)	B	CCCCc1cc2nn(-c3ccccc3)cc2c(C)n1		CHEMBL4246705		Inhibition	%		CHEMBL308	Homo sapiens	INH		
Not Active	18659159	CHEMBL4231766	Inhibition of CDK1 (unknown origin)	B	CCCCCc1cc2nn(-c3ccccc3)cc2c(C)n1		CHEMBL4245000		Inhibition	%		CHEMBL308	Homo sapiens	INH		
Not Active	18659160	CHEMBL4231766	Inhibition of CDK1 (unknown origin)	B	Cc1nc(CCO)cc2nn(-c3ccccc3)cc12		CHEMBL4249260		Inhibition	%		CHEMBL308	Homo sapiens	INH		
Not Active	18659161	CHEMBL4231766	Inhibition of CDK1 (unknown origin)	B	Cc1nccc2nn(-c3ccccc3)cc12		CHEMBL4247304		Inhibition	%		CHEMBL308	Homo sapiens	INH		
Not Active	18659162	CHEMBL4231766	Inhibition of CDK1 (unknown origin)	B	CC(C)c1nc(-c2ccccc2)cc2nn(-c3ccccc3)cc12		CHEMBL4245464		Inhibition	%		CHEMBL308	Homo sapiens	INH		
Not Active	18659163	CHEMBL4231766	Inhibition of CDK1 (unknown origin)	B	CCCCc1cc2nn(-c3ccccc3)cc2c(C(C)C)n1		CHEMBL4237524		Inhibition	%		CHEMBL308	Homo sapiens	INH		
Not Active	18659164	CHEMBL4231766	Inhibition of CDK1 (unknown origin)	B	CC(C)c1nccc2nn(-c3ccccc3)cc12		CHEMBL4247928		Inhibition	%		CHEMBL308	Homo sapiens	INH		
	18665556	CHEMBL4233296	Inhibition of CDK1 (unknown origin)	B	O=C(Cc1cccc(OCCCN2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL4245507	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	nM	10000.0
Not Active	18728874	CHEMBL4259704	Inhibition of CDK1 (unknown origin) at 1 uM after 40 mins by scintillation counting method relative to control	B	O=C(N1CCN(c2ncnc3[nH]nc(Cl)c23)CC1)C1(c2ccc(Cl)c(Cl)c2)CCNCC1		CHEMBL4285143		Inhibition	%		CHEMBL308	Homo sapiens	INH		
	18751051	CHEMBL4263754	Inhibition of CDK1 (unknown origin) at 1 uM relative to control	B	NC1(c2ccc(-c3cnc4c(-c5ccc(S(N)(=O)=O)c6ccccc56)cnn4c3)cc2)CCC1		CHEMBL4278763	=	Inhibition	%	2.0	CHEMBL308	Homo sapiens	INH	%	2.0
	18766458	CHEMBL4267422	Inhibition of CDK1 (unknown origin)	B	CSc1ncc2c(n1)CCc1cnc(Nc3ccc(C(=O)N(C)CCN(C)C)cc3)nc1-2		CHEMBL4294760	=	IC50	nM	1250.0	CHEMBL308	Homo sapiens	IC50	uM	1.25
	18784880	CHEMBL4271328	Inhibition of CDK1 (unknown origin)	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	IC50	nM	30.0	CHEMBL308	Homo sapiens	IC50	nM	30.0
	18784881	CHEMBL4271328	Inhibition of CDK1 (unknown origin)	B	C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc([S@](=N)(=O)C3CC3)cc2)ncc1C(F)(F)F		CHEMBL4282338	=	IC50	nM	7.0	CHEMBL308	Homo sapiens	IC50	nM	7.0
	18784882	CHEMBL4271329	Inhibition of recombinant CDK1 (unknown origin) expressed in Sf9 cells using histone H1 derived biotinylated peptide and 33P-ATP incubated for 1 hr by liquid scintillation counting method	B	Cc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@@H]3CCO)nc12		CHEMBL4292930	=	IC50	nM	3.0	CHEMBL308	Homo sapiens	IC50	nM	3.0
	18786938	CHEMBL4271852	Inhibition of CDK1 (unknown origin) at 30 uM relative to control	B	O=c1cc(-c2ccc(-c3ccccc3)cc2)c2ccc(N3CCC(NCCc4ccccc4)CC3)cc2o1		CHEMBL4276817	=	Inhibition	%	-1.18	CHEMBL308	Homo sapiens	INH	%	-1.18
	18812058	CHEMBL4276185	Inhibition of human CDK1 at 100 uM	B	O=C(NCc1ccccc1)c1ccc(C2CC(=O)N(Cc3ccccc3[N+](=O)[O-])c3ccccc3S2)cc1		CHEMBL4281295	=	Inhibition	%	16.0	CHEMBL308	Homo sapiens	INH	%	16.0
	18812059	CHEMBL4276185	Inhibition of human CDK1 at 100 uM	B	O=C1CC(c2ccc(C(=O)NCc3cccc(Cl)c3)cc2)Sc2ccccc2N1		CHEMBL4277682	=	Inhibition	%	22.0	CHEMBL308	Homo sapiens	INH	%	22.0
Active	18871041	CHEMBL4310012	Binding affinity to CDK1 in human HCT116 cells assessed as induction of thermal stabilization at 4 to 20 uM incubated for 4 hrs by immunoblot analysis	B	O=C1N=C(NCc2cccs2)S/C1=C\c1ccc2ncccc2c1		CHEMBL393929		Activity			CHEMBL308	Homo sapiens	Activity		
Not Active	18871042	CHEMBL4310012	Binding affinity to CDK1 in human HCT116 cells assessed as induction of thermal stabilization at 4 to 20 uM incubated for 4 hrs by immunoblot analysis	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625		Activity			CHEMBL308	Homo sapiens	Activity		
	18871045	CHEMBL4310014	Inhibition of CDK1 (unknown origin) at 10 uM	B	CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL1802728	=	Inhibition	%	44.0	CHEMBL308	Homo sapiens	INH	%	44.0
Active	18907916	CHEMBL4320505	Inhibition of CDC2 phosphorylation in human SUM159 cells at 0.1 to 0.2 uM measured after 48 hrs by Western blot analysis	B	C=C1C(=O)O[C@H]2[C@H]1CC/C(COC(=O)/C=C/c1c(OC)cccc1OC)=C\CC[C@@]1(C)O[C@@H]21		CHEMBL4463727		Inhibition	%		CHEMBL308	Homo sapiens	INH		
	19016010	CHEMBL4346795	Inhibition of CDK1 (unknown origin)	B	CCc1cnc(CSc2cnc(NC(=O)Cc3cccnc3)s2)o1		CHEMBL129396	=	IC50	nM	80.0	CHEMBL308	Homo sapiens	IC50	nM	80.0
	19016011	CHEMBL4346795	Inhibition of CDK1 (unknown origin)	B	COCCNS(=O)(=O)c1ccc(Nc2ncc(-c3cnc4cccnn34)cn2)cc1		CHEMBL4584344	=	IC50	nM	40.0	CHEMBL308	Homo sapiens	IC50	nM	40.0
	19016012	CHEMBL4346795	Inhibition of CDK1 (unknown origin)	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	=	IC50	nM	480.0	CHEMBL308	Homo sapiens	IC50	nM	480.0
	19016019	CHEMBL4346787	Inhibition of recombinant CDK1 (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotinylated-histone H1 as substrate incubated for 1 hr in presence of cyclin by [33P]-ATP-based liquid scintillation counting method	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	=	IC50	nM	3.0	CHEMBL308	Homo sapiens	IC50	nM	3.0
	19016054	CHEMBL4346795	Inhibition of CDK1 (unknown origin)	B	Cc1nc(N)sc1-c1ccnc(Nc2cccc([N+](=O)[O-])c2)n1		CHEMBL298445	=	Ki	nM	80.0	CHEMBL308	Homo sapiens	Ki	nM	80.0
	19016055	CHEMBL4346795	Inhibition of CDK1 (unknown origin)	B	CCOC(=O)Sc1cnc(NC(C)=O)s1		CHEMBL4573345	=	IC50	nM	1900.0	CHEMBL308	Homo sapiens	IC50	nM	1900.0
	19016056	CHEMBL4346795	Inhibition of CDK1 (unknown origin)	B	Cc1cc(C)c(CNc2nc(N[C@@H](C)[C@@H](C)O)nc3c2ncn3C(C)C)cn1		CHEMBL4579344	=	IC50	nM	578.0	CHEMBL308	Homo sapiens	IC50	nM	578.0
	19027199	CHEMBL4348715	Inhibition of CDK1 (unknown origin)	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	=	IC50	nM	330.0	CHEMBL308	Homo sapiens	IC50	nM	330.0
	19027200	CHEMBL4348715	Inhibition of CDK1 (unknown origin)	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	IC50	nM	30.0	CHEMBL308	Homo sapiens	IC50	nM	30.0
	19027201	CHEMBL4348715	Inhibition of CDK1 (unknown origin)	B	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL189963	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	19027202	CHEMBL4348715	Inhibition of CDK1 (unknown origin)	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1		CHEMBL3545110	>=	IC50	nM	100000.0	CHEMBL308	Homo sapiens	IC50	uM	100.0
	19027203	CHEMBL4348715	Inhibition of CDK1 (unknown origin)	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	>	IC50	nM	1000.0	CHEMBL308	Homo sapiens	IC50	uM	1.0
	19027204	CHEMBL4348715	Inhibition of CDK1 (unknown origin)	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1C1CCCC1		CHEMBL4589103	>	IC50	nM	1600.0	CHEMBL308	Homo sapiens	IC50	uM	1.6
	19027226	CHEMBL4348722	Inhibition of recombinant CDK1 (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotinylated peptide as substrate after 1 hr in presence of [33P]ATP by TopCount scintillation counting method	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	=	IC50	nM	3.0	CHEMBL308	Homo sapiens	IC50	nM	3.0
	19112064	CHEMBL4370694	Inhibition of CDK1 (unknown origin)	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	Ki	nM	40.0	CHEMBL308	Homo sapiens	Ki	nM	40.0
	19112080	CHEMBL4370704	Inhibition of human CDK1	B	CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccc(C(F)(F)F)cc4Cl)oc23)[C@@H]1CO		CHEMBL3905910	<	IC50	nM	100.0	CHEMBL308	Homo sapiens	IC50	nM	100.0
	19112081	CHEMBL4370704	Inhibition of human CDK1	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(/C=C/c4c(Cl)cccc4Cl)oc23)[C@H](O)C1		CHEMBL4079206	=	IC50	nM	4.9	CHEMBL308	Homo sapiens	IC50	nM	4.9
	19121971	CHEMBL4373029	Inhibition of CDK1 (unknown origin) at 0.1 uM relative to control	B	COCCC#Cc1c(Cl)c2c(Cl)cc(C(N)=O)nc2n1[C@H]1CCCNC1		CHEMBL4540910	=	Inhibition	%	14.0	CHEMBL308	Homo sapiens	INH	%	14.0
	19121979	CHEMBL4373037	Inhibition of CDK1 (unknown origin) at 1 uM relative to control	B	COCCC#Cc1c(Cl)c2c(Cl)cc(C(N)=O)nc2n1[C@H]1CCCNC1		CHEMBL4540910	=	Inhibition	%	51.0	CHEMBL308	Homo sapiens	INH	%	51.0
	19133285	CHEMBL4375314	Binding affinity to wild-type human full-length CDK1 (M1 to M297 residues) expressed in mammalian expression system measured after 1 hr by kinomescan method	B	O=C(Nc1ccc2cc(C(=O)Nc3nccs3)ccc2c1)c1ccc(Cl)c(Cl)c1		CHEMBL4445812	=	Kd	nM	8020.0	CHEMBL308	Homo sapiens	Kd	uM	8.02
	19219388	CHEMBL4394703	Inhibition of CDK1 (unknown origin) using biotin-labelled STK substrate-1 as substrate incubated for 60 mins by HTRF assay	B	CC(=O)O.CNc1nc(Nc2cnc(C#N)c(O[C@@H]3CCCNC3)c2)ncc1-c1cnn(C)c1		CHEMBL4577258	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	19219488	CHEMBL4394703	Inhibition of CDK1 (unknown origin) using biotin-labelled STK substrate-1 as substrate incubated for 60 mins by HTRF assay	B	COc1cccc(OCCCN)c1-c1cc(Nc2cnc(C#N)cn2)n[nH]1		CHEMBL3544911	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	19225453	CHEMBL4395873	Inhibition of human recombinant CDK1 at 1 uM using Ulight-CFFKNIVTPRTPPPSQGK-amide as substrate incubated for 15 mins in presence of ATP by LANCE assay relative to control	B	CCc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(=O)C3CC3)c2)[nH]1	Outside typical range	CHEMBL4536012	=	Inhibition	%	-11.56	CHEMBL308	Homo sapiens	INH	%	-11.56
	19258236	CHEMBL4403339	Inhibition of CDK1 (unknown origin)	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	IC50	nM	30.0	CHEMBL308	Homo sapiens	IC50	nM	30.0
	19258243	CHEMBL4403339	Inhibition of CDK1 (unknown origin)	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	=	IC50	nM	1500.0	CHEMBL308	Homo sapiens	IC50	nM	1500.0
	19258252	CHEMBL4403339	Inhibition of CDK1 (unknown origin)	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	=	IC50	nM	3.0	CHEMBL308	Homo sapiens	IC50	nM	3.0
	19258257	CHEMBL4403346	Inhibition of CDK1 (unknown origin) by luciferase reporter gene assay	B	CC(C)c1cnn2c(NCc3ccccc3)cc(NC[C@@H]3CCNC[C@H]3O)nc12		CHEMBL4459754	=	IC50	nM	1520.0	CHEMBL308	Homo sapiens	IC50	nM	1520.0
	19258266	CHEMBL4403346	Inhibition of CDK1 (unknown origin) by luciferase reporter gene assay	B	CC(C)c1cnn2c(NCc3ccccc3)cc(NC[C@]3(O)CCNC[C@H]3O)nc12		CHEMBL4471850	=	IC50	nM	1380.0	CHEMBL308	Homo sapiens	IC50	nM	1380.0
	19258269	CHEMBL4403346	Inhibition of CDK1 (unknown origin) by luciferase reporter gene assay	B	CC(C)c1cnn2c(NCc3ccccc3)cc(NC[C@]3(CO)CCNC3)nc12		CHEMBL4553241	=	IC50	nM	41.0	CHEMBL308	Homo sapiens	IC50	nM	41.0
	19258272	CHEMBL4403346	Inhibition of CDK1 (unknown origin) by luciferase reporter gene assay	B	CC(C)c1cnn2c(NCc3ccccc3)cc(NCC3CCNCC3)nc12		CHEMBL4519886	=	IC50	nM	1660.0	CHEMBL308	Homo sapiens	IC50	nM	1660.0
	19258279	CHEMBL4403339	Inhibition of CDK1 (unknown origin)	B	CC(C)c1cnn2c(NCc3ccccc3N(C)C)nc(OC3CCN(C)CC3)nc12		CHEMBL4454044	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	nM	10000.0
	19258285	CHEMBL4403339	Inhibition of CDK1 (unknown origin)	B	CC(C)c1cnn2c(NCc3ccccc3-n3cccn3)nc(OC3CCCNC3)nc12		CHEMBL4562323	=	IC50	nM	53.0	CHEMBL308	Homo sapiens	IC50	nM	53.0
	19258311	CHEMBL4403339	Inhibition of CDK1 (unknown origin)	B	CN(C)C/C=C/C(=O)Nc1cccc(C(=O)Nc2cccc(Nc3ncc(Cl)c(-c4c[nH]c5ccccc45)n3)c2)c1		CHEMBL4303287	=	IC50	nM	13.9	CHEMBL308	Homo sapiens	IC50	nM	13.9
	19279512	CHEMBL4408785	Inhibition of CDK1 (unknown origin) relative to control	B	C=CC(=O)N1CCN(C(=O)OC(C)(C)C)c2ccccc21		CHEMBL4544461	=	Inhibition	%	2.0	CHEMBL308	Homo sapiens	INH	%	2.0
	19279514	CHEMBL4408785	Inhibition of CDK1 (unknown origin) relative to control	B	C=CC(=O)N1CCN(C(=O)OC)c2ccccc21		CHEMBL4578788	=	Inhibition	%	-2.0	CHEMBL308	Homo sapiens	INH	%	-2.0
	19295862	CHEMBL4412339	Inhibition of CDK1 (unknown origin) at 1000 nM relative to control	B	Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1-c1ccc2c(-c3cnn(C4CC4)c3)n[nH]c2c1		CHEMBL4534119	=	Inhibition	%	5.6	CHEMBL308	Homo sapiens	INH	%	5.6
	19295892	CHEMBL4412369	Inhibition of CDK1 (unknown origin) at 100 nM relative to control	B	Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1-c1ccc2c(-c3cnn(C4CC4)c3)n[nH]c2c1		CHEMBL4534119	=	Inhibition	%	1.4	CHEMBL308	Homo sapiens	INH	%	1.4
	19295922	CHEMBL4412399	Inhibition of CDK1 (unknown origin) at 10 nM relative to control	B	Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1-c1ccc2c(-c3cnn(C4CC4)c3)n[nH]c2c1		CHEMBL4534119	=	Inhibition	%	-0.1	CHEMBL308	Homo sapiens	INH	%	-0.1
	19474313	CHEMBL4479301	Inhibition of human CDK1	B	CCC(=O)Nc1nc(C)c(-c2csc(Nc3cc(OC)ccc3OC)n2)s1		CHEMBL4537058	>	Inhibition	%	50.0	CHEMBL308	Homo sapiens	INH	%	50.0
Not Active	19483827	CHEMBL4481062	Effect on CDK1 phosphorylation at Tyr15 residues in human MGC803 cells at 30 to 90 nM by Western blot analysis	B	COc1ccc(CN(C(=O)Cn2cc(COc3ccc4c(C)cc(=O)oc4c3)nn2)c2cc(OC)c(OC)c(OC)c2)cc1		CHEMBL4585153		Activity			CHEMBL308	Homo sapiens	Activity		
	20636329	CHEMBL4611858	Inhibition of CDK1 (unknown origin)	B	CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12		CHEMBL1801932	=	IC50	nM	8100.0	CHEMBL308	Homo sapiens	IC50	nM	8100.0
	20636338	CHEMBL4611858	Inhibition of CDK1 (unknown origin)	B	CC(C)c1cnn2c(NCc3ccccc3)cc(NC[C@H]3CCNC[C@@H]3O)nc12		CHEMBL4297488	=	IC50	nM	1800.0	CHEMBL308	Homo sapiens	IC50	nM	1800.0
	20636348	CHEMBL4611858	Inhibition of CDK1 (unknown origin)	B	Cc1cc(NC2CCN(C(=O)O[C@H]3CCN(C(=O)/C=C/CN(C)C)C3)CC2)n2ncc(C(C)C)c2n1		CHEMBL4635959	>	IC50	nM	8000.0	CHEMBL308	Homo sapiens	IC50	uM	8.0
	20636382	CHEMBL4611858	Inhibition of CDK1 (unknown origin)	B	CN(C)C/C=C/C(=O)Nc1cccc(C(=O)Nc2cccc(Nc3ncc(Cl)c(-c4c[nH]c5ccccc45)n3)c2)c1		CHEMBL4303287	=	IC50	nM	96.9	CHEMBL308	Homo sapiens	IC50	nM	96.9
	20641494	CHEMBL4613376	Inhibition of CDK1 (unknown origin)	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1		CHEMBL3545110	>	IC50	nM	50000.0	CHEMBL308	Homo sapiens	IC50	uM	50.0
	20641495	CHEMBL4613376	Inhibition of CDK1 (unknown origin)	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	>	IC50	nM	500.0	CHEMBL308	Homo sapiens	IC50	nM	500.0
	20641514	CHEMBL4613376	Inhibition of CDK1 (unknown origin)	B	O=S1(=O)NCCCNc2nc(ncc2Br)Nc2cccc1c2		CHEMBL1235529	=	IC50	nM	20.0	CHEMBL308	Homo sapiens	IC50	nM	20.0
	20641527	CHEMBL4613412	Inhibition of CDK1 (unknown origin) in presence of high ATP	B	CCn1cnc2c(NCc3nc4ccc(F)c(F)c4[nH]3)nc(N3CCCC[C@H]3CCO)nc21		CHEMBL4649135	>	IC50	nM	28000.0	CHEMBL308	Homo sapiens	IC50	uM	28.0
	20641531	CHEMBL4613396	Binding affinity to CDK1 (unknown origin)	B	CN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4ccnc(N)n4)cc3)cc2C(F)(F)F)CC1		CHEMBL4472486	=	Kd	nM	52.7	CHEMBL308	Homo sapiens	Kd	nM	52.7
	20641543	CHEMBL4613376	Inhibition of CDK1 (unknown origin)	B	NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL319467	=	IC50	nM	5.0	CHEMBL308	Homo sapiens	IC50	nM	5.0
	22388099	CHEMBL4666411	Inhibition of CDK1 (unknown origin) at 500 nM relative to control	B	Cc1cc(Nc2cc(N3CCN(CCCN(C)C)CC3)ncn2)c(=O)n2c1C(=O)NC21CCCCC1		CHEMBL4757546	=	Inhibition	%	4.0	CHEMBL308	Homo sapiens	INH	%	4.0
Active	22399405	CHEMBL4669258	Activation of CDK1 in human HL60/VCR cells assessed as induction of Bcl2 phosphorylation at Ser70 residue at 300 nM after 24 hrs by Western blot analysis	B	COc1ccc(Nc2nc(N)c(C(=O)c3ccc(OC)c(OC)c3)s2)cc1		CHEMBL552462		Activity			CHEMBL308	Homo sapiens	Activity		
Active	22399427	CHEMBL4669275	Activation of CDK1 in human HL-60 cells assessed as activation of caspase 7 at 300 nM after 24 hrs by Western blot analysis	B	COc1ccc(Nc2nc(N)c(C(=O)c3ccc(OC)c(OC)c3)s2)cc1		CHEMBL552462		Activity			CHEMBL308	Homo sapiens	Activity		
Active	22399439	CHEMBL4669287	Activation of CDK1 in human HL-60 cells assessed as induction of Bcl2 phosphorylation at Ser70 residue at 300 nM after 24 hrs by Western blot analysis	B	COc1ccc(Nc2nc(N)c(C(=O)c3ccc(OC)c(OC)c3)s2)cc1		CHEMBL552462		Activity			CHEMBL308	Homo sapiens	Activity		
Active	22399440	CHEMBL4669288	Activation of CDK1 in human HL60/VCR cells assessed as activation of caspase 7 at 300 nM after 24 hrs by Western blot analysis	B	COc1ccc(Nc2nc(N)c(C(=O)c3ccc(OC)c(OC)c3)s2)cc1		CHEMBL552462		Activity			CHEMBL308	Homo sapiens	Activity		
Not Active	22399441	CHEMBL4669289	Activation of CDK1 in human HL60/VCR cells assessed as induction of Bcl2 phosphorylation at Ser70 residue at 300 nM after 24 hrs in presence of Ro-3306 by Western blot analysis	B	COc1ccc(Nc2nc(N)c(C(=O)c3ccc(OC)c(OC)c3)s2)cc1		CHEMBL552462		Activity			CHEMBL308	Homo sapiens	Activity		
Not Active	22399442	CHEMBL4669290	Activation of CDK1 in human HL60/VCR cells assessed as activation of caspase 7 at 300 nM after 24 hrs in presence of Ro-3306 by Western blot analysis	B	COc1ccc(Nc2nc(N)c(C(=O)c3ccc(OC)c(OC)c3)s2)cc1		CHEMBL552462		Activity			CHEMBL308	Homo sapiens	Activity		
Not Active	22399443	CHEMBL4669291	Activation of CDK1 in human HL-60 cells assessed as induction of Bcl2 phosphorylation at Ser70 residue at 300 nM after 24 hrs in presence of Ro-3306 by Western blot analysis	B	COc1ccc(Nc2nc(N)c(C(=O)c3ccc(OC)c(OC)c3)s2)cc1		CHEMBL552462		Activity			CHEMBL308	Homo sapiens	Activity		
Not Active	22399444	CHEMBL4669292	Activation of CDK1 in human HL-60 cells assessed as activation of caspase 7 at 300 nM after 24 hrs in presence of Ro-3306 by Western blot analysis	B	COc1ccc(Nc2nc(N)c(C(=O)c3ccc(OC)c(OC)c3)s2)cc1		CHEMBL552462		Activity			CHEMBL308	Homo sapiens	Activity		
Not Active	22399445	CHEMBL4669293	Activation of CDK1 in human HL60/VCR cells assessed as induction of Bcl2 phosphorylation at Ser70 residue at 5 uM after 24 hrs in presence of Ro-3306 by Western blot analysis	B	COc1ccc(-c2cc(C(=O)N/N=C(\C)c3ccc(OC)c(OC)c3)[nH]n2)cc1		CHEMBL1289102		Activity			CHEMBL308	Homo sapiens	Activity		
Not Active	22399446	CHEMBL4669294	Activation of CDK1 in human HL60/VCR cells assessed as activation of caspase 7 at 5 uM after 24 hrs in presence of Ro-3306 by Western blot analysis	B	COc1ccc(-c2cc(C(=O)N/N=C(\C)c3ccc(OC)c(OC)c3)[nH]n2)cc1		CHEMBL1289102		Activity			CHEMBL308	Homo sapiens	Activity		
Not Active	22399447	CHEMBL4669295	Activation of CDK1 in human HL-60 cells assessed as induction of Bcl2 phosphorylation at Ser70 residue at 5 uM after 24 hrs in presence of Ro-3306 by Western blot analysis	B	COc1ccc(-c2cc(C(=O)N/N=C(\C)c3ccc(OC)c(OC)c3)[nH]n2)cc1		CHEMBL1289102		Activity			CHEMBL308	Homo sapiens	Activity		
Not Active	22399448	CHEMBL4669296	Activation of CDK1 in human HL-60 cells assessed as activation of caspase 7 at 5 uM after 24 hrs in presence of Ro-3306 by Western blot analysis	B	COc1ccc(-c2cc(C(=O)N/N=C(\C)c3ccc(OC)c(OC)c3)[nH]n2)cc1		CHEMBL1289102		Activity			CHEMBL308	Homo sapiens	Activity		
Not Active	22443470	CHEMBL4679162	Inhibition of CDK1 (unknown origin) at 1 uM	B	O=C(Nc1ccccc1)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1Cc1ccccc1		CHEMBL4781000		Inhibition	%		CHEMBL308	Homo sapiens	INH		
	22485837	CHEMBL4688585	Inhibition of CDK1 (unknown origin) by ATP competitive based analysis	B	NC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCCC1CCN(Cc2ccc(F)cc2)CC1		CHEMBL4747992	>	IC50	nM	300.0	CHEMBL308	Homo sapiens	IC50	nM	300.0
	22751945	CHEMBL4700052	Binding affinity to CDK1 in human K562 cells at 1 mM incubated for 2 hrs by LC-MS/MS analysis based pull down assay relative to control	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3c(N)c(C(N)=O)c4nc5ccc(NCCCN)cc5nc43)cc2)cc1		CHEMBL4776609	=	FC		6.6	CHEMBL308	Homo sapiens	FC		6.6
	22752580	CHEMBL4700120	Inhibition of human CDK1 by kinase-profiling analysis	B	C#Cc1nc(Nc2ccc(S(N)(=O)=O)cc2)nc2[nH]cnc12		CHEMBL4074015	=	IC50	nM	9600.0	CHEMBL308	Homo sapiens	IC50	uM	9.6
	22752581	CHEMBL4700120	Inhibition of human CDK1 by kinase-profiling analysis	B	C#Cc1nc(Nc2ccccc2)nc2[nH]cnc12		CHEMBL4094562	=	IC50	nM	40400.0	CHEMBL308	Homo sapiens	IC50	uM	40.4
	22758192	CHEMBL4701383	Inhibition of CDK1 (unknown origin)	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	IC50	nM	30.0	CHEMBL308	Homo sapiens	IC50	nM	30.0
	22758193	CHEMBL4701383	Inhibition of CDK1 (unknown origin)	B	C[C@H](CO)Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)ncc1Br		CHEMBL4741442	=	IC50	nM	50.0	CHEMBL308	Homo sapiens	IC50	nM	50.0
	22758194	CHEMBL4701383	Inhibition of CDK1 (unknown origin)	B	C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(=N)(=O)C3CC3)cc2)ncc1C(F)(F)F		CHEMBL4442620	=	IC50	nM	7.0	CHEMBL308	Homo sapiens	IC50	nM	7.0
	22758195	CHEMBL4701383	Inhibition of CDK1 (unknown origin)	B	COc1cc(F)ccc1-c1cc(NC(=O)[C@H]2CCC[C@@H](NC(C)=O)C2)ncc1Cl		CHEMBL4755256	=	IC50	nM	94.0	CHEMBL308	Homo sapiens	IC50	nM	94.0
	22758196	CHEMBL4701383	Inhibition of CDK1 (unknown origin)	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	=	IC50	nM	3.0	CHEMBL308	Homo sapiens	IC50	nM	3.0
	22758197	CHEMBL4701383	Inhibition of CDK1 (unknown origin)	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	=	IC50	nM	210.0	CHEMBL308	Homo sapiens	IC50	nM	210.0
	22758256	CHEMBL4701407	Inhibition of human CDK1	B	CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1		CHEMBL1944698	=	IC50	nM	9.0	CHEMBL308	Homo sapiens	IC50	nM	9.0
	22758295	CHEMBL4701432	Inhibition of CDK1 in human MCF7 cells assessed as reduction in PP1alpha phosphorylation at T320 residue incubated for 6 hrs by immunoblot analysis	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)c(Cl)cn2)C1		CHEMBL4462530	=	IC50	nM	370.0	CHEMBL308	Homo sapiens	IC50	nM	370.0
	22758313	CHEMBL4701445	Inhibition of CDK1 (unknown origin) using Ulight-labeled substrate by TR-FRET LANCE method	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(CC(O)CO)CC3)cc12		CHEMBL3668457	>	IC50	nM	1360.0	CHEMBL308	Homo sapiens	IC50	uM	1.36
	22758314	CHEMBL4701445	Inhibition of CDK1 (unknown origin) using Ulight-labeled substrate by TR-FRET LANCE method	B	COc1ccc(F)cc1-c1c(F)cnc2[nH]c(C3=CCN([C@H]4CC[C@H](C(=O)O)CC4)CC3)cc12		CHEMBL4777981	>	IC50	nM	320.0	CHEMBL308	Homo sapiens	IC50	uM	0.32
	22779771	CHEMBL4706938	Inhibition of CDK1 (unknown origin)	B	COC(=O)c1cnc(Nc2cnc(C#N)cn2)cc1NCC1CCNCC1		CHEMBL1928692	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	22779772	CHEMBL4706938	Inhibition of CDK1 (unknown origin)	B	COC(=O)c1cnc(Nc2cnc(C#N)cn2)cc1NCCC1CCNCC1		CHEMBL4797888	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	22779773	CHEMBL4706938	Inhibition of CDK1 (unknown origin)	B	COC(=O)c1cnc(Nc2cnc(C#N)cn2)cc1NCC1CCN(C)CC1		CHEMBL4782716	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	22779774	CHEMBL4706938	Inhibition of CDK1 (unknown origin)	B	COC(=O)c1cnc(Nc2cnc(C#N)cn2)cc1NC1CCN(C)CC1		CHEMBL4784549	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	22779775	CHEMBL4706938	Inhibition of CDK1 (unknown origin)	B	COC(=O)c1cnc(Nc2cnc(C#N)cn2)cc1NC1C[C@@H]2CC[C@H](C1)N2C		CHEMBL4753307	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	22779776	CHEMBL4706938	Inhibition of CDK1 (unknown origin)	B	COC(=O)c1cnc(Nc2cnc(C#N)cn2)cc1NCC1CNCCO1		CHEMBL4782664	>	IC50	nM	10000.0	CHEMBL308	Homo sapiens	IC50	uM	10.0
	22783366	CHEMBL4707896	Inhibition of CDK1 (unknown origin) at 20 uM relative to control	B	CCCSc1nc2c(nnn2CCNC(=S)Nc2cccc3ccccc23)c(=O)[nH]1		CHEMBL4742820	<	Inhibition	%	10.0	CHEMBL308	Homo sapiens	INH	%	10.0
	22887504	CHEMBL4728484	Inhibition of human CDK1 at 1 uM by kinome scan method relative to control	B	CC(C)N1c2cc(Nc3nccc(-c4cncc5ccccc45)n3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4742169	=	Inhibition	%	90.0	CHEMBL308	Homo sapiens	INH	%	90.0
	22908776	CHEMBL4733708	Inhibition of CDK1 (unknown origin) at 300 nM relative to control	B	CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCCCCCCCn1cc(COc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)nn1		CHEMBL4749204	=	Inhibition	%	4.01	CHEMBL308	Homo sapiens	INH	%	4.01
Active	22925753	CHEMBL4737505	Inhibition of cdc2 phosphorylation at Y15 residues in human HeLa cells at 25 to 50 nM after 24 to 48 hrs by Western blot analysis	B	CCOc1ccc(-c2c[nH]cc2-c2cc(OC)c(OC)c(OC)c2)cc1F		CHEMBL4742360		Inhibition	%		CHEMBL308	Homo sapiens	INH		
	22930711	CHEMBL4738662	Inhibition of recombinant CDK1 (unknown origin) expressed in baculovirus infected Sf9 cells using biotinylated Histone H1 peptide as substrate incubated for 1 hr in presence of [33P]ATP by liquid scintillation counting method	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	=	IC50	nM	3.0	CHEMBL308	Homo sapiens	IC50	uM	0.003
	22960887	CHEMBL4768802	Inhibition of human CDK1 at 100 nM in presence of ATP relative to control	B	Cl.O=C1Nc2ccc(F)cc2/C1=C1/Nc2ccccc2/C1=N\OCCN1CCNCC1		CHEMBL4791998	=	Inhibition	%	21.0	CHEMBL308	Homo sapiens	INH	%	21.0
	22990697	CHEMBL4775138	Inhibition of CDK1 (unknown origin)	B	CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1		CHEMBL49120	<	IC50	nM	100.0	CHEMBL308	Homo sapiens	IC50	nM	100.0
	22990698	CHEMBL4775139	Inhibition of MYT1 (unknown origin)	B	CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1		CHEMBL49120	<	IC50	nM	100.0	CHEMBL308	Homo sapiens	IC50	nM	100.0
	23120253	CHEMBL4804356	Inhibition of CDC2 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O	Outside typical range	CHEMBL4855542	=	IC50	nM	-15000.0	CHEMBL308	Homo sapiens	IC50	uM	-15.0
	23120254	CHEMBL4804356	Inhibition of CDC2 in human NCI-H929 cells by mass spectroscopic analysis	B	CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1	Outside typical range	CHEMBL4860979	=	IC50	nM	-26500.0	CHEMBL308	Homo sapiens	IC50	uM	-26.5
	23120255	CHEMBL4804356	Inhibition of CDC2 in human NCI-H929 cells by mass spectroscopic analysis	B	COc1cc(NS(=O)(=O)C2CC2)ccc1-c1cnc(N)c(-c2ccc3c(c2)CCNC3=O)c1		CHEMBL4867931	=	IC50	nM	13700.0	CHEMBL308	Homo sapiens	IC50	uM	13.7
	23120256	CHEMBL4804356	Inhibition of CDC2 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855730	=	IC50	nM	18500.0	CHEMBL308	Homo sapiens	IC50	uM	18.5
	23120257	CHEMBL4804356	Inhibition of CDC2 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2OC2CCCCC2)cc1-c1ccc2c(c1)CCNC2=O	Outside typical range	CHEMBL4868141	=	IC50	nM	-500.0	CHEMBL308	Homo sapiens	IC50	uM	-0.5
	23120258	CHEMBL4804356	Inhibition of CDC2 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O	Outside typical range	CHEMBL4859660	=	IC50	nM	-24700.0	CHEMBL308	Homo sapiens	IC50	uM	-24.7
	23121297	CHEMBL4804538	Inhibition of CDC2 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855542	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	23121298	CHEMBL4804538	Inhibition of CDC2 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1		CHEMBL4860979	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	23121299	CHEMBL4804538	Inhibition of CDC2 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	COc1cc(NS(=O)(=O)C2CC2)ccc1-c1cnc(N)c(-c2ccc3c(c2)CCNC3=O)c1		CHEMBL4867931	=	Inhibition	%	35.0	CHEMBL308	Homo sapiens	INH	%	35.0
	23121300	CHEMBL4804538	Inhibition of CDC2 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855730	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	23121301	CHEMBL4804538	Inhibition of CDC2 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2OC2CCCCC2)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4868141	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	23121302	CHEMBL4804538	Inhibition of CDC2 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4859660	=	Inhibition	%	0.0	CHEMBL308	Homo sapiens	INH	%	0.0
	23125643	CHEMBL4806987	Inhibition of CDK1 in human HT1080 cells assessed as inhibition of IPTG-induced CMV-GFP expression by Hoechst 33342 staining-based fluorescence assay	B	COCCNC(=O)c1ccc(CCNc2ncnc3ccc(C#N)cc23)cc1		CHEMBL4866990	=	EC50	nM	2200.0	CHEMBL308	Homo sapiens	EC50	uM	2.2
	23125644	CHEMBL4806987	Inhibition of CDK1 in human HT1080 cells assessed as inhibition of IPTG-induced CMV-GFP expression by Hoechst 33342 staining-based fluorescence assay	B	N#Cc1ccc2ncnc(NCCc3ccc(C(=O)N4CCOCC4)cc3)c2c1		CHEMBL4874663	=	EC50	nM	3420.0	CHEMBL308	Homo sapiens	EC50	uM	3.42
	23125645	CHEMBL4806987	Inhibition of CDK1 in human HT1080 cells assessed as inhibition of IPTG-induced CMV-GFP expression by Hoechst 33342 staining-based fluorescence assay	B	N#Cc1ccc2ncnc(NCCc3ccc(C(=O)N4CCCCC4)cc3)c2c1		CHEMBL4869939	=	EC50	nM	3825.0	CHEMBL308	Homo sapiens	EC50	uM	3.825
	23125646	CHEMBL4806987	Inhibition of CDK1 in human HT1080 cells assessed as inhibition of IPTG-induced CMV-GFP expression by Hoechst 33342 staining-based fluorescence assay	B	CN1CCN(C(=O)c2ccc(CCNc3ncnc4ccc(C#N)cc34)cc2)CC1		CHEMBL4875632	=	EC50	nM	5210.0	CHEMBL308	Homo sapiens	EC50	uM	5.21
	23125647	CHEMBL4806987	Inhibition of CDK1 in human HT1080 cells assessed as inhibition of IPTG-induced CMV-GFP expression by Hoechst 33342 staining-based fluorescence assay	B	N#Cc1ccc2ncnc(NCCc3ccc(C(=O)N4CCC(N)C4)cc3)c2c1		CHEMBL4858679	=	EC50	nM	9720.0	CHEMBL308	Homo sapiens	EC50	uM	9.72
	23125648	CHEMBL4806987	Inhibition of CDK1 in human HT1080 cells assessed as inhibition of IPTG-induced CMV-GFP expression by Hoechst 33342 staining-based fluorescence assay	B	CN(C)CCNC(=O)c1ccc(CCNc2ncnc3ccc(C#N)cc23)cc1		CHEMBL4859226	=	EC50	nM	4570.0	CHEMBL308	Homo sapiens	EC50	uM	4.57
	23125649	CHEMBL4806987	Inhibition of CDK1 in human HT1080 cells assessed as inhibition of IPTG-induced CMV-GFP expression by Hoechst 33342 staining-based fluorescence assay	B	CNC(=O)c1ccc(CCNc2ncnc3ccc(C#N)cc23)cc1		CHEMBL4849615	=	EC50	nM	2350.0	CHEMBL308	Homo sapiens	EC50	uM	2.35
	23125650	CHEMBL4806987	Inhibition of CDK1 in human HT1080 cells assessed as inhibition of IPTG-induced CMV-GFP expression by Hoechst 33342 staining-based fluorescence assay	B	CN(C)C(=O)c1ccc(CCNc2ncnc3ccc(C#N)cc23)cc1		CHEMBL4874631	=	EC50	nM	2390.0	CHEMBL308	Homo sapiens	EC50	uM	2.39
	23125651	CHEMBL4806987	Inhibition of CDK1 in human HT1080 cells assessed as inhibition of IPTG-induced CMV-GFP expression by Hoechst 33342 staining-based fluorescence assay	B	CN1CCN(C(=O)c2cc(CNc3ncnc4ccc(C#N)cc34)ccc2Cl)CC1		CHEMBL4851465	=	EC50	nM	920.0	CHEMBL308	Homo sapiens	EC50	uM	0.92
	23125652	CHEMBL4806987	Inhibition of CDK1 in human HT1080 cells assessed as inhibition of IPTG-induced CMV-GFP expression by Hoechst 33342 staining-based fluorescence assay	B	N#Cc1ccc2ncnc(NCc3ccc(Cl)c(C(=O)N4CCOCC4)c3)c2c1		CHEMBL4867033	=	EC50	nM	1520.0	CHEMBL308	Homo sapiens	EC50	uM	1.52
	23125653	CHEMBL4806987	Inhibition of CDK1 in human HT1080 cells assessed as inhibition of IPTG-induced CMV-GFP expression by Hoechst 33342 staining-based fluorescence assay	B	N#Cc1ccc2ncnc(NCCc3ccc4cc(C(=O)N5CCOCC5)ccc4c3)c2c1		CHEMBL4878874	=	EC50	nM	930.0	CHEMBL308	Homo sapiens	EC50	uM	0.93
	23125654	CHEMBL4806987	Inhibition of CDK1 in human HT1080 cells assessed as inhibition of IPTG-induced CMV-GFP expression by Hoechst 33342 staining-based fluorescence assay	B	CN1CCN(C(=O)c2ccc3cc(CCNc4ncnc5ccc(C#N)cc45)ccc3c2)CC1		CHEMBL4076837	=	EC50	nM	530.0	CHEMBL308	Homo sapiens	EC50	uM	0.53
	23125655	CHEMBL4806987	Inhibition of CDK1 in human HT1080 cells assessed as inhibition of IPTG-induced CMV-GFP expression by Hoechst 33342 staining-based fluorescence assay	B	N#Cc1ccc2ncnc(NCCc3ccc4ccc(C(=O)N5CCOCC5)cc4c3)c2c1		CHEMBL4867633	=	EC50	nM	1480.0	CHEMBL308	Homo sapiens	EC50	uM	1.48
	23125656	CHEMBL4806987	Inhibition of CDK1 in human HT1080 cells assessed as inhibition of IPTG-induced CMV-GFP expression by Hoechst 33342 staining-based fluorescence assay	B	CN1CCN(C(=O)c2ccc3ccc(CCNc4ncnc5ccc(C#N)cc45)cc3c2)CC1		CHEMBL4869016	=	EC50	nM	1050.0	CHEMBL308	Homo sapiens	EC50	uM	1.05
	23212963	CHEMBL4822883	Inhibition of CDK1 (unknown origin) at 500 nM	B	N[C@H]1CCCN(C(=O)c2ccc(-c3ccc4ncc(-c5ccc6cnccc6c5)n4n3)cc2)C1		CHEMBL4878199	=	Inhibition	%	5.01	CHEMBL308	Homo sapiens	INH	%	5.01
Not Active	23256048	CHEMBL4831999	Inhibition of CDK1 (unknown origin) at 0.3 uM	B	O=C(Nc1cncc(OCC2CCN(Cc3ccc(F)cc3)CC2)c1)c1ccnc(NC(=O)C2CC2)c1		CHEMBL4873612		Inhibition	%		CHEMBL308	Homo sapiens	INH		
	23258727	CHEMBL4832757	Inhibition of CDK1 (unknown origin) at 5 uM using 5-FAM-QSPKKG-CONH2 as a substrate incubated for 60 mins in the presence of ATP by caliper analysis relative to control	B	COCCOc1cc2ncnc(Sc3nc[nH]n3)c2cc1OCCOC		CHEMBL4868123	<	Inhibition	%	2.0	CHEMBL308	Homo sapiens	INH	%	2.0
Not Active	23270422	CHEMBL4835216	Inhibition of CDC2/CDK1 (unknown origin) at 10 uM	B	C[C@H]1CN(C(=O)CC[C@@]2(C3CC3)NC(=O)NC2=O)CCN1c1cc(F)cc(F)c1		CHEMBL4650334		Inhibition	%		CHEMBL308	Homo sapiens	INH		
	23297712	CHEMBL4841248	Inhibition of CDK1 (unknown origin) expressed in Sf9 insect cells using biotinylated peptide derived Histone H1 as substrate incubated for 1 hr in presence of [gamma33P]ATP by liquid scintillation counter method	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	=	IC50	nM	1.0	CHEMBL308	Homo sapiens	IC50	nM	1.0
	23372680	CHEMBL4884645	CDC2 [CDK1(CDK1CGS1)] Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(Cc4ccccc4)nc3C2=O)COc2ccccc21		CHEMBL4088216		IC50	nM	1000.0	CHEMBL308	Homo sapiens	pIC50		6.0
	23373089	CHEMBL4884936	CDC2 [CDK1(CDK1CGS1)] Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3c(nn(Cc4ccccc4)c3Br)C2=O)COc2ccccc21		CHEMBL4549667		IC50	nM	1000.0	CHEMBL308	Homo sapiens	pIC50		6.0
	23373450	CHEMBL4885227	CDC2 [CDK1(CDK1CGS1)] Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(CC4CCS(=O)(=O)CC4)nc3C2=O)COc2ccccc21		CHEMBL4097778		IC50	nM	1000.0	CHEMBL308	Homo sapiens	pIC50		6.0
